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Abstract 
 
Eukaryotic transcripts require a number of complex cotranscriptional modifications and 
processing events before translation to protein. Clp1 and Pcf11 are subunits of cleavage 
factor IA (CFIA), an essential component of the Saccharomyces cerevisiae pre-mRNA 
3’-end processing machinery. The crystal structure of a Clp1-Pcf11 complex was 
determined previously and revealed the binding of ATP to a highly-conserved P-loop 
motif and a tight Pcf11-Clp1 interaction facilitated by a number of highly-conserved 
Pcf11 residues. Nonetheless, the biological function of both Clp1-ATP binding and the 
Pcf11-Clp1 interaction was not well understood.  The work in this thesis combines an in 
vitro and in vivo investigation of the Clp-ATP and Clp-Pcf11 interactions in an effort to 
understand the function of these factors in transcription and pre-mRNA 3’-end 
processing. It is demonstrated that the interaction of ATP and Pcf11 with Clp1 are 
linked events: Loss of Clp1-ATP binding results in the abrogation of the Pcf11-Clp1 
interaction and leads to Clp1 instability in vitro, and similarly, mutations that directly 
uncouple the Pcf11-Clp1 interaction also disrupt Clp1-ATP binding and cause Clp1 
instability in vitro.  An in vivo mutational analysis in S. cerevisiae revealed that both 
Clp1-ATP binding and the Pcf11-Clp1 interaction are essential for yeast survival.  
Further cell and immunoprecipitation studies demonstrated that one essential function 
of Clp1 is as a chaperone of Pcf11, and RT-qPCR analysis of mRNA from a sample set 
of yeast genes points to a role for these proteins in transcription and transcription 
termination rather than in poly(A) site selection.  
 5
Table of contents 
 
Declaration…………………………………………………………….
 
2 
Acknowledgments……………………………………………………. 
 
3 
Abstract………………………………………………………………..
 
4 
Table of contents……………………………………………………... 
 
5 
List of figures………………………………………………………….
 
10 
List of tables…………………………………………………………...
 
12 
List of abbreviations…………………………………………………. 
 
13 
Saccharomyces cerevisiae nomenclature……………………………. 14 
  
1. Introduction……………………………………………………….. 
 
15 
     1.1. Eukaryotic pre-mRNA processing………………………………………. 15 
          1.1.1. Pre-mRNA 5’-end capping…………………………………………… 15 
          1.1.2. Pre-mRNA splicing…………………………………………………… 17 
          1.1.3. Pre-mRNA 3’-end processing………………………………………… 18 
          1.1.4. mRNA export…………………………………………………………. 18 
          1.1.5. Timing of processing events………………………………………….. 
 
19 
     1.2. Pre-mRNA 3’-end processing……………………………………………. 20 
          1.2.1. Sequence elements for mRNA 3’-end formation……………………... 20 
          1.2.2. Protein factors for pre-mRNA 3’-end processing…………………….. 
 
22 
     1.3. Cleavage factor I (CFI)…………………………………………………… 23 
          1.3.1. Rna14 (CFIA)………………………………………………………… 23 
          1.3.2. Rna15 (CFIA)………………………………………………………… 25 
          1.3.3. Pcf11 (CFIA)…………………………………………………………. 29 
          1.3.4. Clp1 (CFIA)…………………………………………………………... 33 
          1.3.5. Hrp1 (CFIB)…………………………………………………………... 
 
37 
     1.4. Cleavage and Polyadenylation Factor (CPF)…………………………… 40 
          1.4.1. The role of CPF in cleavage………………………………………….. 42 
          1.4.2. The role of CPF in polyadenylation…………………………………... 
 
44 
     1.5. A model for pre-mRNA 3’-end processing in S. cerevisiae…………….. 
 
47 
     1.6. Links between 3’-end processing and other processing events………… 49 
          1.6.1. 3’-end processing and 5’-end capping………………………………... 49 
          1.6.2. 3’-end processing and splicing………………………………………... 50 
          1.6.3. 3’-end processing and export…………………………………………. 
 
50 
 6
     
 1.7. Links between 3’-end processing and transcription………………………. 
 
52 
          1.7.1. 3’-end processing and transcription termination……………………… 53 
          1.7.2. 3’-end processing and transcription initiation………………………… 
 
38 
     1.8. Mammalian homologues of 3’-end processing factors…………………. 
 
59 
     1.9. Research objectives……………………………………………………….. 62 
  
2. Materials and Methods…………………………………………….
 
64 
     2.1. Bioinformatics…………………………………………………………….. 64 
          2.1.1. DNA and protein information………………………………………… 64 
          2.1.2. Multiple sequence alignments………………………………………… 
 
64 
     2.2. Molecular biology techniques……………………………………………. 64 
          2.2.1. Bacterial strains………………………………………......................... 64 
          2.2.2. Yeast strains………………………………………………………....... 65 
          2.2.3. Plasmid construction………………………………………………….. 65 
          2.2.4. DNA manipulation and analysis……………………………………… 68 
          2.2.5. Polymerase chain reaction……...…………………………………….. 69 
          2.2.6. Restriction digests…………………………………………………….. 69 
          2.2.7. Ligation reactions……………………………………………………... 70 
          2.2.8. Transformations………………………………………………………. 71 
          2.2.9 Site-directed mutagenesis……………………………………………... 
 
71 
     2.3. Protein expression and purification……………………………………... 74 
          2.3.1. Protein expression…………………………………………………….. 74 
          2.3.2. Bacterial cell lysis…………………………………………………….. 75 
          2.3.3. Purification of glutathione S-transferase fusion proteins……………... 75 
          2.3.4. Nickel affinity purification…………………………………………… 76 
          2.3.5. Size-exclusion chromatography……………………………………… 77 
          2.3.6. SDS-PAGE………………………………………………………........ 77 
          2.3.7. Protein concentration, storage and dialysis…………………………… 78 
          2.3.8. Determination of protein concentration………………………………. 
 
78 
     2.4. Multiangle laser light scattering (MALLS)……………………………... 
 
79 
     2.5. Reversed-phase high-performance liquid chromatography…………… 82 
          2.5.1. Reversed-phase nucleotide assay……………………………………... 82 
          2.5.2. Reversed-phase complex composition assay…………………………. 83 
          2.5.3. Integration of UV absorbance peaks and stoichiometry calculation…. 
 
84 
     2.6. Incorporation of radiolabelled ATP and scintillation counting……….. 
 
84 
     2.7. Circular dichroism spectroscopy…………………………………………
 
85 
     2.8. Yeast methods……………………………………………………………... 86 
          2.8.1. Yeast transformation………………………………………………….. 86 
          2.8.2. Construction of a haploid pcf11 yeast strain………………………... 87 
          2.8.3. 5-FOA Plasmid shuffle……………………………………………….. 88 
          2.8.4. Growth rate assays……………………………………………………. 90 
 7
          2.8.5. Western blotting………………………………………………………. 91 
          2.8.6. Coimmunoprecipitation experiment………………………………….. 92 
          2.8.7. Determination of protein half-life…………………………………….. 93 
          2.8.8. Preparation of total RNA……………………………………………... 
 
93 
     2.9. Poly(A) tail-length assay………………………………………………….. 94 
          2.9.1. Poly(A) tail 3’-end labelling………………………………………….. 94 
          2.9.2. Poly(A) tail digestion and purification……………………………….. 95 
          2.9.3. Visualisation of poly(A) tails…………………………………………. 96 
          2.9.4. Modifications to poly(A) tail-length assay protocols………………… 96 
          2.9.5. DNA ladder preparation……………………………………………… 
 
97 
     2.10. Quantitative real-time PCR…………………………………………….. 97 
          2.10.1. Reaction setup……………………………………………………….. 98 
          2.10.2. ACT1 Poly(A) site selection assay…………………………………... 100
          2.10.3. Analysis of TDH2, ACT1, ADH1, CYC1 and YPT1 transcription…... 102
          2.10.4. ACT1 Transcription readthrough assay……………………………… 102
   
3. in vitro analysis of recombinant Clp1-ATP binding mutants…... 
 
104
     3.1. Introduction and overview……………………………………………….. 
 
104
     3.2. Mutation of the Clp1-ATP binding pocket affects protein stability…… 105
          3.2.1. Design of Clp1 mutants………………………………………………. 105
          3.2.2. Size-exclusion chromatography………………………………………. 106
          3.2.3. Multiangle laser light scattering………………………………………. 110
          3.2.5. Far-UV circular dichroism spectroscopy……………………………... 
 
114
     3.3. ATP is a structural component of Clp1………………………………… 117
          3.3.1. Mutations in Clp1 P-loop and Switch II abrogate Clp1-ATP binding... 117
          3.3.2. ATP is essential for Clp1 stability……………………………………. 
 
120
     3.4. Summary and conclusions……………………………………………….. 124
  
4. Functional analysis of the Clp1-ATP interaction in S. cerevisiae.
 
125
     4.1. Introduction and overview………………………………………………. 
 
125
     4.2. Clp1-ATP binding is essential in S. cerevisiae…………………………... 126
          4.2.1. Mutations that abrogate Clp1-ATP binding are lethal………………... 126
          4.2.2. Overexpression of lethal clp1-ATP mutant alleles restores growth….. 
 
130
     4.3. Analysis of pre-mRNA 3’-end processing in clp1-ATP mutants………. 135
          4.3.1. Analysis of poly(A) tail-lengths……………………………………… 135
          4.3.2. The Clp1-ATP interaction does not affect poly(A) site selection on 
 ACT1 mRNA………....……………………………………………………..
137
          4.3.3. Clp1-ATP binding plays an important role in transcription………….. 140
          4.3.4. Clp1-ATP binding may be important for transcription termination on 
 the ACT1 gene……………………………………………………………… 
 
143
     4.4. Summary and conclusions………………………………………………...
 
144
 8
 
5. in vitro analysis of recombinant Pcf11-Clp1 binding mutants…..
 
 
146
 
     5.1. Introduction and overview……………………………………………….. 
 
146
     5.2. Characterisation of the Pcf11 CTD……………………………………… 147
          5.2.1. Purification of Pcf11 456-626………………………………………… 147
          5.2.2. Multiangle laser light scattering analysis of Pcf11 456-626………….. 149
          5.2.3. Far-UV circular dichroism of Pcf11 456-626………………………… 151
          5.2.4. Pcf11 CTD deletion analysis…………………………………………. 
 
151
     5.3. Mutation of conserved Pcf11 residues in the Clp1 ID affects the 
 stability of Clp1…………………………………………………………… 
 
155
          5.3.1. Design of Pcf11 mutants……………………………………………… 155
          5.3.2. Size-exclusion chromatography………………………………………. 156
          5.3.3. Multiangle laser light scattering………………………………………. 
 
158
     5.4. The Pcf11-Clp1 interaction promotes Clp1-ATP binding and Clp1 
 stability………….…………………………………………………………. 
 
162
          5.4.1. Mutations in the Pcf11-Clp1 ID disrupt the Pcf11-Clp1 interaction…. 162
          5.4.2. The Pcf11-Clp1 interaction promotes Clp1-ATP binding……………. 
 
164
     5.5. Summary and conclusions………………………………………………... 166
  
6. Functional analysis of the Pcf11-Clp1 interaction in  
S. cerevisiae…………………………………………………………… 
 
 
168
     6.1. Introduction and overview……………………………………………….. 
 
168
     6.2. The Pcf11-Clp1 interaction is essential in S. cerevisiae………………… 168
          6.2.1. Previously characterised Pcf11-Clp1 mutants do not disrupt the       
 Pcf11-Clp1 interaction in S. cerevisiae…………………………………………. 
 
168
          6.2.2. Mutation of multiple conserved residues uncouples the Pcf11 Clp1 
 interaction and is lethal…………………………………………………….. 
 
173
          6.2.3. pcf11 RW-A is a temperature sensitive allele………………………… 177
          6.2.4. Overexpression of lethal pcf11-Clp1 mutant alleles does not restore   
 growth……………………………………………………………………… 
 
 
178
     6.3. Abolition of the Pcf11-Clp1 interaction causes increased turnover of 
 Pcf11……………………….………………………………………………. 
 
 
183
     6.4. The Pcf11-Clp1 interaction does not influence poly(A) site choice on 
 ACT1 mRNA….....…………………………………………………………
 
 
185
     6.5. The Pcf11-Clp1 interaction is important for transcription……………. 
 
188
     6.6. The Pcf11-Clp1 interaction is required for transcription termination 
 on the ACT1 gene…………………........…………………………………. 
 
 
191
     6.7 Summary and conclusions………………………………………………… 192
  
 9
 
7. Discussion…………………………………………………………...
 
 
194
     7.1. Clp1, ATP and the enzyme question…………………………………….. 
 
194
     7.2. Clp1-ATP binding and the Pcf11-Clp1 interaction are linked………… 
 
196
     7.3. Subunit composition of CFIA during transcription……………………. 
 
198
     7.4. The function of CFIA in transcription, termination and 3’-end 
 processing………………………………………………………………......
 
 
200
     7.5. Completing the picture…………………………………………………… 203
  
8. Appendix………………………………………………………........
 
208
     8.1. Clp1 multi-species sequence alignment…………………………………..
 
208
     8.2. Mutant plasmid constructs………………………………………………..
 
209
     8.3. Oligonucleotide primers for PCR………………………………………...
 
211
     8.4. Primers and probes for reverse-transcription quantitative real-time 
 PCR experiments……………………………………………....…………. 
 
 
213
     8.5. Clp1 and Pcf11 (454-563) mass spectrum deconvolution reports……... 
 
214
     8.6. CT and quantity data from RT-qPCR experiments……………………..
 
215
    8.7. Analysis of RNA quality by denaturing agarose gel electrophoresis…... 218
  
9. Bibliography……………………………………………………….. 219
 
 
  
 10
 
List of figures 
 
Figure 1.1. A summary of the 3’-end processing steps…………………….. 16 
Figure 1.2. Structure of the Rna15 RRM and Site-I base-binding pocket….. 27 
Figure 1.3. Pcf11 contains binding sites for other pre-mRNA 3’-end 
processing factors………………………………………………. 
 
30 
Figure 1.4. The Pcf11-Clp1 interaction…………………………………….. 32 
Figure 1.5. Crystal structure of the Clp1-Pcf11-ATP complex…………….. 34 
Figure 1.6. Structure of the Clp1 ATP-binding pocket…………………….. 36 
Figure 1.7. CFIA-CPF interaction map…………………………………….. 43 
Figure 1.8. Model for pre-mRNA 3’-end processing………………………. 48 
Figure 1.9. Models of transcription termination……………………………. 54 
Figure 1.10. The interaction between Pcf11 CID and PolII CTD…………… 56 
Figure 1.11. Comparison of S. cerevisiae and mammalian 3’-end processing 
protein complexes………………………………………………. 
 
61 
Figure 2.1. Cloning methods for pRS315-based yeast constructs………….. 67 
Figure 2.2. Primer design for site-directed mutagenesis (SDM)…………… 72 
Figure 2.3. Multiangle laser light scattering (MALLS)…………………….. 80 
Figure 2.4. The 5-FOA plasmid shuffle system……………………………. 89 
Figure 2.5. Hydrolysis (TaqMan) probes for qPCR………………………... 99 
Figure 2.6. Worked example of the relative standard curve method……….. 101 
Figure 2.7. Design of targets for RT-qPCR poly(A) site selection and 
transcription readthrough experiments…………………………. 
 
103 
Figure 3.1. SEC of Clp1 and Clp1-ATP mutants…………………………... 107 
Figure 3.2. SEC profiles of Clp1-ATP mutants……………………………. 109 
Figure 3.3. MALLS analysis of Clp-ATP mutants…………………………. 111 
Figure 3.4. MALLS analysis of Clp-ATP mutants…………………………. 113 
Figure 3.5. Far-UV CD of Clp1-ATP mutants……………………………... 115 
Figure 3.6. Analysis of the nucleotide-content of Clp1-Pcf11 wildtype and 
stable Clp1-ATP binding mutants……………………………… 
 
118 
Figure 3.7. Nucleotide assays with unstable Clp1-ATP binding mutants….. 119 
Figure 3.8. MALLS analysis of Clp1-Pcf11 stability after EDTA chelation  121 
Figure 4.1. 5-FOA plasmid shuffle assay to determine the effects of 
mutations in the clp1 gene on S. cerevisiae viability…………... 
 
127 
Figure 4.2. Analysis of growth rate of CLP1 wildtype yeast, clp1 S138A 
and D161A mutants…………………………………………….. 
 
129 
Figure 4.3. Spot test assays displaying the results of clp1∆ complementation 
with clp1-ATP mutant alleles expressed from the GAL1 
promoter……………………………………………... 
 
 
131 
Figure 4.4. Glucose repression of CLP1 wildtype and clp1 mutant 
transcription…………………………………………………….. 
 
133 
Figure 4.5. Poly(A) tail-length analysis…………………………………….. 136 
Figure 4.6. Poly(A) site selection on ACT1 mRNA in GAL1-clp1 ATP-
binding mutants………………………………………………… 
 
139 
Figure 4.7. Gene expression and transcription termination in GAL1-clp1 
yeast mutants compared to wildtype yeast……………………... 
 
142 
Figure 5.1. Purification of the Pcf11 CTD………………………………….. 148 
Figure 5.2. SEC-MALLS and CD characterisation of the Pcf11 CTD……... 150 
Figure 5.3. Pcf11 CTD deletion analysis…………………………………… 153 
Figure 5.4. SEC analysis of Pcf11-Clp1 mutants…………………………... 157 
Figure 5.5. SEC-MALLS analysis of Pcf11-Clp1 mutants………………… 159 
 11
Figure 5.6. SEC-MALLS analysis of Pcf11-Clp1 mutants………………… 161 
Figure 5.7. Clp1-Pcf11 complex composition assays………………………. 163 
Figure 5.8. RP-HPLC analysis of the nucleotide-content of Pcf11-Clp1 
binding mutants………………………………………………… 
 
165 
Figure 6.1. 5-FOA plasmid shuffle assay to determine the effects of single 
mutations in the pcf11 gene on S. cerevisiae growth…………... 
 
169 
Figure 6.2. Coimmunoprecipitation experiment with yeast extracts from 
pcf11 single mutants……………………………………………. 
 
172 
Figure 6.3. 5-FOA plasmid shuffle assay to determine the effects of 
double/triple mutations in the pcf11 gene on S. cerevisiae 
growth………………………………………………………….. 
 
 
174 
Figure 6.4. Coimmunoprecipitation experiment with yeast extracts from 
pcf11 double/triple mutants…………………………………….. 
 
176 
Figure 6.5. Growth characteristics of the pcf11 RW-A yeast mutant………. 179 
Figure 6.6. Overexpression of pcf11 double/triple mutants from the GAL1 
promoter……………………………………………………….....
 
181 
Figure 6.7. Turnover of Pcf11 and Pcf11 RWW-A after cycloheximide 
inhibition of protein synthesis…………………………………... 
 
184 
Figure 6.8. Results of the RT-qPCR ACT1 poly(A) site selection assay with 
wildtype and pcf11 RW-A yeast…………………………………
 
187 
Figure 6.9. RT-qPCR analysis of gene expression and transcription 
termination in pcf11 RW-A mutant yeast……………………….. 
 
190 
Figure 7.1. The events that lead to Clp1 instability and aggregation..………. 197 
Figure 7.2. A model for CFIA function in transcription, transcription 
termination and pre-mRNA 3’-end processing…………………. 
 
204 
Appendix 8.1. Clp1 multi-species sequence alignment………………………… 208 
Appendix 8.5. Clp1 and Pcf11(454-563) mass spectrum deconvolution reports. 214 
Appendix 8.7. Analysis of RNA quality by denaturing agarose gel 
electrophoresis…………………………………………………... 
 
 
218 
 
 12
List of tables 
 
Table 1.1. Summary of CPF subunit functions……………………………... 41 
Table 2.1. Genotypes of E. coli strains……………………………………… 65 
Table 2.2. Genotypes of S. cerevisiae strains……………………………….. 65 
Table 2.3. Wildtype plasmid constructs…………………………………….. 68 
Table 2.4. Typical PCR setup……………………………………………….. 69 
Table 2.5. Typical thermal cycling conditions for PCR…………………….. 69 
Table 2.6. Typical restriction digestion conditions…………………………. 70 
Table 2.7. Typical phosphatase reaction conditions………………………… 70 
Table 2.8. Ligation reaction conditions……………………………………... 71 
Table 2.9. Typical SDM PCR setup………………………………………… 73 
Table 2.10. Typical SDM PCR thermal cycling conditions………………….. 73 
Table 2.11. Modification of SDM PCR products after QuikChange 
mutagenesis……………………………………………………… 
 
74 
Table 2.12. Modification of SDM PCR products generated using the non-
overlapping primer design………………………………………. 
 
74 
Table 2.13. Ligation reaction conditions to recircularise PCR products after 
5’-end phosphorylation………………………………………….. 
 
74 
Table 2.14. Buffer compositions for protein purification……………………. 77 
Table 2.15. Reversed-phase complex composition assay buffer conditions…. 83 
Table 2.16. Complex composition assay gradient elution profile……………. 83 
Table 2.17. Yeast competent cell mix………………………………………... 87 
Table 2.18. Original and modified reaction setups for 3’-end labelling of 
total RNA samples………………………………………………. 
 
95 
Table 2.19. Original and modified reaction setups for RNA digestion………. 96 
Table 2.20. Reaction setup for oligonucleotide radiolabelling………………. 97 
Table 2.21. Reaction setup for RT-qPCR experiments………………………. 100 
Table 2.22. Thermal cycling conditions for RT-qPCR experiments…………. 100 
Table 3.1. Mutations made in the Clp1-ATP binding pocket in the 
Clp1/Pcf11-EXP construct………………………………………. 
 
105 
Table 3.2. Prediction of Clp1-Pcf11 and Clp1 secondary structure element 
compositions……………………………………………………...
 
117 
Table 3.3. The ATP molecule bound by Clp1 is non-exchangeable………... 123 
Table 4.1. TDH2 and ACT1 mRNA quantities determined by RT-qPCR of 
total RNA extracted from CLP1 wildtype and clp1 mutants……. 
 
140 
Table 5.1. Mutations made in the Pcf11-Clp1 interface in the Clp1/Pcf11-
EXP construct…………………………………………………….
 
155 
Table 6.1. Mutations made in the LEU2-pcf11 constructs for expression of 
Pcf11-Clp1 ID double and triple mutants in S. cerevisiae………. 
 
173 
Table 6.2. TDH2 and ACT1 mRNA quantities determined by RT-qPCR of 
total RNA extracted from PCF11 wildtype and pcf11 RW-A…... 
 
188 
Appendix 8.2. Mutant plasmid constructs………………………………………. 209 
Appendix 8.3. Oligonucleotide primers for PCR……………………………….. 211 
Appendix 8.4. Primers and probes for reverse-transcription quantitative real 
time PCR experiments……………………………………………
 
213 
Appendix 8.6. CT and quantity data from RT-qPCR experiments………………. 215 
 
 13
List of abbreviations 
 
 
 
Abbr. Definition Abbr. Definition 
3'-UTR 3' untranslated region kDa Kilodalton 
5-FOA 5-fluoroorotic acid LS Light scattering 
ADP Adenosine diphosphate MALLS Multi-angle laser light scattering 
AMP Adenosine monophosphate mAU Milli-absorbance units 
ATP Adenosine triphosphate Mr Relative molecular mass 
AU Absorbance units mRNA Messenger ribonucleic acid 
AUC Analytical ultracentrifugation mRNP Messenger ribonucleoprotein 
bp Base pair NIMR National Institute for Medical Research 
CD Central domain/circular dichroism NMR Nuclear magnetic resonance 
cDNA Complementary DNA NPC Nuclear pore complex 
CFIA/B Cleavage factor IA/IB nt Nucleotide 
CFIIm Mammalian cleavage factor II NTD N (amino)-terminal domain 
CFIm Mammalian cleavage factor I OD Optical density 
ChIP Chromatin immunoprecipitation ORF Open reading frame 
ChIP-chip ChIP with microarray analysis PAGE Polyacrylamide gel electrophoresis 
ChIP-seq ChIP with DNA sequencing PCR Polymerase chain reaction 
CID CTD-interacting domain PDB Protein Data Bank 
coIP Coimmunoprecipitation PE Positioning element 
CPF Cleavage and polyadenylation factor pI Isoelectric point 
CPM Counts per million PNK Polynucleotide kinase 
CPSF Cleavage and polyadenylation specificity factor PolII RNA polymerase II 
CstF Cleavage stimulatory factor qPCR Quantitative real-time PCR 
CT Threshold cycle RNA Ribonucleic acid 
CTD C (carboxy)-terminal domain RNA-seq RNA sequencing 
Da Dalton RP-HPLC Reverse-phase high-performance liquid chromatography 
DMSO Dimethyl sulfoxide RRM RNA recognition motif 
DNA Deoxyribonucleic acid RT-qPCR Reverse-transcription quantitative real-time PCR  
DNA-seq DNA sequencing SDM  Site-directed mutagenesis 
dRI Differential refractive index SDS Sodium dodecyl sulfate 
DTT Dithiothreitol SEC Size-exclusion chromatography 
EDTA Ethylenediaminetetraacetic acid snRNA Small nuclear ribonucleic acid 
EE Efficiency element snoRNA Small nucleolar ribonucleic acid 
GMP Guanine monophosphate siRNA Small interfering ribonucleic acid 
GST Glutathione-S-transferase TAP Tandem affinity purification 
HA Human influenza haemaglutinin TCEP Tris(2-carboxyethyl)phosphine 
ID Interaction domain TREX Transcription and export factor complex 
IPTG Isopropyl β-D-1-thiogalactopyranoside UV Ultra-violet 
ITC Isothermal titration calorimetry YPD Yeast peptone-dextrose medium 
 14
Saccharomyces cerevisiae nomenclature 
 
All chapters in this thesis discuss both the results of in vitro experiments with 
recombinantly-purified S. cerevisiae proteins, and the findings of in vivo yeast genetics 
experiments.  Thus, it is important that the text clearly distinguishes between references 
to genes and proteins.  Wildtype genes are denoted by using upper-case italics (e.g. 
CLP1) and mutant alleles are designated in lower-case italics followed by identification 
of the mutation (e.g. clp1 T137A or pcf11-9).  Wildtype proteins are denoted by lower-
case standard text with a first-letter capital (e.g. Clp1 or Pcf11), mutants are designated 
in the same way but with an identification of the mutation (e.g. Clp1 T137A or Pcf11 
RW-A).  All references to proteins concern S. cerevisiae proteins unless another 
organism is specified.   
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1. Introduction 
 
Eukaryotic gene expression is a complex process that commences with deciphering the 
information encoded within genes and results in the production of mature gene 
products. Protein coding genes are transcribed into messenger ribonucleic acid 
molecules (mRNAs) by RNA polymerase II (PolII) in the nucleus.  mRNAs are 
subsequently translated into proteins in the cytoplasm by the ribosome.  There are many 
factors that influence protein expression, beginning with the regulation of chromatin 
conformation and transcription initiation, and ending with post-translational 
modification and protein degradation.  At the level of transcription, it is not only the rate 
of transcription that determines how well expressed a gene is. Cotranscriptional 
modification of mRNA also plays an important part in the control of gene expression by 
dictating the post-transcriptional fate of mRNA.   
 
1.1. Eukaryotic pre-mRNA processing 
 
Nascent transcripts, or “pre-mRNAs”, must undergo a maturation process through a 
series of complex cotranscriptional modifications before relocation to the cytoplasm for 
translation.  These maturation steps introduce many additional opportunities for the 
regulation of gene expression.  The next four sections introduce the four modification 
steps of pre-mRNA maturation: 5’-end capping, splicing, 3’-end processing and export.  
The processes of capping, splicing and export are illustrated in Figure 1.1. 
 
1.1.1. Pre-mRNA 5’-end Capping 
A methylguanosine cap is added to the 5’-end of pre-mRNA after PolII has transcribed 
the first 25-30 nucleotides (nt) of a gene. Capping plays a major part in ensuring mRNA 
stability, protecting against nuclear and cytoplasmic degradation of transcripts by 5’->3’ 
exonucleases [1, 2].  The binding of the translation factor complex eIF-4F to the 5’ cap 
permits circularisation of pre-mRNAs through the interaction of eIF-4F with poly(A) 
binding protein (Pab1) bound to the 3’ poly(A) tails of pre-mRNAs.  Circularisation of 
transcripts promotes translation and translation reinitiation [3, 4].  In the budding yeast 
Saccharomyces cerevisiae, the capping process involves three enzymatic activities 
carried out by three distinct proteins (see Figure 1.1A) [reviewed in 5]: Firstly, the RNA 
triphosphatase (RT) Cet1 removes the -phosphate from the 5’-terminal nucleotide of 
the transcript [6].  Guanine monophosphate (GMP) is then transferred to the free 5’-end 
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Figure 1.1.  A summary of the 3’-end processing steps. (A) 5’-end capping involves 
phosphorylation of PolII CTD at Ser5 (i).  The -phosphate of the terminal nucleotide is 
removed (ii) followed by transfer of a GMP molecule to the 5’-end (iii), which is 
subsequently methylated (iv). (B) Introns are removed by splicing.  Specific sequences 
in pre-mRNA direct the splicing machinery (i).  The branch point (BP) performs a 
nucleolytic attack on the 5’ splice site (5’ss) (ii), creating a lariat intermediate (iii).  The 
free 3’ hydroxyl of the 5’ exon attacks the 3’ splice site (3’ss) (iii) leading to exon 
ligation and intron release (iv). (C) Nuclear export of mRNAs.  The THO complex is 
recruited to PolII during transcription and loaded onto the nascent pre-mRNA.  
Subsequent Yra1 and Sub2 binding forms TREX (circled black) (i).  Mex67 displaces 
Sub2 from Yra1 and escorts the mRNP to the nuclear pore complex (NPC) (ii). 
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-phosphate by the guanylyltransferase (GT) Ceg1 [7].  Finally, N7 of the guanine base 
is methylated by the RNA 7-methyltransferase (MT) ABD1 [8].  All three proteins are 
recruited to the pre-mRNA by PolII C-terminal domain (PolII CTD), only after 
phosphorylation at Ser5 by the TFIIH subunit Kin28 at the promoter [9, 10].  The 
interaction of capping proteins with PolII stabilises the transcription complex, and Ceg1 
also promotes early transcription elongation [11, 12].   
 
1.1.2. Pre-mRNA splicing 
Mammalian genes typically contain multiple, long non-coding intronic sequences that 
fragment the protein coding sequences into short “exons.”  The precise splicing of pre-
mRNAs is fundamental in ensuring that exons are brought together accurately to create 
correctly encoded gene transcripts.  Alternative splicing of pre-mRNAs allows the 
estimated 20-25,000 genes of the human genome to code for around 100,000 different 
proteins [13, 14].  In contrast, there are only ~6000 annotated protein-coding genes in S. 
cerevisiae and only 5% of these contain introns, with genes that contain multiple introns 
being rarer still [15].  Despite this, around 50% of the steady-state RNA population in 
yeast is derived from intron-containing genes [16, 17].  Splicing is achieved by the 
spliceosome, a large macromolecular machine composed of a core of five small uridine-
rich nuclear ribonucleoproteins (UsnRNPs) that are highly conserved throughout 
eukaryotes, with many other associated proteins also involved (reviewed in [18-21]).  
Spliceosome assembly is directed by the association of UsnRNPs and other protein 
factors with three cis sequence elements: the 5’ splice site (5’ss, consensus GUAUGU), 
branch point (BP, consensus UACUAAC), and 3’ splice site (3’ss, consensus AG) [22-
26].  In yeast, the mature spliceosome is formed in a stepwise fashion, firstly with the 
recruitment of U1 (UsnRNP) to the 5’ss and BP of the nascent pre-mRNA.  A 
conformational change allows U2 recruitment followed by recruitment of the tri-
UsnRNP U4/U5/U6.  Subsequent structural rearrangements generate a catalytically 
competent spliceosome [27].  The splicing reaction consists of two transesterification 
reactions (summarised in Figure 1.1B): Firstly, the 2’ hydroxyl of the branch point 
adenosine performs a nucleolytic attack on the phosphate of the 5’ terminal nucleotide 
at the 5’ss, forming a 2’5’ phosphodiester bond which pushes the intron into a lariat 
intermediate.  The free 3’ hydroxyl of the 5’ exon then attacks the 3’ss forming a second 
phosphodiester bond between the 5’ and 3’ exons, releasing the intron (reviewed in [18-
20, 28]).  Aside from the obvious function of removing non-coding RNA from 
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transcripts, splicing is linked to transcription and other pre-mRNA processing steps, 
providing another level for regulation of gene expression.  The presence of introns in 
both mammalian and yeast genes increases polymerase density and the removal of 
splicing signals and introns results in a reduction of nascent transcription [29].  On 
intron-containing genes, the export factors Yra1 and Sub2 associate with pre-mRNA 
only after splicing has occurred, promoting mRNA export [30, 31].   
 
1.1.3. Pre-mRNA 3’-end processing 
Export, transcript stability and translation efficiency all depend upon the generation of a 
polyadenylate tail (polyadenylation) at the 3’-end of transcripts.  Two enzymatic 
processes are required for 3’-end maturation of transcripts: (1) endonucleolytic cleavage 
in the pre-mRNA 3’-untranslated region (3’-UTR) and (2) polyadenylation. The work 
presented in this thesis focuses on the protein factors involved in pre-mRNA 3’-end 
processing and a detailed account of the mechanisms involved is given in section 1.2.   
 
1.1.4. mRNA export 
Export of the message from the nucleus is often seen as the final step of mRNA 
maturation, although in reality export is dependent upon the packaging of mRNAs into 
mRNA ribonucleoprotein particles (mRNPs) whilst the nascent transcript is still 
undergoing other processing events (reviewed in [32, 33]).  Packaging of mRNPs and 
nuclear export is mediated by a number of different multimeric complexes.  
 
 In S. cerevisiae, the Hpr1, Mft1, Thp2 and Tho2 proteins associate to form the THO 
complex, which is recruited to pre-mRNAs at the site of transcription (see Figure 1.1C).  
The THO complex makes subsequent interactions with Sub2 and Yra1 to form the 
transcription/export complex (TREX) [34, 35]. The interaction of the export factor 
Mex67 with the TREX components Sub2 and Yra1 is mutually exclusive, and it is 
possible Mex67 displaces Sub2 to escort the Yra1-associated mRNP to the nuclear pore 
complex (NPC) for export [36-39]. THO is essential for transcription elongation.  In the 
absence of THO, the nascent RNA is free to hybridise with the non-template DNA 
strand, forming R-loops.  These hinder the next round of transcription elongation by 
stalling the next PolII molecule, and can cause recombination leading to genetic 
instability [40, 41].  
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The TREX-2 complex is another important protein complex that serves as a connection 
between transcription and mRNA export.  The SAGA component of TREX-2 is a 
histone acetylase required for transcription activation, and its association with the other 
TREX-2 components has been shown to relocate and anchor genes being actively 
transcribed to the NPC.  It has also been shown that Mex67 and the NPC can interact to 
facilitate “gene-anchoring” [42-44].  It is currently not known whether the TREX and 
TREX-2 complexes act synergistically or gene-specifically when modulating 
transcription, mRNP formation and nuclear export via gene anchoring at the NPC.  
Two other proteins, Npl3 and Nab2 have also been identified as adaptors for Mex67.  
Nab2 has been shown to interact directly with the NPC component Mlp1 [45-47].  Npl3 
and Nab2 are believed to represent two non-redundant, major mRNA export pathways 
in S. cerevisiae (reviewed in [32]).  Intimate links exist between mRNP formation and 
pre-mRNA 3’-end processing, and some key examples of this are presented in section 
1.6.2.  
 
1.1.5. Timing of processing events 
It is convenient to think of capping, splicing, cleavage/polyadenylation and export as 
temporally distinct processes that are all necessary for mRNA maturation.  In the past 
two decades much evidence has been provided to demonstrate that pre-mRNA 
processing events are temporally coupled with transcription and are therefore 
“cotranscriptional”.  Transcriptional coupling of pre-mRNA processing is often 
facilitated by the “loading” of protein factors responsible for processing onto the C-
terminal domain of PolII prior to and during transcription.  Consequentially, PolII CTD 
is often referred to as a “landing pad” or “assembly platform” for pre-mRNA processing 
machineries (reviewed in [48-53]).  
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1.2. Pre-mRNA 3’-end processing 
 
The body of work undertaken for this PhD thesis concentrates on specific proteins 
belonging to the S. cerevisiae Cleavage Factor IA complex (CFIA), and their 
contributions to pre-mRNA 3’-end processing (hereafter referred to as 3’-end 
processing) and transcription.  As stated previously, generation of mature 3’-ends 
requires two enzymatic activities: (1) endonucleolytic cleavage of pre-mRNA in the 3’-
UTR, and (2) polyadenylation. 
 
For gene transcripts, possession of a polyadenylate (poly(A)) tail is imperative for a 
number of reasons. The poly(A) tail serves to recruit protein complexes that assist in 
export of mRNA to the cytoplasm.  The link between 3’-end processing and export of 
mRNA is described further in section 1.6.  Once in the cytoplasm, there is an implicit 
requirement for mRNA to be protected from degradation.  In S. cerevisiae, the major 
mRNA degradation pathways are first dependent on the deadenylation of the poly(A) 
tail (reviewed in [54, 55]).  With this in mind, it serves well to use both a 5’ cap and a 
long poly(A) tail as a buffer to protect the genetic code within the transcript.  The 
poly(A) tail and factors that associate with it have also been shown to be required for 
efficient translation [3, 4, 56].  Finally, the cleavage and polyadenylation machinery is 
intimately linked with transcription, the implications of which are considered in section 
1.7. 
 
Cleavage and polyadenylation is facilitated by the highly-coordinated interaction of two 
multi-subunit protein complexes with an array of loosely conserved cis sequence 
elements in the 3’-UTRs of pre-mRNAs (reviewed in [57-61]).  Sections 1.2.1. to 1.4.2. 
comprise a comprehensive account of the composition and function of the sequence 
elements and protein complexes necessary for 3’-end formation in S. cerevisiae.  A 
model for S. cerevisiae pre-mRNA 3’-end processing is outlined in section 1.5 and 
Figure 1.8B. 
 
1.2.1. Sequence elements for mRNA 3’-end formation 
Several sequence elements required for cleavage/polyadenylation were initially 
identified in mammalian mRNAs.  These sequences were found to show a degree of 
conservation throughout mammalian gene transcripts, exemplified by the highly-
conserved hexanucleotide AAUAAA, termed the polyadenylation signal [62].  It took 
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significantly longer to find equivalent sequences in yeast mRNAs, due to a high amount 
of degeneracy and redundancy in yeast 3’-end forming sequence elements [58, 60]. 
The mechanism of 3’-end formation in S. cerevisiae was elucidated by the discovery 
that whole-cell yeast extract was able to cleave iso-1-cytochrome c (CYC1) pre-mRNA 
at a specific site, and add a poly(A) tail of 60-80 adenylate residues [63, 64].  
Previously, it had been found that a 38 bp deletion in the 3’-UTR of the CYC1 gene 
(cyc1-512) had a negative effect on CYC1 mRNA stability and translational efficiency 
[65].  The subsequent analysis of eight revertant mutants of cyc1-512 led to the 
identification of three separate sequence elements required for efficient 3’-end 
processing: (1) A positioning element (PE); (2) an efficiency element (EE) and (3) the 
cleavage/poly(A) site [66, 67].   
 
The PE is located 10-30 nt upstream of the cleavage/poly(A) site and functions to 
determine the physical location of cleavage and polyadenylation rather than influence 
how efficiently the mRNA is processed [67, 68].  Initially the sequences AAGAA and 
UAAGAAC were identified as PEs in CYC1 mRNA, although saturation mutagenesis 
of these elements revealed that AAUAAA and AAAAAA are optimal sequences [68].  
Indeed, there is a high amount of degeneracy in sequences that can form effective PEs 
and the range of effects observed when the PE is deleted is wide.  For instance, in CYC1 
deletion of the PE shifts the major cleavage/poly(A) site to a weaker downstream site 
[66, 67].  On the other hand, deletion of the PE in the GAL7 gene abolishes cleavage 
and polyadenylation.  This is likely to be because GAL7 contains no redundant PEs 
[69]. 
 
The EE is found at variable distances upstream of the PE and functions to enhance the 
use of the preferred sites located downstream, thereby modulating the efficiency of 3’-
end processing.  The EE sequences UAUAUA, UACAUA and the bipartite 
UAG…UAUGUA were initially identified in cyc1-512 revertant mutants [66, 67].  The 
bipartite UAG…UAUGUA has also been found in TRP1, ARO4 and TRP4 genes and 
the UAUAUA in both GAL7 and MRP2 genes [69-71].  Another sequence element, 
UUUUUAUA, has been identified as an EE in CYC1, GCN4, PHO5 and ADH1 genes 
[70, 72, 73].  These sequences point to an AU-rich preference for EEs in yeast genes, 
allowing a certain amount of degeneracy in the exact sequence.  A consensus sequence 
for the EE was determined from studies of the plant poly(A) sequence UAGUAUGUA 
found embedded in a cauliflower mosaic virus (CaMV) sequence.  This sequence was 
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also able to direct 3’-end processing in yeast.  Mutation of this sequence reduced the 
efficiency of 3’-end formation to 15% of wildtype levels [74] and saturation 
mutagenesis of this sequence revealed UAUAUA produced the most effective EE [75].  
A subsequent computer analysis of 1017 nuclear genes with known 3’-UTRs found that 
the TATATA hexanucleotide was present in the 3’-UTRs of 52% of these genes [72]. 
 
The cleavage/poly(A) site marks the location at which the pre-mRNA is physically 
cleaved, generating a free 3’ hydroxyl group to which poly(A) polymerase 1 (Pap1) 
adds a 60-80 nt poly(A) tail.  The cleavage/poly(A) site is a short sequence element 
consisting of a pyrimidine nucleotide followed by multiple adenosines (Py(A)N).  It is 
cleaved 3’ of an adenosine and the PE tightly controls its location [76, 77]. 
 
More recently, a fourth uridine-rich yeast poly(A) signal has been uncovered.  The 
existence of uridine-spanning sequences immediately flanking the cleavage/poly(A) site 
was revealed by comparison of 1352 expressed sequence tags (ESTs) to genomic 
sequences [78-80].  Remarkably, an in vitro assay showed that these U-rich sequences 
were capable of directing cleavage of short CYC1 and ADH1 substrates in the absence 
of both the EE and PE.  Furthermore, mutation of the U-rich elements reduced cleavage 
activity [81]. 
 
The history of poly(A) signal definition illustrates the redundancy and degeneracy in 
many of the sequence elements involved.  It is consequently difficult to hypothesise one 
model encompassing the function of each type of sequence element.  Instead, it is 
highly likely that sequence elements are utilised in a gene-specific manner: All 
sequence elements on a transcript used in concert would ensure efficient 3’-end 
processing of mRNA, or selective use of sequence elements could be a method by 
which to finely-tune gene expression. 
 
1.2.2. Protein factors for pre-mRNA 3’-end processing 
Definition of the factors required for 3’-end processing began with the demonstration 
that S. cerevisiae cell extract could generate mature 3’-ends on CYC1 pre-mRNA in an 
in vitro assay [63, 64].  Individual protein complexes responsible for the two enzymatic 
steps of 3’-end formation were later characterised by separating them from cell extract 
using ammonium sulphate fractionation and ion exchange chromatography: four 
separate fractions contained cleavage factor I (CFI), cleavage factor II (CFII), 
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polyadenylation factor I (PFI) and poly(A) polymerase (Pap1) respectively [82-84].  
Reconstitution of the cleavage reaction in vitro was shown to require CFI and CFII, 
whereas polyadenylation was facilitated by the combination of CFI, PFI and Pap1.  
Interestingly, cleavage of GAL7 and CYC1 pre-mRNA was dependent on the presence 
of their EE sequences, uncovering for the first time sequence specific protein-RNA 
interactions in the 3’-end processing machinery [82].  It has since been recognised that 
CFII, PFI and Pap1 together with an array of other proteins, form a larger complex 
termed the cleavage and polyadenylation factor (CPF) [85, 86].  The subunit 
compositions and important protein-protein and protein-RNA interactions made by CFI 
and CPF will be discussed in sections 1.3. and 1.4. respectively.  
 
1.3. Cleavage factor I (CFI) 
 
The first separation of 3’-end processing complexes identified CFI as essential for 
reconstitution of both cleavage and polyadenylation.  Further purification of CFI from 
cell extract led to the discrimination of two different components, CFIA and CFIB, both 
of which were essential for cleavage and polyadenylation of GAL7 pre-mRNA [87].  A 
variety of genetic and biochemical approaches were used to illuminate the identities of 
the CFIA and CFIB subunits.  CFIA was shown to contain four subunits, Rna14, Rna15, 
Pcf11 and Clp1, whereas CFIB is a single protein, Hrp1 [88-91].  The stoichiometry of 
CFIA subunits has since been determined as 2:2:1:1 (Rna14:Rna15:Pcf11:Clp1) [92].  
several studies have looked at the importance of CFIA and CFIB subunits to pre-mRNA 
3’-end processing.  The key findings for each subunit are detailed in the following 
sections (1.3.1-1.3.5). 
 
1.3.1. Rna14 (CFIA) 
Rna14 was first identified as a 3’-end processing factor from a genetic screen in which 
the temperature sensitive rna14-1 allele was combined with a temperature sensitive 
allele of Pap1.  The combination of these two temperature sensitive alleles caused a 
synergistic, lethal phenotype indicative of a physical or functional interaction between 
these two proteins [93, 94].  Furthermore, whole-cell extract from yeast bearing the 
rna14-1 allele was unable to both cleave and polyadenylate pre-mRNA in vitro.  
Biochemical complementation of rna14-1 with partially purified CFI restored the ability 
of the extracts to cleave and polyadenylate the GAL7 precursor, thus confirming the role 
of Rna14 in pre-mRNA 3’-end formation [88].  Later attempts to unmask the CFIA 
subunits resulted in the isolation of Rna14 from yeast whole-cell extract, showing it to 
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be a 76 kDa protein [87].  Secondary structure analysis of the Rna14 protein coding 
sequence demonstrated the bulk of the protein is made up of half-TPR (HAT) repeats 
[95].  HAT repeats are formed by three hydrophobic residues with conserved spacing 
and may form similar super-helical structures to those observed in HEAT repeats [96].  
It has been postulated these structures could provide interaction surfaces for other 
proteins.  Furthermore, other HAT-containing proteins have been identified as mRNA 
processing factors [95]. 
 
There is strong evidence to show that Rna14 interacts with other 3’-end processing 
factors.  Firstly, Rna14 was shown to coimmunoprecipitate (coIP) with Rna15 [87]. 
This interaction was later characterised by electron microscopy and analytical ultra-
centrifugation (AUC), revealing a stable heterotetramer of two Rna14 and two Rna15 
molecules, dependent upon the Rna14-mediated association of two Rna14-Rna15 
heterodimers [97].  Recently, the solution structure of the Rna14-Rna15 interface was 
solved by nuclear magnetic resonance (NMR).  The structure showed Rna14 bound 
Rna15 using a “monkeytail” domain located between C-terminal residues 626-677.  The 
Rna14 monkeytail domain binds to Rna15 by wrapping around a core of four alpha 
helices, with N- and C-terminal helices from Rna15 stabilising the interaction [98].  A 
direct Rna14-Pcf11 interaction was also confirmed by glutathione-S-transferase (GST) 
pulldown experiments, even in the absence of other CFIA subunits [99].  Rna14 has 
also been identified as the bridge between CFIA and CFIB (Hrp1) based on the 
observation of synthetic lethality in vivo when double mutants of hrp1/rna14 or 
hrp1/rna15 were made [91].  Following on from this finding, an in vitro pulldown 
experiment using recombinant CFIA components and Hrp1 showed that only Rna14 
bound to Hrp1 [99].   
 
Large-scale analyses of protein-protein interactions has been made possible in yeast by 
tandem affinity purification (TAP), where one protein is “TAP-tagged” and purified in 
combination with its binding partners and other proteins in an associated complex.  This 
approach is often used to isolate whole macro-molecular protein complexes, whose 
subunits can be identified by protein sequencing or mass spectrometry [100, 101].  
When CPF subunits were TAP-tagged, a weak interaction between CPF and Rna14 was 
identified, demonstrating communication between 3’-end processing complexes [102].  
This was consistent with earlier findings from a variety of affinity capture experiments 
which revealed that Cft1, Fip1, Pti1 and Pfs2 subunits of CPF all directly interact with 
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Rna14 [86, 103-105].  Yeast two-hybrid analysis and an in vitro pull down assay 
showed Rna14 also binds to the C-terminal domain of PolII (CTD) when PolII CTD is 
phosphorylated [106].  In contrast to the Pcf11-CTD interaction (discussed in section 
1.7.1.), the significance of the Rna14-PolII interaction is still unclear.  
 
Aside from its function as an essential pre-mRNA processing factor in the nucleus, 
Rna14 has also been discovered localised in the mitochondria. Further to this, the rna-
14-1 mutant (which does not cleave or polyadenylate pre-mRNA) displays no defects in 
mitochondrial function, suggesting Rna14 might have a distinct, but redundant function 
in mitochondrial metabolism [107, 108]. 
 
Despite having an array of interaction partners, no specific activity (enzymatic, RNA-
binding etc.) has been suggested for Rna14.  Instead, evidence points towards Rna14 as 
an architectural component of CFIA that bridges Rna15 and Hrp1, both of which bind 
to pre-mRNA (see sections 1.3.2 and 1.3.5.).  Indeed, it has been shown in vitro that 
Rna14 increases the affinity of both Rna15 and Hrp1 for pre-mRNA [109].  
 
1.3.2. Rna15 (CFIA) 
The importance of Rna15 in pre-mRNA 3’-end processing was unveiled in parallel with 
Rna14 by exploiting the rna15-1 temperature sensitive allele using the same genetic and 
biochemical approaches that were used with Rna14 [88, 93, 94].  Rna15 was first 
isolated from yeast extract, revealing it to be a 38 kDa protein that was essential for 
reconstitution of both cleavage and polyadenylation reactions in vitro [88].  Sequence 
homology and secondary structure analysis show Rna15 contains an N-terminal RNA-
recognition motif (RRM) together with an essential CTD. 
 
Rna15 is essential for pre-mRNA 3’-end maturation because it is the RNA-binding 
component of CFIA, and the position to which it binds to pre-mRNA indirectly defines 
where the transcript will be cleaved and polyadenylated.  The RNA-binding capability 
of Rna15 was first confirmed in an in vitro assay, when irradiation with UV light cross-
linked Rna15, but not other CF1 subunits, to a radiolabelled GAL7 RNA substrate [87].  
Many experiments following on from this finding endeavoured to determine the 
specificity of Rna15 for pre-mRNA sequence elements, and whether other CFI 
components are necessary for recognition of pre-mRNA by Rna15.  Initially, a 
preference for uridine-rich sequences was suggested, when in vitro translated Rna15 
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was pulled-down by poly(U)-agarose, but not poly(A/C/G)-agaroses.  This did not 
require the presence of any other CFI components [110].  In contrast, subsequent UV 
cross-linking experiments demonstrated that recombinant Rna15 bound to a GAL7 
precursor non-specifically.  However, when combined with Rna14 and Hrp1, Rna15 
was UV cross-linked specifically to the A-rich GAL7 PE, inferring that only in a stable 
Rna15-Rna14-Hrp1 complex could the specificity of Rna15 for certain RNA sequences 
be conferred [111].  One study that expanded on this discovery used surface plasmon 
resonance and gel retardation experiments to characterise the Rna14-Rna15-RNA 
interaction.  These fresh approaches enabled lower protein:RNA concentrations to be 
used than in UV cross-linking or affinity-capture experiments, helping to lower the 
possibility of non-specific protein-RNA binding.  This showed that an Rna14-Rna15 
complex interacted strongly with a GAL7 3’-UTR-derived oligonucleotide, but Rna15 
alone did not interact.  This highlighted the necessity of at least Rna14 as a binding 
partner to promote the Rna15-RNA interaction [97].   
 
Perhaps the most robust evidence to date for Rna15-RNA sequence specificity was 
provided from three crystal structures of the Rna15 RRM [112].  The structure of the 
Rna15 RRM alone, together with two structures of Rna15-RNA complexes revealed a 
conserved mechanism for recognition of GU-rich RNAs.  The structures demonstrate 
that the Rna15 RRM comprises a canonical RRM fold (1-1-2-3-2-4-5) that 
binds to a GUUGU penta-ribonucleotide through two nucleotide-binding sites termed 
Site-I and Site-II (see Figure 1.2A).  Specifically, residues located in Site-I of the RRM 
make important base-stacking interactions with guanine or uracil bases, with additional 
hydrogen bonding stabilising the interaction (see Figure 1.2B and legend).  Crucially, 
functional groups on the edges of the U and G bases form Watson-Crick-like hydrogen 
bonds with the backbone of Site-I residues.  These interactions would not be possible 
with A or C bases in the orientation observed in the crystal structure, signifying Site-I 
discriminates against A and C bases in favour of interactions with U or G bases.  The 
base-discrimination mechanism was supported by measurement of the binding affinities 
of the Rna15 RRM for ribo-oligonucleotides of different base compositions.  In these 
experiments, the RRM showed a clear preference for GU-rich or U-rich RNA-oligos 
over RNA-oligos containing C or A bases.  The crystal structures also revealed that a 
second site (Site-II) is important for RNA binding, although this site is probably not for 
base-discrimination.  Instead, the aromatic side chain of Tyr21 in the Site-II pocket 
makes stacking interactions with the bases of a GU di-ribonucleotide.  Furthermore, 
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Figure 1.2. Structure of the Rna15 RRM and Site-I base-binding pocket.  (A) The 
Rna15 RRM (cartoon representation) adopts a 1-1-2-3-2-4-5 topology 
(secondary structure elements are labelled).  The guanine base (yellow sticks) is bound 
within a base-binding site located on the loop connecting 1 and 1. (B) Site-I 
interactions with the guanine base.  The guanine base (yellow sticks) is stacked between 
the side chains of Tyr27 and Arg87.  The conformation of the base-binding pocket is 
maintained by hydrogen bonding (dashed black lines) between the side chain of Arg87 
and both the main carbonyl and side chain hydroxyl of Ser24.  Binding is further 
stabilised by hydrogen bonds between functional groups on the edges of the guanine 
base and the main chains of Tyr27 and Ile25.  The Rna15 RRM is depicted as a cartoon 
with semi-transparent surface representation.  Important residues are illustrated (shown 
in stick representation and labelled).  PDB codes: 2X1A, 2X1B, 2X1F. 
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site-directed mutagenesis of key residues in both Site-I and Site-II reduced RNA 
binding drastically, confirming the importance of these nucleotide-binding sites in RNA 
recognition [112].  The authors also draw attention to the abundance of U-rich 
sequences flanking the cleavage/poly(A) site throughout the yeast genome [78-80, 112].  
They liken this to previous findings that the mammalian homologue of Rna15, CstF64, 
also displays a preference for GU-rich sequences that surround the poly(A) signals of 
mammalian genes [113].  Alignment of the CstF64 RRM and Rna15 RRM structures 
demonstrates strong sequence and structure conservation of Sites-I and II, confirming 
that the mechanism of nucleobase-discrimination is also conserved.  The conservation 
of a mechanism conferring GU specificity taken with the prevalence of U-rich 
sequences flanking yeast cleavage/poly(A) signals makes it highly likely that it is the U-
rich elements that are the preferred Rna15 target sequences [112]. 
 
There is a wealth of evidence to suggest that the specificity of the Rna15-RNA 
interaction is dependent on Rna15 incorporation into CFIA [97, 111].  Rna15 residues 
127-232 contain a core of four -helices that comprise the Rna14 interaction domain 
(described in section 1.3.1) [98].  It was previously shown that Rna14-Rna15 complexes 
formed A2B2 heterotetramers, in which the association of individual Rna14-Rna15 
heterodimers was mediated by the homodimerisation of two Rna14 molecules [97, 98].  
It recently came to light that the stoichiometry of Rna14-Rna15 complexes is important 
for correct pre-mRNA 3’-end formation.  Mutation of the Rna14 dimerisation domain 
prevented the formation of Rna14-Rna15 heterotetramers in vitro.  Yeast extract from a 
strain bearing the same mutation (rna14ES), showed reduced cleavage and 
polyadenylation of a pre-mRNA substrate, signifying that for full 3’-end processing 
function two copies of Rna15 are required [92].  Rna15 also binds to Pcf11 within CFIA 
[87].  The Pcf11 binding site has been mapped to the conserved Rna15 CTD by in vitro 
pulldown assays. Truncation of Rna15, or mutation of Rna15 CTD residues abolished 
the Rna15-Pcf11 interaction and deletion of the Rna15 CTD caused a restrictive-growth 
phenotype in yeast (rna15-t8 temperature sensitive mutant).  The rna15-t8 mutant 
displayed a marked reduction in cleavage and polyadenylation, but chromatin-
immunoprecipitation analysis (ChIP) revealed there was no defect in transcription 
termination [114].  This points to a requirement for the Rna15-Pcf11 interaction in 
efficient pre-mRNA 3’-end processing but not for transcription termination. 
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There have also been reports of other important binding partners for Rna15 outside the 
CFIA complex.  Rna15 may be important in crosstalk between 3’-processing and 
transcription by facilitating gene looping.  These findings will be discussed in greater 
detail in section 1.7.2. 
 
1.3.3. Pcf11 (CFIA) 
Initial separation of CFI components revealed five proteins, two of which had been 
previously determined to be Rna14 and Rna15 [87, 88].  Yeast two-hybrid screens in 
which either Rna14 or Rna15 were used as bait, identified genetic interactions with a 70 
kDa CFI subunit, subsequently termed Pcf11 [89].  Analysis of the Pcf11 protein 
sequence reveals a central stretch of 20 glutamines, and two zinc finger motifs located 
in the CTD.  The N-terminal 140 amino acids of Pcf11 comprise a highly-conserved 
domain that interacts with PolII CTD, termed the CTD-interacting domain (CID) [115].  
The membership of Pcf11 in CFIA was confirmed in the same study by an in vivo 
experiment showing an epitope-tagged version of Pcf11 could copurify with Rna14 and 
Rna15.  The importance of Pcf11 to pre-mRNA 3’-end processing became immediately 
apparent when yeast extract derived from the pcf11-1 or pcf11-2 temperature sensitive 
mutants was unable to correctly cleave or polyadenylate mRNA precursors [89]. 
 
Purification of recombinant CFI factors enabled affinity-capture experiments designed 
to elucidate the protein-protein interactions within CFI.  These experiments revealed 
that Pcf11 interacts with all of the other CFIA subunits, but not Hrp1 (CFIB) [99].  A 
domain map of Pcf11 is shown in Figure 1.3A.  The Pcf11-Rna14/ Rna15 interaction 
domain was mapped by two-hybrid analysis (using various length fragments of Pcf11) 
to residues 288-400 [89].  More detailed information on the Pcf11-Rna14 and Pcf11-
Rna15 interactions can be found in sections 1.3.1. and 1.3.2.  Details of the Pcf11-Clp1 
interaction have been provided by a crystal structure of a Clp1-Pcf11-ATP complex 
[116].  The remarkable conservation of key residues in the Pcf11-Clp1 interaction 
domain (ID) is portrayed along with the structure of the binding interface in Figure 1.4.  
Residues 475-499 of Pcf11 constitute the Clp1-ID, and form an extended conformation 
that is entirely bound to Clp1 within a cleft between the Clp1 central domain (CD) and 
CTD, and a shallow groove in the CD.  A surface representation of the crystal structure 
shows that the Pcf11 fragment is intimately associated with Clp1 (Fig 1.4A). The 
Pcf11-Clp1 interface is maintained largely by hydrogen bonding of the side and main 
chains of Pcf11 residues to Clp1 residues located on the 10-11 loop that lines one 
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Figure 1.3. Pcf11 contains binding sites for other pre-mRNA 3’-end processing factors.  
(A) Domain map of Pcf11.  Interaction domains are displayed in different colours and 
labelled with residue numbers cited above the map.  The two blue areas indicate 
conserved zinc finger motifs.  The light green area within the dashed grey lines contains 
residues 475-499 which signifies the known Clp1 interaction domain.  Q20 indicates the 
polyglutamine tract.  Grey areas show where no function has been inferred. (B) 
Sequence alignment of the Pcf11 CID.  The strength of residue conservation is 
highlighted in shades of blue (dark blue most conserved).  Secondary structure elements 
are marked above the alignment in green, yellow dots indicate residues that interact 
with PolII CTD in the CID-CTD crystal structure, orange dots indicate additional 
residues that display NMR chemical shift patterns on CTD binding.  Species names can 
be found with their abbreviations in Appendix 8.1. 
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side of the CD-CTD cleft.  Three highly-conserved residues in Pcf11 (Arg480, Trp482 
and Trp489) are particularly important for complex formation (see Fig 1.4B).  The side 
chain of Arg480 makes contacts with Ser192 and Gln191 on the 10-11 loop, and also 
Tyr332 and Glu331 located on 7.  The edge of the Clp1 CD-CTD cleft contains a 
small hydrophobic cavity in which the aromatic side chain of Trp482 is buried, making 
solely hydrophobic contacts with the aliphatic side chains of Leu406, Pro426 and 
Val427.  The short -helix of the Pcf11 fragment contains Trp489, which extends into a 
pocket on the surface of the Clp1 central domain, making hydrogen bonds with Gln204 
and Arg236 and hydrophobic contacts with Met206 and Arg236.  Compellingly, a 
sequence alignment reveals that Arg480, Trp482 and Trp489, are absolutely conserved 
in other yeast, mammals, birds, amphibians, fish and invertebrates (Figure 1.4C). The 
function of the Pcf11-Clp1 interaction remains obscure, yet the extensive bonding 
networks of these three Pcf11 residues combined with their strong conservation 
suggests that the Pcf11-Clp1 interaction serves an important purpose, and is likely to be 
essential [116]. Like Rna14, Pcf11 bridges CFIA and CPF complexes through multiple 
connections with CPF subunits. This was demonstrated in an in vitro affinity-capture 
experiment employing four core subunits of CPF, GST-tagged Cft1, Cft2, Ysh1 and 
Pta1, that all bound to in vitro translated Pcf11 [103].  
 
As previously discussed, Pcf11 is essential for correct 3’-end formation of mRNA 
transcripts.  However, Pcf11 has also been implicated as an essential factor in mRNA 
export, transcription termination and more recently transcription initiation.  The multi-
functional nature of Pcf11 has sparked a rich vein of research into how different stages 
of gene expression are tightly coupled and the key findings portraying the centrality of 
Pcf11 in gene expression will be elaborated further in sections 1.6 and 1.7. 
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Figure 1.4. The Pcf11-Clp1 interaction.  (A) Surface representation of the Pcf11-Clp1 
heterodimer shows that Pcf11 (cyan) moulds tightly into a cleft between the Clp1 
central domain (CD, green) and C-terminal domain (CTD, grey), and extends into a 
groove in the CD.  The N-terminal domain (NTD) is shown in red.  (B) The Pcf11-Clp1 
interface contains three highly-conserved Pcf11 residues: Arg480, Trp482 and Trp489.  
The side chains of these residues are oriented into pockets within the Clp1 CD-CTD 
cleft and the groove within the CD.  Pcf11 is shown as a cyan cartoon with residues 
labelled and side chains shown in stick representation.  Clp1 is portrayed in surface 
representation with domain colouring as in (A). (C) Sequence alignment of the Pcf11-
Clp1 ID.  Residues totally conserved with S. cerevisiae are coloured blue, residues 
conserved in most species are coloured orange.  The green cylinder indicates an -helix.  
Species names and their abbreviations can be found in Appendix 8.1.  PDB code: 2NPI. 
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1.3.4. Clp1 (CFIA) 
With various properties of Rna14, Rna15 and Pcf11 already assigned, the 50 kDa CFIA 
subunit remained unidentified.  One study used a range of genetic and biochemical 
techniques to address this issue.  A vector containing a His-tagged RNA15 gene was 
introduced into a yeast strain containing a lethal rna15 deletion, and CFIA components 
were then copurified from yeast extract with His-Rna15 using a variety of 
chromatographic techniques.  Peptide microsequencing of the 50 kDa subunit allowed 
subsequent cloning of the gene open reading frame (ORF), designated CLP1 for 
cleavage/polyadenylation factor IA subunit [90].  In an in vitro assay using individual 
recombinant CFIA factors combined with extract-purified CPF, CYC1 pre-mRNA was 
only cleaved and polyadenylated when Clp1 was present, indicating it is obligatory for 
3’-end processing [99].  Further pull-down experiments using recombinant Clp1 
attached to beads with Clp1 antiserum revealed that within CFIA, Clp1 only interacts 
with Pcf11 and that the Clp1-Pcf11 interaction was obligatory for capture of Rna14 and 
Rna15 by Pcf11.  This suggests that Clp1 is mandatory for CFIA formation [99].  A 
study investigating the interaction partners of core CPF subunits revealed Clp1 also 
interacts strongly with Ysh1, and displays a weaker affinity for Cft1 [103].  The Clp1-
Ysh1 interaction is extremely interesting, since Ysh1 is suspected to provide the 
endonuclease activity that cleaves pre-mRNA (see section 1.4.1). 
 
Sequence analysis of the Clp1 human homologue (hClp1) uncovered a Walker A motif, 
which was shown to be highly-conserved in other eukaryotic Clp1 homologues 
including S. cerevisiae [117].  A multi-species sequence alignment of Clp1 can be found 
in Appendix 8.1.  Walker A motifs are typically found in P-loop NTPase proteins and 
are required for nucleotide-binding.  The motif is composed of a flexible loop between 
an -helix and a -strand, which contains the consensus sequence GxxxxGKT/S and 
binds the triphosphate moiety of a nucleotide [118].  
 
The crystal structure of a nucleotide-bound Clp1-Pcf11 complex provided a detailed 
view of the nucleotide-binding site, and raised questions as to the function of the bound 
nucleotide and Clp1 in general [116].  The structure reveals Clp1 is composed of a large 
central domain (CD), flanked by two smaller N- and C-terminal domains (Figure 1.5A).  
The Clp1 CD comprises both  and  secondary structure elements, and is responsible 
for nucleotide-binding.  It is a member of the SIMIBI class of NTPases, containing the 
characteristic features which are: (1) a P-loop/Walker A motif (herein referred to as P-
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Figure 1.5.  Crystal structure of the Clp1-Pcf11-ATP complex.  (A) Clp1 is composed 
of a large CD (green cartoon) flanked by a smaller NTD (red cartoon) and CTD (grey 
cartoon).  The CD contains a nucleotide-binding pocket within which an ATP molecule 
is bound (stick representation, yellow base) and a magnesium ion is present (purple 
sphere).  A small fragment of Pcf11 comprising residues 475-499 (cyan cartoon) is 
bound to the opposite face of Clp1 from the ATP-binding pocket.  (B) Clp1 NTD 
(shown here as a transparent red cartoon), is a seven-stranded -sandwich that packs 
tightly against the CD rendering the ATP-binding pocket inaccessible.  The colour 
scheme is as in (A). (C) Sequence alignments of the Clp1 P-loop, Switch I and Switch 
II motifs.  Residue conservation is illustrated by blue shading (dark blue most 
conserved).  Secondary structure elements are marked above the sequence.  Residues 
that constitute the motifs are underlined in red and labelled.  Species names and 
abbreviations can be found in Appendix 8.1.  PDB code: 2NPI. 
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loop) containing a third glycine (consensus GxxGxGKT/S); (2) an aspartate responsible 
for magnesium ion coordination termed “Switch I”; (3) a second aspartate, “Switch II”, 
which makes interactions required for structural stability of the nucleotide-binding 
pocket [119].  These three motifs are brought together to form the majority of the 
nucleotide-binding pocket of Clp1.  Close inspection of the P-loop (Figure 1.6A) shows 
the -phosphate of ATP is hydrogen bonded only to the main and side-chains of 
Ser138.  The -phosphate is hydrogen bonded to the main and side-chains of Thr137, 
and also contacts the main-chains of Thr134, Gly135 and Lys136.  The -phosphate 
makes hydrogen bonds with the side-chains of Gln133 and Lys136, as well as a contact 
outside the P-loop with the -amino group of the Lys321 side chain located in the CD.  
The Clp1 P-loop therefore behaves in a classic manner, positioning the phosphate 
moiety of ATP.   
 
Outside the P-loop, there is a hydrogen bond between the 2’OH of the ribose and Lys72 
in the Clp1 N-terminal domain (NTD).  The -amino group of Lys72 also contacts the 
main-chain of Ala315, which helps maintain a close proximity between the adenine 
base and the base-binding loop (residues 308-312).  This allows the main-chains of the 
base-binding loop residues to make Van der Waals interactions with the adenine base.  
The base is also bound by Asp33 in the NTD, in a manner that is suggestive of 
specificity for an adenine base:  The exocyclic N6 amino group of the adenine base is 
contacted by the side-chain of Asp33, whereas the O6 carbonyl oxygen of a guanine 
base in the same position would not be able to form a hydrogen bond [116].  A 
summary map of the interactions between Clp1 residues and ATP is presented in Figure 
1.6B. 
 
Switch I and Switch II are located adjacent to each other and opposite the P-loop, 
enclosing the triphosphate moiety of ATP.  The P-loop and Switch regions of Clp1 
adopt a similar conformation to those observed in the nucleotide-binding site of the 
NifH iron protein of the Azobacter vinelandii nitrogenase.  In NifH, the Switch regions 
contain residues that effect nucleotide hydrolysis.  Instead of interacting directly with 
the bound nucleotide, they coordinate a Mg2+ ion via a network of three equatorially 
positioned water molecules, forming an octahedral geometry of magnesium 
coordination [120].  The Clp1 structure shows Mg2+ ion coordination is similar to that 
of NifH, although in Clp1 only one water molecule is present, possibly due to lack of 
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Figure 1.6. Structure of the Clp1 ATP-binding pocket.  (A) Structural depiction of 
residues that interact with ATP.  ATP is shown as sticks with the base in cyan and the 
phosphates in orange.  The main and side-chains of amino acids involved in ATP-
binding are displayed as sticks:  P-loop residues are shown in yellow, Switch II residues 
in pink, CD residues in green and NTD residues in red.  Non-P-loop residues are 
labelled and hydrogen bonds are marked by dashed black lines.  (B) Summary of Clp1 
residues that interact with ATP.  Residues are labelled, hydrogen bonds are marked by 
dashed black lines and Van der Vaals interactions are marked by dashed red lines. (C) 
Structural depiction of magnesium ion coordination.  The magnesium ion is shown as a 
blue sphere and water molecule as a purple sphere.  Coordination of the water molecule 
and magnesium ion is marked by dashed black lines.  Clp1 is in cartoon representation 
with the side-chains of important residues depicted as sticks.  The colour scheme is as in 
(A), with Switch I shown in grey.  (D) A summary of magnesium ion coordination.  
Coordinating residues/molecules are labelled and coordination is shown by dashed 
black lines. 
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resolution in the structure (Figure 1.6C).   The Mg2+ ion is coordinated by the side-chain 
of Thr137, both  and -phosphates of ATP and a water molecule.  The water molecule 
is positioned by the ATP -phosphate and the side-chain of Switch I Gln164 (Figure 
1.6C, D).  Importantly, there is a hydrogen bond between the side-chains of Switch II 
Asp251 and P-loop Thr137.  This interaction is conserved amongst other ATPases and 
GTPases and acts to bolster the P-loop to Switch II, which is probably crucial for the 
stability of the nucleotide-binding pocket [116].  
 
The crystal structure of Clp1 also reveals that the NTD consists of a seven-stranded -
sandwich, which packs tightly against the CD through interactions between a conserved 
loop separating 3-4 (NTD) and 2 (CD).  Figure 1.5B shows this packing completely 
masks the ATP-binding pocket, meaning a conformational change would be required in 
order to access it.  The CTD contains a mixture of  and  secondary structure, and 
contains a conserved region in the loop separating 20-21.  This loop forms part of the 
border with the CD and encompasses the hydrophobic cleft in which the Pcf11 peptide 
(475-499) is bound (the Pcf11-Clp1 interaction is discussed in section 1.3.3.) [116]. 
 
In the same study from which the crystal structure of Clp1 was provided, it was 
demonstrated that the sole species of nucleotide that could be extracted from Clp1 
(expressed and purified from Escherichia coli) is ATP.  This indicates that ATP bound 
by Clp1 is stable to hydrolysis.  At the time, the authors postulated that the interaction 
of another protein partner may be required to induce a conformational change in Clp1 to 
permit ATP hydrolysis [116].  To date, no evidence has been provided to support this 
theory.  Two recent publications have posited that Clp1 does not turn over ATP, but 
instead ATP can be differentially oriented within the ATP-binding pocket [121, 122].  
In this scenario, the orientation of ATP dictates whether Clp1 can interact with Pcf11, 
which in turn has downstream effects on communication between 3’-end processing 
machineries and PolII [121].  However, the required structural evidence to validate this 
mechanism has also not yet been provided. 
 
1.3.5. Hrp1 (CFIB) 
Hrp1 was originally identified in a genetic screen that showed a mutant hrp1-1 allele 
acted as an extragenic suppressor of the npl3-1 temperature sensitive allele (NPL3 
encodes Npl3, an mRNA export factor).  The HRP1 gene was subsequently cloned and 
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sequence analysis revealed a single domain protein containing two RRMs between 
residues 160-290.  These RRMs shared significant sequence similarity with the human 
hnRNPs A1, A2/B1 and C1 [123].  At around the same time as the HRP1 gene was 
identified, the study in which the individual subunits of CFI were purified revealed a 73 
kDa protein as the only constituent of CFIB [87].  The 73 kDa CFIB protein was 
subjected to a tryptic digest, and the protein sequences of two resulting peptides were 
perfectly matched to the Hrp1 protein sequence [91].  Hrp1 was found to be vital for 
cleavage and polyadenylation of GAL7 pre-mRNA in vitro, and poly(A) tails isolated 
from the hrp1-5 temperature sensitive yeast strain were found to be abnormally short, 
reinforcing the fact that hrp1-5 is required for proper polyadenylation [91]. 
 
Hrp1 is bridged to the rest of CFI via its interaction with Rna14 (see section 1.3.1).  A 
genetic interaction between Hrp1 and Rna15 was observed by both synergistic lethality 
between hrp1-6/rna15-1 and hrp1-8/rna15-1 double mutants, and by a yeast two-hybrid 
approach [91].  However, in vitro pull-down experiments using recombinant proteins 
contradicted the genetic approaches by suggesting these proteins are not binding 
partners [99]. 
 
RNA-binding activity had already been detected within CFI through the Rna15 subunit, 
and the presence of two RRMs in Hrp1 indicated that it might also interact with pre-
mRNAs.  Hrp1-RNA binding was confirmed when it was demonstrated recombinant 
Hrp1 could be UV-crosslinked to a radiolabelled GAL7 substrate.  This interaction was 
specific for the EE of GAL7 pre-mRNA (UAUAUA) [91].  Quantitative gel mobility 
shift assays showed that the Hrp1 binds substrates containing the (UA)3  sequence with 
nanomolar (nM) affinity [124]. Competition assays reinforced these results, showing 
ADH2 pre-mRNA lacking the EE sequence could not compete with a pre-formed Hrp1-
ADH2 RNA (wildtype) complex.  However, a sequence containing the ADH1 gene 3’-
UTR (which does not contain the UAUAUA element) could successfully compete for 
Hrp1 binding with ADH2 RNA, indicating that although Hrp1-RNA binding is specific, 
Hrp1 does recognise other sequences in the 3’-UTRs of pre-mRNAs [125].  The 
structure of the Hrp1-RNA interaction domain in complex with the GAL7 EE has since 
been solved by NMR.  The structure shows two typical RRM folds (1-1-2-3-2-
4-5) with both involved in binding to the EE.  The RRMs interact with each other, 
creating a cleft that is highly positively charged and within which the majority of the EE 
sequence binds.  The first two bases at the 5’-end of the hexa-ribonucleotide are bound 
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by RRM2, whereas the next four bases are bound by RRM1.  Specificity of the adenine 
and uracil bases is mediated by both hydrogen bonding and hydrophobic stacking 
interactions between the most conserved residues in the RRMs and RNA [126, 127].  
Taken together, the biochemical and structural findings point to a specific interaction 
between Hrp1 and the (UA)3 EE in the pre-mRNA 3’-UTRs of S. cerevisiae gene 
transcripts.  Although other sequences can also be recognised, it is unclear what their 
compositions are and how recognition would be conferred at the molecular level. 
 
Although the role of Hrp1 as a pre-mRNA 3’-end processing factor is undisputed, it 
may not be involved in the processing of transcripts from every yeast gene.  An RNA-IP 
microarray analysis revealed Hrp1 was enriched on transcripts containing the UA-rich 
EE, and was also enriched on the transcripts of genes involved in metabolism [128].  
Furthermore, it has been noticed that Hrp1 is rapidly translocated to the cytoplasm 
during hypo-osmotic stress.  The lack of Hrp1 in the nucleus in this scenario implies it 
is not required for the processing of all gene transcripts, or is not required for 
transcriptional processing during the stress response [129].  Taking this into account, it 
is tempting to speculate that Hrp1 may act within CFIA to indirectly position Rna15 on 
templates to which it has low affinity (templates with a lack of GU-rich sequence 
flanking the poly(A) site) using Rna14 as a bridge.  This theory is given substance by 
the fact that Rna15 only recognises the A-rich PE of GAL7 pre-mRNA specifically as a 
Hrp1-Rna14-Rna15 complex [111]. 
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1.4. Cleavage and Polyadenylation Factor (CPF) 
 
The pioneer studies of pre-mRNA 3’-end formation in S. cerevisiae focused on 
determining the minimal set of protein factors that are required to reconstitute the 
cleavage and polyadenylation reactions.  These studies showed that in the presence of 
CFI, CFII provided cleavage activity and PFI directed polyadenylation of pre-mRNA 
[82, 85].  However, advances in protein purification technology enabled the single-step 
purification of a stable complex of CFII and PFI, suggesting the individual complexes 
interact during pre-mRNA processing steps.  This large combinatorial protein complex 
responsible for both cleavage and polyadenylation was termed cleavage and 
polyadenylation factor (CPF) [86].    
 
The CPF subunits derived from CFII and PFI are considered as the “core” of CPF.  
After tagging and purifying Ref2 (a non-essential transcription factor) from yeast 
extract, an even larger “holo” CPF complex was identified.  This complex contained all 
core CPF components, with an additional 6-subunit protein complex, APT (Associated 
with Pta1).  Tagging of different APT subunits indicated holo-CPF was a stable 
complex, although in some purifications APT subunits were found in substoichiometric 
amounts, which could signify formation of holo-CPF is only required for transcription 
and transcript processing of certain genes [102]. 
 
All holo-CPF subunits are essential with the exception of Ref2 and Syc1 from APT.  
There have been many reported cases where the mutation or removal of a single holo-
CPF subunit causes abnormal pre-mRNA cleavage and polyadenylation.  However, not 
all holo-CPF subunits have a direct role in pre-mRNA 3’-end processing.  Moreover, 
some are important in assembly of the complex and disrupting them leads to 
downstream effects on processing.   
 
The subunit composition of holo-CPF is outlined in Table 1.1, with details of sub-
complexes and the known functions of each protein.  A selection of holo-CPF subunits 
are described in the context of their direct functions in pre-mRNA cleavage and 
polyadenylation in the next two sections. 
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CPF 
subunit 
Mammalian 
homologue 
Size 
(kDa) 
Structural Features Function Refs 
Cft1/Yhh1 
(CFII) 
CPSF-160 150 Predicted 3 -propeller 
in CD 
Binds pre-mRNA 
cleavage site, binds PolII 
CTD 
[57, 
130] 
Cft2/Ydh1 
(CFII) 
CPSF-100 105 -CASP domain, -
lactamase domain (non 
metal-binding) 
Binds pre-mRNA EE, 
scaffold for interactions 
with CPF, PolII CTD and 
CFIA 
[57, 
103, 
131, 
132] 
Ysh1 
(CFII) 
CPSF-73 100 -CASP domain, -
lactamase domain 
(metal-binding) 
Endonuclease for pre-
mRNA 3’-end cleavage 
[131, 
133] 
Yth1 
(PFI) 
CPSF-30 26 5 zinc fingers Interacts with U-rich 
sequences on pre-mRNA, 
recruits Fip1 and PAP 
[134-
136] 
Fip1 
(PFI) 
hFip1 55 Central flexible linker Recruits PAP to CPF [104, 
137, 
138] 
Pta1 
(CFII) 
symplekin 88 Unknown Scaffold protein, binds 
PolII CTD 
[139, 
140] 
Pfs2 
(PFI) 
- 53 WD-40 repeats (x7) Bridges CPF to CFIA [86] 
Mpe1 
(PFI) 
- 58 Zinc-knuckle motif Unknown [102, 
141] 
Pap1 
 
PAP 63 -polymerase fold, 
missing thumb domain 
Generates polyadenylate 
tail 
[63, 
64, 
142-
144] 
Pti1 
(APT) 
- 47 N-terminal RRM CPF processing of pre-
mRNA and snoRNAs 
[102, 
105, 
145] 
Ref2 
(APT) 
- 48 Unknown Binds pre-mRNA with 
C/U preference.  
Enhances processing of 
weak poly(A) sites 
[146] 
Swd2 
(APT) 
- 37 WD-40 repeats (x7) CPF assembly [147] 
Syc1 
(APT) 
- 21 P-loop and Leucine 
zipper, both homologous 
to CtD of Ysh1 
Non-essential protein.  
Negative regulator of 
cleavage 
[148] 
Ssu72 
(APT) 
- 23 CX5RS motif (tyrosine 
phosphatases) with 
aspartate loop 
Protein phosphatase, 
dephosphorylates PolII 
CTD Ser5 
[149-
151] 
Glc7 
(APT) 
- 36 Type 1 serine/threonine 
phosphatase 
Protein phosphatase, 
dephosphorylates Pta1 
[152] 
 
Table 1.1. Summary of CPF subunit functions.  In the CPF subunit column, details of subcomplex 
membership are provided in brackets underneath the subunit names.  
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1.4.1 The role of CPF in cleavage 
It is clear that CFIA is essential for cleavage/poly(A) site selection through the Rna15-
RNA interaction, and that Hrp1 may be required for site selection on certain gene 
transcripts.  CPF also binds to pre-mRNA after it has been recruited to the correct site 
by CFIA/B.  There are many cross-complex interactions between CFIA and CPF.  
Those that have been physically characterised are summarised in an interaction map 
found in Figure 1.7.  The association of CPF with pre-mRNA is presumably 
fundamental in bringing its associated endonuclease activity into close proximity with 
the cleavage/poly(A) site.   
 
CPF binds pre-mRNA via multiple subunits, including the two largest subunits, Cft1 
and Cft2.  The 150 kDa Cft1 protein has been shown to bind pre-mRNA in the vicinity 
of the cleavage/poly(A) site.  Analysis of the amino acid sequence of Cft1 revealed the 
central domain contains predicted -propeller-forming repeats, which mediate the Cft1-
RNA interaction [130].  Experiments in which GST-tagged recombinant Cft1 was 
incubated with pre-mRNA substrates demonstrated Cft1 bound to sequences containing 
the cleavage/poly(A) site, although no direct sequence specificity could be inferred. 
[130].  Yeast extracts from different yhh1 (Cft1) temperature sensitive mutants were 
unable to cleave and polyadenylate GAL7 and CYC1 pre-mRNAs in vitro.  Additionally, 
Northern blotting experiments showed that cleavage/poly(A) site selection on ACT1 
transcripts had shifted to weaker distal sites, that had previously been characterised by 
examining ACT1 transcripts from rna15-2 and rna14-3 temperature sensitive yeast 
strains [130, 153].  The next largest subunit of CPF, Cft2, also interacts with pre-
mRNA.  An in vitro experiment showed Cft2 purified from yeast extract could be UV-
crosslinked specifically to the (UA)3 EE sequence of GAL7 pre-mRNA.  This 
interaction was not observed on pre-cleaved RNAs, meaning there is also a requirement 
for sequences downstream of the cleavage/poly(A) site [132].  Extracts derived from 
ydh1 (Cft2) temperature sensitive mutant yeast strains could not cleave or polyadenylate 
CYC1 pre-mRNA in an in vitro assay.  As with the yhh1 (Cft1) temperature sensitive 
mutants, ACT1 mRNA from ydh1 (Cft2) temperature sensitive mutant yeast strains 
displayed a shift in poly(A) site usage towards distal sites [103].  In light of this, it is 
evident that both Cft1 and Cft2 are important in cleavage/poly(A) site selection. 
 
With CPF accurately positioned through interaction with CFIA and the binding of its 
own subunits to pre-mRNA, the transcript is cleaved at a dinucleotide (usually CA) 
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Figure 1.7. CFIA-CPF interaction map.  These interactions have been demonstrated by 
genetic, immunoprecipitation or in vitro pulldown experiments.  Hits generated by large 
scale TAP-tagging and mass spectrometry experiments are not shown. To improve the 
visibility of the map, interactions made by Pcf11 are shown by black lines, Clp1 by red 
lines and Rna14 by light blue lines.  Proteins that bind to PolII CTD are highlighted in 
yellow. 
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within the cleavage/poly(A) site.  The 100 kDa Ysh1 subunit of CPF is the putative 
endonuclease that physically cleaves pre-mRNA.  Although there is no direct evidence 
in yeast that Ysh1 effects transcript cleavage, the mammalian homologue of Ysh1, 
CPSF-73, has been more extensively characterised as the 3’-end endonuclease.  After 
the initial cloning and identification of CPSF-73 as an important pre-mRNA 3’-end 
processing factor, a sequence analysis revealed bovine CPSF-73 shared 53% sequence 
identity with the first 500 amino acids of Ysh1 from S. cerevisiae.  In the same studies it 
was shown that whole-cell extracts derived from the brr5-1 yeast strain (a Ysh1 
temperature sensitive allele), or extracts in which Ysh1 was immunodepleted, were 
unable to cleave or polyadenylate CUP1 and CYC1 pre-mRNAs respectively [154, 155].  
These findings signified the importance of Ysh1 in both steps of 3’-end formation.  The 
crystal structure of CPSF-73 has been solved revealing the protein is a member of the 
metallo--lactamase superfamily of zinc-dependent hydrolases [131].  It contains a 
metallo--lactamase domain with two zinc ions in the active site, and a -CASP 
domain.  The five signature motifs that metallo--lactamase domains usually carry are 
conserved in CPSF-73, and are ligands to the two active site zinc ions present in the 
structure.  The features and arrangement of the active site insinuated that CPSF-73 was 
a catalytically competent nuclease.  This observation was corroborated in a biochemical 
experiment where recombinant CPSF-73 alone could cleave a radiolabelled RNA 
substrate [131].  The fact that Ysh1 also contains predicted metallo--lactamase and -
CASP domains combined with the conservation of active site residues with CPSF-73 
suggests Ysh1 can also provide nuclease activity to the 3’-end processing machinery.  
Indeed, mutation of the Ysh1 active site residues was lethal to S. cerevisiae, meaning 
these residues most probably fulfil an active and essential role in 3’-end processing in 
yeast [133].  Site-specific labelling of a pre-mRNA substrate in conjunction with UV-
crosslinking showed CPSF-73 binds directly to the mammalian poly(A) signal [133].  In 
contrast, no Ysh1-RNA binding activity has yet been detected in yeast, although given 
that other CPF subunits with which Ysh1 interacts bind pre-mRNA in the vicinity of the 
cleavage/poly(A) site, it is feasible Ysh1 is also localised in this position. 
 
1.4.2. The role of CPF in polyadenylation 
After cleavage, a homo-polymeric tail of 60-80 adenines is added to the newly 
generated 3’-end of pre-mRNA transcripts [63, 64].  The enzymatic activity required to 
achieve polyadenylation is confined to a single protein, Pap1.  There is some debate as 
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to whether Pap1 is a member of CPF.  Initial fractionation of yeast extracts responsible 
for cleavage and polyadenylation isolated Pap1 within its own fraction [82].  However, 
more advanced purification techniques used in later studies found Pap1 to be associated 
in stoichiometric quantities with the other posited core-CPF factors [102].  For the sake 
of clarity, Pap1 will be considered as a core-CPF subunit in addition to the CFII and PFI 
sub-complexes (see Table 1.1) in future discussion. 
 
The enzymatic properties of Pap1 were first characterised after it was purified to 
homogeneity from yeast extract.  It was discovered that in vitro, Pap1 could generate 
large polyadenylate tails on different RNA substrates in the absence of other protein 
factors.  This lead to the presumption that specificity and regulation of tail-length must 
be conferred through Pap1 interaction with other proteins [84].  Subsequent cloning and 
sequence analysis of the PAP1 gene revealed it shares 47% sequence identity with the 
first 400 amino acids of mammalian Pap1, and biochemical characterisation of the 
recombinant protein confirmed its enzymatic activity [83].  There are various crystal 
structures of Pap1 complexed with different ligands now available.  They have provided 
key insights into the mechanism of polyadenylation in S. cerevisiae.  The first structure 
revealed a three-domain protein with a large, central cleft [144].  The NTD comprised 
the classic polymerase “palm”, in which the active site is located.  Below the palm the 
CD forms the “fingers”, which are shown interacting with the phosphates of a 3’-dATP 
molecule (a structural analogue of ATP).  This nucleotide is equivalent to the predicted 
position of an incoming nucleotide ready to be incorporated into the pre-mRNA chain.  
The “thumb” domain present in other polymerases is completely absent whilst the CTD 
makes up the wall of the cleft opposite the palm in a distal position relative to the active 
site [144].  Subsequent kinetic analyses revealed Pap1 harbours an induced-fit 
mechanism that dictates nucleotide specificity [143].  More recently, a ternary structure 
has been solved of a stalled Pap1 in complex with a five-residue adenylate ribo-
oligonucleotide [142].  This structure adopts a “closed” conformation compared to the 
original structure due to folding of the catalytic NTD permitting contacts with residues 
on the CTD.  The structure reveals that Pap1 makes contact with only the last three 
residues of the adenylate RNA-oligo within a tunnel created by the closed 
conformation, with the -1 AMP located close to MgATP in the active site in the correct 
position for initiating the adenylation reaction.  Whilst Pap1 can polyadenylate freshly-
cleaved RNA in vitro with no apparent specificity for residues at the 3’-end of the 
transcript, this crystal structure suggests poly(A) RNA and MgATP are both required to 
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induce a conformational change that shifts Pap1 into the closed complex required for 
processive polyadenylation [63, 64, 142]. 
 
As discussed above, in vitro Pap1 does not require protein partners to polyadenylate an 
RNA substrate.  Therefore in vitro, polyadenylation is totally unregulated, with large 
poly(A) tails generated without proper selection of RNA substrate [83, 84].  It has since 
been shown that the CPF subunit Fip1 displays a degree of control over Pap1 
polyadenylation.  Interaction of Fip1 and Pap1 was first demonstrated both in vitro and 
in vivo using biochemical and genetic approaches.  This interaction was found to be 
crucial for polyadenylation, as yeast extracts from fip1 mutant strains were able to 
cleave but not polyadenylate CYC1 pre-mRNA [104].  Fip1 regulates the processivity of 
Pap1 in vitro by binding Pap1 CTD at a location overlapping a Pap1-RNA binding site.  
By occluding RNA-binding, Fip1 can drastically limit Pap1 polyadenylation [156].  
Biochemical and biophysical analyses of recombinant Fip1 showed that although the 
protein was soluble, it was nearly completely disordered in the absence of binding 
partners [157].  In light of these findings, it was not surprising that a flexible linker was 
found in the centre of Fip1, between the Pap1 and Yth1 interaction domains.  
Manipulating the length of the linker was found to decrease polyadenylation in vitro and 
in vivo, signifying that as well as Fip1 recruiting Pap1 to pre-mRNAs, the linker may 
also be important in allowing Pap1 to reach the cleaved 3’-end of pre-mRNAs [137]. 
    
It has been suggested that another CPF subunit, Yth1, may fulfil an important role in 
facilitating polyadenylation.  Yth1 is a 30kDa protein with a conserved central section 
comprised of five zinc fingers, and interacts with pre-mRNA around the poly(A) site of 
CYC1 pre-mRNA [134, 135].  Functional dissection of Yth1 revealed zinc finger 4 
(ZF4) was necessary for the binding of both pre-mRNA and Fip1.  A competition assay 
demonstrated that the efficiency of UV-crosslinking Yth1 to GAL1 pre-mRNA was 
decreased dramatically in the presence of increasing concentrations of Fip1, indicating 
that the binding of pre-mRNAs and Fip1 to Yth1 is mutually exclusive.  Considering 
this, it may be that Yth1 acts as a switch between cleavage and polyadenylation: Yth1 is 
stably associated with pre-mRNAs prior to cleavage and after cleavage it is released and 
free to interact with Fip1, which recruits Pap1 to initiate polyadenylation [136]. 
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1.5. A model for pre-mRNA 3’-end processing in S. cerevisiae 
 
Following the above detailed introduction to the pre-mRNA sequence elements and 
protein factors involved in 3’-end processing, it is apt to bring this information together 
into a simplified, general model, presented in Figure 1.8 and described in the following 
text.  In this model, the CFIA complex first facilitates cleavage/poly(A) site selection 
through the specific interactions of Rna15 with GU-rich sequences and Hrp1 with the 
PE.  CFIA then recruits CPF via multiple interactions between subunits of these 
complexes.  CPF is stabilised on the transcript by the binding of Cft1 and Yth1 to 
sequences surrounding the cleavage/poly(A) site, and Cft2 association with the EE.  
Ysh1 binds directly to the Py(A)N cleavage/poly(A) site and employs its endonuclease 
activity to cleave the pre-mRNA at the 3’ of an adenosine.  A subsequent rearrangement 
of CPF allows Yth1 to break free from the pre-mRNA and interact with Fip1.  The 
flexible linker of Fip1 positions Pap1 at the newly generated 3’hydroxyl of the cleaved 
pre-mRNA.  Poly(A) polymerase recognises the cleaved 3’-end and begins to 
polyadenylate.  The first few adenylate residues added to the pre-mRNA are bound in 
the tunnel leading to the Pap1 active site.  Together with MgATP in the Pap1 active site, 
this drives Pap1 into the closed conformation that is required for processive 
polyadenylation. 
 
This model does not account for how poly(A) tail-length is regulated in S. cerevisiae.  
In the past, it was thought that poly(A) tail-length was controlled by the deposition of 
the major cytoplasmic poly(A)-binding protein Pab1 on the growing polyadenylate tail, 
followed by trimming of the tail by a 3’->5’ exonuclease, Pab1-dependent poly(A) 
nuclease (PAN) [90, 158, 159].  It has since emerged that a previously identified mRNA 
export factor, Nab2, may in fact exert more direct control over poly(A) tail-length.  
Depletion of Nab2 in vivo causes the accumulation of hyper-adenylated mRNAs in the 
nucleus, and an in vitro experiment demonstrated that the addition of recombinant Nab2 
to yeast extract stimulates polyadenylation of CYC1 pre-mRNA, but limits poly(A) tail-
length to 60-80 nt [160].  In line with these findings, recombinant Nab2 mutant proteins 
displayed a decreased affinity for poly(A) RNA-binding in vitro, and the corresponding 
nab2 mutant yeast strains showed poor poly(A) tail-length control in vivo [161].  
Crucially, association of Nab2 with the poly(A) tail was also shown to prevent the 
cleavage and polyadenylation machinery still associated at with the transcript from 
cleaving the poly(A) tail [162].  From a logical point of view, although Pab1 can shuttle 
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Figure 1.8. Model for pre-mRNA 3’-end processing. (A) pre-mRNA sequence elements 
with details of optimal consensus sequences. (B) CFIA and Hrp1 control site selection 
(i) allowing holo-CPF recruitment and pre-mRNA cleavage by the Ysh1 subunit (ii). 
Subsequent rearrangement of CPF allows Pap1 to engage the cleaved 3’-end of the pre-
mRNA (iii) and initiate polyadenylation, with Nab2 regulating poly(A) tail-length (iv).  
The red lightning bolt signifies the cleavage reaction. 
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between the nucleus and cytoplasm [163], the fact that it is predominantly located in the 
cytoplasm [164] deems it unlikely one of its direct functions is poly(A) control.  
Research into the role of Nab2 and polyadenylation presents a strong case for Nab2 
being the key regulator of poly(A) tail-length, and as a result this has been built into the 
model portrayed in Figure 1.8 accordingly.  However, the nature of the distribution of 
Nab2 along poly(A) RNA remains enigmatic. 
 
The above model is simplistic in that it does not consider the timing of pre-mRNA 3’-
end processing, or the crosstalk between different processing events.  The integration of 
other pre-mRNA processing events and transcription with 3’-end formation will be 
reviewed in sections 1.6. and 1.7. respectively, with a focus on findings associated with 
CFIA factors. 
 
1.6. Links between 3’-end processing and other processing events 
 
There are a variety of protein factors that associate with poly(A) tails and the 3’-end 
processing machinery that play important roles in other processing events.  These may 
serve to couple distinct processing steps temporally, or may be required to determine 
the fate of mRNAs after nuclear export.  Some of the most well documented links 
between pre-mRNA 3’-end processing and other steps of mature mRNA formation are 
presented in this section. 
 
1.6.1. 3’-end processing and 5’-end capping 
The association of Pab1 with the poly(A) tails of pre-mRNA has been shown to 
stimulate translation initiation [165].  Following on from this finding, the purification of 
mRNA from yeast extracts through 7mGDP chromatography (affinity for the 5’ cap of 
pre-mRNA) revealed that Pab1 was found associated with the eIF-4F cap-binding 
complex [3].  To elucidate the finer molecular details, a mutational analysis showed that 
the eIF-4G subunit of eIF-4F mediated the Pab1-eIF-4F interaction.  Although the 
interaction was not required for poly(A)-dependent translation in an in vitro system, it 
was shown to synergistically stimulate translation [166].  Combining these facts with 
other studies in the translation initiation field, a model was proposed in which the 
poly(A) tail bound to Pab1 stimulates translation by interacting with eIF-4G and 
enhancing the recruitment of the 40S ribosomal subunit [167].  This model hypothesises 
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that the Pab1-eIF-4G interaction circularises the mRNA (forming a mRNP).  Supporting 
this hypothesis, atomic force microscopy clearly showed that the combination of eIF-
4E, eIF-4G (together eIF-4F complex) and Pab1 with capped and polyadenylated 
mRNA facilitated circularisation of the transcript into an mRNP [56].  In summary, 
communication between proteins associated at the 5’ cap and 3’ poly(A) tail of mRNAs 
promotes efficient translation. 
 
1.6.2. 3’-end processing and splicing 
There is some evidence from experiments with mammalian cells that implies splicing 
factors can have a stimulatory effect on pre-mRNA 3’-end formation (reviewed in [48]).  
However, a parallel has not been drawn in S. cerevisiae.  This could be due to the 
comparative lack of introns in the S. cerevisiae genome.   
 
1.6.3. 3’end processing and export 
As discussed in section 1.5, the association of the Nab2 protein with poly(A) RNA 
controls poly(A) tail-length in S. cerevisiae.  Recent studies have implied that Nab2 has 
a second function in mRNA export.  Purification of Nab2 by TAP uncovered it is 
associated with the key export factors Yra1, Mex67 and the THO-TREX complex.  
Furthermore, Nab2 was shown to be commonly associated with mRNA throughout the 
S. cerevisiae transcriptome [47].  The interaction of Nab2, Yra1 and Mex67 was 
confirmed in vitro, and shown to be necessary to guide mRNA to the NPC, where 
exchange of mRNA into the cytoplasm is mediated by Nab2 interaction with the NPC 
subunit Mlp1 [32, 46]. 
 
Intriguingly, the Swd2 subunit of CPF has an indirect effect on mRNA export.  
Immunoprecipitation of HA-tagged Swd2 unearthed the export factors Npl3, Nab2 and 
Mex67 as binding partners.  Binding experiments showed that both formation of the 
APT sub-complex of CPF, as well as Swd2 association with export factors, was 
dependent on the ubiquitylation of Swd2 at key residues.  Correctly assembled CPF is 
therefore likely able to recruit components of the mRNA export machinery [168]. 
 
Particularly relevant to the work presented in this thesis is the observation that the 
export factor Yra1 interacts directly with the CFIA complex through the Pcf11 subunit.  
Yra1 is a member of the RNA and export factor (REF) family of RNA-binding proteins 
whose role in mRNA export is briefly outlined in section 1.1.4.  The Yra1-Pcf11 
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interaction was discovered in one seminal study using both in vitro and in vivo 
approaches [169].  A chromatin immunoprecipitation (ChIP) analysis of Yra1 
occupancy on the PMA1 and ACT1 genes demonstrated that Yra1 is recruited 
progressively throughout transcription, and is enriched at the 3’-end of genes.  Further 
ChIP experiments in this study revealed Yra1 occupancy on the TEF1 gene was almost 
eliminated in the pcf11-2 and pcf11-9 temperature sensitive yeast strains, pointing to a 
possible Yra1-Pcf11 interaction.  The interaction was confirmed when it was shown that 
HA-tagged Pcf11 could coIP Yra1.  Subsequent pull-down assays mapped the Yra1 
binding site on Pcf11 to the zinc-finger/Clp1-ID domain.  The authors postulated that 
the early recruitment of export factors to the transcription complex via Pcf11-Yra1 
might serve as a quality control mechanism, as only a fully-assembled transcription 
elongation complex containing CFIA would be competent to recruit Yra1 for its role in 
subsequent mRNA export [169].  Recently, research into the interplay between Yra1 
and Pcf11 has been extended, illuminating a more direct role for Yra1 in pre-mRNA 3’-
end processing [170].  Because the Clp1 and Yra1 binding sites on Pcf11 were thought 
to overlap, an in vitro binding experiment was employed to show if Pcf11 bound each 
protein in a mutually exclusive manner.  The experiment clearly showed that 
recombinant Clp1 and Yra1 compete for the binding of Pcf11.  This disrupted CFIA 
activity, and abolished cleavage and polyadenylation of GAL7-1 pre-mRNA.  The idea 
that Clp1 may not be incorporated into CFIA at the same time as Pcf11 was novel, and 
was tested by looking at the ChIP profiles of Pcf11 and Clp1 across a large set of 
different genes.  The occupancy of Clp1 was shown to be distinct from that of Pcf11, 
with a marked bias towards the poly(A) region of genes compared to the relatively 
evenly-distributed Pcf11, strengthening the notion that CFIA assembly may not be 
straightforward.  Compellingly, ChIP profiles of Yra1-depleted transcripts revealed 
early recruitment of Clp1 along genes, indicating the Pcf11-Yra1 interaction may 
preclude the Pcf11-Clp1 interaction during transcription elongation.  Because this could 
have implications for 3’-end formation, poly(A) site choice across the yeast 
transcriptome was monitored after Yra1 depletion by RNA-seq (sequencing of total 
yeast mRNA).  Strikingly, poly(A) site choice had been altered in nearly one third of all 
transcripts compared to the wildtype S. cerevisiae transcriptome [170].  It is therefore 
clear that as well as being an export factor, Yra1 is also a 3’-end processing factor with 
the ability to assert a certain degree of control over cleavage/poly(A) site selection.  
However, the mechanism for Yra1-mediated poly(A) site selection remains obscure.   
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1.7. Links between 3’-end processing and transcription 
 
Because pre-mRNA processing events are targeted to distinct locations on gene 
transcripts, it is easy to presume they occur successively after transcription is complete.  
However, in the last two decades it has become apparent that processing events are not 
only linked with each other, but they are also intimately coupled to transcription.  In 
other words, the pre-mRNA is secured with a 5’cap, and introns spliced from the coding 
sequence whilst PolII is still transcribing the rest of the gene.  This is enabled by the 
loading of capping and splicing machineries onto PolII at the promoters of genes, and 
throughout transcription elongation (reviewed in [48, 52, 53, 171]). 
 
It is obvious that maturation of pre-mRNA 3’-ends must happen slightly later than 
capping and splicing, as the signal sequences for cleavage/poly(A) must first be 
transcribed.  However, it is now known that elements of the 3’-end processing 
machinery are also recruited at an early stage, and that this is crucial for gene 
expression.  Not only does correct 3’-end processing require PolII, the polymerase also 
requires interaction with the 3’-end processing machinery for transcription termination.  
In short, the formation of a mature 3’-end drives the dissociation of PolII from the 3’-
UTRs of genes. 
 
PolII CTD is the communication centre of the polymerase, acting as a landing pad for 
the pre-mRNA processing machineries, including 3’-end processing factors [49].  In S. 
cerevisiae, CTD contains 26 heptad repeats of the sequence YSPTSPS, and is connected 
to the rest of PolII by a flexible linker [172].  Individual residues in the repeat sequences 
are phosphorylated in a dynamic manner. For example, the serine at position 5 of the 
repeat (Ser5) is phosphorylated at promoters but declines 5’ to 3’ along genes, whereas 
phosphorylation of the serine at position 2 of the repeat (Ser2) occurs only in coding 
regions [9].  Dynamic phosphorylation may be gene-specific, and act as a “CTD code” 
that specifies the recruitment of specific protein factors at precise intervals in the 
transcription cycle [173]. 
 
Components of CFIA and CPF 3’-end processing complexes have been found to 
interact with CTD (see Figure 1.7).  Probing the importance of these interactions by 
mutagenesis has been key in demonstrating how transcription and 3’-end processing are 
entwined.  Breaking the interactions can cause aberrant 3’-end processing, inefficient 
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transcription termination, lower levels of transcription and sometimes a combination of 
these effects.  The next two sections will consider specific examples where 3’-end 
processing factors are linked to transcription termination and initiation respectively, 
with a focus on CFIA subunits. 
 
1.7.1. 3’-end processing and transcription termination 
Attempts to explain the mechanism behind the 3’-end processing and transcription 
termination connection have culminated in the proposal of two models: the “allosteric” 
(or “anti-terminator”) and “torpedo” models of transcription termination (reviewed in 
[174]).   
 
The allosteric model (Figure 1.9A) stresses the importance of the cleavage/poly(A) site 
and PolII CTD.  Here, transcription of the cleavage/poly(A) site induces a 
conformational change, resulting in the depletion of anti-termination factors and 
recruitment of pro-termination factors to PolII CTD.  The end result is the release of the 
PolII transcription elongation complex (TEC) from the gene [51, 174].  The problem 
with this model is that cleavage is not a prerequisite for termination, which contradicts 
the fact that 3’-end processing factors are essential for efficient transcription 
termination.  The torpedo model (Figure 1.9B) is similar to Rho-dependent transcription 
termination in bacteria, and unlike the allosteric model, the cleavage reaction is 
fundamental.  In the torpedo model, transcription of the cleavage/poly(A) site is 
followed by the cleavage reaction and release of the transcript.  As the TEC continues to 
transcribe, the free 5’-end of the nascent RNA is critical in allowing entry of Rat1, a 5’-
>3’ exonuclease.  Rat1 degrades the nascent RNA, effectively chasing the TEC.  When 
Rat1 catches the TEC, it somehow induces a conformational change that promotes 
dissociation of the TEC leading to transcription termination [174, 175].  However, a 
complex RNP-immunoprecipitation experiment showed that loss of transcription 
termination observed in the rat1-1 temperature sensitive mutant did not correspond with 
the accumulation of nascent RNA, suggesting the exonuclease activity of Rat1 alone 
does not drive transcription termination [176]. 
 
In response to the shortcomings of both the allosteric and torpedo models, a third model 
has now been proposed (Fig 1.9C), in which elements of both previous models are 
unified [176].  This model was driven by a series of ChIP experiments that 
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Figure 1.9. Models of transcription termination. (A) The “allosteric” model.  After 
transcription of the cleavage/poly(A) site a rearrangement of PolII CTD-associated 
factors causes TEC release and transcription termination.  Red - indicates the departure 
of anti-termination factors, Blue + indicates the recruitment of pro-termination factors. 
(B) The “torpedo” model.  After cleavage, Rat1 degrades nascent RNA 5’->3’ and 
displaces the TEC from the gene causing transcription termination.  (C) A unified 
allosteric/torpedo model where both rearrangements of factors on PolII CTD and 
degradation of nascent RNA leads to TEC release and transcription termination. 
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demonstrated the colocalisation of Rat1 and the 3’-end processing factors Pcf11 and 
Rna15 at the 3’-end of the ADH4 gene.  These experiments also showed that pcf11-2 
and pcf11-9 yeast strains displayed a reduction in Rat1 recruitment, and the rat1-1 
mutation led to a decrease in Pcf11 and Rna15 levels, pointing to a codependence of 
these factors in their recruitment to the 3’-ends of genes.  The unified model proposes 
that a combination of nascent RNA degradation by Rat1 and conformational changes to 
the TEC after transcription of the poly(A) site is required for dissociation of the TEC 
and transcription termination [176]. 
 
In S. cerevisiae, crosstalk between 3’-end processing and transcription termination was 
first observed with the CFIA subunits Pcf11, Rna14 and Rna15.  Mutated forms of these 
proteins had all previously been shown to cause aberrant cleavage and polyadenylation 
in vitro and in vivo (see section 1.3).  Using yeast extracts derived from strains carrying 
the rna14-1, rna15-1 and pcf11-9 alleles, a transcription run-on analysis of the CYC1 
gene revealed transcription failed to terminate at the correct location with all three 
mutants [110].  Since these observations, a range of other 3’-end processing factors that 
also affect transcription termination have been identified, but only Cft1 and Ssu72 
directly interact with PolII CTD [130, 177].  It is now clear there is a family of 3’-end 
processing factors that are important for transcription termination.  Pcf11 is central to 
the work presented in this thesis, and as such it is important to consider the attributes 
that allow it to couple 3’-end processing and transcription. 
 
As mentioned previously, PolII interacts with various RNA-processing factors through 
its CTD.  Pcf11, along with several other factors, contains a conserved CTD-interacting 
domain (CID).  Figure 1.3B illustrates the conservation of the CID amongst Pcf11 
homologues.  The crystal structure of the Pcf11 CID in complex with a phosphopeptide 
containing the PolII CTD repeat sequence has been solved [115], and is depicted in 
Figure 1.10.  The CID is composed of eight -helices in a right-handed superhelical 
arrangement (Figure 1.10A).  The CTD phosphopeptide adopts a -turn conformation 
around pSer2-Pro3-Thr4-Ser5 that binds to a conserved groove in CID (Figure 1.10B).  
Although phosphorylation of Ser2 is required for CID-binding, the phosphor group of 
the side-chain is actually oriented away from the CID and is not directly involved in the 
interaction.  However, the phosphor group makes hydrogen bonds that stabilise the β-
turn conformation and thus is intimately involved in CID recognition.  The PolII CTD- 
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Figure 1.10. The interaction between Pcf11 CID and PolII CTD. (A)  Crystal structure 
of the Pcf11 CID-PolII CTD complex.  CID is shown as a pale cyan cartoon, CTD as 
yellow sticks. (B) Magnified view of the CID-CTD interface.  The CTD 
phosphopeptide binds Pcf11 CID within a conserved groove.  CID is shown as a pale 
cyan cartoon with a semi-transparent surface and side-chains involved in the interaction 
are illustrated in stick representation and are labelled.  The CTD phosphopeptide is 
shown as yellow sticks (phosphate in orange).  P6a denotes the proline in one copy of 
the repeat, S7b denotes the terminal serine of the next repeat.  (C) CTD binding surface 
of CID.  CID is shown in pale cyan surface representation.  Residues involved in CTD-
binding observed in the crystal are shown in yellow, additional interacting residues 
identified by NMR chemical shift assays are shown in orange. (D) The CTD binding 
surface of CID is conserved.  CID is shown as before, but conserved residues are 
highlighted in shades of blue (dark blue most conserved), refer to the Pcf11 CID 
sequence alignment in Figure 1.3.  PDB codes: 1SZA, 1SZ9, 2BF0. 
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Pcf11 CID crystal structure is consistent with other in vitro studies that have 
demonstrated that CID prefers Ser2-phosphorylated CTD.  It has also been shown by 
ChIP that Pcf11 recruitment along genes correlates with CTD Ser2 phosphorylation 
[173, 178].  Comparison of the CID structure with the sequence alignment shows it is 
mainly completely or near-completely conserved residues that constitute the CID-CTD 
interaction surface (compare Figure 1.3 with Figure 1.10D).  Another seminal study 
provided a similar structure with an extensive biophysical interrogation of the binding 
mechanism [179].  Chemical shift mapping by NMR revealed the interaction surface is 
probably slightly larger than seen in the crystal structure (Figure 1.10C).  Although it 
had been previously suggested that CID-CTD recognition depended on a preformed 
CTD structure (a heptad repeat β-turn facilitated by Ser2 phosphorylation), a series of 
biophysical experiments determined that this was not the case.  The far-UV circular 
dichroism (far-UV CD) and 31P NMR spectra of CTD-derived peptides showed that 
they do not form stable secondary structure elements after phosphorylation of serine 
residues within the heptad repeat sequences.  Furthermore, NMR experiments revealed 
that CID-CTD binding caused a chemical shift perturbation in the 31P NMR spectrum of 
a Ser2-phosporylated CTD peptide and that residues within the peptide underwent a 
conformational transition.  These findings pointed to an induced fit mechanism of CID-
CTD binding, in which CID forces CTD into the -turn conformation observed in the 
crystal structure.  The binding affinity measured by isothermal titration calorimetry 
(ITC) determined that the CTD-CID interaction was weak, although increasing the copy 
number of the repeat sequence increased the apparent affinity.  The authors postulated 
that the presence of many repeats in the full CTD would elevate the binding affinity by 
increasing the local concentration of binding sites for CID.  Additionally, the same 
study identified that the CTD prolines exist in a mixed cis-trans population with a trans 
dominance, but only the trans form of CTD is selected for interaction with CID [179].  
Considering these findings, it can be hypothesised that PolII CTD recognition by pre-
mRNA processing factors is mediated by two types of site-specific modification 
(phosphorylation and proline cis-trans isomerisation) and by the local concentration of 
binding sites.  
 
There are conflicting reports on the necessity of the CID-CTD interaction for both 3’-
end processing and transcription.  Experiments conducted by Sadowski et al [106] 
found mutations in Pcf11 that abrogated CTD binding (pcf11-9, pcf11-13) abolished 
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transcription termination on the CYC1 gene in vivo but not cleavage and 
polyadenylation of CYC1 precursor in vitro.  The reverse was also true, as mutations in 
Pcf11 that caused defective cleavage and polyadenylation (pcf11-2) had no effect on 
transcription termination.  On the other hand, a later study by Luo et al [176] showed 
the pcf11-2 allele which displays cleavage and polyadenylation defects also does not 
allow transcription termination.  These disparities have not been resolved, and as a 
result it remains unclear as to whether the 3’-end processing and transcription 
termination functions of Pcf11 can be separated. 
 
Clp1 has also been recently implicated as a transcription termination factor.  A new 
pcf11 temperature sensitive allele (pcf11 RW-A) that abrogates Pcf11-Clp1 binding at 
the restrictive temperature was identified by work described in this thesis and by others 
[122].  This work revealed that yeast extracts from pcf11 RW-A were unable to support 
mature 3’-end formation in a coupled cleavage and polyadenylation assay in vitro.  A 
further in vitro experiment demonstrated that this mutation also caused defective 
transcription termination on ADH2 and GAL7 genes [122].  Another study confirmed 
Clp1 is necessary for transcription termination after in vivo depletion of Clp1 reduced 
termination of transcription on snoRNA genes [121].  Recombinant CFIA containing 
Clp1 P-loop mutants which remove the Clp1-ATP interaction were found to 
complement the 3’-end processing and termination defects associated with Clp1 
depletion in a coupled in vitro assay [180].  This suggests Clp1-ATP binding is not 
essential for its functions in 3’-end processing and transcription termination.  The 
results section of this thesis presents contrasting data on the topic of Clp1-ATP binding 
and an analysis of this disparity is provided in the discussion. 
 
1.7.2. 3’-end processing and transcription initiation 
The classical view of the PolII transcription cycle is that PolII assembles at the 
promoter, transcribes a linear piece of DNA encoding a gene, terminates transcription 
and dissociates from the gene ready to be recruited back to the promoter for another 
round of transcription.  However, in recent years evidence has been provided that 
suggests transcription may not be as simple as this, and that gene looping may provide a 
mechanism for transcription re-initiation.  Gene looping is defined as the interaction 
between the promoter and terminator regions of a gene during transcription (reviewed in 
[181]).   
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The transcription factor TFIIB is crucial for gene looping, and is able to interact with 
both the promoter and sequences downstream of the cleavage/poly(A) signal [182].  It is 
now clear that the interaction of 3’-end processing factors with TFIIB is fundamental to 
gene looping.  The CPF subunit Ssu72 is particularly important.  The cross-linking of 
TFIIB to terminator regions of the PMA1 and BLM10 genes requires Ssu72 [182].  
Furthermore, Ssu72 is a PolII CTD phosphatase, and its phosphatase activity has been 
shown to be essential for the looping of BUD3 and SEN1 genes during transcription 
[149, 151, 183].  It is therefore likely that Ssu72 is involved in erasing phosphorylation 
marks on PolII CTD after one round of transcription to enable the same PolII molecule 
to cross over to the adjacent promoter region and re-initiate transcription [183].  As well 
as Ssu72, three subunits of CFIA have been identified as critical for gene looping.  A 
ChIP experiment showed functional Rna15 was obligatory for the recruitment of TFIIB 
to the terminator region of the MET16 and INO1 genes and it was found that mutation 
of the rna15 gene corresponded with decreased levels of transcription.  This was 
supported by the observation from chromosome conformation capture analysis [183] 
that gene looping had been abolished in an rna15-1 mutant strain [184].  The same 
analysis has since been applied to Rna14 and Pcf11, as well as Pap1.  These factors 
were also shown to physically interact with TFIIB, and are required for localisation of 
TFIIB to the terminator and for gene looping [185]. 
 
The requirement for CFIA in gene looping suggests it may have an essential function in 
transcription initiation.  The gene looping evidence is perfectly complemented by 
previous observations that pcf11 temperature sensitive alleles or depletion of Pcf11 in 
vivo results in a marked decrease in transcription levels [89, 176, 186].  The evidence 
points to further roles for CFIA and CPF in transcription initiation, in which 
components of these complexes physically link gene promoters and terminator regions 
to facilitate PolII re-initiation and subsequent rounds of transcription. 
 
1.8. Mammalian homologues of 3’-end processing factors 
 
Aberrant 3’-end processing in humans has been shown to cause a variety of disease 
states (reviewed in [187]).  The continued use of S. cerevisiae as a model organism for 
3’-end processing studies is justified by the degree of conservation of 3’-end processing 
protein factors between yeast and mammals.   
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Mammalian 3’-end processing is conducted in the same fashion as in S. cerevisiae: 
cleavage and polyadenylation at the 3’-end of gene transcripts.  There are mammalian 
homologues of most yeast 3’-end processing factors, although the composition of the 
large multi-subunit protein complexes differs (reviewed in [57, 60]).  Mammalian 
homologues of the yeast CPF subunits are listed in Table 1.1, and differences in the 
composition of 3’-end processing complexes can be viewed in Figure 1.11.  Briefly, the 
Cft1, Cft2, Ysh1 and Yth1 subunits of yeast CPF are found in the cleavage and 
polyadenylation specificity factor (CPSF) complex in mammals as the 160, 100, 73 and 
30 kDa subunits respectively. CPSF also contains hFip1, the mammalian homologue of 
Fip1.  The Pta1 protein of yeast CPF is separated in mammals and is referred to as 
symplekin.  Likewise, the poly(A) polymerase (PAP) is thought of as a separate protein 
in mammals.  The homologues of yeast CFIA factors are split into two different 
complexes in mammals: The Rna14 and Rna15 homologues are found in the cleavage 
stimulatory factor complex (CstF) as CstF-77 and CstF-64 subunits respectively.  hClp1 
and hPcf11 are the Clp1 and Pcf11 homologues, and comprise Cleavage Factor II 
(CFIIm).  The mammalian poly(A) binding protein (PABP) is essential for 3’-end 
formation in mammalian cells as with yeast, and further additional factors found in 
yeast holo-CPF are either not present or not yet identified in mammals.   
 
In S. cerevisiae, CFIA, CFIB and the CFII activity of CPF are necessary for in vitro 
cleavage, whilst there is an additional requirement for the whole CPF complex and Pab1 
for in vitro polyadenylation.  In contrast, mammalian 3’-end processing requires all 
factors bar PABP for in vitro cleavage, and in vitro polyadenylation requires only 
CPSF, PAP and PABP (see Figure 1.11) [57, 60]. 
 
This thesis focuses on the function of Clp1 in 3’-end processing in S. cerevisiae.  
However, important similarities and key differences between Clp1 and mammalian 
hClp1 have recently come to light, making it necessary to provide a more detailed 
background for hClp1.  hClp1 was first isolated from HeLa cell nuclear extract by a 
variety of chromatographic techniques, and its identity was assigned after sequence 
alignments showed it shared 23% sequence identity with yeast Clp1 [117].  A series of 
in vitro experiments demonstrated hClp1 was necessary for cleavage, but not 
polyadenylation, whereas yeast Clp1 is required for both processes [117, 121].  By 
identifying cross-factor interactions using immunoprecipitation experiments, it has been 
suggested the role of hClp1 in mammalian 3’-end processing is to bridge CFIm, CFIIm 
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Figure 1.11.  Comparison of S. cerevisiae and mammalian 3’-end processing protein 
complexes.  (A) In S. cerevisiae, CFIA (green) and Hrp1 (yellow) are required for site 
selection.  Cleavage and polyadenylation in vitro requires the addition of CPF.  Core 
CPF subunits are shown in red, the additional CPF subunits without homologues in 
mammalian CPSF are shown in blue.  (B) In mammals, site selection is mediated by 
CstF (red), CFIm (green) and CFIIm (blue).  Cleavage in vitro requires the presence of 
CPSF (grey), PAP (orange) and symplekin (yellow), whereas in vitro polyadenylation 
requires only CPSF, PAP and PABP (brown). 
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(of which it is a subunit) and CPSF [117].  During purification, hClp1 copurified with 
components of the splicing and transcription machineries, implying that the role of yeast 
Clp1 in transcription termination may also be conserved in mammals [117]. 
 
A sequence alignment (see Figure 1.5 and Appendix 8.1) reveals the P-loop, Switch 
domains and base-binding loop are all conserved between yeast Clp1 and hClp1.  The 
key difference is that a catalytic function separate to its role in pre-mRNA processing 
has been assigned to hClp1, whereas no catalytic activity has been detected in yeast 
Clp1.  hClp1 has been shown to provide the kinase activity required to phosphorylate 
the 5’-OH groups of synthetic short interfering RNAs (siRNAs) in vivo.  In the same 
study, it was shown hClp1 copurified with components of the tRNA ligase machinery 
responsible for joining tRNA exons.  Subsequent in vitro experiments revealed hClp1 
provided the kinase activity required as a prerequisite for the ligation of tRNA exons 
[188].  The tRNA kinase activity of hClp1 has since been confirmed in vivo in a yeast 
system.  A genetic approach demonstrated that the lethal phenotype caused by 
elimination of the trl1 gene (yeast tRNA ligase/kinase) could be reversed by the 
introduction of hClp1.  Furthermore, mutation of the P-loop and Switch I aspartate of 
hClp1 resulted in a reversion back to the lethal phenotype, indicating the kinase activity 
of hClp1 was essential in rescue of the yeast trl1 mutant.  In contrast, mutation of the 
same motifs in yeast clp1 had no visible effects on yeast cell viability [189].  An in vitro 
kinase assay also showed that whilst hClp1 was able to efficiently phosphorylate the 5’-
ends of RNA and DNA substrates, yeast Clp1 displayed no kinase activity [189].  It 
therefore seems that both yeast Clp1 and hClp1 share functions in 3’-end processing, 
although hClp1 is also a tRNA kinase which yeast Clp1 is clearly not.  Interestingly, 
hClp1 was unable to complement a clp1 null mutation in S. cerevisiae [189].  Taken 
together, these findings imply there is an element of functional divergence between 
yeast Clp1 and hClp1. 
 
1.9. Research objectives 
 
Clp1 and Pcf11 are two essential proteins that are required for efficient 3’-end 
processing of pre-mRNAs in S. cerevisiae.  The previously determined crystal structure 
of a Clp1-Pcf11-ATP complex revealed that Clp1 binds ATP via a set of conserved 
structural motifs, and that the interaction of Pcf11 with Clp1 is facilitated by highly-
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conserved Pcf11 residues.  However, although the conserved nature of both of these 
interactions suggests each may have essential functions, they remain poorly 
characterised. 
 
The principle objectives of this thesis are to determine the specific functions of Clp1-
ATP binding and the Pcf11-Clp1 interaction in transcription, transcription termination 
and pre-mRNA 3’-end processing.  This begins with the in vitro characterisation of 
recombinant Clp1-ATP binding and Pcf11-Clp1 binding mutant proteins using 
hydrodynamic, biophysical and biochemical techniques.  Following this, the effects of 
mutations are probed using an in vivo analysis to determine whether these interactions 
are essential in S. cerevisiae.  Finally, mRNA extracted from conditional clp1 and pcf11 
mutant yeast strains is analysed using experiments designed to determine the precise 
functions of Clp1-ATP binding and the Pcf11-Clp1 interaction in transcription, 
transcription termination and pre-mRNA 3’-end processing. 
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2. Materials and Methods 
 
2.1. Bioinformatics 
 
2.1.1. DNA and protein information 
Sequence information for CLP1 and PCF11 genes, their flanking regions and the 
proteins they encode was obtained from the Saccharomyces genome database 
(http://www.yeastgenome.org/).  Automated DNA sequencing was performed by GATC 
Biotech (http://www.gatc-biotech.com/en/index.html).  Sequences were analysed using 
the SeqMan Pro (v8.0.2) software from the DNASTAR Lasergene 8 sequence analysis 
suite.  Purification of a recombinant protein and subsequent determination of its 
concentration requires calculation of its theoretical isoelectric point (pI), molar 
extinction coefficient at 280 nm (ε280) and molecular weight (Mr).  These parameters 
were calculated using the Protean (v8.0.2) software from DNASTAR Lasergene 8. 
 
2.1.2. Multiple sequence alignments 
Protein sequences for multiple sequence alignments of Clp1 and Pcf11 were obtained 
from the UniProt (http://www.uniprot.org/) and NCBI 
(http://www.ncbi.nlm.nih.gov/protein/) databases.  A full list of organism names for 
sequences used in alignments is presented in Appendix 8.1.  Multiple sequence 
alignments were performed using MegAlign (v8.0.2) software from DNASTAR 
Lasergene 8, using the ClustalV method [190-192].  Multiple sequence alignments were 
annotated using GeneDoc (2.7.0.0) software (http://www.nrbsc.org/gfx/genedoc/). 
 
2.2. Molecular biology techniques  
 
2.2.1. Bacterial strains 
E. coli NovaBlue “Singles” competent cells were used for cloning of protein expression 
constructs.  Recombinant proteins were expressed in E. coli BL21(DE3) “Singles” 
competent cells.  This strain contains a chromosomal copy of bacteriophage T7 RNA 
polymerase under control of the lacUV5 promoter.  Induction with isopropyl β-D-1-
thiogalactopyranoside (IPTG) results in constitutive production of T7 polymerase.  For 
expression vectors in which DNA encoding the target protein is under control of the T7 
promoter, the mRNA is transcribed at high copy-number leading to overexpression of 
the target protein.  The genotypes of strains used in this study can be found in Table 2.1. 
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E. coli strain name Genotype Function 
NovaBlue endA1 hsdR17 (rK12– mK12+) supE44 thi-1 recA1 
gyrA96 relA1 
lac F′[proA+B+ lacIqZΔM15::Tn10] (TetR)  
Cloning 
BL21 (DE3) F –ompT hsdSB(rB- mB-) gal dcm (DE3) pLysS 
(CamR)  
Protein 
expression 
 
Table 2.1. Genotypes of E. coli strains. 
 
2.2.2. Yeast strains 
The clp1 and pcf11 deletion yeast strains were obtained from the European 
Saccharomyces Cerevisiae Archive for Functional Analysis (EUROSCARF-
http://web.uni-frankfurt.de/fb15/mikro/euroscarf/index.html).  These are diploid strains 
in which one chromosomal copy of the clp1 or pcf11 gene has been deleted by insertion 
of a cassette encoding kanamycin resistance.  The genotypes of diploid clp1 and pcf11 
strains are presented in Table 2.2.  Some experiments required the creation of haploid 
strains in which the single chromosomal copy of clp1 or pcf11 was deleted and the 
deleted gene complemented with a copy of CLP1 or PCF11 on a plasmid with a 
selectable marker.  The creation of a haploid pcf11∆ strain is described in section 2.8.2.  
The haploid clp1∆ strain was supplied by Dr. M. Geymonat (formerly NIMR).  The 
sexes of the haploid strains have not been determined.  
 
S. cerevisiae strain 
( EUROSCARF accession number) 
Genotype Function 
clp1∆/CLP1 
(Y22506) 
BY4743; Mat a/; 
his31/his31; leu20/leu20; 
lys20/LYS2; MET15/met150; 
ura30/ura30; 
clp1::kanMX4/CLP1 
Creation of a haploid 
clp1∆ strain 
pcf11∆/PCF11 
(Y23587) 
BY4743; Mat a/; 
his31/his31; leu20/leu20; 
lys20/LYS2; MET15/met150; 
ura30/ura30; 
pcf11::kanMX4/PCF11 
Creation of a haploid 
pcf11∆ strain 
 
Table 2.2. Genotypes of S. cerevisiae strains. 
 
2.2.3. Plasmid construction 
The details of wildtype plasmid constructs are presented in Table 2.3, mutant constructs 
are listed in Appendix 8.2.  The Pcf11 456-626 EXP construct was used for expression 
of Pcf11 456-626 with a C-terminal hexahistidine sequence (His-tag) and was provided 
by Dr. I. Taylor (NIMR).  Other Pcf11 CTD protein fragments were expressed from the 
pGEX-6P-1 construct (GE Healthcare, see Table 2.3).  The Pcf11 pGEX-6P-1 
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constructs were created by cloning BamHI/SalI fragments containing DNA encoding 
the relevant residues of Pcf11 into pGEX-6P-1.  The Clp1/Pcf11-EXP construct used 
for expression of the Clp1-Pcf11 (454-563) protein complex was provided by Dr. I. 
Taylor (NIMR).  This construct is a pACYCDuet1 vector (Novagen) containing the full-
length CLP1 gene sequence in multiple cloning site 1 (MCS1), fused to a C-terminal 
His-tag.  A fragment of PCF11 encoding residues 454-563 is present in MCS2.  The 
URA3-PCF11 construct was created by cloning a BamHI/SalI fragment containing the 
PCF11 gene and promoter (500 bp sequence upstream of PCF11 gene) into pRS316 
(provided by Dr. M. Geymonat, formerly NIMR).  This construct was used to create a 
haploid pcf11∆ yeast strain.  LEU2-CLP1 and LEU2-PCF11 constructs were generated 
from the pRS315 vector provided by Dr. M. Geymonat.  The cloning method used is 
illustrated in Figure 2.1.  These constructs were used to complement clp1∆ and pcf11∆ 
yeast strains.  LEU2-CLP1(HA) and LEU2-PCF11(HA) contain in-frame fusions at the 
3’-ends of their ORFS, with a 444 nt fragment encoding a 3X repeat sequence of a 
human influenza haemagglutinin DNA (HA-tag), for use in western blotting 
applications.  GAL1-CLP1(HA) and GAL1-PCF11(HA) are identical to the 
aforementioned constructs, but their promoters were replaced by the S. cerevisiae GAL1 
promoter (see Figure 2.1) which is constitutively expressed during yeast growth in the 
presence of galactose.  All constructs were generated using standard cloning techniques: 
polymerase chain reaction (see section 2.2.5), restriction digestion (see section 2.2.6) 
and ligation (see section 2.2.7) of DNA sequences.  Clp1/Pcf11-EXP as well as LEU2-
CLP1(HA), LEU2-PCF11(HA) (and their GAL1 promoter derivatives) were all used as 
templates for site-directed mutagenesis (see section 2.2.9). 
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Figure 2.1. Cloning methods for pRS315-based yeast constructs.  The CLP1 and 
PCF11 promoters were cloned independently of their gene sequences to enable their 
replacement with the GAL1 promoter.  Solid black lines between restriction sites 
indicate where PCR-derived DNA sequences have been inserted by restriction digestion 
and ligation.  The black dashed lines show how different restriction sites were used at 
the junction with the HA-tag. Cloning of the desired gene sequence fragment using 
NcoI/PstI or NcoI/BglII created an in-frame fusion with the HA-tag allowing the 
production of a C-terminally HA-tagged protein. Cloning using the NcoI/XbaI sites 
introduced a translational stop codon allowing production of an untagged protein.  
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Construct name Vector Organism Marker Function 
Pcf11 456-626 EXP pET-22b 
(Novagen) 
 
E. coli ampR Expression of Pcf11 
456-626 
Pcf11 400-626 EXP pGEX-6P-1 
(GE Healthcare) 
 
E. coli ampR Expression of Pcf11 
400-626 
Pcf11 416-626 EXP pGEX-6P-1 
(GE Healthcare) 
 
E. coli ampR Expression of Pcf11 
416-626 
Pcf11 400-499 EXP pGEX-6P-1 
(GE Healthcare) 
 
E. coli 
 
 
ampR Expression of Pcf11 
400-499 
Pcf11 416-499 EXP pGEX-6P-1 
(GE Healthcare 
) 
E. coli ampR Expression of Pcf11 
416-499 
Clp1/Pcf11-EXP pACYCDUET1 
(Novagen) 
 
E. coli camR Expression of Clp1-
Pcf11 (454-563) 
complex 
URA3-PCF11 pRS316 
(ATCC) 
 
S. cerevisiae/ E. coli URA3 
ampR 
Creating haploid 
pcf11∆ yeast strain 
LEU2-CLP1 pRS315 
(ATCC) 
 
S. cerevisiae/ E. coli LEU2 
ampR 
Complementation of 
clp1∆ strain 
LEU2-PCF11 pRS315 
(ATCC) 
 
S. cerevisiae/ E. coli LEU2 
ampR 
Complementation of 
pcf11∆ strain 
LEU2-CLP1(HA) pRS315 
(ATCC) 
 
S. cerevisiae/ E. coli LEU2 
ampR 
Complementation of 
clp1∆ strain 
LEU2-PCF11(HA) pRS315 
(ATCC) 
 
S. cerevisiae/ E. coli LEU2 
ampR 
Complementation of 
pcf11∆ strain 
GAL1-CLP(HA) pRS315 
(ATCC) 
S. cerevisiae/ E. coli LEU2 
ampR 
Complementation of 
clp1∆ strain, CLP1 
overexpression 
GAL1-PCF11(HA) pRS315 
(ATCC) 
S. cerevisiae/ E. coli LEU2 
ampR 
Complementation of 
pcf11∆ strain, PCF11 
overexpression 
 
Table 2.3. Wildtype plasmid constructs.  Mutant constructs are listed in Appendix 8.2. 
 
2.2.4. DNA manipulation and analysis 
Plasmid DNA was purified from overnight cultures of E. coli NovaBlue “Singles” 
Competent Cells using the QIAprep Spin Miniprep and QIAgen Plasmid Midi kits 
(QIAGEN) following the manufacturer’s instructions.  Plasmid DNA was eluted in 30-
50 µl dH2O.  DNA was visualised by agarose gel electrophoresis as described by 
Sambrook et al. [193].  Final DNA concentrations were determined from UV 
absorbance at 260 nm using a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific). 
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2.2.5. Polymerase chain reaction. 
DNA sequences were amplified by polymerase chain reaction (PCR) using an 
Eppendorf Mastercycler PCR machine (Eppendorf), and the KOD Hot Start DNA 
Polymerase kit (Novagen).  All reactions were carried out in 0.2 ml PCR tubes 
(STARLAB) at a final volume of 50 µl.  The PCR protocol used was modified from that 
of the manufacturer (Novagen), an example of which is outlined in Tables 2.4 and 2.5.  
The addition of dimethyl sulfoxide (DMSO) reduces DNA secondary structure in the 
template and primers.  PCR primers were synthesised by Eurofins MWG and are listed 
in Appendix 8.3.  PCR products were purified using the QIAquick PCR Purification kit 
(QIAGEN) in accordance with the manufacturer’s instructions.  DNA was eluted in 30 
µl dH2O. 
 
Reagent Volume (µl) 
KOD Hot Start buffer (10X) 5 
MgSO4 (25 mM) 3 
dNTPs (2 mM each) 5 
Forward oligonucleotide primer (10 µM) 1.5 
Reverse oligonucleotide primer (10 µM) 1.5 
DMSO (100%) 2.5 
Template DNA (plasmid 10 ng/µl) 
(genomic 100 ng/l) 
1 
dH2O 29.5 
KOD Hot Start DNA Polymerase (1 U/µl) 1 
Total 50 
 
Table 2.4. Typical PCR setup.  DMSO is added to a final concentration of 5% to reduce template and 
primer secondary structure.   
 
Step Temperature Time 
 103 ºC ( constant lid temperature)  
1 95 ºC (initial melting) 2 min 
2 95 ºC (melting) 20 s 
3 57 ºC (annealing) 10 s 
<0.5 kb 0.5-1 kb 1-3 kb >3 kb 4 70 ºC (extension) Target size: 
10 s/kb 15 s/kb 20s/ kb 25 s/kb 
5 Repeat steps 2-4, 25-30 cycles  
6 4 ºC 5 min 
 
Table 2.5. Typical thermal cycling conditions for PCR.  The manufacturer’s guidelines were used with 
slight modifications.  Instead of using the lowest primer melting temperature (Tm, ºC) for the annealing 
step, 57 ºC was found to be effective. 
 
2.2.6. Restriction digests 
Double restriction digests were carried out using restriction enzymes from New England 
Biolabs (NEB).  Where possible, a buffer system compatible with both enzymes was 
chosen in accordance with the NEBuffer Activity Chart for Restriction Endonucleases 
(see http://www.neb.com/).  The reaction conditions for a typical restriction digest are 
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presented in Table 2.6.  Where a common buffer for both enzymes could not be found, a 
sequential digestion was performed.  Restriction digests were carried out in a volume of 
30 l at 37°C for 2 h, sequential digestions were in a final volume of 40 l at 37°C for a 
total of 4 h. 
 
Digested DNA products were separated by agarose gel electrophoresis using standard 
1% agarose tris-acetate-EDTA (TAE) gels stained with 0.5 g/ml ethidium bromide 
(Bio-Rad).  Separated digestion products were then visualised on a Benchtop 3UV 
Transilluminator (UVP).   
 
After restriction digestion, vector DNA was treated with Antarctic phosphatase (NEB) 
to remove 5’-phosphate groups to prevent vector recircularisation (see Table 2.7).  
Digested vectors were then separated by electrophoresis and purified directly from 
agarose gels using the QIAquick Gel Extraction Kit (QIAGEN) following the 
manufacturer’s instructions.  Digested PCR products were purified using the QIAquick 
PCR Purification kit (QIAGEN) in accordance with the manufacturer’s instructions.  
Purified vector DNA and PCR products were eluted in 30 l dH2O. 
 
Reagent Volume (l) 
NEB buffer (10X) 3 
BSA (100X) 0.3 
DNA (vector 1-3 g) 
(total PCR product) 
1-3 
NEB enzyme A (10 U/l) 2 
NEB enzyme B (10 U/l) 2 
dH2O to final volume 30 
 
Table 2.6. Typical restriction digestion conditions.  For sequential digests DNA was first digested in 30 
l volume with enzyme A for 2 h in compatible buffer, then enzyme B and compatible buffer was added 
and DNA digested in 40 µl volume for a further 2 h.  
  
Reagent Volume (l) 
NEB Antarctic phosphatase buffer (10X) 4 
Restriction digest 30 
dH2O 4 
NEB Antarctic phosphatase (5 U/l) 2 
Total 40 
 
Table 2.7. Typical phosphatase reaction conditions. 
 
2.2.7. Ligation reactions 
All ligation reactions were performed for a minimum period of 16 h at 16°C using T4 
DNA Ligase (NEB).  Reaction conditions can be found in Table 2.8. 
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Reagents Volume (l) 
NEB T4 DNA ligase buffer (10X) 2 
Digested vector (25 ng/l) 4 
Digested PCR insert (x ng/l) x 
NEB T4 DNA ligase (400 U/l) 1 
dH2O to final volume 20 
 
Table 2.8. Ligation reaction conditions.  The amount of vector used was always 100 ng.  All ligations 
used a molar ratio of 3:1 (PCR insert:vector), with the exact volume of insert required being dependent on 
the concentration of the purified PCR product. 
 
2.2.8. Transformations  
E. coli NovaBlue “Singles” and E. coli BL21(DE3) “Singles” competent cells 
(Novagen) were used for cloning and protein expression purposes respectively.  
Transformation of both strains was carried out in the same manner: 1 l of plasmid 
DNA (10 ng/l) or 4 l of a ligation reaction was added to a 50 l aliquot of the 
relevant competent cells and the cells incubated on ice for 5 min.  Cells were then heat 
shocked at 42°C for 30 s, and subsequently placed on ice for a further 2 min.  A 
recovery step was then performed in which 200 l of Luria-Bertani broth (LB) was 
added to cells followed by incubation at 37°C for 30 min.  The entire transformation 
volume was then plated on LB agar containing the appropriate antibiotic.  All plates 
were incubated overnight at 37°C.  Transformation of yeast strains is described in 
section 2.8.1. 
 
2.2.9. Site-directed mutagenesis 
Site-directed mutagenesis (SDM) was carried out by PCR using an Eppendorf 
Mastercycler PCR machine (Eppendorf), and the KOD Hot Start DNA Polymerase kit 
(Novagen).  Mutagenic primers (Eurofins MWG) were designed primarily according to 
the QuikChange protocol (Stratagene), however a non-overlapping primer design was 
also used in which single reverse primers could be used in conjunction with a choice of 
forward primers containing different mutations (see Figure 2.2).  A list of mutagenic 
primers is presented in Appendix 8.3.  The typical PCR protocol used for mutagenesis 
was adapted from the KOD Hot Start protocol (Novagen), and is outlined in Tables 2.9 
and 2.10. 
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Figure 2.2. Primer design for site-directed mutagenesis (SDM).  Most primers for SDM 
were designed in accordance with the “classic” QuickChange method.  The overlapping 
primers result in amplification of template creating staggered nicks.  The 
complementary sequence between the nicks is sufficient for recircularisation of the 
vector.  With the non-overlapping design, a single reverse primer can be used with a 
choice of forward primers containing different mutations.  The primers are abutting (no 
sequence overlap) and as a result the nicks on each strand are in the same location.  A 
ligation step is required to facilitate recircularisation. 
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Reagent Volume (µl) 
KOD Hot Start buffer (10X) 5 
MgSO4 (25 mM) 3 
dNTPs (2 mM each) 5 
Forward oligonucleotide primer (10 µM) 1 
Reverse oligonucleotide primer (10 µM) 1 
Template DNA (plasmid construct 10 ng/µl) 1 
dH2O 33 
KOD Hot Start DNA Polymerase (1 U/µl) 1 
Total 50 
 
Table 2.9. Typical SDM PCR setup.  This reaction mixture was effective for both mutagenic strategies. 
 
Step Temperature Time 
1 95 ºC (initial melting) 2 min 
2 95 ºC (melting) 20 s 
3 57 ºC (annealing) 10 s 
4 70 ºC (extension) 25 s/kb 
5 (repeat steps 2-4, 20 cycles)  
6 70°C (final extension) 5 min 
7 4 ºC 5 min 
 
Table 2.10. Typical SDM PCR thermal cycling conditions.  
 
PCR products were purified using the QIAquick PCR purification kit (QIAGEN), and 
eluted in 30 l dH2O.  Methylated parental DNA template was digested with the 
restriction enzyme DpnI (NEB).  The 5’-ends of constructs amplified using non-
overlapping primers were phosphorylated with polynucleotide kinase (NEB), and 
constructs recircularised by ligation using T4 DNA ligase (NEB).  The reaction 
conditions for template digestion, phosphorylation and ligation of constructs are 
summarised in Tables 2.11, 2.12 and 2.13. 
 
After final purifications, 10 ng of each mutant construct was transformed into E. coli 
Novablue “Singles” competent cells as described in section 2.2.8, and constructs 
purified as described in section 2.2.4. 
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QuikChange primer design 
  
Reagent Volume (l) 
NEB buffer 4  (10X) 4 
PCR product 30 
dH2O 4.5 
NEB DpnI (20 U/l)) 1.5 
Total 40 
  
 Incubation at 37°C 1 h 30 min 
 Purification (QIAGEN kit) 
 
Table 2.11.  Modification of SDM PCR products after QuikChange mutagenesis.  When QuikChange 
primers have been used DpnI treatment is required before transformation. 
 
Non-overlapping primer design 
  
Reagent Volume (l) 
NEB T4 DNA ligase buffer  (10X) 4 
PCR product 30 
dH2O 3.5 
NEB DpnI (20 U/l)) 1.5 
NEB T4 PNK (10 U/l) 1 
Total 40 
  
 Incubation at 37°C 1 h 30 min 
 Purification (QIAGEN kit) 
 
Table 2.12. Modification of SDM PCR products generated using the non-overlapping primer design.  
PCR products require 5’-end phosphorylation. 
 
 
Reagent Volume (l) 
NEB T4 DNA Ligase Buffer  (10X) 4 
 5’-phosphorylated construct PCR product 30 
dH2O 5 
NEB T4 DNA ligase (400 U/l) 1 
Total 40 
  
 Incubation at room temperature 30 min 
 Purification (QIAGEN kit) 
 
Table 2.13. Ligation reaction conditions to recircularise PCR products after 5’-end phosphorylation. 
 
 
2.3. Protein expression and purification 
 
2.3.1. Protein expression 
Constructs for protein expression were transformed into E. coli BL21 (DE3) Singles 
competent cells (Novagen) as described in section 2.2.8.  For protein expression, a 
single colony from an overnight plate was inoculated into 200 ml LB supplemented 
 75
with 34 g/ml chloramphenicol (Sigma) (pACYCDuet1 constructs used in this study 
confer chloramphenicol resistance).  Cultures were then incubated overnight in a 
shaking incubator (200 RPM) at 37°C.  The following day, 7.5 ml of the starter culture 
was inoculated into 750 ml Terrific Broth (TB) supplemented with 34 g/ml 
chloramphenicol.  The culture was incubated with shaking at 37°C and monitored by 
measurement of OD600 using an Ultrospec cell density meter (GE Healthcare).  When 
the culture density reached an OD600 of 0.6-0.8 the temperature of the incubator was 
dropped to 20°C and when the OD600 reached 1-1.5, IPTG was added to a final 
concentration of 1 mM to induce protein expression.  The induced culture was 
incubated at 20°C for a further 16 h and the cells harvested by centrifugation at 4,500g 
for 20 min.  Cell pellets were resuspended in 50 ml phosphate-buffered saline solution 
(PBS), and transferred to 50 ml centrifuge tubes (Corning Life Sciences).  Cells were 
harvested again by centrifugation at 3,000g for 20 min.  The supernatant was discarded 
and cells stored at -20°C.  Typically, expression of recombinant proteins for in vitro 
studies was carried out at a three litre scale using 4 X 750 ml cultures. 
 
2.3.2. Bacterial cell lysis 
All cell lysis procedures were performed on ice.  Cell pellets were defrosted and then 
resuspended at 10 ml/g (buffer/pellet) in the appropriate Buffer A (see Table 2.14 for 
buffer compositions).  In addition, 15 kU/g rLysozyme and 12.5 kU/g Benzonase 
Nuclease (both Novagen) were added to aid lysis and reduce lysate viscosity.  Two 
Complete Mini EDTA-free Protease Inhibitor Cocktail tablets (Roche) were also added 
to reduce protein degradation by E. coli proteases.  The cell suspension was incubated 
on ice for 30 min.  Cells were then lysed by sonication using a Branson Sonifer 450 set 
at 40% power with six 1 min pulses (1 min rests between each pulse).  The insoluble 
fraction of the lysate was removed by centrifugation at 61,000g for 1 h.  Samples of the 
clarified lysate and insoluble pellet (dissolved in 10 M urea) were removed for SDS-
PAGE analysis (see section 2.3.6). 
 
2.3.3. Purification of glutathione S-transferase fusion proteins 
The Glutathione S-transferase Gene Fusion System (GE Healthcare) enables the 
expression and purification of fusion proteins produced in E. coli.  The system is 
designed to overexpress a protein of interest that has been fused (at its C-terminus) with 
the 26 kDa Glutathione S-transferase protein (GST) derived from Schistosoma 
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japonicum.  The fusion protein can be purified from bacterial lysate by affinity 
chromatography using immobilised glutathione. 
 
GST purifications were carried out at room temperature.  In each protein purification, 2 
ml of glutathione sepharose 4B resin (GE Healthcare) was prepared according to the 
manufacturer’s instructions.  Clarified bacterial cell lysates (see section 2.3.2) were 
incubated with prepared glutathione Sepharose in 50 ml Falcon tubes at room 
temperature for 30 min with gentle agitation.  The resin (containing bound proteins) was 
pelleted by centrifugation at 500g for 2 min and the supernatant was discarded.  The 
resin was resuspended with 5 ml GST-A buffer (see Table 2.14) and incubated at room 
temperature for 10 min with gentle agitation.  Resin was then pelleted again by 
centrifugation at 500g for 2 min and the supernatant was discarded.  This wash step was 
repeated twice more and the resin was finally resuspended in 5 ml GST-A.  Samples of 
the insoluble cell pellet, clarified lysate, bound fraction (resin after lysate incubation) 
and each wash were analysed by SDS-PAGE gel electrophoresis (see section 2.3.6).  To 
remove the GST-tag from target proteins, non-cleavable GST-tagged 3C protease (GE 
Healthcare) was added to the resin according to the manufacturer’s instructions and 
incubated with gentle agitation overnight at 4°C.  The protease and the free GST 
generated by the cleavage remain bound to the resin.  The efficiency of cleavage and 
cleavage products were analysed by SDS-PAGE (see section 2.3.6). 
 
2.3.4. Nickel affinity purification 
His-Tag sequences enable the isolation of recombinant proteins through the affinity of 
histidine residues to a matrix containing chelated nickel ions. Nickel affinity 
purification was carried out at room temperature using buffers chilled on ice.   A 3 ml 
Ni-NTA Superflow (QIAGEN) gravity-flow column was equilibrated with 15 ml of 
Buffer Ni-A (see Table 2.14 for buffer compositions).  Clarified lysate (prepared as 
described in section 2.3.2) was applied to the column and allowed to drain by gravity-
flow.  The column was washed with 15 ml Ni-A, then 25 ml Ni-Wash Buffer to remove 
proteins bound non-specifically to the nickel resin.  The column was eluted with 25 ml 
Ni-B into 1 ml fractions.  Samples of the lysate flow-through, washes and every other 
eluted fraction were saved for analysis by SDS-PAGE (see section 2.3.6). 
 77
 
Buffer Composition Purpose 
GST-A 25 mM Tris-HCl pH 8.0, 150 mM NaCl, 
0.5 mM TCEP 
Cell lysis and GST purification 
Ni-A 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 
20 mM Imidazole pH 8.0, 5 mM MgCl2, 
0.5 mM TCEP 
Cell lysis, binding of target protein to 
nickel column 
Ni-Wash 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 
50 mM Imidazole pH 8.0, 5 mM MgCl2, 
0.5 mM TCEP 
Removal of proteins bound non-
specifically to nickel column 
Ni-B 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 
300 mM Imidazole pH 8.0, 5 mM MgCl2, 
0.5 mM TCEP 
Elution of 6-His-Tagged proteins 
Gel Filtration 
(GF) 
25 mM Tris-HCl pH 8.0, 150 mM NaCl, 
5 mM MgCl2, 0.5 mM TCEP 
SEC, protein storage 
 
Table 2.14. Buffer compositions for protein purification. 
 
2.3.5. Size-exclusion chromatography  
Size-exclusion chromatography (SEC) allows separation of proteins by size.  The 
matrices of SEC columns contain pores of a specified size, which allow proteins in the 
mobile phase to differentially penetrate the pores depending on the size of protein 
molecules.  After analysis by SDS-PAGE, protein fractions from nickel affinity 
purification containing the desired protein product were pooled and concentrated (see 
section 2.3.7) to a volume of 2-5 ml.  The concentrated protein was then loaded onto a 
HiLoad 16/60 Superdex (75 or 200) Prep grade SEC column linked to an AKTA prime 
system (all GE Healthcare).  The column was eluted at a flow rate of 0.5 ml/min at 4°C.  
The first 30 ml of eluate corresponding to the column dead volume was allowed to flow 
to waste.  After this, eluate was collected in 1 ml fractions.  The protein content of 
fractions was analysed using the AKTA PrimeView Evaluation software (v5.0 GE 
Healthcare) and by SDS-PAGE (see section 2.3.6).  Fractions containing purified target 
protein were pooled and concentrated as described in section 2.3.7. 
 
2.3.6. SDS-PAGE 
SDS-PAGE was used to analyse target protein purity after GST affinity 
chromatography, nickel affinity chromatography and SEC.  All SDS-PAGE 
experiments were performed using NuPAGE Bis-Tris precast polyacrylamide gels with  
1X NuPAGE MES SDS running buffer (Invitrogen).  Gels were run at 200 V for 35 min 
in an XCell SureLock mini-cell using a PowerEase 500 power supply (both Invitrogen).  
10 l of prepared sample was loaded per lane, composed of an equal mixture of protein 
sample, 3X SDS loading buffer and 100 mM dithiothreitol (DTT, 30 mM final 
concentration).  Samples were heated to 100°C for 5 min prior to loading.  The Novex 
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Sharp Pre-stained Protein Standard (Invitrogen) was used as a molecular size marker.  
Gels were developed by staining with a Coomassie solution (50% methanol, 10% acetic 
acid, 0.05% Coomassie Brilliant Blue R-250) for 5 min, then destained with at least 
three 5 min washes with a destain solution (10% methanol, 10% acetic acid).  Results 
were recorded with a Canon powershot PC1234 digital camera. 
 
2.3.7. Protein concentration, storage and dialysis 
Prior to SEC or storage, proteins were concentrated by centrifugal ultrafiltration at 
4,000g using 20 ml Vivaspin ultrafiltration concentrators (Vivaproducts) of an 
appropriate molecular weight cut-off (MWCO).  For storage after final concentration, 
the protein was snap-frozen in liquid nitrogen in aliquots of 30 or 100 l (depending on 
yield) and stored at -20°C.  Before circular dichroism experiments (see section 2.7), it 
was necessary to dialyse protein samples into phosphate buffer (10 mM Na2HPO4 
/NaH2PO4 pH 7.4, 150 mM NaCl).  A protein sample of typically 100-200 l volume 
was defrosted on ice, and diluted with pre-chilled phosphate buffer to a final volume of 
500 l.  The protein sample was injected into a 0.1-0.5 ml capacity 10,000 kDa MWCO 
Slide-A-Lyzer Dialysis Cassette (Thermo Scientific), and the sample dialysed against 2 
l of phosphate buffer for 2 h at 4°C.  The buffer was then replaced with a fresh 2 l of 
phosphate buffer and the dialysis continued overnight at 4°C.  For CD, dialysed protein 
was removed from the cassette and concentrated to 0.15 mg/ml by centrifugation at 
4,000g in a 500 µl capacity 10,000 MWCO Vivaspin 500 ultrafiltration (Vivaproducts). 
 
 
2.3.8. Determination of protein concentration 
Protein concentration was determined spectrophotometrically using a NanoDrop ND-
1000 spectrophotometer (Thermo Scientific).  For each sample, a UV spectrum (200 nm 
to 350 nm) was recorded.  Concentration was determined using the Beer-Lambert law 
(see Equation 2.1). 
 
Cm = A280/ε280.l  (Equation 2.1) 
 
Where Cm is the Molar concentration, A280 is the absorbance at 280 nm, ε280 is the 
protein molar extinction coefficient at 280 nm (see section 2.1.1 for ε280 determination) 
and l is the optical path length, usually 1 cm.  
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2.4. Multiangle laser light scattering  
 
Multiangle laser light scattering (MALLS) is a photometric method that uses the 
measurement of Rayleigh scattering (the scattering of light by molecules far smaller 
than the wavelength of the incident light beam) of molecules in solution to determine 
their absolute molar mass.  When used in conjunction with SEC (SEC-MALLS), this 
technique is frequently used to elucidate protein molar mass, oligomerisation states and 
for the detection of protein aggregates [194].  A common SEC-MALLS laboratory setup 
uses an analytical SEC column to remove aggregates and separate proteins in a sample 
by size before the chromatographic peaks are passed through a series of absorbance 
(UV-Vis), light scattering (LS) and differential refractive index (dRI) detectors.  Within 
the LS detector, a vertically-polarised laser beam is projected into the flow cell through 
which the eluted chromatographic peaks pass.  The light intensity scattered by 
molecules in the sample (I) is measured by multiple detectors placed at different angular 
positions around the sample (see Figure 2.3A).  The incident light is also measured as a 
reference (I0). The detectors provide a response directly proportional to the intensity of 
the scattered light they receive, which is relayed to a computer for processing.  The light 
scattering data is then used to calculate the Rayleigh ratio (R, see Equation 2.2), which 
is the light scattered by the sample at an angle  in excess of the light scattered by the 
pure solvent. This can be expressed as: 
R  I r
2
I0
  (Equation 2.2) 
 
where I0 is the intensity of the incident light beam, I  is the total intensity of scattered 
light (in excess of that scattered by the pure solvent) observed at angle  at a distance r 
from the point of scattering.  The Rayleigh ratio is an integral part of the equation that is 
used to determine the absolute molar mass [195]: 
 
KC
R 
1
M
2A2C   (Equation 2.3) 
 
where C is the solute (protein) concentration in g/ml, M is the weight-averaged molar 
mass, A2 is the second virial coefficient (a measure of solution non-ideality) and K is an 
optical parameter equal to Equation 2.4: 
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Figure 2.3.  Multiangle laser light scattering (MALLS). (A) Design of a light scattering 
instrument.  A collimated laser beam is passed into a flow cell (or a static cell) 
containing the sample.  Molecules in the sample scatter the light from the laser in all 
directions.  Detectors placed at different angular positions around the sample provide a 
response directly proportional to the intensity of scattered light they receive.  The 
analogue signals from detectors are digitised and processed by relevant computer 
software. (B) Example of a Debye plot.  Each point of the plot represents the KC/R  
value for a given detector angle (sin2(/2)).  The intercept of the points (red line) is used 
to calculate the weight averaged molar mass from Equation 2.3.  The computer software 
generates plots or “slices” at short time intervals throughout the elution of a 
chromatographic peak.  Combining and averaging the data of all the plots within a 
defined peak is used to calculate average molar mass and polydispersity. (C) Example 
of a MALLS chromatogram generated using ASTRA v5.3.4.19 software (Wyatt 
Technology).  Light scattering (LS), differential refractive index (dRI) and UV traces 
indicate the position of chromatographic peaks (see inset key).  The thick black line is 
composed of individual points that represent the weight-averaged molar mass 
determined by individual Debye plots as illustrated in (B). 
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K  4
2n0
2 (dn /dC )2
(4 N )   (Equation 2.4) 
 
where n0 is the refractive index of the solvent, dn/dC is the refractive index increment of 
the solute at the same wavelength as the light scattering measurement, NA is Avogadro’s 
number and 0 is the vacuum wavelength of the incident light. 
 
As can be seen in Equation 2.3, estimation of protein molar mass requires knowledge of 
the protein concentration in a sample.  Consequentially, the LS detector is used in 
conjunction with a differential refractometer, which measures the very small differences 
between the refractive index of the sample and the solvent (n - n0), allowing 
determination of protein concentration from the refractive index increment dn/dC. 
 
In a SEC-MALLS experiment used to determine the absolute molar mass of a protein, 
the scattered light intensities and corresponding protein concentration are measured at a 
series of time intervals throughout peak elution and used to construct Rayleigh  (KC/R 
vs C) or Debye (KC/R vs sin2(/2)) plots.  Weight-averaged molar masses can then be 
determined from the intercept of individual plots, and an overall average molar mass 
and polydispersity term for the entire protein peak can be calculated by combining and 
averaging the data from all of the plots. The use of Debye plots to determine protein 
absolute molar mass is summarised in Figure 2.3B, and an example of a chromatogram 
demonstrating a series of Debye plots generated through a chromatographic peak is 
shown in Figure 2.3C. 
 
In a typical SEC-MALLS analysis, samples were applied to a Superdex (75 or 200) 
10/300 GL SEC column (GE Healthcare) equilibrated in 25 mM Tris-HCl pH 8.0, 150 
mM NaCl, 4.9 mM MgCl2, 0.5 mM TCEP and 3 mM NaN3 (unless otherwise stated).  
The column was connected to a Jasco HPLC system equipped with UV detection (Jasco 
UV-970M) controlled by the Chrompass v1.8.6.1. software package (Jasco).  The 
scattered light intensity of the column eluent was measured at sixteen angles using a 
DAWN-HELEOS photometer (Wyatt Technology) with a laser wavelength of 658 nm.  
The protein concentration of the eluate was determined using an Optilab rEX 
differential refractometer (Wyatt Technology) with its light source also set at 658 nm 
and a refractive index increment (dn/dC = 0.186 ml/g). The weight-averaged molar 
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mass of material contained in the chromatographic peaks was determined by combining 
data from the LS and dRI detectors using the ASTRA v5.3.4.19 software (Wyatt 
Technology).   
 
2.5. Reversed-phase high-performance liquid chromatography  
 
Reversed-phase high-performance liquid chromatography (RP-HPLC) can be used to 
separate and purify biomolecules within a sample based upon their hydrophobic 
properties.  The separation mechanism is based upon the hydrophobic interaction of 
molecules dissolved in an aqueous mobile phase with immobilised hydrophobic ligands 
(the stationary phase) [196].  Typically, the stationary phase is made up of linear 
hydrocarbon chains attached to a silica matrix.  The addition of an ion-pairing agent 
such as trifluoroacetic acid can be used to modify the retention time of proteins and 
peptides on a reversed-phase (RP) column.  This is achieved through an ionic 
interaction between the pairing agent and positively charged basic residues in a protein 
or peptide, reducing their hydrophilicity.  Introduction of an organic modifier lowers the 
polarity of the aqueous mobile phase and causes elution of biomolecules from the 
stationary phase.  By using an elution gradient in which the polarity of the mobile phase 
is gradually lowered, it is possible to separate different biomolecules based on their 
varying degrees of hydrophobicity.  By monitoring the eluate from a RP column using 
the chromophore absorbance, it is possible to visualise “resolved” peaks for further 
analysis or purification. 
 
2.5.1. Reversed-phase nucleotide assay 
Nucleotides were extracted from protein samples by addition of perchloric acid to 0.7%.  
Samples were immediately neutralised by addition of sodium acetate to 200 mM, and 
the supernatant containing the extracted nucleotides separated from precipitated protein 
by centrifugation at (17,000g) for 5 min at 4 ºC.  The sample (80 l at a concentration 
of 25 M) was applied to a Zorbax SB-C18 column (4.6 x 250 mm, 5 µm pore size, 
Agilent Technologies) equilibrated in 100 mM K2HPO4/KH2PO4 (pH 6.5), 8% 
acetonitrile, 10 mM tetrabutylammonium bromide (TBAB), mounted on a Jasco HPLC 
system controlled by Chrompass v1.8.6.1. software (Jasco).  The column temperature 
was maintained at 30°C.  The retention time of the eluted nucleotide under these 
isocratic conditions was monitored at 260 nm using a Jasco MD-2010 Plus multi-
wavelength detector fitted with a semi-micro flow cell.  This multi-wavelength detector 
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also permitted the extraction of UV-absorbance spectra from the eluted nucleotide to 
confirm the identity of the nucleotide base.  The column retention times of a set of 
nucleotide standards were determined to enable comparison with individual nucleotide 
species (i.e. to distinguish between AMP, ADP and ATP). 
 
2.5.2. Reversed-phase complex composition assay 
10 g protein samples were dissolved in 20 mM Tris-HCl pH 8.0, 10 M urea, 2 mM 
EDTA, 5 mM TCEP, 1% acetic acid to give a final volume of 20 µl.  The sample was 
applied to a Zorbax 300SB-C3 Narrow-Bore column (2.1 x 150 mm, 5 µm pore size, 
Agilent technologies) equilibrated in Buffer CC-A (see Table 2.15), mounted on a Jasco 
HPLC system controlled by Chrompass v1.8.6.1. software (Jasco).  The column 
temperature was maintained at 60°C.  The column was eluted using a gradient from 
Buffer CC-A to Buffer CC-B (see Table 2.16).  The retention times of the eluted peaks 
were monitored at 220 nm using a Jasco MD-2010 Plus multi-wavelength detector fitted 
with a semi-micro flow cell.   
 
Buffer CC-A Buffer CC-B 
HPLC- H2O Acetonitrile 
0.05% TFA 0.05% TFA 
 
Table 2.15.  Reversed-phase complex composition assay buffer compositions. 
 
 
Step Time (min) % A % B 
Pre-run 0 95 5 
Start ramp 7 95 5 
End ramp/start gradient 13 75 25 
End gradient 40 40 60 
Final elution 45 0 100 
Final elution end 50 0 100 
Re-equilibrate 55 95 5 
End of experiment 65 95 5 
 
Table 2.16.  Complex composition assay gradient elution profile.  Proteins in this assay did not elute 
before 25% B so a ramp step was introduced to save time.  The final elution was a precaution to wash off 
any contaminants strongly bound to the column.  The re-equilibration step ensured the column was ready 
for the start of another experiment. 
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2.5.3. Integration of UV absorbance peaks and stoichiometry calculation 
Peak areas of chromatographic peaks were determined by integration of their UV 
absorbance and were used to quantify the amount of protein/nucleotide (in moles) 
contained within the peak using Equation 2.5. 
 
N  A 
f
1000
 (Equation 2.5) 
 
Where N is the amount of protein/nucleotide in moles, A is the integrated peak 
absorbance at a given wavelength (220 nm or 280 nm for proteins, 260 nm for 
nucleotides) and f is the flow rate in ml per min.  For proteins, when A is measured at 
280 nm, ε is the molar extinction coefficient (ε280). For nucleotides, measured at 260 
nm, ε is the molar extinction coefficient of the nucleotide at 260 nm (ε260). For data 
collected at 220 nm in RP-HPLC complex composition assays, assuming an average 
amino acid composition, ε is replaced by the number of residues of each chain (445 in 
Clp1, 107 in Pcf11(454-561)). The stoichiometry of Clp1-Pcf11 complexes was 
determined from the mole ratio of Pcf11 and Clp1 derived from 280 nm data or from 
the ratio of the residue-normalised Pcf11 and Clp1 absorbance at 220 nm. 
 
 
2.6. Incorporation of radiolabelled ATP and scintillation counting 
 
A stock solution of radiolabelled ATP was made in the following manner: 499 l of 
ATP (concentration 1 mM) was spiked with 1 l ATP [-32P] (6000 Ci/mmol 10 
mCi/ml, Perkin Elmer) to give a final ATP [-32P] concentration of 20 Ci/ml.  The 1 
mM ATP [-32P] stock was diluted into buffered protein samples to give molar ratios of 
2:1, 5:1 and 10:1 (ATP [-32P]: protein) in final volumes of 100 l.  Control reactions 
were prepared by dilution of 1 mM ATP [-32P] into buffer containing no protein.  
Samples were incubated at room temperature for 1 h.  After incubation, 1 l of sample 
was removed for scintillation counting.  Unincorporated ATP [-32P] was then removed 
by centrifugation using PD spinTrap G25 desalting spin columns (GE healthcare) 
equilibrated in 25 mM Tris-HCl pH 8.0, 150 mM NaCl, 4.9 mM MgCl2, 0.5 mM TCEP 
(the volume of sample after centrifugation was equal to the input volume), and 1 l of 
the eluate was removed for scintillation counting.  Samples were diluted into 500 l 
dH2O and 8 ml Liquiscint scintillation fluid (National Diagnostics), then mixed 
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thoroughly.  Scintillation counting was performed on a Beckman LS 5000 CE 
scintillation counter using the 32P channel.  In samples containing protein, ATP 
exchange was measured by the difference between total ATP [-32P] counts per million 
(CPM, before desalting) and eluted ATP [-32P] CPM (after desalting) minus the 
background CPM (eluate from samples not containing protein). 
 
2.7. Circular dichroism spectroscopy 
 
Circular dichroism is the phenomenon that arises from the differential absorption of 
left- and right-handed circularly polarised light by chiral molecules.  Circular dichroism 
spectroscopy (CD) exploits this effect to gain information about the structures of 
biomolecules.  The peptide bonds of a protein are chromophores in the far-UV spectral 
region (190-250 nm) and are chiral. When in a regular, folded environment, secondary 
structure elements of proteins give rise to characteristic CD signals: -helices display 
intense negative absorbance peaks at ~208 and 222 nm and an intense positive peak at 
~198 nm.  -sheets give rise to a negative peak at ~215 nm and a positive peak at ~198 
nm, and random coil has a weak positive absorbance peak at ~220 nm and a strong 
negative peak at 195-198 nm. 
 
For CD experiments, protein samples were dialysed into phosphate buffer and 
concentrated to 0.15 mg/ml (as described in section 2.3.7).  Far-UV CD spectra were 
recorded on a Jasco-J715 spectropolarimeter using a quartz cuvette with 1 mm 
pathlength.  Spectra were taken with a 100 nm/min scan rate, 0.25 s time constant and 2 
nm spectral bandwidth.  Final spectra were the average of at least 20 scans.  Data 
analysis was carried out with Dr S. Martin (NIMR) using the SpecPro program.  The 
CD signal was measured in millidegrees and converted to the mean residue weight 
differential molar extinction (mrw) using Equation 2.6. 
 
 mrw  S (mrw)
(3290) C l  (Equation 2.6) 
 
where S is the CD signal in millidegrees, mrw is the protein mean residue weight (a 
value close to 110 Da), C is the protein concentration in mg/ml and l is the pathlength of 
the cuvette. 
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Fitting of protein secondary structure content from far-UV CD spectra was carried out 
using the CDpro program (with Dr S. Martin, NIMR):  the CONTIN, SELCON3 and 
CDSSTR methods of secondary structure estimation from CD data were used as 
recommended by Sreerama and Woody [197].  The final estimated secondary structure 
content was calculated by averaging the results provided by each method. 
 
2.8. Yeast methods 
 
2.8.1. Yeast transformations 
A small amount of a glycerol stock of the desired yeast strain was inoculated into 20 ml 
yeast extract peptone dextrose medium (YPD, composition as described by Amberg et 
al. [198]) and incubated overnight at 30°C with shaking (180 RPM).  The following 
morning, 1 ml of the overnight culture was inoculated into 50 ml fresh YPD and 
incubated for 5 h at 30°C in with shaking, and the yeast cells were harvested by 
centrifugation at 3,000g for 2 min.  The cell pellet was washed in 30 ml dH2O, then in 1 
ml 100 mM lithium acetate, before being resuspended in 400 l of 100 mM lithium 
acetate.  A competent cell mix containing an aliquot of this cell suspension and the 
desired plasmid for transformation was prepared as described in Table 2.17.  The 
competent cell mix containing the plasmid construct (transformation mix) was mixed 
thoroughly and incubated at 30°C for 30 min, followed by 42°C for at least 30 min and 
incubation on ice for 5 min.  Transformed cells were then harvested by centrifugation at 
6, 200g for 1 min, and resuspended in 600 l dH2O.  200 l of transformed cells were 
plated on the appropriate selective medium (minimal medium minus leucine for LEU2 
plasmid constructs or minus uracil for URA3 constructs, media compositions as 
described by Amberg et al. [198]) and plates incubated at 30°C.  Colonies from 
successful transformants were typically visible after 2 days and at optimum size for 
selection after 3 days. 
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Reagent Volume (l) 
Yeast cell suspension 50 
50% PEG 3350 kDa 240 
1 M lithium acetate 36 
Carrier DNA 2 mg/ml * 
(single stranded salmon sperm, Sigma) 
50 
Desired plasmid construct (75 ng/l) 2 
dH2O 32 
Total 410 
 
Table 2.17. Yeast competent cell mix.  For multiple transformations, a master mix was made and divided 
between different tubes containing the desired plasmid constructs. * Salmon sperm DNA was denatured 
by incubation at 95°C for 10 min, then cooled on ice for 5 min prior to addition to the competent cell mix. 
 
2.8.2. Construction of a haploid pcf11 yeast strain 
A diploid pcf11/PCF11 yeast strain (see section 2.2.2) was transformed with the 
URA3-PCF11 construct (see section 2.2.3) as described in section 2.8.1.  Individual 
colonies were streaked onto minimal medium (minus uracil) and incubated at 30°C for 
3 days until a thick patch of cells had grown.  Cells were streaked from this plate onto 
minimal sporulation medium (composition as described by Amberg et al. [198]) and 
incubated at 23°C for 1-2 weeks.  Cells were analysed under a light microscope for 
formation of tetrads (4 haploid spores).  When sufficient numbers of tetrads were 
visible, the asci (capsules encasing the spores) were digested by mixing cells into 200 l 
of 5% Glusulase solution (Perkin Elmer) and incubating at 30°C for 45 min.  After this 
time, spores were settled at the base of the tube and the supernatant was decanted.  The 
spores were resuspended in 500 l dH2O and then diluted 1 in 10.  50 l aliquots of the 
diluted spore solution were deposited onto the edge of a YPD plate.  10-20 intact tetrads 
were dissected using a Singer MSM System dissection microscope.  Individual spores 
from dissected tetrads were separated on the YPD plate using the microscope’s 
computer grid system.  The YPD plate containing dissected spores was incubated for 2-
3 days to allow spores to germinate.  Where 3 or 4 spores from a tetrad had germinated 
and multiplied by vegetative growth, the resulting haploid cells were streaked onto both 
YPD plates containing 100 g/ml G418 antibiotic (Sigma) and 5-FOA plates (see 
section 2.8.3) and incubated at 30°C for 3 days.  Yeast that were resistant to G418 but 
sensitive to 5-FOA were prospective haploid pcf11 strains: only yeast that is pcf11 
could grow on G418 antibiotic as the cassette that disrupts pcf11 confers 
kanamycin/G418 resistance, and sensitivity to 5-FOA confirmed the presence of the 
URA3 plasmid construct containing the PCF11 gene.  To confirm the creation of a 
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haploid pcf11 strain, 5-FOA plasmid selection was then performed with haploid 
pcf11 transformed with the LEU2-PCF11 construct (see section 2.8.3). 
 
2.8.3. 5-FOA Plasmid shuffle  
There are various methods by which a yeast strain can be manipulated so that the effects 
of mutations in target genes can be observed.  A common approach to assay the 
functionality of a S. cerevisiae mutant is to delete the gene of interest from the 
chromosome and complement the deletion with a plasmid-borne copy of the gene 
containing the desired mutation.  However, when genes are essential this poses a 
problem, as their deletion is lethal.  To overcome this problem, a plasmid shuffle system 
has been developed based upon the principle that URA+ yeast strains are sensitive to 5-
fluoroorotic acid (5-FOA).  This system allows the eventual phenotype of a gene mutant 
to be observed [199, 200]. 
 
The principles of the 5-FOA plasmid shuffle system are summarised in Figure 2.4.  The 
first step in the system is to create a haploid strain in which the chromosomal copies of 
the target, URA3 and LEU2 genes have been deleted.  Functional copies of the target 
and URA3 genes are present at this stage on a URA3 plasmid (see section 2.8.2 for 
haploid strain construction).  This strain is subsequently transformed with a LEU2 
plasmid containing a functional copy of LEU2 and a mutagenised copy of the target 
gene.  Plating on minimal medium containing 5-FOA then allows selection against 
URA3+ yeast.   
 
5-FOA selection depends upon the conversion of the non-toxic 5-FOA compound to 
highly-toxic 5-flurouracil by the orotidine 5’-phosphate decarboxylase enzyme (OMP 
decarboxylase) encoded by the URA3 gene [199, 200].  The 5-flurouracil product is a 
potent and irreversible inhibitor of thymidine synthase.  Inhibition of thymidine 
synthase blocks the production of thymidine monophosphate (dTMP), leading to a 
cessation in DNA replication and lethality.  Therefore, 5-FOA selection leads to the 
death of yeast cells containing the URA3 plasmid bearing the wildtype copy of the 
chromosomally deleted target gene.  Where the URA3 plasmid has been lost by 
asymmetric plasmid segregation during mitosis, the yeast can survive on 5-FOA if they 
bear the LEU2 plasmid with the mutagenised gene only if the encoded protein is viable. 
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Figure 2.4. The 5-FOA plasmid shuffle system.  The example given is for the haploid 
pcf11 strain.  The wildtype copy of the target gene in the LEU2 plasmid can be 
mutated directly by SDM.  The 5-FOA plasmid shuffle can then be used to obtain a 
transformed yeast strain only expressing the mutant protein for further experiments.  
Where genes are essential, this is only possible if mutations within the gene do not 
completely abrogate essential functions.   
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The clp1 haploid yeast strain was supplied by Dr. M. Geymonat (formerly NIMR), 
and the pcf11 haploid yeast strain was created as described in section 2.8.3.  These 
strains were transformed with LEU2 plasmids containing copies of wildtype or mutant 
clp1 or pcf11 as described in section 2.8.1.  An individual colony from LEU2+ 
transformants was streaked onto minimal medium minus leucine and incubated at 30°C 
for 2-3 days.  5-FOA selection was carried out in the following manner: Cells were 
taken from the colony-derived cell patch and resuspended in 1 ml dH2O.  A further 
dilution of 30 l into 1 ml was made to obtain the first point in a dilution series of cell 
suspensions.  Three serial dilutions of 1:10 ratio (cells:dH2O) were made from the first 
point in the series (total four points).  5 l of each dilution was plated onto both minimal 
medium containing 5-FOA (1 mg/ml) and YPD.  Plates were allowed to dry and 
incubated at 23°C for 5 days.  To look for temperature sensitive phenotypes, a duplicate 
set of plates was incubated at 37°C (or other specified temperatures) for 3 days. 
 
2.8.4. Growth rate assays 
After 5-FOA selection, the desired yeast mutant was plated onto YPD and incubated 
overnight at 30°C.  The following evening, cells from the plate were inoculated into 20 
ml YPD broth and incubated overnight with shaking (180 RPM) at 30°C.  The 
following morning, the cell density of the culture was measured.  Briefly, 50 l of cell 
culture was mixed with 10 ml 1X CASYton cell culture dilution solution (Schärfe 
system) in a sample vial. The mixture was then sonicated at 20% power for 3 s and the 
cell density measured using a CASY1 TT cell counter (Schärfe system).  For growth 
rate assays, the overnight culture was diluted into fresh YPD broth to give a density of 1 
X 106 cells/ml, and incubated with shaking at 30°C unless another temperature was 
specified.  The cell density was measured every hour for eight hours as described above. 
 
For assays with mutant yeast under control of the GAL1 promoter, growth rate assays 
were performed as above except using YPD with 2% galactose and 2% sucrose (YPD 
gal/suc) as carbon sources (instead of glucose).  To monitor the repression of the GAL1 
promoter, the desired yeast mutant was initially cultured in YPD gal/suc broth and 
diluted into fresh YPD glucose (YPD glu) broth before the start of the 8 h time course.  
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2.8.5. Western Blotting 
A LEU2 construct containing the desired gene mutant was transformed into the 
appropriate haploid deletion strain as described in section 2.8.1.  A single colony from 
the transformation plate was streaked onto minimal media and incubated at 30°C for 3 
days.  Using a sterile loop, cells were deposited into 20 ml liquid minimal medium 
(minus leucine), and cultured overnight at 30°C with shaking (180 RPM).  The 
following morning, 2 ml of the culture was diluted into 50 ml fresh liquid minimal 
medium (minus leucine) and incubated for 5 h at 30°C with shaking.  The yeast cells 
were then harvested by centrifugation at 3,000g, washed once with 1 ml PBS then snap 
frozen in liquid nitrogen and stored at -80°C.  
 
Whole cell extract was prepared by the following procedure. Defrosted yeast cell pellets 
were resuspended in 500 l of yeast lysis buffer (50 mM Tris pH 7.4, 250 mM NaCl, 
0.5 mM EDTA).  To assist with lysis, Nonidet P-40 was added to a final concentration 
of 0.2% and 5 l of 100X Halt Protease Inhibitor Cocktail (Thermo Scientific) was also 
added to inhibit protein degradation.  Yeast cells were lysed with 500 m diameter acid-
washed glass beads (Sigma) using a FastPrep-24 Ribolyzer (MP Biomedicals). 
Typically, six 10 s bursts with 2 min rests on ice between bursts was sufficient for cell 
lysis.  The whole-cell extract lysate was collected by centrifugation at 3,000g for 2 min, 
and clarified by centrifugation twice at 17,000g for 15 min at 4°C.  The protein 
concentration of whole cell extract was determined by the Bio-Rad Protein assay 
following the manufacturer’s protocol (Bio-Rad), using an Eppendorf BioPhotometer 
(Eppendorf). 
 
Samples for Western blotting were composed of an equal mixture of yeast whole cell 
extract, 3X SDS loading buffer and 100 mM DTT.  The final protein concentration of 
loading samples was 2 mg/ml.  Before loading, samples were heated to 100°C for 5 
min.  SDS-PAGE was performed as described in section 2.3.6.  After SDS-PAGE, the 
gel was soaked in 40 ml Western transfer buffer (25 mM Tris-HCl pH 8.3, 194 mM 
glycine, 10% methanol) for 20 min and the proteins transferred to an Immobilon-P 
Transfer membrane (Millipore) in a BioRad Trans-Blot Cell run at 100 V for 1 h.  After 
protein transfer, the membrane was blocked overnight with 10 ml 1X Western Blocking 
Reagent (Roche) at 4°C with gentle agitation.  The following morning the membrane 
was placed into 10 ml fresh 0.5X Western Blocking Reagent.  The membrane was 
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probed by addition of a 1:10,000 dilution of mouse Anti-HA antibody (clone 12CA5, 
Roche) and incubation at room temperature for 1 h at room temperature with gentle 
agitation.  To remove non-specifically associated primary antibody, the membrane was 
washed three times for 10 min with 20 ml Tris-buffered saline plus 0.1% Tween-20 
(TBST).  For detection, the membrane was placed into 20 ml 0.5X Western blocking 
buffer and a 1:20,000 dilution of peroxidise-conjugated goat anti-mouse secondary 
antibody added (Thermo Scientific).  The membrane was incubated at room temperature 
for 1 h with gentle agitation and then washed three times as described above. 
SuperSignal West chemiluminescent substrate was applied in accordance with the 
manufacturer’s protocol (Thermo Scientific) and protein bands visualised using X-ray 
film (Amersham Hyperfilm MP, GE healthcare). Exposures were 10-30 s, and the films 
were developed using a FujiFilm FPM-3800AD film processor. 
 
2.8.6. Coimmunoprecipitation experiment 
The desired yeast mutant was cultivated as described in section 2.8.5, except the culture 
volume was increased to 100 ml.  Whole cell extract was prepared immediately as 
described in section 2.8.5 with the following modifications: the lysis buffer was 
composed of 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2 and 5% glucose, 
with no addition of EDTA or Nonidet-P40.  Protease inhibitors were used as before.  In 
the absence of detergent, the lysate was clarified by centrifugation twice at 17,000g for 
15 min at 4°C, and finally at 17,000g for 30 min at 4°C.  
 
CoIP of HA-tagged proteins with associated binding partners was performed with the 
Pierce HA Tag IP/Co-IP Kit (Thermo Scientific) using the manufacturer’s protocol, 
except that Tween-20 was omitted from buffers.  20 l of the CoIP elution volume was 
resolved by SDS-PAGE as described in section 2.3.6 and the proteins were transferred 
to an Immobilon-P Transfer membrane as described in section 2.8.5.  The membrane 
was blocked and probed with primary antibody as described in section 2.8.5 except a 
1:1,000 dilution of rabbit anti-Clp1 antibody (produced for us by BioServ UK, 
Sheffield, UK) was used.  The membrane was washed as described in section 2.8.5, and 
detection and visualisation with a 1:20,000 dilution of peroxidase conjugated goat anti-
rabbit secondary antibody (Thermo Scientific) was performed as described in 2.8.5.  For 
corresponding anti-HA detection, the membrane was stripped by incubation at room 
temperature for 15 min in 20 ml Restore Western Blot Stripping buffer (Thermo 
Scientific).  The membrane was briefly washed in TBST before blocking and detection 
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of anti-HA tagged protein was performed (using the same protocol as described in 
2.8.5). 
 
2.8.7. Determination of protein half-life 
The desired HA-tagged construct was transformed into the appropriate haploid yeast 
strain and selected by growth on 5-FOA as described in sections 2.8.1 and 2.8.3 
respectively.  Cells from the 5-FOA plate were streaked onto YPD and incubated at 
30°C for 2 days.  Cells from the YPD plate were inoculated into 20 ml YPD broth and 
cultured with shaking (180 RPM) overnight at 30°C.  The following morning, the cell 
density of the culture was measured as described in section 2.8.4.  The appropriate 
volume of culture was inoculated into 100 ml fresh YPD broth to give a cell density of 
2 X 106 cells/ml, and the culture grown for 8 h with shaking at 30°C.  After this time, 
cycloheximide (Sigma) was added to the culture to a final concentration of 50 g/ml to 
inhibit protein synthesis, and 5 ml samples withdrawn from the culture at 0, 30, 60, 90 
and 120 min time points post cycloheximide treatment.  Cells from these samples were 
harvested immediately by centrifugation at 3,000g, and the cell pellets flash frozen in 
liquid nitrogen and stored at -20°C.  Yeast whole cell extract was prepared as described 
in section 2.8.5, except the volume of lysis buffer used was reduced to 100 l.  Western 
blotting was performed as described in section 2.8.5.  The developed film was scanned 
using an Epson Perfection V700 duplex scanner and the ImageJ v1.45s software 
(National Institutes of Health) was used to quantify the intensity of individual protein 
bands. The apparent half-life of proteins was derived from plots of band intensity (A) 
against time after cycloheximide treatment (t). The data were fitted directly to Equation 
2.7 that describes the exponential decaying signal in terms of the initial amplitude (Ao) 
and the protein half-life (t1/2). 
  
A = A0e ((-(ln2)/t1/2)t)                           (Equation 2.7) 
 
2.8.8. Preparation of total RNA 
The desired mutant HA-tagged construct was transformed into the appropriate haploid 
yeast strain and selected by growth on 5-FOA as described in sections 2.8.1 and 2.8.3 
respectively.  Cells from the 5-FOA plate were streaked onto YPD and incubated at 
30°C for 2 days.  Cells from the YPD plate were inoculated into 20 ml YPD broth and 
cultured overnight at 30°C with shaking (180 RPM).  The following morning, the cell 
density of the culture was measured as described in section 2.8.4.  The appropriate 
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volume of culture was inoculated into 50 ml fresh YPD broth to give a cell density of 2 
X 106 cells/ml, and the culture grown for 8 h with shaking at 30°C.  Cells were 
harvested by centrifugation at 3,000g, and the cell pellet flash frozen in liquid nitrogen 
and stored at -20°C overnight.  The following day, total RNA was extracted from the 
cell pellet using the RiboPure Yeast Kit (Ambion) according to the manufacturer’s 
protocol.  Purified RNA was divided into 5 l aliquots and stored at -80°C.  The purity 
of RNA samples was assessed by UV absorbance using the A260:A280 ratio (a high 
purity sample has a A260:A280 ratio of 1.8 to 2.1).  The quality of RNA samples was 
assessed by comparing the intensities of the 18S and 28S ribosomal RNA (rRNA bands) 
that were visualised by denaturing agarose gel electrophoresis (following the 
manufacturer’s instructions, Ambion, see Appendix 8.7). 
 
2.9. Poly(A) tail-length assay 
 
The poly(A) tail-length assay is a technique used to assess the ability of specific yeast 
strains to polyadenylate pre-mRNA.  The assay involves extracting and radiolabelling 
total RNA samples from the desired yeast strain.  Total RNA is then digested using 
specific RNases that do not cleave at adenine bases, leaving polyadenylate tails as the 
only RNA fragments of significant length.  Poly(A) tail-length is then analysed after 
denaturing polyacrylamide gel electrophoresis, and differences in polyadenylation are 
determined by changes in the size distribution of poly(A) tails between wildtype and the 
desired mutant yeast strains.  Various adaptations of a similar poly(A) tail-length assay 
protocol have been cited in the literature in the past 25 years [91, 94, 104, 201, 202].  
These protocols are very concise, and had to be considered as templates to formulate 
our own protocols, described below. 
 
2.9.1. Poly(A) tail 3’-end labelling 
Total RNA was radiolabelled using poly(A) polymerase and the ATP analogue, 
cordycepin 5’-triphosphate [-32P] (Perkin Elmer) that lacks a 3’-hydroxyl moiety and 
causes chain termination during RNA synthesis (hence each RNA chain is radiolabelled 
with one molecule of cordycepin).  The components of the 3’-end labelling reaction 
used in the first method for poly(A) tail-length analysis are listed in Table 2.18. 3’-end 
labelling was performed at 37°C for 30 min, and then poly(A) polymerase heat 
inactivated by incubation at 65°C for 15 min. Unincorporated cordycepin was removed 
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by centrifugation using an Illustra MicroSpin G25 spin column (GE Healthcare) that 
was pre-equilibrated in 1X PAP buffer (Ambion). 
 
 
Table 2.18.  Original and modified reaction setups for 3’-end labelling of total RNA samples.  Poly(A) 
polymerase and associated buffers were purchased from Ambion.  Cordycepin 5’-triphosphate: 3’-
deoxyadenosine 5’-triphosphate [-32P], 250 Ci (9.25 MBq), 10 mM tricine pH 7.6, concentration 10 
mCi/ml (Perkin Elmer). 
 
2.9.2. Poly(A) tail digestion and purification 
The volume of the radiolabelled RNA solution retrieved after spin column purification 
(described in section 2.9.1) was increased to 95 l by addition of 65 l 1X PAP buffer.  
RNA was then digested at 37°C for 2 h with a combination of RNase A and RNase T1 
enzymes (Ambion), which hydrolyse RNA chains at C/U ribonucleotides and G 
ribonucleotides respectively.  The reaction setup for RNA digests is presented in Table 
2.19. After digestion, reactions were stopped and RNases removed by addition of 100 l 
of termination buffer (2.5% SDS, 130 mM EDTA, 2 mg/ml proteinase K- Ambion) and 
incubation at 37°C for 30 minutes. 200µl of  phenol:chloroform:IAA (25:24:1) pH 6.7 
(Ambion) was then added to the mixture, and after vigorous mixing and centrifugation 
at 17,000g for 2 min, the aqueous phase containing the RNase A and RNase T1 resistant 
poly(A) tails was removed (~180 µl).  The extracted RNA was precipitated overnight at 
-20°C following the addition of 20 l 3M ammonium acetate (Ambion), 5 l yeast 
tRNA (10 mg/ml, Ambion) and 2.5X volumes of 100% ethanol (500 l).  The following 
morning, RNA was recovered by centrifugation at 17,000g for 30 min at 4°C.  The 
RNA pellet was washed once with 500 l of ice-cold 70% ethanol to remove residual 
salt, and the pellet was recovered by centrifugation for 10 min at 4°C.  Ethanol was 
removed by aspiration and the pellet was allowed to dry at room temperature.  The 
RNA pellet containing poly(A) tails was dissolved in 20 l of Gel loading buffer II (a 
formamide-based loading dye, Ambion).   
 Original Modified 
Reagent Volume (l) Volume (l) 
Total RNA sample (1 g/l) 2.5 0.5 
Poly(A) polymerase buffer (5X) 6 6 
MnCl2 (12.5 mM) 6 6 
E. coli poly(A) polymerase 2U/l 2 2 
Nuclease-free water 13 15 
 [-32P] Cordycepin 5’-triphosphate (see legend) 0.5 0.5 
Total 30 30 
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 Original Modified 
Reagent Volume (l) Volume (l) 
Radio-labelled RNA sample 30 30 
poly(A) polymerase buffer (1X) 65 - 
100mM Tris-HCl pH 8.0 
3M NaCl, 30 mM EDTA 
- 4 
Yeast tRNA (10 mg/ml) 2 - 
RNase A (1 mg/ml) 2 3 
RNase T1 (1000 U/l) 1 3 
Total 100 40 
 
Table 2.19. Original and modified reaction setups for RNA digestion.  Yeast tRNA and RNases were 
purchased from Ambion. 
 
2.9.3. Visualisation of poly(A) tails 
Prior to electrophoresis, poly(A) tail samples were heated at 95°C for 10 min.  RNA 
poly(A) tail samples were resolved on 8.3 M urea 10% acrylamide/Bis (19:1, Ambion) 
polyacrylamide gels by electrophoresis at a constant power of 35 watts for 90 min in an 
EV500 DNA sequencing gel tank (Cambridge electrophoresis).  After drying, gels were 
exposed to a storage-phosphor screen (GE Healthcare) and visualised on a Storm 860 
phosphor-imager (GE Healthcare). 
 
2.9.4. Modifications to poly(A) tail length assay protocols 
Different modifications were made to the protocols described in sections 2.9.1-2.9.3 in 
an attempt to improve the resolution of poly(A) tails on acrylamide gels (discussed in 
section 4.3.1). Changes in the components of 3’-end labelling and RNA digestion 
reactions are listed in Tables 2.18 and 2.19 respectively. The modifications to the 
protocol that resulted in the largest improvements in resolution are as follows. 
 
1) The volume of the RNA digest reaction was reduced to 40 l (see Table 2.19).   
2) RNA digests were terminated by adding 2.5 l 10% SDS, 4 l proteinase K and 
3.5 l dH2O with incubation at 37°C for 30 min (total volume of terminated 
reaction is reduced from 200 l to 50 l).   
3) RNA was precipitated overnight at -20°C after addition of either 5 l 3 M 
ammonium acetate or 5 l 3 M sodium acetate with 5 l yeast tRNA (10 mg/ml, 
Ambion), 5 l glycogen (5 mg/ml, Ambion) and 2.5X volumes of 100% ethanol 
(150 l).  RNA pellets were washed either once or twice with 70% ethanol.   
4) The percentage of acrylamide/Bis in gels was increased to 15% to allow a more 
complete separation of poly(A) tails of different sizes. 
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2.9.5. DNA ladder preparation 
A DNA oligonucleotide size standard ladder was created by mixing single-stranded 
DNA oligonucleotides of the following sizes (2 l each, concentration 10 M, oligos 
synthesised by Eurofins MWG): 12, 15, 20, 25, 30, 35 40, 46 50, 57, 65, 77, 96 and 125 
nucleotides.  The 5’-ends of oligonucleotides in this mixture were radiolabelled with 
ATP [-32P] (Perkin Elmer) using T4 PNK (NEB).  The components of the 5’-end 
labelling reaction are listed in Table 2.20.  The labelling mixture was incubated at 37°C 
for 30 min and then T4 PNK was heat inactivated at 65°C for 15 min.  Unincorporated 
ATP [-32P] was removed by centrifugation using an illustra MicroSpin G25 spin 
column (GE Healthcare) and the oligonucleotide size standard mixture was purified by 
phenol-chloroform isoamyl alcohol extraction and ethanol precipitation as described in 
section 2.9.2.  The DNA pellet was dissolved in 20 l Gel loading buffer II (Ambion) 
and 2 µl was loaded onto polyacrylamide gels along with radiolabelled poly(A) tail 
RNA samples. 
 
Reagent Volume (l) 
Oligonucleotide mixture 5 
T4 PNK buffer (10X) 4 
ATP  [-32P] (see legend) 2 
T4 PNK (10 U/l) 2 
dH2O 27 
Total 40 
 
Table 2.20. Reaction setup for oligonucleotide radiolabelling.  T4 PNK was purchased from NEB. ATP 
[-32P] 250 Ci (9.25 MBq), 6000 Ci/mmol, concentration 10 mCi/ml (Perkin Elmer). 
 
2.10. Quantitative real-time PCR 
 
Quantitative real-time PCR (qPCR) is a technique that allows quantification of the 
amount of a target DNA sequence in a sample. Quantification is achieved by monitoring 
the amplification of target sequences through fluorescence reporter systems (reviewed 
in [203]).  qPCR is also commonly used to quantify gene expression using reverse-
transcribed RNA as template (RT-qPCR).  It is also a useful tool in other areas of life 
sciences research.  For example, qPCR of ChIP purified DNA has allowed 
quantification of genomic DNA sequences associated with nuclear proteins [204-206].  
qPCR has also been used for single nucleotide polymorphism (SNP) genotyping [207], 
which has proved important for the detection of disease-associated SNPs in molecular 
diagnostics. 
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The RT-qPCR experiments used in this study employed the 5’ nuclease (TaqMan) assay 
rather than the alternative SYBR-green based detection [208].  The 5’ nuclease assay 
uses hydrolysis probe technology and takes advantage of the 5’->3’ exonuclease 
activity of Thermus aquaticus DNA polymerase (Figure 2.5) [209].  During the 
annealing step of PCR, a dual-labelled hydrolysis probe hybridises to its complementary 
sequence within the target sequence.  At this stage, the fluorescent reporter covalently 
attached to the 5’-end of the probe is in close proximity to a non-fluorescent quencher 
attached to the 3’-end of the probe.  As a result, the fluorescence emitted by the reporter 
when excited by light of the appropriate wavelength is quenched.  As the polymerase 
extends from 5’ to 3’ from the forward primer, the 5’ exonuclease activity cleaves the 
probe, freeing the reporter and allowing detection of the fluorescent signal.  
 
The most useful measurement for quantitative means is the determination of the 
threshold cycle (CT), the PCR cycle at which the fluorescent signal of the reporter 
crosses a threshold where there is first a detectable significant increase in fluorescence 
(in the exponential phase of PCR).  Different methods can be applied to derive the 
absolute or relative quantities of target from CT values (see Applied Biosystems User 
Bulletin #2 [210]).  The RT-qPCR experiments described in sections 2.9.3 and 2.9.4 
were analysed using the relative standard curve method [210].  In this method, target is 
quantified in a dilution series of an RNA or DNA standard (of known quantity) to 
generate a standard curve.  Comparison of the CT value of a sample with the CT values 
of the standard curve is used to determine the quantity of target (given as a number 
without units).  Relative quantification is achieved by dividing the quantity of the 
sample through the quantity of a calibrator to give a final target quantity expressed as an 
n-fold difference to the calibrator (for example gene expression in a mutant relative to 
wildtype gene expression).  For a worked example refer to Figure 2.6. 
 
2.10.1. Reaction setup 
RT-qPCR experiments were carried out in an Applied Biosystems 7500 Fast Real-Time 
PCR System.  All primers and probe sequences were designed in accordance with 
parameters defined in the Primer Express 2.0 software (Applied Biosystems) and 
purchased from Applied Biosystems. Primers and probes for RT-qPCR are listed in 
Appendix 8.4.  All target amplicons were detected by the 5’ nuclease (TaqMan) assay 
using 5’-6-carboxyfluorescein (6-FAM) 3’-minor groove binder (MGB) labelled probes 
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Figure 2.5. Hydrolysis (TaqMan) probes for qPCR.  During the PCR cycle, (1) Primers 
(green) and probe (blue) bind to their complementary sequences (sense strand, dark 
blue) and (2) Taq polymerase extends from the primers (dashed green line) to transcribe 
the amplicon. (3) Upon reaching the probe (annealed to the sense strand here), Taq 
polymerase displaces and cleaves the probe using its 5’->3’ exonuclease activity.  This 
frees the fluorophore (yellow sphere) from the quencher (grey sphere) allowing 
emission of light from the fluorophore when excited by light of the correct wavelength 
in the thermal cycler. (4) The thermal cycler can quantify the fluorescent signal for 
further analysis, and PCR product is generated. 
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and TaqMan One-Step RT-PCR Master Mix Reagents Kit (Applied Biosystems).  
Reactions were set up on ice in 0.1 ml MicroAmp Fast Optical 96-Well Reaction Plates 
(Applied Biosystems).  The reaction set up used for quantitation of all targets is shown 
in Table 2.21 and cycling parameters in Table 2.22.  Each target was detected in 
triplicate within a single reaction plate and each reaction plate was duplicated (each 
target was detected a total of six times).  Eight-point standard curves were generated for 
targets and endogenous controls from two-fold serial dilutions of S. cerevisiae genomic 
DNA (Stratagene) of concentration 100 g/ml.  Reaction thresholds were determined 
automatically by the 7500 v2.0.5 analysis software (Applied Biosystems). 
 
Reagent Volume (l) 
Master mix (2 X) 12.5 
Reverse transcriptase mix (40 X) 0.625 
Forward primer (10 M) 2.25 
Reverse primer (10 M) 2.25 
TaqMan probe (10 M) 0.625 
RNA Template (20 ng/l) 
or 
Genomic DNA (serial dilution) 
 
5 
dH2O (RNase free) 1.75 
Total 25 
 
Table 2.21. Reaction setup for RT-qPCR experiments.  The concentration of RNA was determined by 
UV absorbance at 260 nm.  The A260:A280 ratios for RNA samples was always between 1.8 and 2.1.  For 
each target, a master mix was made and 20 l aliquoted into individual wells of a PCR plate containing 5 
l sample RNA or genomic DNA standard. 
 
Step Temperature Time 
1 48°C (reverse transcription) 15 min 
2 95°C (DNA polymerase activation) 10 min 
3 95°C (melting)  15 s 
4 60°C (annealing/extension) 1 min 
5 Repeat 3-4, 40 cycles  
 
Table 2.22. Thermal cycling conditions for RT-qPCR experiments.  These conditions are identical to 
those specified by the Applied Biosystems 7500 Fast Real-Time PCR System software v2.0.5 for a 
standard one-step amplification from an RNA template. 
 
2.10.2. ACT1 Poly(A) site selection assay 
The ACT1 poly(A) site selection assay was designed to determine changes in ACT1 
cleavage/poly(A) site usage in cDNA derived from wildtype and mutant yeast strains.  
The reaction setup was as described in 2.10.1.  Primer and probe choice was influenced 
by the previous identification of cleavage/poly(A) sites in the S. cerevisiae ACT1 3’-
UTR using an RNase H cleavage/Northern blotting assay [153].  Primers and probes for 
quantification of target cDNA were designed to amplify only if cleavage/poly(A) sites 
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Figure 2.6. Worked example of the relative standard curve method.  The fluorescence 
from the reporter is normalised (Rn) to the signal of a passive reference.  The baseline-
corrected normalised reporter (Rn) is calculated for each PCR cycle as follows: Rn 
(cycle) = Rn (cycle) – Rn (baseline).  The quantity of target in the sample (yellow 
curves) is calculated by comparing the point at which the reporter signal in the sample 
crosses the CT (purple line), with the CT values of the genomic DNA standards (cyan 
curves) of known concentration.  The calculations show how to derive the relative 
quantity of target in a mutant sample compared to a wildtype sample. 
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were intact (see target design in Figure 2.7A).  The mean quantities of target cDNA 
were normalised to the mean quantity of TDH2 cDNA, and the normalised quantities of 
each target were used to calculate the frequency at which each poly(A) site had been 
processed (this calculation is summarised in a worked example presented in Figure 
2.7B). 
 
2.10.3.  Analysis of TDH2, ACT1, ADH1, CYC1 and YPT1 transcription 
Changes in the quantities of TDH2, ACT1, ADH1, CYC1 and YPT1 cDNAs between 
mutant and wildtype yeast strains (and therefore changes in the expression of these 
genes) were determined by RT-qPCR.  Primers and probes for quantification of target 
cDNA were designed to amplify sequences within the ORFs or overlapping with 3’-
UTRs of cDNA (but before poly(A) sites, see Appendix 8.4 for primer and probe 
sequences).  The reaction setup was as described in section 2.10.1.  Data was analysed 
by the relative standard curve method: quantities of mutant cDNA target were expressed 
relative to wildtype cDNA target.  
 
2.10.4. ACT1 Transcription readthrough assay 
Changes in the levels of readthrough transcription (and therefore transcription 
termination efficiency) on the ACT1 gene between mutant and wildtype yeast strains 
were determined by RT-qPCR. The locations of primers and probes for quantification of 
total ACT1 cDNA and ACT1 readthrough cDNA are shown in Figure 2.7A.  The 
reaction setup was as described in 2.10.1.  Data was normalised to the mean quantity of 
TDH2 cDNA and analysed by the relative standard curve method: within a sample, the 
quantity of readthrough cDNA (R-T target) was expressed relative to the quantity of 
total ACT1 cDNA (3’-UTR target). 
 103
 
 
Figure 2.7. (A) Design of targets for RT-qPCR poly(A) site selection and transcription 
readthrough experiments.  In the ACT1 poly(A) site selection assay, targets were 
designed to overlap specific poly(A) sites: amplification was only possible where 
poly(A) sites were intact.  Targets were designed to quantify the amounts of three intact 
poly(A) sites: 1, 2/3 and 4 (sites 2 and 3 are in such close proximity they were treated as 
a single site).  In the ACT1 transcription readthrough assay, the detected quantities of R-
T and 3’-UTR amplicons were compared to quantify the level of readthrough 
transcription.  All targets are labelled and indicated by dashed black lines. 3’-UTR, 
target to quantify gene expression; poly(A)-1/2/3/4, target to quantify intact poly(A) 
sites; R-T, target to quantify readthrough transcription.  Primers are displayed as arrows, 
probes as solid black lines.  Orange boxes represent poly(A) sites, blue boxes 3’-UTR 
sequence and red boxes the 3’-ends of genes.  Distances between poly(A) sites are 
indicated in green. (B) Worked example of calculating poly(A) site usage from RT-
qPCR data generated from a wildtype CLP1 yeast-derived total RNA sample.  Mean 
cDNA quantities in the left box are normalised to the mean cDNA quantity of TDH2.  
Poly(A) site selection can be compared between wildtype and mutants using histograms 
(right box). 
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3. in vitro analysis of recombinant Clp1-ATP binding mutants 
 
3.1. Introduction and overview 
 
Clp1 is a subunit of the cleavage factor IA complex (CFIA), an essential multi-subunit 
protein complex required for the cleavage and polyadenylation of pre-mRNAs in S. 
cerevisiae (see sections 1.3 and 1.3.4).  Clp1 is associated with the CFIA complex only 
through its interaction with Pcf11 [99], but has also been shown to bind to several 
subunits of Cleavage and Polyadenylation Factor (CPF) including Ysh1, the proposed 
endonuclease that effects pre-mRNA cleavage [103].  The crystal structure of a Clp1-
Pcf11 heterodimer is available, and shows that Clp1 is a three-domain protein that binds 
ATP at a nucleotide-binding site located within its large central domain (CD, see 
section 1.3.4 and Figure 1.5) [116].  The Clp1 CD is a member of the SIMIBI class of 
NTPases and contains three characteristic features: a P-loop/Walker A motif together 
with Switch I and Switch II motifs.  These motifs are arranged around the ATP 
molecule with the majority of the Clp1-ATP interaction occurring between the Clp1 P-
loop residues and the phosphate groups of ATP (see section 1.3.4 and Figure 1.6), 
although the interaction of Clp1 with ATP is also mediated by coordination of a 
magnesium ion by Switch I residues and a water molecule.  The arrangement of the 
nucleotide-binding pocket observed in the crystal structure suggests that the putative 
catalytic residue is of insufficient proximity to initiate catalysis of ATP.  In addition, 
biochemical experiments have failed to detect that any other nucleotide species are 
bound by recombinant Clp1, implying that ATP bound by Clp1 is stable to hydrolysis 
[116].  Despite these findings, it has been proposed that Clp1 possesses catalytic 
activity that is promoted by a conformational change induced by the interaction of Clp1 
with an unidentified binding partner [116].  It has also been proposed that the 
orientation of ATP in the nucleotide-binding pocket may modulate the interaction of 
Clp1 with Pcf11 and that this is a method of communication between 3’-end processing 
and transcription machineries [121, 122].  Despite these theories, the role of the Clp1-
ATP interaction remains enigmatic. 
 
In order to understand the importance of the Clp1-ATP interaction, conserved residues 
in the Clp1-ATP binding pocket were mutated and the properties of the resultant 
recombinant mutant proteins were analysed in a series of hydrodynamic, biochemical 
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and biophysical experiments.  These aimed to determine which mutations uncoupled 
ATP from Clp1, the effects of Clp1-ATP uncoupling on protein stability and secondary 
structure, and whether Clp1-ATP binding was also important for the Clp1-Pcf11 
interaction.   
 
3.2 Mutation of the Clp1-ATP binding pocket affects protein stability 
 
3.2.1. Design of Clp1 mutants 
To study the importance of Clp1-ATP binding, it was necessary to weaken ATP-
binding or remove bound ATP completely and characterise any effects this had on 
purified recombinant Clp1.  To achieve this, point mutations were introduced into the 
Clp1/Pcf11-EXP construct by SDM.  Mutations were designed based upon interactions 
between Clp1 residues and ATP observed in the Clp1-Pcf11 crystal structure [116] (see 
section 1.3.4 and Figure 1.6), and from information about Clp1 residue conservation 
(see Figure 1.5C and Appendix 8.1).  A full list of mutations is provided in Table 3.1.  
Mutation of P-loop residues and Lys321 in the CTD aimed to break the interaction of 
Clp1 with the triphosphate moiety of ATP.  Switch II Asp251 was mutated to remove a 
hydrogen bond it shares with P-loop Thr137, a conserved interaction required for 
stability of the ATP-binding pocket.   The crystal structure of Clp1 suggests Switch I 
Asp161 is not involved in ATP-binding or magnesium ion coordination.  However, the 
equivalent Switch I residue in the NifH nitrogenase of Azobacter vinelandii is at the 
centre of the active site [116, 120].  It was therefore necessary to include Asp161 in the 
mutational analysis in the event that it makes an important contact with an extended 
water/magnesium ion network that may have been missed due to the limited resolution 
of the crystal structure.  Clp1-ATP binding pocket mutants are hereafter referred to as 
Clp1-ATP mutants. 
 
Residue Location Function Mutated to Mutant name 
Lys136 P-loop Binds ATP  and -phosphates Glu K136E 
Thr137 P-loop Binds ATP -phosphate, ATP-binding 
pocket stability 
Ala T137A 
Ser138 P-loop Binds -phosphate Ala S138A 
Asp161 Switch I Putative catalytic residue Ala D161A 
Asp251 Switch II ATP-binding pocket stability Ala D251A 
Lys321 CTD Binds -phosphate Ala K321A 
 
Table 3.1. Mutations made in the Clp1-ATP binding pocket in the Clp1/Pcf11-EXP construct.  
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3.2.2. Size-exclusion chromatography  
SEC is a technique used to separate proteins by particle size and shape.  For folded 
globular proteins, particle size is likely to increase in proportion with molar mass.  
Therefore SEC can be used as a relatively low-resolution method to distinguish proteins 
of different molar mass, oligomeric states and the formation of protein complexes such 
as heterodimers. 
 
SEC was used as a purification step for recombinant Clp1-Pcf11(454-563) (hereafter 
Pcf11 refers to Pcf11(454-563)).  When comparing the SEC profiles from different 
protein preparations it became evident that the hydrodynamic properties of some 
mutants had changed significantly compared to wildtype.  As a result, the final step for 
purification of recombinant proteins (by SEC) also served as a first step in analysing the 
effects of mutations in the Clp1-ATP binding pocket. 
 
The SEC profile of Clp1-Pcf11 wildtype showed a single peak with a retention volume 
of ~74 ml from a Superdex 200 (16/60) column (Figure 3.1A). Analysis of the protein 
composition of this peak by reversed-phase high-performance liquid chromatography 
(RP-HPLC) revealed two proteins with column retention times of 17 and 32 minutes 
(Figure 3.1B, both panels).  SDS-PAGE of the RP-HPLC-eluted proteins showed the 
17-minute peak contains a 15 kDa protein, slightly larger than the expected size of 12 
kDa for Pcf11(454-563) (Figure 3.1C).  The 32-minute peak contains a 50 kDa protein 
which corresponds to the expected size of 51.7 kDa for Clp1 (Figure 3.1C).  The 
molecular weights of both proteins were verified by mass spectrometry (performed by 
Dr. S. Howell (NIMR)) and mass spectrum deconvolution reports are presented in 
Appendix 8.5).  This confirmed that the 17 minute RP-HPLC peak contained protein 
with a molar mass of 12017.5 Da, which is equal to the calculated molar mass of a 
Pcf11 polypeptide containing residues 454-561.  This is two residues shorter than the 
Pcf11 454-563 polypeptide encoded by the Clp1/Pcf11-EXP construct, and is probably 
the result of a C-terminal cleavage event in E. coli that shortens the polypeptide by two 
residues.  Mass spectrometry of the 17 minute peak also revealed two smaller proteins 
of 5794.5 kDa and 6239.6 kDa (see Appendix 8.5).  These proteins are Pcf11 residues 
454-508 and 509-561 respectively.  The amino acids at positions 508 and 509 are Asp 
and Pro respectively.  The peptide bond between these amino acids is particularly acid 
labile, and it is likely that a significant amount of Pcf11 454-561 was 
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Figure 3.1. SEC of Clp1 and Clp1-ATP mutants.  (A) Comparison of Clp1 wildtype 
(black line) and Clp1 K136E (red line) SEC profiles.  The three separate peaks from 
K136E SEC are labelled with asterisks and numbered.  (B) Comparison of SEC peak 
compositions determined by RP-HPLC for Clp1 wildtype (black lines), K136E peak 1 
(red line, left panel) and K136E peak 2 (red line, right panel).  (C) SDS-PAGE 
characterisation of protein peaks from the Clp1-wildtype RP-HPLC experiment.  The 
retention times of the collected RP-HPLC peaks are indicated above the gel lanes. (D) 
SDS-PAGE of fractions eluted in K136E peak 3. 
 108
 
cleaved between these residues through exposure to RP-HPLC conditions (60 ºC, 0.05% 
TFA) for a significant period prior to mass spectrometry.  Mass spectrometry of the 32 
minute RP-HPLC peak showed protein within it had a molar mass of 51777.3 Da 
(Appendix 8.5), which is equal to the calculated molar mass of full-length Clp1 with an 
intact C-terminal hexahistidine sequence (His-tag).  
 
In contrast to wildtype, SEC of Clp1 K136E gave rise to three distinct peaks (Figure 
3.1A).  The first and largest peak eluted at ~45 ml, which is approaching the void 
volume of the SEC column (where particle size is larger than the pore size of the gel 
matrix, leading to particle exclusion).  The second peak had a retention volume of ~76 
ml, which corresponds well with the single wildtype Clp1-Pcf11 peak.  The third peak 
eluted at ~92 ml, indicating the presence of a protein with a smaller molar mass than 
wildtype.   RP-HPLC of a sample from Clp1 K136E peak 1 revealed only the 32 minute 
Clp1 peak (Figure 3.1B, left panel), whereas RP-HPLC of K136E peak 2 displayed both 
the 17 minute Pcf11 peak and 32 minute Clp1 peak, indicating the Clp1 K136E peak 2 
sample is a Clp1-Pcf11 complex (Figure 3.1B, right panel).  The protein concentration 
of Clp1 K136E peak 3 was insufficient for RP-HPLC analysis, however an SDS-PAGE 
experiment revealed this peak contained only Pcf11 (Figure 3.1D).  Similar to Clp1 
K136E, SEC of Clp1 T137A also gave rise to three resolved peaks with retention times 
of ~45 ml, ~76 ml and ~92 ml (peaks 1-3 respectively, Figure 3.2), showing the T137A 
mutation also generates a different SEC profile of protein peaks compared to wildtype.  
The SEC profile of Clp1 D251A was also distinct from that of wildtype Clp1-Pcf11, 
with peaks at ~45 ml and ~92 ml, corresponding to peaks 1 and 3 observed in SEC 
experiments with the Clp1 K136E and T137A mutants (Figure 3.2).  However, no peak 
corresponding to a Clp1-Pcf11 complex was observed with this mutant.  The SEC 
profiles of S138A and K321A closely resembled the Clp1-Pcf11 wildtype SEC profile 
(Figure 3.2), with only single peaks (retention times of ~75 ml) revealing these protein 
samples contain only Clp1-Pcf11 complex. 
 
SEC revealed that point mutation of Lys136, Thr137 and Asp251 in the Clp1-ATP 
binding pocket disrupted the Clp1-Pcf11 complex, but mutation of Ser138 and Lys321 
had little or no effect.  The disruption of the Clp1-Pcf11 complex by mutation of 
residues in the Clp1 P-loop was intriguing, as the Clp1-ATP binding pocket is located 
on the opposite face of the protein to the Clp1-Pcf11 interface (see Figure 1.5A), 
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Figure 3.2.  SEC profiles of Clp1-ATP mutants.  Each mutant (red line) is labelled and 
the wildtype SEC profile (black line) is shown for comparison.  Resolved peaks in SEC 
of T137A and D251A are labelled with asterisks and numbered. 
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providing no obvious reason as to why a mutation in one site should affect the function 
of the other.  The fact that Clp1 eluted close to the void volume in the K136E and 
T137A SEC experiments suggested that these mutations render the Clp1-Pcf11 complex 
unstable and lead to the aggregation of Clp1. 
 
3.2.3. Multiangle laser light scattering 
MALLS is a technique that combines static light scattering and protein concentration 
measurements to determine the absolute molar mass of molecules in solution.  It can be 
used to determine the molar masses and oligomerisation states of proteins, and when 
combined with size-exclusion chromatography (SEC-MALLS), to assess the 
distribution of different molar mass species within chromatographic peaks.  If the 
protein within a chromatographic peak is of a single molar mass the distribution is said 
to be “uniform” or narrow. However, if a peak contains multiple protein species of 
different molar masses the distribution is “non-uniform” and can be very broad [211-
213].  Thus a non-uniform mass distribution of a single protein is indicative of protein 
self-association or aggregation.  SEC experiments revealed that mutation of the Clp1-
ATP binding pocket likely affects protein stability.  To further probe the effects of 
mutations on protein stability, SEC-MALLS experiments were conducted to investigate 
whether mutations affected the oligomerisation state, or caused aggregation of Clp1-
Pcf11. 
 
In a SEC-MALLS experiment with SEC-purified wildtype Clp1-Pcf11, the signal from 
the differential refractive index (dRI) detector showed a peak eluted from a Superdex 
200 (10/30) SEC column with a retention time of ~26 minutes (Figure 3.3).  Combining 
the dRI and light scattering (LS) data from this peak enabled calculation of the molar 
mass of protein within it and an assessment of the distribution of different molar mass 
species.  Protein in this peak showed a narrow distribution of molar mass (0.3% of the 
weight-averaged molar mass indicative of a uniformly-distributed protein species) and 
analysis of Debye plots gave a weight-averaged molar mass of 60.2 kDa, close to the 
expected mass of 63.8 kDa for a Clp1-Pcf11 heterodimer (Figure 3.3).  SEC-MALLS 
analysis of the Clp1 S138A and K321A mutants also revealed single chromatographic 
peaks that eluted with retention times of ~26 minutes.  These peaks both contained a 
narrow molar mass distribution and gave derived molar masses of 62.4 kDa and 61.6 
kDa respectively, consistent with the molar mass of a Clp1-Pcf11 heterodimer.  This 
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Figure 3.3.  MALLS analysis of Clp-ATP mutants.  The S138A, D161A and K321A 
mutants eluted from SEC with similar profiles to Clp1 wildtype (see Figure 3.2).  The 
chromatograms recorded by the differential refractometer (dRI, blue line) for each 
sample are shown. Black dots are individual measurements of the molar mass of 
material recorded at 1 s intervals throughout elution of chromatographic peaks. Each dot 
represents the molar mass determined from an individual Debye plot and the 
combination and averaging of these measurements was used to determine the overall 
weight-averaged molar mass of protein in a peak. The derived molar masses are 
displayed next to peaks along with a percentage error associated with the averaging that 
provides a measure of the mass spread within each peak. 
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was in agreement with the findings of SEC experiments that the retention times of 
S138A and K321A protein peaks corresponded with the retention time of a Clp1-Pcf11 
complex (see section 3.2.2 and Figure 3.2).  A further Clp1 mutant, Clp1 D161A 
(Switch I point mutation) was also included in the SEC-MALLS analysis.  This D161A 
sample also eluted in a single peak with a retention time of ~26 minutes, had a uniform 
distribution and a derived molar mass of 60.8 kDa, close to that of a Clp1-Pcf11 
complex (Figure 3.3).  In contrast to these results, the first SEC-purified peaks (peak 1) 
from K136E, T137A and D251A mutants eluted with retention times of ~16 minutes, 
which is around the void volume of the SEC column (Figure 3.4). In these samples the 
protein was excluded from the column because of the high molar mass, greater than 1.0 
x 106 Da.  Moreover, individual Debye plots generated at short intervals throughout the 
elution of the excluded peaks in K136E (peak 1), T137A (peak 1) and D251A (peak 1) 
samples showed molar mass distributions that varied by up to an order of magnitude, 
signifying Clp1 in these peaks was highly heterogeneous and in a self-associated or 
aggregated state. SEC-MALLS experiments with the second SEC-purified peaks (peak 
2) of Clp1 K136E and T137A revealed these samples also contained a significant 
proportion of material excluded from the SEC column with high molar mass and large 
non-uniform molar mass distribution. However, the K136E (peak 2) and T137A (peak 
2) protein samples also contained four additional poorly resolved chromatographic 
peaks not observed in SEC-MALLS experiments with wildtype Clp1-Pcf11 and other 
mutants (Figure 3.4, peaks labelled A-D). The dRI signals showed the amount of 
protein eluting in these peaks was far greater than that in the excluded protein peaks 
(~16 minute peaks), indicating that the majority of Clp1 in the K136E (peak 2) and 
T137A (peak 2) samples was not aggregated.  This is in stark contrast to the distribution 
and concentration of protein peaks in the K136E (peak 1) and T137A (peak 1 samples), 
in which Clp1 eluted solely in the void volume of the SEC column. The LS signals of 
the additional A-D peaks observed in the K136E (peak 2) and T137A (peak 2) samples 
were decreased compared to that of the excluded aggregated peaks, which suggested the 
A-D peaks contained protein of lower particle size that permeated the SEC matrix. The 
calculated molar masses of the ‘B’ peaks in K136E (peak 2) and T137A (peak 2) 
samples were 59.2 and 62.5 kDa respectively, revealing that these samples still contain 
intact Clp1-Pcf11 complex (Figure 3.4).  The calculated molar masses of the ‘A’ peaks 
in these samples were 95.1 and 98.1 kDa respectively (Figure 3.4), close to the expected 
molar mass of two Clp1 molecules (a Clp1 homodimer, 102.4 kDa), and could be 
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Figure 3.4. MALLS analysis of Clp-ATP mutants.  The K136E, T137A and D251A 
mutants eluted from SEC with profiles distinct from Clp1 wildtype (see Figures 3.1 and 
3.2). The chromatograms recorded by the light scattering (R) and differential refractive 
index detectors (dRI) are shown in red and blue respectively. Peaks A-D that are 
referred to in the text are labelled. Black dots are individual measurements of the molar 
mass. The overall weight averaged molar mass and percentage errors are derived and 
displayed as in Figure 3.3. 
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representative of the beginning of Clp1 aggregation that may only occur after loss of the 
Pcf11 fragment.  The molar masses of proteins in the ‘C’ and ‘D’ peaks observed in 
SEC-MALLS experiments with the Clp1 K136E (peak 2) and T137A (peak 2) samples 
could not be determined due to limitations of low protein concentration and low 
scattered light intensities.  If the aggregation of Clp1 is preceded by loss of Clp1-Pcf11 
binding, it is likely that one of the ‘C’ or ‘D’ peaks could contain released Pcf11. SEC-
MALLS analysis of the protein content of Clp1 K136E (peak 3), T137A (peak 3) and 
D251A (peak 3) was also not possible due to low protein concentrations and low 
scattered light intensities, although previous SDS-PAGE gel analysis showed these 
samples are comprised only of free Pcf11 (Figure 3.1D). 
 
SEC-MALLS experiments showed that mutation of Lys136, Thr137 and Asp251 
residues within the Clp1-ATP binding pocket causes instability of Clp1-Pcf11 
complexes and results in the aggregation of recombinant Clp1. The possible 
identification of an intermediate Clp1 species of ~100 kDa, points to the formation of a 
Clp1 homodimer.  This is likely a precursor to larger Clp1 aggregates and also suggests 
that the loss of Clp1-Pcf11 binding precludes Clp1 instability.  Misfolding of protein 
into an incorrect conformation often causes aggregation.  In the case of the Clp1 
K136E, T137A and D251A, it appears that mutations in the Clp1-ATP binding pocket 
that reduce Clp1-ATP binding have dramatic effects on Pcf11-binding and overall 
protein stability. One possibility is that the Clp1-ATP pocket mutations directly affect 
Clp1 secondary structure leading to misfolding. Another possibility is that ATP-binding 
is intimately linked to Pcf11-binding and that loss of Pcf11 causes the instability of 
Clp1.  These ideas are examined in the proceeding sections 
 
3.2.4. Far-UV circular dichroism spectroscopy 
Circular dichroism (CD) spectroscopy measures the differential absorption of left- and 
right-handed circularly polarised light by chiral molecules.  In the far-UV region, CD 
can give information about the secondary structure of proteins.  Far-UV CD spectra of 
Clp1 mutants were recorded to determine whether protein instability observed by SEC-
MALLS was associated with changes in Clp1 secondary structure. 
 
The wildtype Clp1-Pcf11 CD spectrum displayed negative CD peaks at ~208 nm and 
~222 nm (Figure 3.5A), characteristic of a mixed / protein and in agreement with the 
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Figure 3.5. Far-UV CD of Clp1-ATP mutants.  (A) CD spectra of mutants that have 
similar hydrodynamic properties to wildtype, (B) CD spectra of samples from mutants 
containing aggregated Clp1 and (C) CD spectra of samples from mutants that contain 
Clp1-Pcf11 heterodimers, but with wide molar mass distributions. (D) Comparison of 
the CD spectra recorded from Clp1 and the Clp1-Pcf11 complex. The spectra are 
expressed in mean residue weight differential molar extinction and lines corresponding 
to individual CD spectra are identified in the key on the right hand side of each set of 
spectra. 
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Clp1-Pcf11 crystal structure (see Figure 1.5A).  The S138A and K321A mutants had 
CD spectra indistinguishable from wildtype, indicating they are also mixed / proteins 
with identical secondary structures to wildtype Clp1-Pcf11 (Figure 3.5A).  In contrast, 
the CD spectra of K136E (peak 1), T137A (peak 1) and D251A (peak 1) overall had 
diminished amplitude compared to Clp1-Pcf11 and a pronounced reduction in negative 
CD at ~222 nm (Figure 3.5B).  This likely reflects a partial loss in secondary structure 
and was also observed in the CD spectra of K136E (peak 2) and T137A (peak 2) 
(Figure 3.5C).  One possibility is that the diminished amplitude of K136E, T137A and 
D251A CD spectra compared to wildtype were due to the loss of the Pcf11 fragment, as 
Clp1 and a Clp1-Pcf11 complex may give rise to significantly different CD spectra.  To 
rule out the changes in CD spectra were not due to loss of the Pcf11 fragment, the CD 
spectra of a Clp1-Pcf11 complex and Clp1, shown to be monomeric by SEC-MALLS, 
were compared (Figure 3.5D). These data demonstrate that the CD spectrum of Clp1 
actually displays a small increase in amplitude at 208-225 nm compared to the Clp1-
Pcf11 spectrum, implying Clp1 has an increased secondary structure content compared 
to a Clp1-Pcf11 complex.  To investigate the differences in the CD spectra, the CDpro 
program [197] was used to analyse and compare the Clp1-Pcf11 complex and free Clp1 
secondary structure element compositions, the results of which are presented in Table 
3.2.  Secondary structure prediction revealed that the percentages of β-sheet and turn do 
not change significantly between Clp1-Pcf11 complex and free Clp1.  However, The α-
helix content of free Clp1 is higher than a Clp1-Pcf11 complex, at 37% compared to 
27% (Table 3.2).  This corresponds with an increased random coil content in the Clp1-
Pcf11 complex over free Clp1, with 37% compared with 29%.  These changes in 
secondary structure composition show it is likely that Pcf11 is largely unstructured, and 
that the differences in the bound and free CD spectra can be explained by the averaging 
that is used to obtain the mean residue weight CD.  Thus, the CD of Clp1-Pcf11 at 208 
and 225 nm is reduced because it is averaged to include the unstructured Pcf11 
fragment.  This finding is also consistent with results presented in chapter 5 that show a 
larger Pcf11 fragment containing two zinc-finger motifs is still largely unstructured (see 
section 5.2.3).  
 
CD spectroscopy has demonstrated that residues in the Clp1-ATP binding pocket are 
important for the maintenance of Clp1 secondary structure.  Combining these findings 
with the hydrodynamic characterisation of Clp1-ATP mutants, it is evident that 
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mutations cause loss of secondary structure that results in Clp1 instability and leads to 
protein aggregation.  It is possible that loss of Clp1 secondary structure could be the 
direct result of amino acid substitutions, or alternatively it could be indirectly caused 
through alteration of Clp1 interaction with ATP.   
 
 α-helix (%) β-sheet (%) Turn (%) Random coil (%) 
Clp1-Pcf11 complex 26.87 
(1.44) 
17.63 
(1.32) 
18.10 
(2.13) 
37.4 
(3.67) 
     
Clp1 36.75 
(2.48) 
15.90 
(1.84) 
18.28 
(1.62) 
29.07 
(2.71) 
 
Table 3.2. Prediction of Clp1-Pcf11 and Clp1 secondary structure element compositions (using the 
CDpro program [197].  
 
3.3. ATP is a structural component of Clp1 
 
3.3.1. Mutations in Clp1 P-loop and Switch II abrogate Clp1-ATP binding 
The hydrodynamic and biophysical characterisation of Clp1-ATP mutants revealed that 
some mutations cause loss of secondary structure and protein instability.  To determine 
whether protein instability correlated with a loss of Clp1-ATP binding, the nucleotide 
contents of Clp1-ATP mutants were analysed by RP-HPLC nucleotide assays. 
 
A previous study demonstrated that ATP was the only nucleotide extracted from 
recombinant Clp1 expressed and purified from E. coli [116].  In agreement with this, the 
extracted nucleotide from wildtype Clp1-Pcf11 had a column retention time of ~8 
minutes, which was consistent with the retention time of an ATP nucleotide standard 
(Figure 3.6A).  A UV absorbance spectrum recorded from the eluted nucleotide showed 
a maximal absorbance at 260 nm, confirming the nucleotide had an adenine base 
(Figure 3.6A, inset).  Importantly, no ADP was detected suggesting that bound ATP is 
stable to hydrolysis.  Nucleotide assays with samples extracted from Clp1 S138A, 
D161A and K321A mutants showed these proteins also copurify from E. coli with a 
single nucleotide species that has a retention time of ~8 minutes consistent with ATP.  
Contrary to this, nucleotide assays with samples extracted from Clp1 K136E (peaks 1 
and 2), T137A (peaks 1 and 2) and D251A (peak 1) mutants did not detect any bound 
nucleotides (Figure 3.7), signifying these mutants do not copurify with bound ATP. 
 
The results of nucleotide assays show that mutation of Clp1 Lys136, Thr137 and 
Asp251 abrogates Clp1-ATP binding, but Ser138, Asp161 and Lys321 mutations do not 
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Figure 3.6. Analysis of the nucleotide content of Clp1-Pcf11 wildtype and stable Clp1-
ATP binding mutants. (A) Comparison of the retention time of the Clp1-extracted 
nucleotide (red line) with nucleotide standards AMP (blue), ADP (green) and ATP 
(black). A UV-absorbance spectrum recorded at the time of elution of the Clp1-
extracted nucleotide peak is shown (inset). (B) Chromatograms from nucleotide assays 
with samples extracted from Clp1 S138A, D161A and K321A mutants (labelled above 
chromatograms). 
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Figure 3.7.  Nucleotide assays with unstable Clp1-ATP binding mutants.  Each mutant 
sample is labelled above the relevant chromatogram.  Compare with the retention times 
of nucleotide standards in Figure 3.6A. 
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affect Clp1-ATP binding.  These findings demonstrate that the instability and 
aggregation of Clp1 is linked directly to the abolishment of Clp1-ATP binding.  In light 
of these findings, it is probable that the Clp1-Pcf11 interaction is dependent on Clp1-
ATP binding, as without ATP Clp1 cannot maintain the necessary conformation for its 
interaction with Pcf11.  On the other hand it still remains possible that the K136E, 
T137A and D251A mutations are the cause of structural changes in Clp1, with loss of 
ATP a consequence. 
 
3.3.2. ATP is essential for Clp1 stability 
Mutation of Clp1 at Lys136 and Thr137 in the P-loop and Asp251 in the Switch II motif 
abrogates Clp1-ATP binding.  This loss of ATP corresponds strongly with a loss of the 
Clp1-Pcf11 interaction, a reduction in Clp1 secondary structure and protein instability.  
To ascertain that these effects were a result of uncoupling the Clp1-ATP interaction and 
not merely a consequence of mutation, it was necessary to characterise the effects of 
ATP removal on wildtype Clp1-Pcf11. 
 
To remove bound ATP, the wildtype Clp1-Pcf11 complex was incubated with 20 mM 
EDTA for 12 h.  EDTA is a chelating agent that is commonly used to remove metal ions 
from the active sites of enzymes.  In the Clp1-Pcf11 crystal structure, there is a Mg2+ ion 
present in the ATP-binding pocket coordinated by the phosphate groups of the bound 
ATP molecule, a water molecule and the side-chains of surrounding amino acids (see 
Figure 1.6).  Thus, disruption of this network of interactions by chelation of the Mg2+ 
ion should release ATP from the Clp1 nucleotide-binding site.  In a SEC-MALLS 
experiment with untreated Clp1-Pcf11, two chromatographic peaks eluted from the SEC 
column with retention times of ~16 minutes and ~26 minutes respectively (Figure 
3.8A).  Protein in the ~16 minute peak was shown to be of high molar mass with a wide 
molar mass distribution, consistent with aggregated Clp1 observed in previous SEC-
MALLS experiments (see section 3.2.3 and Figure 3.4).  The ~26 minute peak 
contained a protein species with a calculated molar mass of 60.6 kDa, and a narrow 
molar mass distribution, characteristic of a Clp1-Pcf11 heterodimer.  Integration of the 
UV absorbance peak areas at 280 nm allowed quantification of the amounts of protein 
in the different chromatographic peaks.  The 26 minute peak contained 2.74 nmoles (+/- 
0.3) of Clp1-Pcf11 complex in the untreated sample, whereas after EDTA treatment the 
amount of Clp1-Pcf11 complex was much lower at 1.29 nmoles (+/- 0.08) (this is also  
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Figure 3.8. MALLS analysis of Clp1-Pcf11 stability after EDTA chelation of the Mg2+ 
ion in the Clp1-ATP binding pocket.  (A) SEC profiles from MALLS experiments with 
Clp1-Pcf11 (black line) and a sample treated with 20 mM EDTA (red line). The 
MALLS chromatograms (inset) demonstrate protein aggregation in the 16 minute peak 
and the Clp1-Pcf11 heterodimer in the 26 minute peak. The asterisk indicates an 
additional peak observed at 39 minutes after EDTA treatment (B) The increased 
absorbance at 260 nm of the 39 minute peak after treatment with 20 mM EDTA (red 
line and asterisk), demonstrating the release of ATP from Clp1 after chelation of Mg2+ 
from the nucleotide binding site. 
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evident from the height of absorbance peaks at 280 nm, Figure 3.8A).  The decrease in 
the amount of Clp1-Pcf11 complex after EDTA treatment also corresponded with a 
large increase in the amount of Clp1 in the 16 minute peak from 0.78 nmoles (+/-0.06) 
to 2.6 nmoles (+/- 0.2) (Figure 3.8A).  The change in proportion of these peaks after 
EDTA treatment shows that EDTA chelation causes an increase Clp1 instability that is 
characterised by increased Clp1 aggregation.  This was accompanied by the appearance 
of a peak with a retention time of ~39 minutes and a maximal UV absorbance at 260 
nm, indicative of released ATP (Figure 3.8B).  Furthermore, another small peak in UV 
absorbance at 280 nm was present in the SEC-MALLS experiment with untreated Clp1-
Pcf11 (retention time ~32 minutes, Figure 3.8A), although the low protein concentration 
and scattered light intensity of this peak prohibited derivation of the molar mass of 
protein within it.  After EDTA treatment, the UV absorbance peak area of this peak 
increased four-fold (illustrated well by the increase in peak height, Figure 3.8A).  It is 
likely that the increase in the area of this peak denotes a rise in the amount of free Pcf11 
that follows destabilisation of the Clp1-Pcf11 complex by abrogation of Clp1-ATP 
binding.   
 
SEC-MALLS analysis of Clp1-Pcf11 demonstrated that chelation of Mg2+ by EDTA 
releases ATP from Clp1, causing Pcf11 dissociation, Clp1 instability and subsequent 
aggregation. The tendency for apo-Clp1 (ATP free Clp1) to aggregate made it 
impossible to characterise the affinity of the Clp1-ATP interaction by direct titration. 
However, because Clp1 stability depends on ATP, it was hypothesised that perhaps 
Clp1 is constitutively ATP-bound. To test this hypothesis, attempts were made to 
exchange the ATP bound by Clp1 (in a Clp1-Pcf11 complex) with radiolabelled ATP 
(ATP [-32P]). Here, Clp1-Pcf11 was incubated with increasing amounts of ATP [-32P], 
and then the free-ATP removed by desalting prior to scintillation counting. The results 
of these exchange experiments are presented in Table 3.3 and details of the 
experimental method are presented in section 2.6.  Upon incubation of ATP [-32P] with 
Clp1-Pcf11 at a 2:1 (ATP [-32P]: protein) molar ratio, the radioactive signal detected by 
scintillation counting of the protein fraction after desalting was 3,670 counts per minute 
(CPM). This corresponds to the background level of ATP [-32P] observed in control 
experiments with no Clp-Pcf11, far less than the expected radioactive signal of 16,001 
CPM for a sample in which 100% of ATP in Clp1 is exchanged.  This result showed 
that a 2:1 (ATP [-32P]:protein) molar ratio was not sufficient to promote the exchange 
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of ATP bound in Clp1 with ATP [-32P].  At the higher molar ratio of 5:1 (ATP [-
32P]:protein), ATP exchange was also not observed as the radioactive signal of 6,062 
CPM was actually lower than the background level and far below the expected signal of 
20,697 CPM for 100% ATP exchange.  A final attempt to exchange ATP bound by 
Clp1 was made by incubating ATP [-32P] with Clp1-Pcf11 at a 10:1 (ATP [-
32P]:protein) molar ratio.  After the incubation period and removal of free-ATP, the 
radioactive signal was 10,263 CPM.  This was lower than the background signal and not 
close to the expected signal of 33,055 CPM for 100% ATP exchange indicating no ATP 
had been exchanged. 
 
The results of this assay designed to exchange the ATP bound in Clp1 with 
radiolabelled ATP shows that ATP is “non exchangeable” under the conditions tested 
and that ATP is likely very tightly bound in the Clp1 nucleotide-binding pocket.  The 
fact that ATP was not exchanged can be explained by details provided by the Clp1-
Pcf11 crystal structure (see section 1.3.4 and Figure 1.5B) [116].  In the structure the 
Clp1 nucleotide-binding pocket is completely occluded by the packing of the Clp1 NTD 
against the Clp1 CD, and this lack of access makes it highly unlikely that free ATP can 
exchange with that already bound.  Taken with the results of the SEC-MALLS 
experiment with EDTA-chelated Clp1-Pcf11, it is likely that Clp1 is constitutively 
bound to ATP, which maintains the stability of Clp1 and facilitates the Clp1-Pcf11 
interaction.  
  
ATP [-32P]:protein 
molar ratio 
Total 
ATP 
[-32P] 
CPM 
Background 
ATP [-32P] 
CPM 
Expected ATP 
[-32P] CPM 
with 50 M 
Clp1-Pcf11 
Actual ATP 
[-32P] CPM 
with 50 M 
Clp1-Pcf11 
% ATP 
exchanged 
2:1 24,852 3,575 16,001 3,670 0 
5:1 65,750 8,271 20,697 6,062 0 
10:1 122,552 20,629 33,055 10,263 0 
 
Table 3.3. The ATP molecule bound by Clp1 is non-exchangeable.  To try to exchange bound ATP, 
Clp1-Pcf11 samples were incubated with increasing molar ratios of ATP [-32P].  Expected ATP [-32P] 
CPM represents the expected radioactive signal if 100% of the cold ATP bound by Clp1-Pcf11 is 
exchanged with radioactive ATP [-32P].  The results showed ATP [-32P] was never detected above 
background levels, indicating no ATP was exchanged (highlighted red). 
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3.4. Summary and conclusions 
 
Hydrodynamic characterisation of recombinant Clp1-ATP mutants by SEC and SEC-
MALLS showed that in the Clp1 K136E and T137A P-loop mutants, and Clp1 D251A 
Switch II mutant, the Clp1-Pcf11 interaction is uncoupled causing protein instability 
and subsequent aggregation of Clp1. Differences in the far-UV CD spectra of these 
mutants compared to wildtype Clp1-Pcf11 revealed a reduction in secondary structure 
was also associated with Pcf11 dissociation.  Reversed-phase nucleotide assays 
demonstrated that the Clp1 K136E, T137A and D251A mutants do not contain bound 
ATP, providing a link between loss of Clp1-ATP binding and abolishment of the Clp1-
Pcf11 interaction.  This link was confirmed when it was shown that EDTA chelation of 
the Mg2+ ion and subsequent loss of ATP from the Clp1-nucleotide binding pocket 
directly caused dissociation of Pcf11 and Clp1 instability.  The fact that ATP bound by 
Clp1 could not be exchanged with radiolabelled ATP even at high molar ratios suggests 
that the Clp1-ATP interaction is very tight and that Clp1 may be constitutively ATP-
bound.  Considering the results presented in this chapter, it is hypothesised that Clp1 
requires ATP as a co-factor to maintain a stable folded conformation necessary for 
interaction with Pcf11. Loss of Clp1-ATP binding is associated with changes in Clp1 
secondary structure and the release of Pcf11, which is likely to disrupt CFIA formation 
in vivo. 
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4. Functional analysis of the Clp1-ATP interaction in S. cerevisiae 
 
4.1 Introduction and overview 
The functions of the Rna14, Rna15 and Pcf11 subunits of CFIA in pre-mRNA 3’-end 
processing and transcription have been investigated in a number of different studies 
using a combination of in vitro and in vivo techniques (described in sections 1.3.4 and 
1.7).  Until recently, there was little information available with regards to Clp1 function.  
However, during the completion of this work, two studies were published that have 
shed some light upon the role of Clp1 in transcription and 3’-end processing.  Firstly, 
Haddad et al. uncovered two clp1 temperature sensitive mutants (clp1-5 and clp1-12) 
that were unable to cleave and polyadenylate pre-mRNA in vitro [121].  They also 
found that in vivo depletion of Clp1 led to defective transcription termination on small 
nucleolar RNA (snoRNA) genes.  The second study by Holbein et al. showed that 
cellular depletion of Clp1 interfered with both pre-mRNA 3’-end formation and PolII 
transcription termination [180].  In terms of the function of Clp1-ATP binding, there are 
now contrasting results in the literature.  Ghazy et al. recently claimed that mutation of 
Clp1 P-loop residues did not abrogate Clp1-ATP binding, but was lethal in S. cerevisiae 
because it trapped Clp1 in a conformation that prohibited its association with Pcf11 
[122].  On the other hand, Holbein et al. recognised that mutation of P-loop residues 
removes bound ATP [180].  However, they argued that Clp1-ATP binding was not 
necessary for transcription, transcription termination, 3’-end processing and indeed S. 
cerevisiae viability. 
 
A thorough characterisation of recombinant Clp1 mutants using hydrodynamic, 
biophysical and biochemical methods showed that preventing Clp1 from binding ATP 
resulted in the loss of Pcf11-binding, protein instability and aggregation of Clp1 (see 
chapter 3). As Clp1 is an essential protein in S. cerevisiae, it was hypothesised that the 
effects of mutations that abrogate Clp1-ATP binding could be lethal.  Alternatively, 
Clp1-ATP mutants may reveal new phenotypes that may illuminate the role of Clp1 in 
transcription termination or pre-mRNA 3’-end processing. 
 
In order to investigate whether Clp1-ATP binding is obligatory for the function of Clp1 
in pre-mRNA 3’end processing and transcription termination, a comprehensive in vivo 
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mutational analysis was employed to probe the phenotypes of clp1 ATP-binding 
mutants in S. cerevisiae. 
 
4.2. Clp1-ATP binding is essential in S. cerevisiae 
 
4.2.1. Mutations that abrogate Clp1-ATP binding are lethal 
To investigate the effects of Clp1-ATP mutations in S. cerevisiae, the 5-FOA plasmid 
shuffle system was used to determine if any of the clp1-ATP mutants characterised in 
vitro could rescue the lethal phenotype of a chromosomal clp1 deletion (clp1). 
 
The haploid clp1 yeast strain (which contains the URA3-CLP1 construct) does not 
grow on 5-FOA medium (Figure 4.1A), consistent with the sensitivity of URA3+ yeast 
to 5-FOA and that deletion of the only chromosomal copy of clp1 is lethal.  Haploid 
clp1 yeast formed colonies on 5-FOA medium after transformation with the LEU2-
CLP1 construct, indicating that a plasmid-borne copy of the CLP1 gene is able to 
reverse the lethal phenotype (Figure 4.1A, upper panel).  Yeast transformed with 
constructs harbouring the clp1 S138A and clp1 D161A alleles also formed colonies 
after 5-FOA selection, and the density of yeast growth in each serial dilution “spot” 
revealed there is no obvious difference between the growth of these mutants compared 
with wildtype CLP1 yeast. When the growth temperature was shifted to 37°C, clp1 
S138A and D161A mutants still grew comparably with wildtype yeast, confirming the 
gene products are stable and that these alleles are not temperature sensitive at 37 ºC 
(Figure 4.1A, lower panel).  In contrast, yeast transformed with the clp1 K136E, T137A 
and D251A alleles displayed no growth after 5-FOA selection at either 23 ºC or 37 ºC 
(Figure 4.1A, both panels).  However, each mutant grew comparably with wildtype 
CLP1 yeast on the pre-5-FOA selection control plate (transformed strain plated on YPD 
medium, Figure 4.1A, left panels).  This ruled out the possibility that the inability of 
these yeast mutants to grow on 5-FOA was due to unrelated growth defects that could 
have been introduced into the haploid clp1∆ yeast strain.  Western blotting experiments 
confirmed that the level of protein expression of all mutants was comparable to 
wildtype (Figure 4.1B), excluding the possibility that the lethality of clp1 K136E, 
T137A and D251A alleles was due to abnormalities in protein expression from these 
genes.  The clp1 K136E, T137A and D251A alleles are therefore lethal in S. cerevisiae.  
It was hypothesised that the K136E mutation may significantly disrupt the conformation 
of the Clp1 nucleotide-binding pocket (as the charge of the amino acid side chain at this
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Figure 4.1.  5-FOA plasmid shuffle assay to determine the effects of mutations in the 
clp1 gene on S. cerevisiae viability.  (A) “Spot test” assays displaying the results of 
clp1∆ complementation with clp1-ATP mutant alleles performed at 23°C (top panels) 
and 37°C (bottom panels).  Each spot represents a serial dilution (left to right: 104-101).  
The right panels show yeast transformants plated on 5-FOA medium and the left panels 
show transformants plated on YPD medium (control for growth defects in the clp1∆ 
strain).  URA3-CLP1 (top lanes) were not transformed with LEU2 constructs containing 
CLP1/clp1 alleles (control to check the efficacy of 5-FOA against URA3+ yeast).  
LEU2-CLP1 (second lanes from top) denotes the clp1∆ strain transformed with the 
LEU2-CLP1 construct (wildtype gene).  The lower lanes are the clp1∆ strain 
transformed with LEU2 constructs containing each mutant allele indicated on the left 
hand side. (B) Evaluation of Clp1 expression by western blotting of protein extracts 
derived from CLP1 wildtype and clp1 mutants. Detection is with an antibody directed 
against the HA-tag at the C-terminus of Clp1 wildtype and mutants. Each mutant is 
labelled above the relevant lane of the blot. 
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position is swapped from positive to negative by this mutation), and that instead the 
K136A mutation may be more conservative in its effects on Clp1-ATP binding.  When 
the clp1∆ strain was transformed with a construct bearing the clp1 K136A allele, no 
growth was observed after 5-FOA selection at either 23°C or 37°C (Figure 4.1A, both 
panels).  The pre-5-FOA selection control showed this was not due to growth defects in 
the clp1∆ strain (Figure 4.1A, left panels), or decreased expression of the Clp1 K136A 
protein (Figure 4.1B), indicating that the clp1 K136A allele is also lethal in S. 
cerevisiae. 
 
Although the 5-FOA plasmid shuffle assay showed that clp1 S138A and D161A yeast 
mutants grew comparably with wildtype CLP1 yeast, it could not be ruled out that there 
were minor growth defects associated with these mutants that were not observed due to 
the relatively insensitive spot test assays.  To investigate the possibility that the clp1 
S138A and D161A mutations might cause minor growth defects in S. cerevisiae, growth 
rate assays were performed to allow a more quantitative comparison of the growth 
characteristics of these mutants with wildtype CLP1 yeast.  Figure 4.2 shows that the 
growth of the clp1 S138A and D161A yeast mutants is indistinguishable from wildtype 
CLP1 yeast over an 8 hour time period, with both reaching the exponential growth 
phase (doubling time of 1.5-2 hours in YPD medium) after 2 hours when cultured in 
YPD at 30°C.  This demonstrates that the growth characteristics of clp1 S138A and 
D161A mutants are identical to wildtype and as a result these mutants were considered 
poor candidates for analysis of pre-mRNA processing abnormalities. 
 
Analysis of the effects of clp1-ATP mutations in S. cerevisiae using the 5-FOA plasmid 
shuffle system revealed that the K136A, K136E, T137A and D251A mutations (which 
disrupt Clp1-ATP binding in vitro, see section 3.3.1) in the clp1 gene were lethal.  
However, the clp1 S138A and D161A mutant alleles (these mutations did not affect 
Clp1-ATP binding in vitro, see section 3.3.1) were able to restore growth to a clp1∆ 
strain to wildtype levels.  These results demonstrate that Clp1-ATP binding is likely to 
be essential in S. cerevisiae.  The fact that the clp1 D161A allele (the putative catalytic 
residue mutant) is viable suggests that either there is no enzymatic activity associated 
with Clp1, or that Clp1 enzymatic activity is not essential.  Because the clp1 K136A, 
K136E, T137A and D251A mutants were not viable, it was not possible to extract RNA 
in order 
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Figure 4.2. Analysis of growth rate of CLP1 wildtype yeast (black), clp1 S138A (red) 
and D161A (blue) mutants. The assay was conducted in YPD broth at 30°C.  
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to investigate the consequences of breaking the Clp1-ATP interaction on pre-mRNA 3’-
end processing. 
 
4.2.2. Overexpression of lethal clp1-ATP mutant alleles restores growth 
When the deletion of a gene of interest is lethal (as is the case for deletion of clp1), the 
classical yeast genetics approach to investigate gene function is to characterise the 
effects of “conditional” mutations.  Conditional mutations affect the gene product so 
that it can function in a “permissive” condition allowing propagation of yeast cells, but 
a shift to a “restrictive” condition renders the gene product inactive allowing 
experiments to test the effects of gene function loss to be performed.  The most 
common example of conditional mutants are temperature sensitive mutants.  A 
temperature sensitive mutant is able to grow at the permissive temperature (usually 25-
30°C) but not at a temperature sufficiently high enough to induce the yeast heat shock 
response (35-40C), but that is still permissive to the growth of wildtype cells [214]. 
 
None of the clp1 mutants from the in vivo experiment described in section 4.2.1 
displayed temperature sensitive phenotypes, meaning that mRNA could only be 
extracted and analysed from the viable S138A and D161A clp1 mutants where the 
Clp1-ATP interaction was shown to be intact in vitro (see section 3.3).  In an attempt to 
rescue lethal phenotypes and procure mRNA for later experiments, clp1 mutants were 
overexpressed using a GAL1 promoter and the 5-FOA plasmid shuffle assay was 
repeated to identify viable yeast mutants.  The GAL1 promoter is constitutively active in 
the presence of galactose and repressed in the presence of glucose [215].  It was 
reasoned that if Clp1 K136E, K136A, T137A and D251A still possessed any affinity for 
ATP, overexpression of these mutants could generate a small fraction of ATP-bound 
Clp1 sufficient enough to support yeast cell propagation.   
 
The haploid clp1∆ URA3+ yeast strain did not grow on 5-FOA in the presence of either 
galactose or glucose, consistent with the sensitivity of URA3+ yeast to 5-FOA and the 
lethality of the chromosomal clp1 deletion (Figure 4.3, central and right panels).  
Haploid yeast transformed with the GAL1-CLP1 construct formed colonies on 5-FOA 
containing galactose (Figure, 4.3, central panel).  This demonstrates that constitutive 
transcription of CLP1 from the GAL1 promoter in the presence of galactose is able to 
reverse the lethal phenotype of the chromosomal clp1 deletion.  However, transcription 
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Figure 4.3 Spot test assays displaying the results of clp1∆ complementation with clp1-
ATP mutant alleles expressed from the GAL1 promoter.  Each spot represents a serial 
dilution (left to right 104-101).  The left panel shows yeast transformants plated on YPD 
medium (control for growth defects in the clp1∆ strain). The central panel shows yeast 
plated on 5-FOA medium containing galactose and sucrose (galactose activation of the 
GAL1 promoter) and the right panel shows yeast plated on 5-FOA medium containing 
glucose (glucose repression of the GAL1 promoter).  The clp1∆ strain was transformed 
with GAL1 constructs containing each mutant allele (labelled on the left hand side).  
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of CLP1 from the GAL1 promoter should have been shut off in the presence of glucose 
(glucose repression) resulting in lethality and the absence of yeast colonies from the 5-
FOA glucose plate.  This was not the case, as yeast colonies formed on 5-FOA 
containing glucose in all serial dilution spots (Figure 4.3, right panel).  This indicates 
that glucose repression of the GAL1 promoter was not completely effective, and that 
there was enough transcription of CLP1 to support yeast growth.  Similarly, the GAL1-
clp1 S138A and D161A alleles also restored growth to the clp1∆ strain after 5-FOA 
selection on both galactose and glucose media, reaffirming the inefficient glucose 
repression of GAL1 promoter activity (Figure 4.3, central and right panels respectively).  
Yeast transformed with the GAL1-clp1 K136E construct was unable to grow on 5-FOA 
containing either galactose or glucose (Figure 4.3, central and right panels respectively), 
demonstrating that overexpression of K136E was unable to complement the lethal clp1 
deletion.  Growth of GAL1-clp1 K136E yeast on the pre-5-FOA selection control was 
comparable to wildtype yeast, showing that the absence of growth on 5-FOA media was 
not due to defects in the clp1∆ strain (Figure 4.3, left panel).  In contrast to this, when 
the clp1∆ yeast strain was transformed with GAL1-clp1 K136A, T137A or D251A 
constructs, growth was observed in all serial dilution spots after 5-FOA selection on 5-
FOA plates containing galactose, but no growth was observed on 5-FOA glucose plates 
(Figure 4.3, compare central and right panels).  This demonstrates that overexpression 
of clp1 K136A, T137A and D251A alleles from the GAL1 promoter is able to rescue the 
lethal phenotypes of the same clp1 alleles expressed at natural levels (see section 4.2.1 
and Figure 4.1A).  The absence of growth on 5-FOA glucose suggests that glucose 
repression of the transcription of these clp1 mutants is sufficient to cause lethality to 
yeast. 
 
Because 5-FOA is a toxic compound, it was deemed necessary to rule out that its 
presence in growth media did not contribute to the glucose repression-induced lethality 
of the GAL1-clp1 K136A, T137A and D251A yeast mutants.  The growth 
characteristics of GAL1-clp1 yeast mutants were determined at 30°C on minimal agar 
medium containing galactose or glucose without 5-FOA.  Figure 4.4A shows that 
GAL1-CLP1 (LEU2+) yeast grew equally well on both minimal galactose and minimal 
glucose media, reaffirming that glucose repression of CLP1 transcription from the 
GAL1 promoter was not sufficient to cause lethality.  Contrary to the results of the 5-
FOA plasmid shuffle assay (see Figure 4.3), the growth of the GAL1-clp1 D251A yeast  
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Figure 4.4. Glucose repression of CLP1 wildtype and clp1 mutant transcription. (A) 
Plate-based growth assay. Mutants are labelled to the left of each panel and the 
composition of the growth medium indicated below the panels.  (B) Growth rate assays 
comparing the growth of GAL1-clp1 K136A and T137A yeast mutants with GAL1-
CLP1 wildtype yeast (identified by inset key) at 30°C before and after glucose 
repression.  The composition of the growth media are indicated above the graphs.  Error 
bars represent the standard deviation from the mean of a set of three replicate assays. 
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mutant was not significantly different on medium containing galactose to growth on 
medium containing glucose (Figure 4.4A).  This suggests that in the initial experiment, 
both the toxicity of 5-FOA and transcriptional repression of clp1 D251A contributed 
towards lethality on the 5-FOA glucose plate.  However, in keeping with the results of 
the 5-FOA plasmid shuffle assay, growth of the GAL1-clp1 K136A and T137A yeast 
mutants was diminished on minimal media containing glucose compared to growth of 
these mutants on minimal media with galactose (Figure 4.4A).  Growth rate assays were 
conducted to further characterise the growth phenotypes of the GAL1-clp1 K136A and 
T137A mutants.  In the presence of galactose, the growth of the GAL1-clp1 K136A and 
T137A mutants were reduced 1.5-fold and 2-fold respectively compared with GAL1-
CLP1 wildtype yeast growth after 8 hours (Figure 4.4B, left panel).  Differences in 
growth rates were also observed when strains were initially grown in galactose then 
shifted to glucose to repress GAL1 promoter activity (Figure 4.4B, right panel).  Growth 
of GAL1-clp1 K136A yeast was 2.3-fold reduced compared to wildtype yeast after 8 
hours, but with no evidence of a gradual cessation in growth that would be indicative of 
successful glucose repression.  On the other hand, after 8 hours the cell density of the 
GAL1-clp1 T137A yeast mutant was 8.2-fold less than that of GAL1-CLP1 wildtype 
yeast.  Furthermore, GAL1-clp1 T137A growth was static between the 5 and 8 hour 
time points, suggesting the combination of transcriptional repression by glucose and the 
effect of the T137A mutation on Clp1-ATP binding acted together to cause lethality. 
 
The restoration of growth to the clp1∆ yeast strain by overexpression of clp1 K136A, 
T137A and D251A mutants is probably the result of an increase in the amount of ATP-
bound Clp1.  Yeast containing the clp1 T137A allele under control of the GAL1 
promoter is similar to a conditional mutant where galactose conditions are permissive 
due to a high level of induction of T137A expression, and the lethal phenotype is 
observed upon a shift to the restrictive conditions of glucose repression.  The glucose 
repression observed in these experiments on the whole is poor and it is possible that the 
cessation of T137A growth in glucose is due to a combination of 5-FOA toxicity, 
reduced T137A transcription and the consequences of disrupting Clp1-ATP binding.  
However, the experiments described above point to T137A as being a promising 
candidate for the investigation of 3’-end processing defects in mRNA associated with 
disruption of the Clp1-ATP interaction.  
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4.3. Analysis of pre-mRNA 3’-end processing in clp1-ATP mutants 
 
Previous studies have shown that S. cerevisiae rna14, rna15 and pcf11 temperature 
sensitive mutants exhibit defects in pre-mRNA 3’-end cleavage and polyadenylation 
[88-94].  More recently, the same effects have been demonstrated with clp1 temperature 
sensitive mutants, although no link between Clp1-ATP binding and 3’-end processing 
has been uncovered [121]. Clp1 is an essential component of the CFIA complex that is 
obligatory for both cleavage and polyadenylation of pre-mRNAs in S. cerevisiae.  It was 
hypothesised that mutations that disrupt Clp1-ATP binding might result in aberrant pre-
mRNA 3’-end processing and are lethal for this reason. 
 
4.3.1. Analysis of poly(A) tail-lengths 
Within the pre-mRNA processing field, the cleavage and polyadenylation 
characteristics of a yeast strain are typically investigated separately using in vitro 
assays.  Cleavage assays involve testing the ability of partially-purified extracts from 
the desired yeast strains to cleave in vitro-transcribed RNA precursors (such as GAL7 
and CYC1 precursor RNAs).  The most commonly utilised polyadenylation assays 
either test the ability of extracts from the desired yeast strains to polyadenylate a pre-
cleaved RNA precursor, or assess the length distribution of poly(A) tails in total RNA 
samples extracted from the desired yeast strains.  Poly(A) “tail-length assays” can be 
used to compare the length distribution of poly(A) tails generated in wildtype and 
mutant yeast strains in order to reveal if a yeast mutant displays defects in transcript 
polyadenylation.  The method involves extraction and purification of total RNA from 
the desired yeast strain, followed by digestion of non-poly(A) RNA by RNases and 
radiolabelling at the 3’-ends of poly(A) tails [201] (see section 2.9).  Poly(A) tails are 
then visualised using autoradiography after their separation (by size) by denaturing 
polyacrylamide gel electrophoresis.  To determine if clp1 mutations that abrogate Clp1-
ATP binding affect polyadenylation of pre-mRNAs, poly(A) tail-length assays were 
conducted using total RNA isolated from GAL1-CLP1 wildtype yeast and GAL1-clp1 
yeast mutants. 
 
Poly(A) tails isolated from a wildtype GAL1-CLP1 total RNA sample were detected by 
autoradiography (Figure 4.5A).  Comparison of the position of these poly(A) tails with 
the position of DNA size standards showed that poly(A) tail size distribution ranged 
from ~20 to ~80 nucleotides.  This is consistent with the range of S. cerevisiae poly(A)  
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Figure 4.5. Poly(A) tail-length analysis.  (A) poly(A) tails purified from GAL1-CLP1 
wildtype yeast cultures that were separated by electrophoresis on 10% polyacrylamide 
gels and visualised by autoradiography.  Lane 1: digestion and purification protocol as 
cited in section 2.9; Lane 2: modified conditions, once ethanol precipitated (see section 
2.9); Lane 3: modified conditions, twice ethanol precipitated (see section 2.9).  The far 
left lane contains radiolabelled oligonucleotide size standards (sizes marked on left-
hand side).  The intense bands at 77, 65 and 46 nt are contaminants on the phosphor-
screen from a previous experiment with the 14C radioisotope. (B) Poly(A) tails purified 
from GAL1-CLP1 wildtype yeast cultures that were separated by electrophoresis on 
15% polyacrylamide gels and visualised by autoradiography.  The modified digestion 
and purification conditions used are described in section 2.9.  The amount of total RNA 
radiolabelled before RNase digestion is indicated above each lane.  The far left lane 
contains radiolabelled oligonucleotide size standards (sizes marked on left-hand side). 
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tail-lengths observed in other studies that have used poly(A) tail-length assays [91, 94, 
202].  However, the bands observed were poorly resolved.  This indicated that the 
isolation of poly(A) tails was not optimal or that the conditions of the polyacrylamide 
gel electrophoresis were not appropriate for the level of resolution required.  
Modifications were made to the digestion and electrophoresis conditions according to 
published protocols (described in section 2.9) and Figure 4.5B shows the best results 
that were achieved using a modified tail-length assay.   Intense poly(A) tail bands of 25, 
30 and 40 nucleotides in length were visible that were not previously observed 
(compare Figure 4.5A and B).  However, the overall resolution was still poor and not 
sensitive enough to confidently infer changes in pre-mRNA polyadenylation.  
Resolution did not improve when increasing the amount of RNA that was labelled 
(Figure 4.5B), indicating that the signal amplitude itself was not a problem and that sub-
optimal digest and gel electrophoresis conditions were the likely cause of poor poly(A) 
tail resolution. 
 
Poly(A) tail-length assays demonstrated that poly(A) tails of a normal length 
distribution were generated on mRNAs transcribed by wildtype GAL1-CLP1 yeast.  
However, high-resolution, defined by visualisation of individual bands of different 
poly(A) tail-lengths, is required to infer differences in polyadenylation between 
wildtype yeast and mutants.  Because the resolution of this technique could not be 
improved it was deemed insufficient to continue its use as a method for uncovering pre-
mRNA processing phenotypes. 
 
4.3.2. The Clp1-ATP interaction does not affect poly(A) site selection on ACT1 
mRNA 
After the discontinuation of poly(A) tail-length assays it was decided to utilise reverse 
transcription quantitative real-time PCR (RT-qPCR) as a “readout” for pre-mRNA 
processing phenotypes. The RT-qPCR “poly(A) site selection assay” was designed to 
quantify the utilisation of different processing sites in the 3’-UTRs of mRNAs 
transcribed from the yeast actin gene (ACT1), allowing a comparison of the site usage in 
CLP1 wildtype yeast and the clp1 ATP-binding yeast mutants.  Using wildtype CLP1, 
the relative usage of each ACT1 processing site was determined in order to formulate 
the pattern of cleavage/poly(A) site usage on the ACT1 gene (see section 2.9.2 and 
Figure 2.6 for experimental design). Comparison of cleavage/poly(A) site (hereafter 
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termed poly(A) site) usage between wildtype yeast and mutants was therefore able to 
determine whether Clp1-ATP binding is important for poly(A) site selection. To enable 
the conditional phenotype of T137A to be exploited, total RNA was extracted from 
yeast where the expression of CLP1 wildtype or clp1 mutants had been subjected to 
glucose repression (see section 2.8.8). 
 
The RT-qPCR experiment using total RNA from a GAL1-CLP1 wildtype yeast RNA 
sample revealed 98% of ACT1 mRNA is processed at the first poly(A) site, 
demonstrating that the first site proximal to the 3’ exon is the major poly(A) site of this 
gene (Figure 4.6B, location of cleavage/poly(A) sites depicted in Figure 4.6A).  This is 
consistent with the findings of the study which first characterised the ACT1 3’-UTR 
using northern blotting experiments [153].  The second and third sites are situated close 
together in the ACT1 3’-UTR and were assayed as one poly(A) site due to limitations in 
primer and probe design.  Transcripts processed at the second/third poly(A) sites 
comprised just 2% of total ACT1 mRNA and ACT1 mRNA processed at the fourth 
poly(A) site was not detected at all.  ACT1 poly(A) site selection assays with total RNA 
from the GAL1-clp1 K136A mutant revealed poly(A) site usage on the ACT1 gene was 
comparable to wildtype, with 97% processing occurring at the first poly(A) site, but 
with no processing at the second/third sites and 3% usage of the fourth site (Figure 
4.6B).  ACT1 poly(A) site selection was also similar to wildtype in both GAL1-clp1 
S138A and D161A yeast mutants, with the respective frequencies of site usage being 
95% and 96% for the first site, 4% and 0% for the second/third sites and 1% and 4% for 
the fourth site (Figure 4.6B).  The GAL1-clp1 T137A yeast mutant was considered 
promising for the analysis of pre-mRNA processing defects because of its conditional 
phenotype.  Here, the ACT1 poly(A) site selection assay showed that ACT1 mRNA 
processed at the first site comprised 90% of total mRNA, with the frequencies of 
second/third and fourth site selection determined to be 4% and 6% respectively (Figure 
4.6B).  However, whilst this represents a 10% decrease in the usage of the first poly(A) 
site compared with wildtype, no radical redistribution of poly(A) site usage is apparent, 
suggesting that the loss of Clp1-ATP binding results in only modest effects on poly(A) 
site selection on  ACT1 pre-mRNAs. 
 
Examination of the raw data generated from RT-qPCR amplification plots revealed that 
although site selection was only moderately affected, it was apparent that the mean 
quantity of ACT1 mRNA in GAL1-clp1 T137A RNA samples was ~2-fold reduced 
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Figure 4.6.  Poly(A) site selection on ACT1 mRNA in GAL1-clp1 ATP-binding 
mutants.  (A) A schematic of the ACT1 3’-UTR. The 3’-end of the ACT1 ORF is 
coloured red, 3’-UTR sequence is coloured blue and poly(A) sites are coloured orange 
and are numbered.  Distances between poly(A) sites in bp are indicated as defined by 
Mandart and Parker [153].  (B) Results of the ACT1 poly(A) site selection RT-qPCR 
experiment.  The histograms show the percentages of total ACT1 mRNA that were 
processed at each of three poly(A) sites in wildtype and mutant yeast.  In each panel, the 
degree of processing at poly(A) sites in  mutants compared to wildtype is displayed.  
The panels are labelled above histograms with the identity of each mutant, wildtype 
histograms are depicted in blue, mutants in red.  Error bars represent the standard 
deviation from the mean of two experiments and in each experiment targets were 
detected in triplicate.  
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compared to the mean quantity found in GAL1-CLP1 wildtype RNA samples (a mean 
mRNA quantity of 80.3 compared to 136.5, see Table 4.1).  Similarly, the mean 
quantity of TDH2 mRNA (the normalisation control used in this experiment) was 42.4 
in GAL1-clp1 T137A RNA samples compared to 211.75 in GAL1-CLP1 wildtype RNA 
samples, which represents a 5-fold decrease in TDH2 transcription.  A reduction in the 
mRNA levels of these genes was not observed in any of the mutant samples tested 
 
The results of the RT-qPCR poly(A) site selection assay demonstrated that Clp1-ATP 
binding does not contribute significantly to poly(A) site choice on the ACT1 gene in S. 
cerevisiae.  However, the quantities of ACT1 and TDH2 mRNAs were significantly 
lower in clp1 T137A total RNA samples compared to wildtype CLP1 and other clp1 
mutant RNA samples.  These genes are normally highly-expressed, so it is likely that 
loss of Clp1-ATP binding caused by the T137A mutation results in transcription 
defects.  A reduction in ACT1 and TDH2 mRNA levels was not observed in the clp1 
K136A mutant.  However, this mutant also did not display a conditional phenotype 
when its transcription was repressed by glucose (see section 4.4.2), and so it is likely 
transcription is far less affected in this case. 
 
 CLP1 K136A T137A S138A D161A 
Mean Quantity 
TDH2 (SD) 
211.75 
(2.1) 
351.55 
(17.75) 
42.4 
(7.3) 
225.95 
(168.95) 
309 
(22.95) 
      
Mean Quantity 
ACT1 (SD) 
136.5 
(5.85) 
202.1 
(3.85) 
80.3 
(19.05) 
137.9 
(88.95) 
195.75 
(14.5) 
 
Table 4.1.  TDH2 and ACT1 mRNA quantities determined by RT-qPCR of total RNA extracted from 
CLP1 wildtype and clp1 mutants.  TDH2 and ACT1 mRNA quantities in the T137A RNA sample are 
highlighted red to illustrate their reduction compared to wildtype and other mutant quantities.  The 
quantities displayed were determined by comparison to the relevant standard curves and are not 
normalised to or expressed as relative to the expression of any other gene. The figures in brackets are the 
standard error derived from evaluation of the mean.  CT and quantity values generated in all RT-qPCR 
experiments are located in Appendix 8.6. 
 
4.3.3. Clp1-ATP binding plays an important role in transcription  
To investigate the effects of disrupting the Clp1-ATP interaction on transcription, the 
quantities of mRNAs transcribed from ACT1, TDH2 and three other genes were 
analysed by RT-qPCR of total RNA samples extracted from wildtype GAL1-CLP1 and 
GAL1-clp1 yeast mutants.  This enabled a comparison of the amounts of transcription of 
these genes in GAL1-clp1 yeast mutants relative to the amounts of transcription in 
wildtype (GAL1-CLP1) yeast.  The three additional genes chosen for transcript 
quantification were ADH1 (alcohol metabolism), YPT1 (membrane trafficking) and 
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CYC1 (respiration).  These genes were chosen because they are involved in different 
cellular pathways, are highly-expressed and their expression does not fluctuate 
significantly during the yeast cell cycle (gene expression information obtained from 
Saccharomyces Genome Database, http://www.yeastgenome.org/).    
 
The mean quantity of TDH2 mRNA detected in total RNA samples extracted from the 
GAL1-clp1 K136A yeast mutant represented 147% of the quantity detected in GAL1-
CLP1 wildtype total RNA samples (Figure 4.7A).  Similarly, the amount of ACT1 
transcription was also increased in the GAL1-clp1 K136A mutant at 149% of the 
amount of wildtype transcription.  The quantities of YPT1, ADH1 and CYC1 mRNAs 
detected relative to wildtype were 80%, 100% and 80% respectively, demonstrating that 
transcription of these genes is not significantly affected by the clp1 K136A mutation.  In 
the GAL1-clp1 S138A yeast mutant, the quantities of ACT1, YPT1, ADH1 and CYC1 
mRNAs were between 70-100% of the GAL1-CLP1 wildtype mRNA quantities (Figure 
4.7A), showing that transcription of these genes in this yeast mutant is similar to 
wildtype.  In the GAL1-clp1 D161A mutant, the quantities of transcription of TDH2, 
ACT1, YPT1, ADH1 and CYC1 genes compared to wildtype was more variable than in 
the K136A and S138A mutants.  Transcription of TDH2 was decreased nearly 2-fold 
(61% of wildtype) and transcription of ACT1 was increased ~1.5-fold (145% of 
wildtype) compared to wildtype (Figure 4.7A).  On the other hand, transcription of 
YPT1, ADH1 and CYC1 genes was relatively similar in GAL1-clp1 D161A to wildtype 
transcription (relative quantities of 74%, 95% and 99% respectively).  The largest 
differences in transcription were found in the GAL1-clp1 T137A mutant.  The quantity 
of TDH2 mRNA detected in this yeast mutant was just 10% of the quantity of TDH2 
detected in GAL1-CLP1 wildtype yeast, indicating a severe reduction in the amount of 
transcription of this gene (Figure 4.7, A).  This was around 2-fold lower than was 
detected in the ACT1 poly(A) site selection assay (TDH2 transcription in T137A was 
20% relative to wildtype here).  ADH1 transcription in this mutant was also diminished 
to 10%, and ACT1 transcription reduced to 40% of wildtype transcription.  The 
quantities of CYC1 and YPT1 mRNAs detected in GAL1-clp1 T137A RNA samples 
were ~80% of the mRNA quantities detected in wildtype yeast RNA samples, indicating 
transcription of these genes is not significantly affected by the clp1 T137A mutation. 
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Figure 4.7.  Gene expression and transcription termination in GAL1-clp1 yeast mutants 
compared to wildtype yeast.  (A) Histogram to show the amounts of transcription from 
TDH2, ACT1, YPT1, ADH1 and CYC1 genes in GAL1-clp1 ATP-binding mutants 
compared to wildtype.  The amount of mRNA transcribed from each gene was 
determined by RT-qPCR of total RNA samples extracted from GAL1-clp1 ATP-binding 
mutants.  Each gene is identified in the inset key. (B) Histogram to show quantification 
of transcription termination on the ACT1 gene (determined by percentage of ACT1 
readthrough transcription) in GAL1-CLP1 wildtype yeast and GAL1-clp1 ATP-binding 
mutants (each mutant is labelled).  Error bars represent the standard deviation from the 
mean of two experiments and in each experiment targets were detected in triplicate.   
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Analysis of mRNA quantities by RT-qPCR revealed the clp1 T137A mutation, causes 
reduced transcription of the TDH2, ACT1 and ADH1 genes.  The differences in the 
levels of transcription of these genes between the GAL1-clp1 T137A yeast mutant and 
GAL1-CLP1 wildtype yeast were far more prominent than the small increases/decreases 
in transcription observed between wildtype yeast and the other GAL1-clp1 yeast 
mutants. Taking these results into consideration, it is possible that the growth defects 
displayed by the GAL1-clp1 T137A mutant are the result of severe defects in 
transcription caused by loss of Clp1-ATP binding, and that defective transcription 
results in lethality (when clp1 T137A is not overexpressed).  A wider profile of the 
GAL1-clp1 T137A yeast mutant transcriptome is required to determine the extent of 
transcriptional abnormalities associated with this mutant.  The clp1 K136A mutation 
seemingly does not affect transcription although it has also been shown to abolish the 
Clp1-ATP interaction (see section 3.3.1).  It is probable that reduced transcription was 
not observed with the GAL1-clp1 K136A mutant as it did not display the same 
conditional phenotype as GAL1-clp1 T137A after glucose repression of the GAL1 
promoter (see section 4.2.2).  
 
4.3.4. Clp1-ATP binding may be important for transcription termination on the 
ACT1 gene 
Two recent studies have demonstrated that cellular depletion of Clp1 affects PolII 
transcription termination in S. cerevisiae [121, 180]. The most recent research into 
transcription termination in S. cerevisiae points to a unified allosteric/torpedo model in 
which both transcription of the cleavage/poly(A) site and cleavage of the pre-mRNA are 
essential in halting transcription  (see section 1.7.1) [176].  Aberrant transcription 
termination is defined by “transcription run-on” or “readthrough transcription”, where 
PolII continues to transcribe after passing the most distal poly(A) site from the gene 
being transcribed.  To determine whether Clp1-ATP binding is important for 
transcription termination, an RT-qPCR assay was used to compare the quantities of 
readthrough transcription on the ACT1 gene in wildtype yeast and the GAL1-clp1 
K136A, T137A, S138A and D161A yeast mutants. 
 
RT-qPCR experiments using total RNA extracted from GAL1-CLP1 wildtype yeast 
showed that ACT1 readthrough transcripts comprised ~9% of total ACT1 mRNA 
(Figure 4.7B).  This amount was higher than expected and is indicative of inefficient 
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transcription termination.  The amount of ACT1 readthrough transcription in GAL1-
CLP1 yeast is noticeably higher than that observed in experiments with PCF11 
wildtype yeast described in chapter 6 (less than 1% readthrough transcription on the 
ACT1 gene), and may reflect decreased levels of Clp1 protein caused by reduced CLP1 
gene transcription (after glucose repression of the GAL1 promoter).  To confirm this, it 
would be necessary to perform further experiments that use more efficient methods to 
deplete Clp1 in S. cerevisiae (for example the degron approach).  The amount of ACT1 
readthrough transcription was lower in the GAL1-clp1 K136A, S138A and D161A 
mutants compared to wildtype, with ACT1 readthrough transcripts comprising 4%, 7% 
and 5% of total ACT1 mRNA respectively (Figure 4.7B).  In contrast, the proportion of 
ACT1 readthrough transcripts to total ACT1 mRNA was slightly elevated in the GAL1-
clp1 T137A mutant at 15%, revealing a small increase in readthrough compared to 
wildtype (Figure 4.7B).   
 
The GAL1-clp1 T137A yeast mutant displayed a small increase in ACT1 readthrough 
transcription compared to wildtype GAL1-CLP1 yeast, suggesting Clp1-ATP binding 
may be important for transcription termination.  However, because this increase was 
only small (~5%) it is difficult to ascertain as to whether it is significant.  Results 
presented in chapter 6 show that the Pcf11-Clp1 interaction is necessary for 
transcription termination on the ACT1 gene.  When considering the fact that the T137A 
mutation causes loss of the Clp1-Pcf11 interaction in vitro (see section 3.2), it is 
possible that the increase in ACT1 readthrough transcription in the GAL1-clp1 T137A 
mutant is significant.  Clarification of the role of Clp1-ATP binding in PolII 
transcription termination will require a more in-depth analysis of yeast transcripts from 
a larger selection of genes. 
 
4.4. Summary and conclusions 
 
An in vivo analysis in S. cerevisiae of the effects of mutations in the CLP1 gene showed 
that clp1 ATP-binding yeast mutants that abrogate Clp1-ATP binding in vitro are not 
viable (clp1 K136A, K136E, T137A and D251A), whereas clp1 ATP-binding mutants 
that do not affect Clp1-ATP binding in vitro displayed no growth abnormalities 
compared to CLP1 wildtype yeast (clp1 S138A and D161A).  The upregulation of 
mutant clp1 gene transcription by galactose induction of the GAL1 promoter was able to 
reverse the lethal phenotypes of the clp1 K136A, T137A and D251A mutations.  This 
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was likely due to the fact that these mutations may not completely abolish Clp1-ATP 
binding and that increased protein levels might produce a small fraction of ATP-bound 
Clp1 that is sufficient to maintain the essential function of Clp1 to S. cerevisiae.  The 
clp1 T137A yeast mutant showed a conditional phenotype where growth in medium 
containing glucose provides a restrictive condition which is possibly caused by a 
combination of repression of GAL1 promoter activity, 5-FOA toxicity and the loss of 
Clp1-ATP binding caused by this mutation.  Analysis of mRNA extracted from GAL1-
clp1 yeast mutants by RT-qPCR showed that the frequency of poly(A) site usage on 
ACT1 mRNA was only modestly affected in the GAL1-clp1 T137A yeast mutant 
compared to wildtype, indicating that  Clp1-ATP binding may not be a major effector of 
poly(A) site selection.  However, the quantities of mRNA transcribed from five 
different genes were significantly lower in the GAL-clp1 T137A mutant compared to 
wildtype and other mutants, positing a role for the Clp1-ATP interaction in the 
maintenance of transcription levels in S. cerevisiae.  Results of RT-qPCR experiments 
also suggested that the Clp1-ATP interaction may be involved in effecting transcription 
termination, although a deeper investigation is required to provide conclusive evidence 
of this. 
 
The fact that mutation of the Clp1 putative catalytic residue, Asp161, had no effect on 
Clp1-ATP binding in vitro and caused no growth abnormalities in S. cerevisiae suggests 
that Clp1-ATP binding fulfils no catalytic function, or that the catalytic capability of 
Clp1 is redundant.  This gives further substance to the idea that ATP is a structural 
component of Clp1 that is essential for Clp1 stability and the adoption of a 
conformation that is conducive to CFIA assembly.  It is likely that this is necessary for 
the maintenance of appropriate levels of transcription from a variety of essential genes 
and for efficient PolII transcription termination.    
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5. in vitro analysis of recombinant Pcf11-Clp1 binding mutants 
 
5.1. Introduction and overview 
 
Pcf11 is a subunit of the cleavage factor IA complex (CFIA), an essential multi-subunit 
protein complex required for the cleavage and polyadenylation of pre-mRNAs in S. 
cerevisiae (see sections 1.3 and 1.3.3).  Pcf11 interacts with all three other CFIA 
subunits (Rna14, Rna15 and Clp1) and also core subunits of the cleavage and 
polyadenylation factor complex (CPF) [89, 99, 103].  The amino-terminal domain 
(NTD) of Pcf11 interacts with PolII CTD, which has been shown to be crucial for 
transcription termination at a number of gene loci [106, 110, 115], and cellular 
depletion of Pcf11 has also been associated with a decrease in transcription [89, 176, 
186].  The crystal structure of a Clp1-Pcf11 heterodimer shows an intimate association 
between Clp1 and Pcf11 [116].  In particular, in Pcf11 three highly conserved residues 
in the Pcf11-Clp1 interaction domain (Clp1 ID) are extensively associated with residues 
in the Clp1 CD and in a cleft between the Clp1 CD and CTD via hydrogen bonding and 
hydrophobic interactions.  The results of a study published during the completion of the 
work presented here showed that the pcf11 RW-A temperature sensitive allele (which 
was identified independently in this study) causes a weakened Pcf11-Clp1 interaction 
that results in defects in pre-mRNA 3’-end processing and transcription termination 
[122].  However, despite the obvious importance of the Pcf11-Clp1 interaction in both 
of these processes, the mechanism by which the interaction of these proteins influence 
3’-end processing and transcription termination is still unclear.   
 
To study the significance of the Pcf11-Clp1 interaction, it was necessary to first assess 
the properties of the Pcf11 CTD that contains the Clp1 ID.  Following this, conserved 
residues in the Clp1 ID were mutated and properties of the resultant recombinant mutant 
proteins were characterised using hydrodynamic and biochemical techniques.  The 
experiments aimed to determine which mutations uncoupled Clp1 from Pcf11, the 
effects of Pcf11-Clp1 uncoupling on Clp1 stability, and whether the Pcf11-Clp1 
interaction was important for Clp1-ATP binding.   
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5.2. Characterisation of the Pcf11 CTD 
 
Analysis of the Pcf11 amino acid sequence together with findings from previous studies 
has shed some light onto the properties of the Pcf11 CTD.  The crystal structure of a 
Clp1-Pcf11 heterodimer revealed that the Pcf11-Clp1 ID is comprised of Pcf11 CTD 
residues 475-499 (see section 1.3.3 and Figure 1.4) [116].  Furthermore, it has been 
shown that the Pcf11-Yra1 binding site overlaps this region (for a domain map of Pcf11 
see Figure 1.3A) [170].  Other prominent features of the Pcf11 CTD are two zinc finger 
motifs that flank the Clp1/Yra1 ID.  Zinc finger motifs are structural motifs that use 
zinc ions to stabilise their folds, and commonly serve as interaction modules that bind to 
other proteins, DNA or RNA.  However, no functions of Pcf11 have yet been associated 
with these motifs.  Apart from residues 475-499, no structural information is available 
for the Pcf11 CTD, yet it is known to be the interaction site for at least two protein 
factors.     
 
5.2.1. Purification of Pcf11 456-626 
Characterisation of the Pcf11 CTD required the production of recombinant protein 
containing this domain.  A pET-22b construct containing DNA sequence encoding 
Pcf11 residues 456-626 fused to a C-terminal hexahistidine sequence tag had been 
generated previously and was made available by Dr I. Taylor (NIMR).  This fragment 
of Pcf11 contains the Clp1/Yra1 ID and the second zinc finger motif of Pcf11.  Pcf11 
456-626 was overexpressed from the pET-22b construct in E. coli BL21(DE3) cells and 
purified by nickel-affinity chromatography and size-exclusion chromatography.  SDS-
PAGE gel analysis of protein fractions from the nickel-affinity chromatography 
purification showed a dense band of overexpressed protein was visible in the crude 
lysate but not in the insoluble pellet fraction (Figure 5.1A).  Comparison of this protein 
band with protein size standards showed it was between 20-30 kDa in size, which is 
slightly larger than the estimated molecular weight of 20.3 kDa for the Pcf11 456-626 
protein.  The fact that Pcf11 456-626 was not visible in the fraction extracted from the 
nickel column flow-through demonstrated that the C-terminal His-tag was present and 
bound the nickel resin, although some protein was lost in two subsequent wash steps 
along with some higher molecular weight contaminants that bound non-specifically to 
the nickel column (Figure 5.1A).  Protein with the correct SDS-PAGE migration was 
observed in fractions 1-11 after elution of the nickel column with an imidazole buffer, 
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Figure 5.1. Purification of the Pcf11 CTD. (A) SDS-PAGE of nickel-affinity 
purification of Pcf11 456-626 (6-His Tagged) after overexpression of the protein in E. 
coli.  Each stage of the purification was analysed: Pl., cell pellet (insoluble protein); Cr., 
crude clarified lysate; Ft., flow-through from nickel column; W1, first wash of nickel 
column; W2, second wash of nickel column; 1-11 (ml), eluted fractions from nickel 
column.  Protein size standards are labelled on the left (in kDa). (B) SEC purification 
profile of Pcf11 456-626 (black line) following nickel-affinity purification. (C) SDS-
PAGE of fractions eluted by SEC.  Protein size standards are labelled on the left (in 
kDa). 
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along with small amounts of a lower molecular weight protein contaminant present in 
fractions 3-5 (Figure 5.1A).  As a further purification step, SEC was performed to 
separate any remaining contaminants and protein oligomers by size using a HiLoad 
16/60 Superdex 75 SEC column.  The SEC profile of Pcf11 456-626 displayed a single 
peak that eluted from the column with a retention volume of ~85 ml (Figure 5.1B).  
This suggested that the protein was pure and that its oligomeric state was likely to be 
homogeneous.  SDS-PAGE analysis of sample fractions taken throughout the elution of 
the chromatographic peak showed that it contained Pcf11 456-626 with no other visible 
contaminants (Figure 5.1C), and so was suitable for use in subsequent biophysical 
experiments. 
 
5.2.2. Multiangle laser light scattering analysis of Pcf11 456-626 
A study published during the completion of this work determined the stoichiometry of 
the CFIA complex subunits to be 2:2:1:1 (Rna14:Rna15:Clp1:Pcf11) [92].  SEC-
MALLS experiments described here aimed to determine the oligomerisation state and 
solution molar mass of Pcf11 456-626. 
 
In a SEC-MALLS experiment with Pcf11 456-626, the signal from the dRI detector 
showed a peak eluted from the SEC column (Superdex 75 10/30) with a retention time 
of ~30 minutes (Figure 5.2A).  The combination of dRI and light scattering 
measurements taken from this peak allowed calculation of molar mass and therefore the 
oligomeric state of the protein within it. Pcf11 456-626 displayed a narrow molar mass 
distribution (0.4% of the weight-averaged molar mass) with a weight-averaged molar 
mass of 19.4 kDa. This experimentally obtained value is very close to the expected 
mass of a Pcf11 456-626 monomer (20.3 kDa with the His-tag fusion), meaning its 
migration by SDS-PAGE (between the 20-30 kDa size standards, see Figure 5.1A, C) is 
anomalous rather than a result of an incorrect sequence. 
 
The fact that Pcf11 456-626 is monomeric in solution is in agreement with the recently 
determined stoichiometry of Pcf11 in the CFIA complex (1 molecule of Pcf11 per CFIA 
complex) [92], although the analysis provided here does not rule out the possibility that 
the oligomeric state of Pcf11 is regulated by its N-terminal or central domains. 
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Figure 5.2. SEC-MALLS and CD characterisation of the Pcf11 CTD. (A) 
Chromatogram from SEC-MALLS analysis of Pcf11 456-626. The differential 
refractive index (dRI, blue line) is plotted to show the location of chromatographic 
peaks. The points in black are individual measurements taken from Debye plots of the 
weight-averaged molar mass of material eluted in the chromatographic peaks. (B) Far-
UV CD spectrum (260-200 nm) of Pcf11 456-626 expressed as the differential mean 
residue weigh molar extinction (∆mrw). 
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5.2.3. Far-UV circular dichroism of Pcf11 456-626 
Residues 475-499 of Pcf11 comprise the protein interface in the crystal structure of a 
Clp1-Pcf11 heterodimer [116].  However, with regards to the structure of the remainder 
of the Pcf11 CTD, no data is available.  Pcf11 associates with many other proteins 
including CFIA and CPF subunits, and PolII.  In order to dynamically associate with its 
many different binding partners, Pcf11 might require a degree of flexibility, 
accomplished by adopting an unstructured and highly adaptable conformation.  
Alternatively, the Pcf11 CTD could adopt a highly-ordered folded conformation, with a 
number of interaction surfaces presented to facilitate the binding of protein partners.  To 
gain insight into the secondary structure of the Pcf11 CTD, far-UV CD spectroscopy 
was performed with recombinant Pcf11 456-626. 
 
The far-UV CD spectrum of Pcf11 456-626 displays negative CD peaks at ~222 nm and 
205 nm (Figure 5.2B), indicative that Pcf11 456-626 contains both  and  secondary 
structure elements.  However, the intense negative CD in the ~205 nm region and below 
indicates that a high proportion of the protein is composed of irregular or random coil, 
and is therefore disordered.  The CDpro program [197] was used to predict the 
composition of Pcf11 456-626 secondary structure elements from far-UV CD data.  The 
predicted secondary structure content of Pcf11 456-626 is 16.7% -helix, 14.5% -
sheet, 15.9% turn and 52.9% random coil.  This analysis has revealed that the Pcf11 
456-626 is likely to be considerably unstructured.  
 
It is probable that the predicted  and  secondary structure elements of Pcf11 456-626 
are confined to the second zinc finger motif of the Pcf11 CTD, and that few or none of 
the remaining residues are structured.  The Clp1 and Yra1 binding sites have previously 
been mapped to the Pcf11 CTD, although it may contain the interaction domains for 
other protein factors.  Considering this, the disordered nature of the Pcf11 CTD may be 
necessary for it to act as a flexible binding platform for multiple interaction partners. 
 
5.2.4. Pcf11 CTD deletion analysis 
Although the Pcf11-Clp1 ID has already been characterised by the determination of a 
high-resolution crystal structure, it is possible that the structure only shows a small 
segment of the Pcf11-Clp1 ID. To date, the Pcf11-Clp1 interaction has not been 
investigated in great detail and it is possible that the Pcf11-Clp1 ID is more extensive 
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than is currently thought, or that there are multiple sites that mediate the Pcf11-Clp1 
interaction. To determine if other parts of the Pcf11 CTD are involved in Clp1-binding, 
biophysical experiments were planned to map the Pcf11-Clp1 ID in greater detail.  In 
order to carry out these experiments, several different Pcf11 CTD deletion mutants were 
cloned, overexpressed and purified from E. coli using a pGEX-6P-1 expression system, 
glutathione-S-transferase-affinity chromatography and SEC (see sections 2.3.3 and 
2.3.5). Figure 5.3A shows a schematic of the Pcf11 CTD from which a variety of 
constructs were designed. Pcf11 400-626 encompasses the entire Pcf11 CTD, Pcf11 
416-626 excludes the residues N-terminal to the first zinc finger motif, Pcf11 400-499, 
416-499 and 420-499 are constructs that all contain the first zinc finger and Clp1 ID 
observed in the crystal structure, but lack the second zinc finger and C-terminal 
residues. 
 
The consecutive steps of the glutathione-S-transferase (GST) purification were analysed 
by SDS-PAGE. Analysis of the Pcf11 400-499 purification showed three intensely-
stained protein bands were visible in a sample of the protein that bound to the 
glutathione sepharose beads (Figure 5.3B, lane labelled ‘B.’). Comparison of these 
bands with protein size standards showed that two species had molar masses of 
approximately 30 and 35 kDa respectively.  The larger of these bands was likely to be 
the GST-Pcf11 400-499 fusion (expected molar mass of 38 kDa), and the second band 
possibly a degradation product of this protein. A third band was present with a lower 
molar mass of around 25 kDa.  The identity of this band was also unclear, and it is 
likely that this was also a degradation product of the GST-Pcf11 400-499 fusion. After 
cleavage of the GST-tag with 3C protease, a further intensely-stained band was visible 
at around 20 kDa (Figure 5.3B, lane labelled ‘C.B.’).  Although the apparent molar 
mass of this band was slightly lower than that expected for the cleaved GST-tag (26 
kDa), its intensity and the fact it appears in the other Pcf11-GST purifications suggests 
it can only be cleaved GST.  Furthermore, the appearance of this band corresponded 
with a reduction in the intensity of the 35 kDa band, signifying that the GST-tag had 
been cleaved from Pcf11 400-499.  However, the post cleavage eluted fraction (labelled 
‘C.E.’ in Figure 5.3B) did not contain a 12 kDa protein equivalent to Pcf11 400-499, 
with only low levels of protein contaminants and some carry-over of the GST-tag 
visible.  Similarly, SDS-PAGE analysis of the Pcf11 416-499 and Pcf11 420-499 GST-
purifications showed that these GST-fusion proteins were also expressed, but no 
proteins of the correct size (10 and 9.5 kDa respectively) were recovered after 
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Figure 5.3. Pcf11 CTD deletion analysis.  (A) Schematic of the Pcf11 CTD.  The zinc 
finger regions and the Clp1/Yra1 ID are coloured blue and green respectively and 
residue positions indicated above. The light green box represents Pcf11 residues 
observed in the Clp1-Pcf11 crystal structure. (B) SDS-PAGE of Pcf11 CTD construct 
GST purifications.  The identity of each construct is shown above the relevant section of 
the gel and lanes are labelled: B., protein bound to glutathione sepharose beads; C.B., 
sample of resin after cleavage of the GST tag from target protein with 3C protease; 
E.B., sample of the protein eluted into buffer after 3C protease digestion.  The red boxes 
indicate soluble target protein.  Sizes of molecular weight standards are shown to the 
left of each gel (sizes in kDa) (C) Chromatograms from SEC-MALLS experiments with 
Pcf11 400-626 and Pcf11 416-626. The differential refractive index (dRI, blue line) of 
each protein sample (labelled) is plotted to illustrate the location of chromatographic 
peaks. The black points are measurements of the weight-averaged molar mass recorded 
throughout the elution of the chromatographic peak. 
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cleavage of the GST-tags (Figure 5.3B).  These results demonstrate that Pcf11 400-499, 
416-499 and 420-499 are unstable in the absence of a fused GST-tag. On the other hand, 
GST purification of Pcf11 400-626 and 416-626 was successful.  SDS-PAGE analysis 
showed in the Pcf11 400-626 purification, a ~50 kDa protein was bound by the 
glutathione Sepharose beads, and in the Pcf11 416-626 purification an overexpressed 
~45 kDa protein was visible (Figure 5.3B, lanes labelled ‘B.’).  These molar masses 
were comparable to the expected combined masses of each protein fused with a GST-
tag (51 kDa and 48 kDa respectively).  After cleavage, intensely-stained bands 
corresponding to cleaved GST-tags were bound to Sepharose beads in both purifications 
(Figure 5.3B, lanes labelled ‘C.B.’).  SDS-PAGE of the eluted fractions from Pcf11 
400-626 and Pcf11 416-626 GST purifications revealed both of these fractions 
contained intensely-stained protein species that migrated between 20 kDa and 30 kDa 
relative to the protein size standards (Figure 5.3B, lanes labelled ‘C.E.’).  These proteins 
were consistent with the expected molar masses of Pcf11 400-626 (26.2 kDa) and Pcf11 
416-626 (24.2 kDa). 
 
After a SEC purification step, the molar masses and oligomeric states of these proteins 
were analysed by SEC-MALLS.  Both proteins eluted from the SEC column with a 
retention time of ~30 minutes (Figure 5.3C).  The molar mass determined by Debye 
analysis of the light scattering data for Pcf11 400-626 was 24.7 kDa, close to the 
expected molar mass of 26.2 kDa. The molar mass determined for Pcf11 416-626 was 
22.5 kDa, close to the expected molar mass of 24.2 kDa. The uniformity of molar 
masses calculated from the individual Debye plots generated throughout both of the 
protein peaks showed the proteins were monomeric with no tendency for self-
association. 
 
Purification of recombinant Pcf11 CTD deletion mutants showed that when protein 
constructs were terminated at residue 499, recombinant protein was unstable/insoluble 
after cleavage of GST-tags. The fact that the crystal structure of Clp1-Pcf11 shows that 
this residue is located in an unstructured loop suggests that it is unlikely that termination 
of the construct here affects the fold of the protein. However, the two protein constructs 
that were soluble (Pcf11 400-626 and 416-626) both contain the second zinc finger.  
Therefore, an alternative explanation is that the second zinc finger is important for the 
stability of the Pcf11 CTD, and that its deletion results in the protein misfolding. The 
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initial objective of purifying recombinant Pcf11 CTD deletion mutants was to use them 
in biophysical experiments aimed at probing the full extent of the Pcf11-Clp1 
interaction.  However, the fact that Clp1 is unstable and aggregates in the absence of 
bound Pcf11 made it impossible to perform these experiments (see sections 3.3 and 
5.3). 
 
5.3. Mutation of conserved Pcf11 residues in the Clp1-ID affects the stability of 
Clp1 
 
5.3.1. Design of Pcf11 mutants 
It has been shown that disrupting ATP from the Clp1-ATP binding pocket results in 
Clp1 instability and loss of the Pcf11-Clp1 interaction (see sections 3.2 and 3.3).  
Therefore, in addition to ATP-binding it is possible that the Pcf11-Clp1 interaction may 
be important for Clp1 stability.  To further assess the nature and function of the Pcf11-
Clp1 interaction, point mutations designed to weaken and/or disrupt the binding 
interface were introduced into the Clp1/Pcf11-EXP construct by SDM.  These 
mutations were designed based upon interactions between Pcf11 and Clp1 residues 
observed in the Clp1-Pcf11 crystal structure [116] (see section 1.3.3. and Figure 1.4B), 
and the conservation of Pcf11 residues in the Clp1 ID of Pcf11 (see Figure 1.6C).  A 
full list of mutations is presented in Table 5.1.  Gln478 makes multiple contacts with 
other polar residues in Clp1.  Arg480, Trp 482 and Trp489 are all involved in extensive 
hydrogen-bonding networks with Clp1 residues, with Trp482 and Trp489 also 
mediating hydrophobic interactions.  These three residues are also highly-conserved 
across a wide range of organisms, implying that they may contribute to an essential 
function.  Recombinant mutant proteins were all expressed from the Clp1/Pcf11(454-
563)-EXP construct in E. coli  (see section 2.2.3) and are hereafter referred to as Pcf11-
Clp1 mutants. 
 
Residue Location Function Mutated to Mutant name 
Gln478 Clp1 ID Binds Clp1 CD-CTD cleft residues 
Ser342, Ala197, Gly196, Thr194  
Asn Q478N 
Arg480 Clp1 ID Binds Clp1 CD-CTD cleft residues 
Gln191, Ser192, Glu331, Tyr332 
Ala R480A 
Trp482 Clp1 ID Binds Clp1 CD-CTD cleft residues 
Leu406, Pro426, Val427 
Ala W482A 
Trp489 Clp1 ID Binds Clp1 CD residues Gln204, 
Met206, Arg236 
Ala W489A 
 
Table 5.1. Mutations made in the Pcf11-Clp1 interface in the Clp1/Pcf11-EXP construct. 
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5.3.2. Size-exclusion chromatography 
SEC experiments with recombinant Clp1-ATP binding mutant proteins revealed that 
some mutations caused the Clp1-Pcf11 complex to be separated into distinct 
chromatographic peaks.  Subsequent experiments confirmed this was due to the 
instability of Clp1 after loss of ATP (see sections 3.2 and 3.3).  To determine if 
mutations in the Pcf11-Clp1 interface also affected the stability of Clp1, SEC 
experiments with Pcf11-Clp1 mutants were also performed. 
 
The SEC profile of recombinant wildtype Clp1-Pcf11 displayed a single peak with a 
retention volume of ~75 ml (Figure 5.4).  The retention volume of this peak is 
consistent with a peak that was previously shown to contain Clp1-Pcf11 complex (see 
section 3.2.2).  SEC of the Pcf11 Q478N mutant also produced a single peak with a 
retention volume of ~75 ml, consistent with a Clp1-Pcf11 heterodimer (Figure 5.4).  In 
contrast, the SEC profile of the R480A mutant showed that protein eluted in three 
separate peaks (Figure 5.4).  The first peak had a retention volume of ~45 ml, which is 
close to the void volume of the SEC column.  This indicated the presence of a protein of 
high molar mass, and it is likely that this was aggregated Clp1 that had previously been 
observed in SEC experiments with Clp1-ATP mutants (see section 3.2.2).  The second 
peak displayed a retention volume of ~82 ml, which is ~7 ml later than the wildtype 
Clp1-Pcf11 complex.  This shift in retention volume suggested that this peak contained 
protein of a slightly lower molar mass than a Clp1-Pcf11 heterodimer, and was likely to 
be monomeric Clp1.  The third peak eluted with a retention volume of ~92 ml, which 
was consistent with the retention volume of Pcf11 454-561 (previously characterised by 
SEC and SDS-PAGE, see section 3.2.2 and Figure 3.1).  Similar to the R480A mutant, 
the SEC profiles of the W482A and W489A mutants displayed three resolved peaks, 
with retention volumes of ~45 ml, ~82 ml and ~92 ml (peaks 1-3 respectively, Figure 
5.4), showing that these samples are also composed of a mixture of aggregated and 
monomeric Clp1. 
 
SEC revealed that point mutation of Arg480, Trp482 and Trp489 in the Pcf11-Clp1 ID 
resulted in Clp1 instability that is characterised by a chromatographic peak containing 
aggregated Clp1.  The resolution of three protein peaks was also observed in the SEC 
profiles of Clp1-ATP mutants, and it was shown that this was due to loss of Clp1-Pcf11 
binding leading to instability and aggregation of Clp1 (see sections 3.2 and 3.3).  It is 
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Figure 5.4. SEC analysis of Pcf11-Clp1 mutants. Chromatograms from each mutant 
(red line) are displayed and compared to the wildtype SEC profile (black line). 
Resolved peaks in the R480A, W482A and W489A chromatograms are labelled with 
asterisks and numbered. 
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therefore likely that Clp1 instability observed in SEC experiments with Pcf11-Clp1 
mutants is also caused by direct abrogation of the Pcf11-Clp1 interaction.   
 
5.3.3. Multiangle laser light scattering 
SEC experiments revealed that mutation of the Pcf11-Clp1 interface may affect the 
stability of Clp1.  To ascertain the effects of Pcf11-Clp1 mutations on Clp1 stability, 
SEC-MALLS experiments were conducted to determine the composition of protein 
species in samples purified by SEC and to look for evidence of Clp1 instability and 
aggregation.    
 
In a SEC-MALLS experiment with SEC-purified wildtype Clp1-Pcf11, the signal from 
the differential refractive index (dRI) detector showed a peak eluted from the SEC 
column with a retention time of ~26 minutes (Figure 5.5). The weight-averaged molar 
mass of protein in this peak was determined to be 60.2 kDa, close to the expected mass 
of 63.8 kDa for a Clp1-Pcf11 heterodimer. Analysis of individual Debye plots 
throughout the eluted peak demonstrated that the molar mass distribution was narrow, 
consistent with a single protein species with no indication of self-association.  SEC-
MALLS analysis of the Q478N mutant also revealed a single chromatographic peak 
containing protein with a narrow molar mass distribution and a weight average of 57.4 
kDa (Figure 5.5).  This lies between the expected values of Clp1 (51.7 kDa) and a Clp1-
Pcf11 complex (63.7 kDa).  However, the column retention volume/time of Q478N in 
both the SEC and SEC-MALLS experiments was identical to that of a wildtype Clp1-
Pcf11 complex (see section 5.3.2, Figure 5.4 and Figure 5.5).  Furthermore, the 
distribution of molar mass derived from individual Debye plots throughout the eluted 
peak suggested the Clp1-Pcf11 stoichiometry was not affected in the Q478N mutant.  In 
contrast to Clp1-Pcf11 wildtype and Q478N, the first SEC-purified peak of the R480A 
mutant (peak 1) eluted with a retention time of ~16 minutes, which is close to the void 
volume of the SEC column (Figure 5.5). The average molar mass of protein within this 
peak was very high (above 1.0x107 Da) and the molar mass distribution throughout the 
peak was also very broad (1.0x107 to 4.0x108 Da), similar to what was observed in 
SEC-MALLS experiments with recombinant Clp1-ATP binding mutants (see section 
3.2.3 and Figure 3.4). A SEC-MALLS experiment with the second SEC-purified peak 
of the R480A mutant (peak 2) revealed two chromatographic peaks (Figure 5.6).  This 
was somewhat unexpected as the protein purified previously as a single 
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Figure 5.5.  SEC-MALLS analysis of Pcf11-Clp1 mutants.  Chromatograms (blue line) 
recorded by the differential refractometer for wildtype and mutants are shown in each 
panel.  The black points are individual measurements of the molar mass from Debye 
plots generated from the LS and dRI data recorded throughout the elution of the 
chromatographic peak. The overall weight-averaged molar mass derived from averaging 
the individual measurements is displayed next to each peak along with an associated 
error giving an indication of spread of molar mass. 
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chromatographic peak using SEC.  The first peak had a retention time of ~16 minutes, 
and contained protein of high molar mass and wide molar mass distribution (1.0x107-
1.0x108 kDa), consistent with the heterogeneous aggregates of Clp1 observed 
previously.  The second peak had a retention time of ~29 minutes, slightly greater than 
that of Clp1-Pcf11, suggesting the protein in this peak was likely to be of a lower molar 
mass than the Clp1-Pcf11 complex.  Subsequent analysis of Debye plots yielded a 
narrow molar mass distribution and showed that the weight-averaged molar mass of 
protein in this peak was 53.8 kDa, close to the expected mass of 51.8 kDa for 
monomeric Clp1.  SEC-MALLS analysis of W482A (peak 2) and W489A (peak 2) 
mutants revealed the characteristics of these samples were similar to those of R480A 
(peak 2).  Both of these samples gave rise to two chromatographic peaks with retention 
times of ~16 minutes and ~29 minutes (Figure 5.6).  The ~16 minute peaks contained 
wide distributions of high molar mass and the ~29 minute peaks contained proteins with 
weight-averaged molar masses of 50 kDa (W482A) and 52 kDa (W489A).   
 
The molar masses of the ~29 minute protein peaks observed in the R480A (peak 2), 
W482A (peak 2) and W489A (peak 2) samples are close to that of monomeric Clp1. 
This suggests that in these cases Pcf11(453-561) no longer copurifies with His-tagged 
Clp1, and that mutation of Pcf11 Arg480, Trp482 and Trp489 abolishes the interaction 
with Clp1. By contrast, introduction of the conservative mutation Q478N into Pcf11 
still supports Pcf11-Clp1 interaction and copurification of an intact Clp-Pcf11 complex.  
Unexpectedly, samples from R480A (peak 2), W482A (peak 2) and W489A (peak 2) 
mutants also contained protein of high molar mass despite the fact that they had already 
been purified by SEC to separate protein aggregates (Figure 5.6). The dRI of 
chromatographic peaks in these samples showed that the amount of protein eluting as 
high molar mass aggregates was similar to the ~50 kDa peaks, indicating a large 
proportion of Clp1 had aggregated subsequent to SEC purification.  This reveals that 
disruption of the Pcf11-Clp1 interaction has a negative impact on Clp1 stability. 
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Figure 5.6.  SEC-MALLS analysis of Pcf11-Clp1 mutants.  Chromatograms (blue line) 
recorded by the differential refractometer for each mutant are shown in each panel. The 
x-axes of chromatograms are broken at 25 minutes to allow re-scaling of the y-axes (in 
grey) for better illustration of the molar mass of peaks that eluted after 25 minutes. The 
black points are individual measurements of the molar mass from Debye plots generated 
from the LS and dRI data recorded throughout the elution of the chromatographic peak. 
The overall weight-averaged molar mass derived from averaging the individual 
measurements is displayed next to each peak along with an associated error giving an 
indication of spread of molar mass. 
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5.4. The Pcf11-Clp1 interaction promotes Clp1-ATP binding and Clp1 stability 
 
5.4.1. Mutations in the Pcf11-Clp1 ID disrupt the Pcf11-Clp1 interaction 
SEC-MALLS experiments with recombinant Pcf11-Clp1 binding mutants strongly 
suggested that mutation of the Pcf11-Clp1 ID at Arg480, Trp482 or Trp489 abrogated 
the Pcf11-Clp1 interaction.  However, to prove conclusively that these residues are 
essential for Pcf11-Clp1 binding, a reversed-phase high-performance liquid 
chromatography (RP-HPLC) complex composition assay was used to determine 
whether Pcf11-Clp1 mutations had indeed disrupted the interaction and prohibited the 
copurification of Pcf11 with His-tagged Clp1 from E. coli. 
 
Analysis of the protein complex composition of a Clp1-Pcf11 wildtype sample showed 
two protein peaks eluted from the reversed-phase column with retention times of 17 and 
32 minutes respectively (Figure 5.7).  SDS-PAGE of the RP-HPLC-eluted proteins 
revealed the 17 minute peak contained Pcf11(454-561) and the 32 minute peak 
contained Clp1 (see section 3.2.2 and Figure 3.1C).  The integration of the areas of both 
the 220 nm and 280 nm UV absorbance peaks corresponding to these proteins showed 
that the Clp1-Pcf11 complex has a stoichiometry of 1:1 (Clp1:Pcf11, for peak 
integration and stoichiometry calculation method see section 2.5.3).  A complex 
composition assay with the Q478N mutant also revealed two peaks with retention times 
of 17 and 32 minutes (Figure 5.7).  Integration of the UV absorbance peak areas 
demonstrated that the ratio of Clp1 to Pcf11 was 1:1, confirming the findings of SEC 
and SEC-MALLS experiments that mutation of Gln478 does not affect Pcf11-Clp1 
binding or the stoichiometry of the complex.  In contrast, analysis of R480A (peak 1) 
showed that only the 32 minute peak corresponding to Clp1 was present (Figure 5.7).  
Complex composition assays with R480A (peak 2), W482A (peak 2) and W489A (peak 
2) protein samples also showed these samples only contained Clp1 (Figure 5.7).   
 
The complex composition assays with Pcf11-Clp1 binding mutants demonstrate that 
mutation of Arg480, Trp482 and Trp489 results in loss of the Pcf11-Clp1 interaction, 
confirming that Clp1 aggregation is preceded by loss of its interaction with Pcf11.  
Moreover, previous SEC experiments with R480A and W482A mutants revealed a ~92 
ml peak that was shown to contain isolated Pcf11 (Figure 5.4 and Figure 3.1).  This 
suggests the mutant Pcf11 fragments do interact with Clp1 when initially expressed in 
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Figure 5.7. Clp1-Pcf11 complex composition assays. Chromatograms from RP-HPLC 
analysis of Clp1-Pcf11 wildtype and Pcf11-Clp1 binding mutants are presented. In each 
panel a wild type chromatogram (black) is overlaid with that from the mutant (red) 
indicated. 
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E. coli.  However, it is evident that the interaction is substantially weaker and 
throughout purification dissociation of the complex occurs, notably prior to SEC.  When 
considering the results of RP-HPLC complex composition assays and SEC experiments 
together, it is evident that mutation of Arg480, Trp482 and Trp489 weakens, but not 
abolishes the Pcf11-Clp1 interaction. These “weakened” complexes were actually 
utilised to purify isolated Clp1 with some success and enabled the raising of a Clp1 
antibody (see sections 2.8.6 and 6.3). However, it was not possible to use Clp1 in direct 
binding experiments aimed at quantifying the Pcf11-Clp1 affinity due to the aggregation 
of Clp1 in the absence of Pcf11. Nevertheless, these results now posit a role for Pcf11 in 
the maintenance of Clp1 structure and stability, although it is unclear whether this is 
linked with Clp1-ATP binding.  
 
5.4.2. The Pcf11-Clp1 interaction promotes Clp1-ATP binding 
Characterisation of Clp1-ATP mutant proteins by hydrodynamic, biophysical and 
biochemical approaches showed that bound ATP is essential for Clp1 stability, and that 
the aggregation of Clp1 is preceded by dissociation of Pcf11 (see sections 3.2 and 3.3).  
The results of SEC-MALLS experiments and RP-HPLC complex composition assays 
with Pcf11-Clp1 mutant proteins demonstrated that the Pcf11-Clp1 interaction is also 
important for Clp1 stability, suggesting that Clp1-ATP binding and the Pcf11-Clp1 
interaction may be linked. To test whether disruption of the Pcf11-Clp1 interaction 
affected Clp1-ATP binding, RP-HPLC nucleotide assays were performed with Pcf11-
Clp1 mutant protein samples. 
 
An RP-HPLC nucleotide assay with a sample extracted from Clp1-Pcf11 wildtype 
showed that only a single nucleotide species copurifies with Clp1-Pcf11 from E. coli 
(Figure 5.8A).  This nucleotide had a retention time of ~8 minutes, which was 
consistent with the retention time of an ATP nucleotide standard.  A UV absorbance 
spectrum taken from the eluted nucleotide showed a peak in absorbance at 260 nm, 
confirming the nucleotide had an adenine base (Figure 5.8A, inset).  Nucleotide with a 
retention time identical to the ATP standard was also extracted from Clp1 in the Pcf11 
Q478N mutant sample (Figure 5.8B, compare nucleotide retention time to ATP in 
Figure 5.8A).  However, nucleotide was absent from the Clp1 in the Pcf11-Clp1 R480A 
(peak 1) mutant sample (Figure 5.8B), and similarly to when ATP is lost through direct 
mutation of Clp1-ATP binding residues, the result is protein instability (see section 3.3, 
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Figure 5.8. RP-HPLC analysis of the nucleotide content of Pcf11-Clp1 binding 
mutants. (A) Comparison of the retention time of the Clp1-extracted nucleotide (red 
line) with nucleotide standards AMP (blue), ADP (green) and ATP (black). A UV-
absorbance spectrum recorded at the time of elution of the Clp1-extracted nucleotide 
peak is shown (inset). (B) Chromatograms from nucleotide assays with samples 
extracted from the Pcf11-Clp1 binding mutants (identities of mutants are labelled). 
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Figures 3.7 and 3.8).  Nucleotide assays with samples extracted from peak 2 mutants 
(where only Clp1 is present but not mutant Pcf11 fragments) showed that these proteins 
do contain bound ATP (Figure 5.8B).  The fact that ATP is bound in these samples 
suggests that the Pcf11-Clp1 interaction is not totally required for Clp1-ATP binding. 
However, SEC-MALLS experiments with these samples showed that large proportions 
of Clp1 had subsequently aggregated after SEC purification (see 5.3.3, Figures 5.5 and 
5.6). Therefore, as Clp1 instability and aggregation has been shown to be a direct 
consequence of ATP removal (see section 3.3.2 and Figure 3.8), it is likely that some of 
the ATP observed in RP-HPLC nucleotide assays of peak 2 samples may have already 
been released from Clp1. 
 
The findings of RP-HPLC nucleotide assays with Pcf11-Clp1 mutants show that the 
Pcf11-Clp1 interaction is required for the tight association of ATP with Clp1 and that 
bound ATP is an absolute requirement for Clp1 stability.  Comparison of the nucleotide 
content and stability of Pcf11-Clp1 mutants also suggests that free Clp1 displays a 
reduced affinity for ATP compared to a Clp1-Pcf11 complex, which leads to ATP 
dissociation and subsequent Clp1 instability.  Drawing from these results, it is evident 
that Clp1-ATP binding and the Pcf11-Clp1 interaction are both equally important for 
Clp1 stability because they are dependent upon each other.  Clp1-ATP binding was 
found to be essential in S. cerevisiae, which could be due to an important role in 
transcription (see sections 4.2 and 4.3).  Because the Pcf11-Clp1 interaction and Clp1-
ATP binding are likely to be linked, it is probable that direct disruption of the Pcf11-
Clp1 interaction will also be lethal in S. cerevisiae.   
 
5.5. Summary and conclusions 
 
Biophysical studies of the Pcf11 CTD reveal it is a largely disordered domain, with CD 
data showing it contains a small number of  and  structural elements likely confined 
to the zinc fingers that flank the Pcf11-Clp1 ID. Based on these observations, it is 
proposed that the unstructured nature of the Pcf11 CTD might serve to create the 
flexibility required for the interaction of Pcf11 with multiple protein partners. The 
biophysical characterisation of recombinant Pcf11-Clp1 binding mutants showed that 
mutation of Arg480, Trp482 and Trp489 in the Pcf11-Clp1 ID weakened the Clp1-
Pcf11 interaction, which in turn caused ejection of bound ATP and resulted in an 
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unstable Apo form of Clp1. Moreover, the findings of reversed-phase nucleotide assays 
inferred that although Clp1 does bind ATP in the absence of Pcf11, the nucleotide was 
rapidly lost when Pcf11 is not bound. These results suggest that the binding of Pcf11 
and ATP to Clp1 are linked events and demonstrate that that removal of either 
interaction destabilises the other. As both ATP and Pcf11 are critical for the 
maintenance of Clp1 structure and stability, it is likely that nucleotide-bound holo-Clp1 
and associated Pcf11 are obligatory for formation of functional CFIA. 
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6. Functional analysis of the Pcf11-Clp1 interaction in S. cerevisiae 
 
6.1. Introduction and overview 
Numerous studies have identified that Pcf11 is essential for pre-mRNA 3’-end 
formation and efficient PolII transcription termination (described in sections 1.3.3 and 
1.7.1).  Despite this, information about the functional relevance of the Pcf11-Clp1 
interaction has only been provided very recently in a single study that was published 
during the completion of this work.  Although it was shown that the Pcf11-Clp1 
interaction was required for both 3’-end processing and transcription termination, the 
method by which this interaction modulates these processes was not determined. Now, 
characterisation of recombinant Pcf11-Clp1 mutants in Chapter 5 of this thesis clearly 
demonstrates that disrupting the Pcf11-Clp1 affects the Clp1-ATP interaction causing 
nucleotide loss and resulting in Apo-Clp1 instability. Based on these in vitro 
observations, it was hypothesised that the weakening of the Pcf11-Clp1 interaction 
would be lethal or produce growth-restricted phenotypes in S. cerevisiae, similar to that 
caused by the GAL1-clp1 T137A allele (see section 4.2). Therefore, in order to 
investigate whether the Pcf11-Clp1 interaction is important for pre-mRNA 3’-end 
processing and transcription termination, an in vivo mutational analysis was conducted 
to probe the phenotypes of pcf11 Clp1-binding mutants in S. cerevisiae. 
 
6.2. The Pcf11-Clp1 interaction is essential in S. cerevisiae 
 
6.2.1. Previously characterised Pcf11-Clp1 mutants do not disrupt the Pcf11-Clp1 
interaction in S. cerevisiae 
To investigate the effects of Pcf11-Clp1 ID mutations in S. cerevisiae, the 5-FOA 
plasmid shuffle system was used to determine if any of the pcf11 Clp1-ID mutants that 
were characterised in vitro could rescue the lethal phenotype of a chromosomal pcf11 
deletion (pcf11). 
 
The haploid pcf11 yeast strain (which contains the URA3-PCF11 construct) does not 
grow on 5-FOA medium (Figure 6.1A), consistent with the lethality of the 
chromosomal pcf11 deletion and the sensitivity of URA3+ yeast to 5-FOA.  Haploid 
pcf11 yeast formed colonies on 5-FOA medium after transformation with the LEU2-
PCF11 construct, indicating a plasmid-borne copy of the PCF11 gene is able to reverse 
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Figure 6.1. 5-FOA plasmid shuffle assay to determine the effects of single mutations in 
the pcf11 gene on S. cerevisiae growth.  (A) “Spot test” assays displaying the results of 
pcf11∆ complementation with pcf11-Clp1 ID mutant alleles performed at 23°C (top 
panels) and 37°C (bottom panels).  Each spot represents a serial dilution (left to right: 
104-101).  The right panels show yeast transformants plated on 5-FOA medium and the 
left panels show transformants plated on YPD medium (control for growth defects in 
the pcf11∆ strain).  URA3-PCF11 (top lanes) were not transformed with LEU2 
constructs containing PCF11/pcf11 alleles (control to check the efficacy of 5-FOA 
against URA3+ yeast).  LEU2-PCF11 (second lanes from top) denotes the pcf11∆ strain 
transformed with the LEU2-PCF11 construct (wildtype gene).  The pcf11∆ strain was 
transformed with LEU2 constructs containing each mutant allele (labelled on the left 
hand side). (B) Western blotting of protein extracts derived from PCF11 wildtype and 
pcf11 mutants to evaluate Pcf11 protein expression levels using an antibody directed 
against the HA-tag attached to the C-terminus of Pcf11 wildtype and mutants.  Each 
mutant is labelled above the relevant section of the blot.  The position of the expected 
Pcf11 band is indicated on the left-hand side of the blot. 
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the lethal phenotype (Figure 6.1A, upper panel).  Yeast transformed with constructs 
harbouring the mutant pcf11 Q478N, R480A, R480K, W482A and W489A alleles also 
formed colonies after 5-FOA selection (Figure 6.1A, upper panel).  The density of yeast 
growth in each serial dilution spot revealed there is no obvious difference between the 
growth of these mutants and wildtype PCF11 yeast.  Western blotting was performed to 
determine if Pcf11 protein expression in pcf11 yeast mutants was similar to the 
expression of Pcf11 in wildtype yeast.  Probing PCF11 wildtype yeast extract with an 
anti-HA antibody (proteins were C-terminally HA-tagged) produced two bands (Figure 
6.1B).  The larger band corresponded well with the molar mass of Pcf11-HA (76 kDa).  
The smaller band is likely a degradation product of Pcf11, or an uncharacterised 
isoform of the protein.  Probing extracts from pcf11 Q478N, R480A, R480K, W482A 
and W489A yeast mutants with anti-HA antibody showed that the intensities of these 
two bands were similar in all mutants compared to wildtype.  This clearly demonstrates 
that there are no significant differences in the expression of Pcf11 mutant proteins 
compared to wildtype (Figure 6.1B).   
 
The fact that the R480A, W482A and W489A mutant alleles were capable of 
complementing the lethal chromosomal deletion of pcf11 was surprising given the 
results of in vitro experiments that showed these mutations weakened the Pcf11-Clp1 
interaction (see section 5.3).  In an effort to obtain reduced growth or lethal phenotypes, 
the growth temperature of the 5-FOA plasmid shuffle assay was increased to 37°C.  
Figure 6.1A (lower panel) shows that at 37°C, the pcf11 R480A, R480K, W482A and 
W489A yeast mutants grew in all dilution spots after 5-FOA selection, demonstrating 
that growth of these mutants is unchanged at 37°C compared to 23°C and suggesting the 
gene products are stable.  One possibility is that the pcf11 R480A, W482A and W489A 
yeast mutants are viable due to the fact that the Pcf11-Clp1 interaction is not essential in 
S. cerevisiae.  However, it is more likely that these single mutations are not sufficient to 
disrupt the Pcf11-Clp1 interaction in vivo.  
 
To determine whether the mutant proteins expressed from pcf11 alleles were able to 
interact with Clp1, coimmunoprecipitation (CoIP) of Clp1 with Pcf11 from yeast 
extracts derived from pcf11 mutant yeast strains was undertaken. After 
immunoprecipitation (IP) of proteins associated with Pcf11 in wildtype PCF11 yeast, 
Western blotting analysis with an anti-Clp1 antibody revealed a single Clp1 band 
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migrating at a slightly lower molar mass than the Clp1-HA positive control (Figure 6.2, 
upper panel).  This finding affirms that wildtype Pcf11 and Clp1 are interaction partners 
in S. cerevisiae.  CoIP of proteins associated with Pcf11 Q478N followed by anti-Clp1 
detection revealed a band of the same size and intensity to that observed in the 
experiment with wildtype yeast, reaffirming the finding from in vitro experiments that 
this mutation does not affect Pcf11-Clp1 binding (Figure 6.2, upper panel).  Clp1 was 
also detected in CoIP experiments with pcf11 R480A, W482A and W489A mutant 
yeast extracts (Figure 6.2, upper panel).  Furthermore, the intensity of each Clp1 band 
was similar to the intensity of the Clp1 band detected in the experiment with wildtype 
PCF11 yeast extract.  These results clearly demonstrate that mutation of Pcf11 Arg480, 
Trp482 and Trp489 individually is not sufficient to abolish the Pcf11-Clp1 interaction 
in vivo.  CoIP experiments with extracts from the pcf11 Q478N, R480A and W482A 
mutants also showed a second band of slightly lower molecular weight than Clp1 
(Figure 6.2, upper panel).  The identity of this band has not been confirmed, although it 
may represent a Clp1 degradation product.  To check that the level of Pcf11-HA 
captured by the anti-HA agarose used in CoIP experiments was comparable in mutants 
and wildtype, the CoIP Western blot was stripped and re-probed with an anti-HA 
antibody. Figure 6.2 (lower panel) shows that similar amounts of two intense bands 
corresponding to Pcf11-HA and a possible Pcf11 degradation product or shorter 
isoform, are detected in CoIP experiments with PCF11 wildtype yeast and all of the 
tested mutant yeast extracts. 
 
In a further effort to disrupt the Pcf11-Clp1 interaction, a construct harbouring a pcf11 
CTD deletion allele (pcf11 CTD) was made (see Figure 1.3A and Appendix 8.2 for 
construct details). This construct was unable to restore growth to the pcf11 yeast strain 
after 5-FOA selection (Figure 6.1A).  However, Western blotting revealed a lack of 
protein expression (Figure 6.1B), indicating the encoded protein is either not expressed 
or it is rapidly degraded. 
 
The findings of the 5-FOA plasmid shuffle assay and CoIP experiments showed that 
mutation of Arg480, Trp482 and Trp489 did not affect S. cerevisiae viability and did 
not sufficiently diminish or abolish the Pcf11-Clp1 interaction in vivo.  Based on these 
observations, it was apparent that in order to determine if Pcf11-Clp1 binding is 
essential in S. cerevisiae a more comprehensive mutational analysis was required. 
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Figure 6.2. Coimmunoprecipitation experiment with yeast extracts from pcf11 single 
mutants using anti-HA antibody agarose (see section 2.8.6).  The top panel shows the 
CoIP Western blot probed with anti-Clp1 antibody and the bottom panel shows the 
same blot probed for Pcf11 (with the anti-HA antibody).  Yeast extracts that were used 
in this experiment are indicated above the blots. CLP1 is a positive control for the anti-
Clp1 and anti-HA antibodies.  The identity of protein bands is shown on the right-hand 
side of the blots. 
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6.2.2. Mutation of multiple conserved residues uncouples the Pcf11-Clp1 
interaction and is lethal 
Point mutation of the conserved Pcf11 Arg480, Trp482 and Trp489 residues did not 
substantially affect the Pcf11-Clp1 interaction in S. cerevisiae.  Therefore, in a further 
effort to uncouple the Pcf11-Clp1 interaction in S. cerevisiae, LEU2-pcf11 constructs 
that express double and triple Pcf11-Clp1 ID mutants were created (see Table 6.1 and 
Appendix 8.2).  The 5-FOA plasmid shuffle system was used to determine whether 
these mutants could restore growth to the pcf11 strain. 
 
Residue Location Function Mutated to Mutant name 
Arg480 
Trp482 
Clp1 ID See Table 5.1 Ala 
Ala 
RW-A 
Trp482 
Trp489 
Clp1 ID See Table 5.1 Ala 
Ala 
WW-A 
Arg480 
Trp482 
Trp489 
 
Clp1 ID 
 
See Table 5.1 
Ala 
Ala 
Ala 
 
RWW-A 
 
Table 6.1. Mutations made in the LEU2-pcf11 constructs for expression of Pcf11-Clp1 ID double and 
triple mutants in S. cerevisiae. 
 
As observed previously, the lethal phenotype of the chromosomal pcf11 deletion was 
reversed by complementation with a wildtype copy of the PCF11 gene or the pcf11 
W482A allele (Figure 6.3A).  Haploid pcf11 yeast transformed with a construct 
containing the pcf11 RW-A double mutant also formed colonies after 5-FOA selection.  
At 23°C, this yeast mutant displayed growth in all serial dilution spots that is 
indistinguishable from wildtype growth (Figure 6.3A, upper panel).  However, when the 
growth temperature was shifted to 37°C, only small colonies were formed by pcf11 
RW-A yeast at the first point in the cell dilution series, indicating that the growth of the 
pcf11 RW-A mutant was severely restricted (Figure 6.3A, lower panel).  The inability 
of this mutant to grow at the higher temperature condition raised the possibility that the 
pcf11 RW-A allele is temperature sensitive (further investigated in section 6.2.3).  
When the pcf11 strain was transformed with the pcf11 WW-A and pcf11 RWW-A 
alleles, no growth was observed after 5-FOA selection at either 23°C or 37°C (Figure 
6.3A, both panels).  Transformants of these alleles displayed no growth defects on the 
pre-5-FOA selection control (transformed pcf11 strain plated on YPD medium).  To 
rule out that the lethal phenotypes of pcf11 WW-A and RWW-A mutants were due to 
 174
 
 
 
 
Figure 6.3.  5-FOA plasmid shuffle assay to determine the effects of double/triple 
mutations in the pcf11 gene on S. cerevisiae growth.  (A) “Spot test” assays displaying 
the results of pcf11∆ complementation with pcf11-Clp1 ID mutant alleles performed at 
23°C (top panels) and 37°C (bottom panels).  Each spot represents a serial dilution (left 
to right: 104-101).  The right panels show yeast transformants plated on 5-FOA medium 
and the left panels show transformants plated on YPD medium (control for growth 
defects in the pcf11∆ strain).  URA3-PCF11 (top lanes) were not transformed with 
LEU2 constructs containing PCF11/pcf11 alleles (control to check the efficacy of 5-
FOA against URA3+ yeast).  LEU2-PCF11 (second lanes from top) denotes the pcf11∆ 
strain transformed with the LEU2-PCF11 construct (wildtype gene).  The pcf11∆ strain 
was transformed with LEU2 constructs containing each mutant allele (labelled on the 
left hand side). (B) Western blotting of protein extracts derived from PCF11 wildtype 
and pcf11 mutants to evaluate Pcf11 expression levels using an anti-HA antibody.  Each 
mutant is labelled above the relevant section of the blot, CLP1 is a positive control for 
the anti-HA antibody.  The position of expected bands are indicated on the left-hand 
side of the blot. 
 175
 
abnormalities in protein expression, Western blotting was performed.  Detection of HA-
tagged Pcf11 (with anti-HA antibody) in protein extract from wildtype PCF11 yeast 
showed an intense band that correlated with the expected position of Pcf11-HA, and a 
less intense band of a lower molar mass (Figure 6.3B).  The positions of these bands on 
the Western blot were consistent with those detected in a previous Western blotting 
experiment (see section 6.2.1 and Figure 6.1B).  Western blotting of pcf11 W482A, 
RW-A, WW-A and RWW-A yeast extracts revealed identical bands of similar 
intensities to those observed in the experiment with wildtype yeast extract (Figure 
6.3B), indicating that protein expression was not significantly different in any of these 
mutants compared with wildtype yeast.  Therefore, the inability of pcf11 WW-A and 
pcf11 RWW-A alleles to complement the pcf11 strain is due to the fact that the pcf11 
WW-A and pcf11 RWW-A mutations are lethal in S. cerevisiae.   
 
To determine if lethality was due to the uncoupling of the Pcf11-Clp1 interaction, 
attempts were made to CoIP Clp1 with Pcf11 from yeast extracts derived from the 
double/triple pcf11 yeast mutants (CoIP performed before 5-FOA selection, see section 
2.8.6).  As seen previously, CoIP experiments with wildtype PCF11 and pcf11 W482A 
mutant yeast extracts demonstrated intact Pcf11-Clp1 interactions.  This is evident from 
intense single bands observed after probing the CoIP Western blot with anti-Clp1 
antibody (Figure 6.4, upper panel).  Clp1 was also coimmunoprecipitated with Pcf11 
RW-A, although the diminished intensity of the Clp1 band revealed that the amount of 
Clp1 was severely reduced (Figure 6.4, upper panel).  Clp1 was not detected in CoIP 
experiments with extracts from pcf11 WW-A and RWW-A yeast mutants (Figure 6.4, 
upper panel).  To determine that diminished levels of Clp1 or absence of Clp1 was not 
due to poor expression of Pcf11 (and hence reduced amounts of Clp1), the CoIP blot 
was stripped and re-probed using an anti-HA antibody against the Pcf11 HA-tag.  Bands 
corresponding to Pcf11-HA and a possible Pcf11 degradation product were clearly 
visible in extracts from PCF11 wildtype and the pcf11 W482A and RW-A mutants 
(Figure 6.4, lower panel).  The intensities of the Pcf11 bands were also similar between 
wildtype and these mutants indicating there were no abnormalities in protein 
expression.  Therefore, the reduced intensity of the Clp1 band in the pcf11 RW-A CoIP 
experiment was likely a consequence of loss of Clp1 through the weakening of the 
Pcf11-Clp1 interaction.  Bands corresponding to Pcf11 were also visible in pcf11 WW-
A and RWW-A yeast extracts, confirming that Clp1 was not detected in CoIP 
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Figure 6.4. Coimmunoprecipitation experiment with yeast extracts from pcf11 
double/triple mutants using anti-HA agarose. The top panel shows the CoIP Western 
blot probed for bound Clp1 (with anti-Clp1 antibody) and the bottom panel shows the 
same blot probed for Pcf11 (with the anti-HA antibody).  Yeast extracts that were used 
in this experiment are labelled above the blots, CLP1 is a positive control for the anti-
Clp1 and anti-HA antibodies.  The identities of protein bands are indicated with the 
labels on the right-hand side of the blots.  The asterisk indicates bands that may be 
Pcf11 degradation products. 
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experiments because the WW-A and RWW-A mutations abrogate Pcf11-Clp1 binding.  
However, although Pcf11 WW-A and RWW-A were detected on the CoIP Western 
blot, the intensities of the detected bands were significantly reduced compared to the 
wildtype levels (Figure 6.4, lower panel).  This implies that the expression of these 
mutant proteins is reduced compared to wildtype Pcf11 expression.  However, 
significant quantities of bands of lower molar mass were also present, suggesting that 
Pcf11 WW-A and Pcf11 RWW-A mutants are more prone to degradation than wildtype.  
 
The characterisation of double and triple pcf11 mutants in S. cerevisiae revealed that the 
Pcf11-Clp1 interaction is essential.  The findings of CoIP experiments also suggested 
that Pcf11 mutants that were unable to interact with Clp1 were also prone to 
degradation.  As it is known that these Pcf11 mutations are in an unstructured loop, it is 
unlikely that they cause misfolding of Pcf11 and protein instability. Instead, it is 
possible that Clp1-binding is required for the maintenance of Pcf11 stability.  Growth of 
the pcf11 RW-A mutant was significantly reduced in elevated temperature conditions, 
suggesting that pcf11 RW-A could be a temperature sensitive allele.  The identification 
of a condition that completely restricts the growth of the pcf11 RW-A yeast mutant 
would be beneficial for investigation of pre-mRNA 3’-end processing and transcription 
defects associated with the disruption of the Pcf11-Clp1 interaction. 
 
6.2.3. pcf11 RW-A is a temperature sensitive allele 
The findings of the 5-FOA plasmid shuffle assay described in section 6.2.2 revealed that 
growth could be restored to the pcf11 yeast strain after complementation with the 
pcf11 RW-A allele.  However, an increase in temperature to 37°C severely inhibited the 
growth of this mutant, which implied pcf11 RW-A is a temperature sensitive allele (see 
section 4.2.2 for an explanation of temperature sensitive alleles).  Despite this, because 
the presence of 5-FOA in growth media had enhanced negative growth effects observed 
in clp1 ATP-binding yeast mutants (see section 4.2.2), it was necessary to further 
investigate the growth characteristics of the pcf11 RW-A yeast mutant.  To ascertain 
whether pcf11 RW-A is a temperature sensitive allele, growth of the pcf11 RW-A yeast 
mutant was monitored in the absence of 5-FOA (after 5-FOA selection) on both 
minimal and YPD media at 30C and 39C. 
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The pcf11 strain complemented with a construct containing a wildtype copy of the 
PCF11 gene grew densely on YPD and minimal agar plates at both 30°C and 39°C 
(Figure 6.5A, upper panels).  The growth of the pcf11 RW-A yeast mutant on both YPD 
and minimal media was indistinguishable from wildtype at 30°C (Figure 6.5A, lower 
left panels).  However, at 39°C growth of the pcf11 RW-A mutant was abolished on 
both YPD and minimal media (Figure 6.5A, lower right panels).  Although 
encouraging, a quantitative comparison of the growth of pcf11 RW-A and wildtype 
yeast at 39°C was required, and to achieve this a growth rate assay was performed 
(Figure 6.5B). The assay demonstrated that the cell density of PCF11 wildtype yeast 
cultured in YPD broth at 39°C increases steadily over an 8 hour period, although the 
exponential growth phase is not reached (Figure 6.5B).  The fact that the exponential 
growth phase was not reached after 8 hours is likely due to reduced growth rate caused 
by induction of the yeast thermal stress response at 39C [214].  Steady growth was also 
observed when PCF11 wildtype yeast was cultured in minimal broth (Figure 6.5B), 
although the cell density reached after 8 hours was not as high as in rich media.  In 
contrast, the cell densities of pcf11 RW-A yeast cultures (YPD and minimal) did not 
change over the 8 hour time period, with cell counts after 8 hours that were ~3-fold 
reduced compared to wildtype cultures (Figure 6.5B).  
 
The fact that growth of the pcf11 RW-A yeast mutant was wildtype-like at 30°C, but 
completely restricted at 39°C confirmed that pcf11 RW-A is a conditional yeast mutant 
in which the function of the gene product is inactivated at 39°C.  The identification of 
the pcf11 RW-A temperature sensitive allele provides a useful tool for experiments 
designed to investigate 3’-end processing and transcription abnormalities that may be 
associated with the uncoupling of the Pcf11-Clp1 interaction.   
 
6.2.4. Overexpression of lethal pcf11-Clp1 mutant alleles does not restore growth 
The work presented in chapter 4 of this thesis demonstrated that mutations that abrogate 
Clp1-ATP binding are lethal in S. cerevisiae, but lethal phenotypes can be overcome by 
up-regulating clp1-ATP mutant gene transcription (see sections 4.2.1 and 4.2.2).  In an 
attempt to rescue the lethal phenotypes of the pcf11 WW-A and RWW-A mutants, these 
alleles were overexpressed from the GAL1 promoter (after galactose induction), and the 
5-FOA plasmid shuffle assay was repeated to identify viable yeast mutants. 
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Figure 6.5. Growth characteristics of the pcf11 RW-A yeast mutant.  (A) Viability of 
PCF11 wildtype yeast and the pcf11 RW-A mutant on YPD agar and minimal media 
agar at 30°C (permissive temperature) and 39°C (restrictive temperature), growth 
temperatures and media are indicated in each panel. (B) Growth rate assay comparing 
the culture density of the pcf11 RW-A mutant with wildtype yeast in both YPD and 
minimal media broths at 39°C.  The inset key identifies each condition and error bars 
represent the standard deviation from the mean of a set of three replicate assays. 
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The haploid pcf11∆ yeast strain did not grow on 5-FOA in the presence of either 
galactose or glucose, which is consistent with the sensitivity of URA3+ yeast to 5-FOA 
and the lethality of the chromosomal pcf11 deletion (Figure 6.6A, central and right 
panels).  Haploid yeast transformed with the GAL1-PCF11 construct formed colonies 
on 5-FOA containing galactose (Figure 6.6A, central panel).  This demonstrates that 
constitutive transcription of the PCF11 gene after activation of the GAL1 promoter by 
galactose reverses the lethal phenotype of the chromosomal pcf11 deletion and that 
overexpression is not deletrious to yeast viability.  GAL1-PCF11 wildtype yeast also 
formed colonies on 5-FOA containing glucose (Figure 6.6A, right panel).  However, 
although GAL1-PCF11 wildtype yeast colonies were visible in all serial dilution spots 
on 5-FOA glucose medium, the size of individual colonies was visibly reduced 
compared to the size of colonies on galactose medium (see last serial dilution spot in 
series, Figure 6.6A, right panel).  This observation suggests that glucose repression of 
the GAL1 promoter did not completely suppress PCF11 transcription, but gene 
expression was reduced sufficiently to produce a mild growth defect.  Similarly, the 
GAL1-pcf11 W482A allele also restored growth to the pcf11 strain after 5-FOA 
selection on both galactose and glucose media (Figure 6.6A, central and right panels).  
The small colonies on the glucose plate reaffirmed that there is probably a mild growth 
defect caused by glucose repression of GAL1 promoter activity.  The growth of GAL1-
pcf11 RW-A yeast was indistinguishable from wildtype GAL1-PCF11 yeast on 5-FOA 
galactose (Figure 6.6A, central panel).  However, on the 5-FOA glucose plate, growth 
of GAL1-pcf11 RW-A yeast was limited to a few small colonies in the first serial 
dilution spot.  This indicates that the reduced transcription of this mutant combined with 
the weakened Pcf11-Clp1 interaction caused by the pcf11 RW-A mutation (see section 
6.2.2) results in a severe growth defect.  No growth was observed on galactose or 
glucose media after 5-FOA selection when the pcf11 strain was complemented with 
pcf11 WW-A or pcf11 RWW-A alleles (Figure 6.6A, central and right panel).  
However, growth of GAL1-pcf11 WW-A/RWW-A yeast on the pre-5-FOA selection 
control was comparable to wildtype GAL1-PCF11 yeast, showing that the absence of 
growth on 5-FOA media was not due to defects in the pcf11∆ strain (Figure 6.6A, left 
panel).  To rule out that growth was not observed after complementation with these 
alleles because of aberrant expression of the mutant proteins, Western blotting was 
performed.  Detection of wildtype Pcf11 by Western blotting of GAL1-PCF11 wildtype 
yeast extract produced two intense bands (Figure 6.6B).  The larger molar mass 
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Figure 6.6. Overexpression of pcf11 double/triple mutants from the GAL1 promoter. 
(A) Spot test assays displaying the results of pcf11∆ complementation with pcf11 
mutant alleles expressed from the GAL1 promoter.  Each spot represents a serial 
dilution (left to right 104-101).  The left panel shows yeast transformants plated on YPD 
medium (control for growth defects in the pcf11∆ strain). The central panel shows yeast 
plated on 5-FOA medium containing galactose and sucrose (galactose activation of the 
GAL1 promoter) and the right panel shows yeast plated on 5-FOA medium containing 
glucose (glucose repression of the GAL1 promoter).  The pcf11∆ strain was transformed 
with GAL1 constructs containing each mutant allele (labelled on the left hand side). (B) 
Western blotting of protein extracts to evaluate Pcf11/mutant Pcf11 protein expression 
levels (using anti-HA antibody).  The amount of Pcf11 detected was compared (from 
equal quantities of protein extract) when PCF11/pcf11 genes were transcribed from the 
native PCF11 promoter (first five lanes) and from the GAL1 promoter after galactose 
induction (last five lanes).  Each mutant is labelled above the relevant section of the blot 
and the expected size of Pcf11-HA is indicated. (C) Glucose repression of PCF11 
wildtype and pcf11 RW-A transcription (labelled to left of panels).  The composition of 
the growth medium is indicated below the panels. 
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band was consistent with the molar mass of Pcf11-HA, and the lower molar mass band 
was consistent with a possible Pcf11 degradation product or smaller isoform (also 
observed in previous Western blotting experiments).  The Pcf11 band intensities were 
far greater than those detected in the same amount of yeast extract derived from PCF11 
wildtype yeast, where PCF11 transcription was controlled by the native PCF11 
promoter (Figure 6.6B).  This demonstrated that the Pcf11 protein was successfully 
overexpressed after upregulation of PCF11 gene transcription from the GAL1 promoter.  
Western blotting of extracts derived from the GAL1-pcf11 RW-A, WW-A and RWW-A 
yeast mutants also revealed two intense bands that were indicative of overexpressed 
protein (Figure 6.6B).  Therefore, the reason that the pcf11 WW-A and RWW-A yeast 
mutants did not grow after 5-FOA selection was because these alleles are lethal in S. 
cerevisiae and not because of defective protein expression. Western blotting of the 
GAL1-pcf11 W482A extract failed to detect any Pcf11, and although this suggested that 
Pcf11 W482A expression was abnormal, it is more likely due to experimental error 
(incorrect loading of the SDS-PAGE gel) considering the fact that the GAL1-pcf11 
W482A allele was able to restore growth to the pcf11 strain after 5-FOA selection 
(Figure 6.6A). 
 
The fact that the GAL1-pcf11 RW-A yeast mutant did not grow well on 5-FOA glucose 
medium suggested that the introduction of glucose into growth media could provide a 
restrictive condition that may be advantageous for the extraction of mRNA and analysis 
of mRNA processing defects.  However, because 5-FOA is a toxic compound, it was 
deemed necessary to rule out that its presence in growth media did not contribute to the 
glucose repression-induced lethality. The growth characteristics of the GAL1-pcf11 
RW-A yeast mutant were determined at 30°C on minimal agar medium containing 
galactose or glucose without 5-FOA.  Figure 6.6C (top panels) shows that GAL1-PCF11 
wildtype yeast grew equally well on YPD and minimal media that contained either 
galactose or glucose.  This reiterated the finding that glucose repression of PCF11 
transcription from the GAL1 promoter was not sufficient to cause lethality.  The growth 
of the GAL1-pcf11 RW-A yeast mutant was comparable to growth of GAL1-PCF11 
wildtype yeast on YPD and minimal agar plates that contained either galactose or 
glucose (Figure 6.6C, bottom panels), demonstrating that the GAL1-pcf11 RW-A yeast 
mutant does not display a conditional phenotype after glucose repression of the GAL1 
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promoter, and that 5-FOA toxicity in the initial assay was partly responsible for the 
observed growth defect. 
 
GAL1-overexpression of the lethal pcf11 WW-A and RWW-A alleles did not restore 
yeast viability.  This result was not surprising, as CoIP experiments had previously 
revealed that these mutations completely abolish the Pcf11-Clp1 interaction, which is 
essential in S. cerevisiae (see section 6.2.2).  The GAL1-pcf11 RW-A yeast mutant did 
not display a conditional phenotype after glucose repression of the GAL1 promoter, 
although this allele was already confirmed to be temperature sensitive (see section 
6.2.3). 
 
6.3. Abolition of the Pcf11-Clp1 interaction causes increased turnover of Pcf11 
 
CoIP experiments designed to probe the ability of Pcf11 double/triple mutants to 
interact with Clp1 in vivo showed that Pcf11 WW-A and Pcf11 RWW-A appeared to be 
degraded and that cellular extracts contained much lower amounts of full-length Pcf11 
(see section 6.2.2 and Figure 6.4).  Based on this observation, it was hypothesised that 
the lower amounts of Pcf11 WW-A and RWW-A mutants were not due to their poor 
expression, but possibly the result of an increase in Pcf11 degradation directly 
associated with the loss of the Pcf11-Clp1 interaction.  To test this hypothesis, the half-
life of Pcf11 wildtype protein and the Pcf11 RWW-A mutant protein were determined 
using Western blotting of cellular extracts as a function of time following the inhibition 
of protein synthesis by cycloheximide. 
 
As expected, upon the introduction of cycloheximide to block nascent protein synthesis, 
the intensity of the wildtype Pcf11 band decreased slowly over the time course, 
consistent with slow protein turnover (Figure 6.7A).  Similarly, the Pcf11 W482A band 
intensity also decreased at a rate comparable to wildtype.  Although the 30 minute time 
point has increased intensity relative to the zero time point, this is likely a loading error 
as in the remainder of the time course the band intensity decreases in a similar fashion 
to wildtype Pcf11 band intensity.  Western blotting of extracts derived from the pcf11 
RWW-A showed that the intensity of the Pcf11 RWW-A band detected at the 0 minute 
time point was comparable to that of Pcf11 and Pcf11 W482A bands (Figure 6.7A).  
However, at subsequent time points the intensities of Pcf11 RWW-A bands were 
diminished compared to wildtype Pcf11 and Pcf11 W482A bands.  Furthermore, after 
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Figure 6.7.  Turnover of Pcf11 and Pcf11 RWW-A after cycloheximide inhibition of 
protein synthesis. (A) Western blot analysis of Pcf11, Pcf11-W482A and Pcf11-RWW-
A in yeast extracts taken at the indicated time points after cycloheximide treatment.  
Pcf11 and mutants (labelled on left) were detected with anti-HA antibody.  (B) 
Intensities of Pcf11 and Pcf11 RWW-A protein bands detected by Western blotting 
(bands denoted as individual points, see inset key) were fit to an exponential decay 
function (black lines), allowing calculation of each protein’s apparent half life (see inset 
key). 
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120 minutes only a very faint band corresponding to Pcf11 RWW-A was visible, 
indicating the protein was almost entirely turned over. 
 
In order to quantify Pcf11 turnover in terms of a cellular protein half-life, the signal 
intensities of Pcf11 wildtype and Pcf11 RWW-A protein bands were integrated and the 
fall in signal intensities fit to an exponential decay function (see section 2.8.7).  Plotting 
these data shows that the signal amplitude of the Pcf11 RWW-A band drops at a more 
rapid rate than the signal amplitude of wildtype Pcf11 bands (Figure 6.7B).  Analysis of 
these data gives a calculated half-life of Pcf11 wildtype of 72 minutes.  By comparison, 
the calculated half-life of Pcf11 RWW-A is only 23 minutes, a 3.1-fold reduction 
compared to wildtype Pcf11 half-life.  These results confirm that the turnover of Pcf11 
RWW-A is increased compared to wildtype Pcf11.  Intriguingly, the reduction in the 
Pcf11 RWW-A half-life is coincident with the loss of the Pcf11-Clp1 interaction caused 
by the RWW-A mutation (determined by the CoIP experiment, see section 6.2.2 and 
Figure 6.4).  Although there is still a remote possibility that Pcf11 RWW-A is rapidly 
turned over because the mutations cause instability, it is more likely these findings 
demonstrate that the interaction of Clp1 with Pcf11 is essential for maintaining Pcf11 
levels in the cell. 
 
6.4. The Pcf11-Clp1 interaction does not influence poly(A) site choice on ACT1 
mRNA 
 
Investigation of the growth characteristics of the pcf11 RW-A yeast mutant revealed it 
has a conditional phenotype that is affected by growth temperature (temperature 
sensitive mutant/allele, see section 6.2.3).  The conditional phenotype enables function 
of the gene product supporting growth of yeast in “permissive” conditions, and 
inactivation of the gene product by moving to “restrictive conditions”, allowing 
experiments that test the effects of losing gene function to be performed.  To investigate 
the effect of uncoupling the Pcf11-Clp1 interaction on pre-mRNA 3’-end processing, 
total RNA samples were extracted from the pcf11 RW-A yeast mutant after growth at 
permissive (30°C) and restrictive (39°C) temperatures.  Total RNA samples were also 
extracted from PCF11 wildtype yeast as a control.  These total RNA samples were used 
as templates in reverse transcription quantitative real-time PCR (RT-qPCR) experiments 
designed to detect the quantities of specific ACT1 mRNA sequences. The quantities of 
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each ACT1 mRNA sequence were compared to formulate the pattern of 
cleavage/poly(A) site usage on the ACT1 gene (see section 2.9.2 and Figure 2.7 for 
experimental design).  Comparison of cleavage/poly(A) site (hereafter termed poly(A) 
site) usage between wildtype PCF11 and pcf11 RW-A yeast at permissive and 
restrictive temperatures was therefore able to determine whether the Pcf11-Clp1 
interaction is important for poly(A) site selection. 
 
When total RNA samples extracted from PCF11 yeast grown at 30°C were used as 
template, RT-qPCR poly(A) site selection assays showed that 97% of ACT1 mRNA had 
been processed at the first poly(A) site, indicating the first site is the major poly(A) site 
of this gene (Figure 6.8).  ACT1 mRNA processed at the second/third and fourth 
poly(A) sites comprised just 1% and 2%  of total ACT1 mRNA respectively.  These 
results were mirrored when total RNA samples extracted from PCF11 yeast grown at 
39C were used as template (Figure 6.8), with 95% of processing occurring at the first 
poly(A) site, 2% of processing at the second/third site and 3% processing at the fourth 
site.  When total RNA samples extracted from the pcf11 RW-A yeast mutant grown at 
30°C were used as template, the poly(A) site selection assay revealed an ACT1 mRNA 
poly(A) site selection pattern similar to that observed in experiments with PCF11 
wildtype RNA (Figure 6.8).  The first site was selected for processing in 95% of ACT1 
mRNA and the second/third and fourth sites were used far less frequently, comprising 
just 1% and 4% of ACT1 mRNA respectively.  The ACT1 poly(A) site selection assay 
using total RNA template derived from pcf11 RW-A yeast that had been subjected to a 
period of growth at the restrictive high temperature of 39°C  revealed a pattern of site 
selection that was slightly altered compared with wildtype (Figure 6.8).  The first site 
was processed in 92% of ACT1 mRNA and no ACT1 mRNA that had been processed at 
the second/third poly(A) site was detected at all.  Processing of the fourth site was 
slightly elevated at 8% of total processing.  However, these differences are very small 
and it is still clear that the first poly(A) site on ACT1 mRNA remains the dominant site 
for 3’-end processing compared to the other three sites tested in the assay. 
 
When examining the raw data generated from RT-qPCR amplification plots, it was 
evident that the mean quantity of ACT1 mRNA in pcf11 RW-A 39°C total RNA 
samples was nearly 4-fold less than that observed in pcf11 RW-A 30°C total RNA 
samples (see Table 6.2).  Similarly, the mean quantity of TDH2 mRNA was 2.6-fold 
reduced in pcf11 RW-A 39°C samples compared to wildtype 39°C samples.  However,
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Figure 6.8.  Results of the RT-qPCR ACT1 poly(A) site selection assay with wildtype 
and pcf11 RW-A yeast.  The histograms show the percentages of total ACT1 mRNA 
that were processed at each of three poly(A) site locations in wildtype (PCF11) and 
mutant (pcf11 RW-A) yeast (see colour scheme inset) at 30°C (left histogram) and 39°C 
(right histogram).  Error bars represent the standard deviation from the mean of two 
experiments and in each experiment targets were detected in triplicate.  
 
 188
 
 the quantities of these transcripts were similar in wildtype and mutant RNA samples 
when yeast had been cultured at 30°C (the mean quantity of TDH2 mRNA was 149.6 in 
pcf11 RW-A samples compared to 137.15 in wildtype samples, and the mean quantity 
of ACT1 mRNA was 113.15 in pcf11 RW-A samples compared to 145.5 in wildtype 
samples). 
 
The results of the RT-qPCR poly(A) site selection assay demonstrated that ACT1 
mRNA poly(A) site selection is not significantly different in the pcf11 RW-A yeast 
mutant compared to PCF11 wildtype yeast even during growth at a temperature at 
which pcf11 RW-A is inviable (39°C) due to loss of the Pcf11-Clp1 interaction (see 
sections 6.2.2 and 6.2.3).  This demonstrates that the Pcf11-Clp1 interaction is not 
required for poly(A) site selection on ACT1 pre-mRNA.  However, the lower quantities 
of ACT1 and TDH2 mRNAs in total RNA samples extracted from the pcf11 RW-A 
yeast mutant grown at 39°C may reflect defects in transcription caused by loss of the 
Pcf11-Clp1 interaction. 
 
 PCF11 30°C PCF11 39°C RW-A 30°C RW-A 39°C 
Mean Quantity 
TDH2 (SE) 
137.15 
(10.9) 
114.7 
(11.45) 
149.6 
(15.8) 
43.4 
(3.9)) 
     
Mean Quantity 
ACT1 (SE) 
145.5 
(14.25) 
64.8 
(5.95) 
113.15 
(6.15) 
17.1 
(0.6) 
 
Table 6.2.  TDH2 and ACT1 mRNA quantities determined by RT-qPCR of total RNA extracted from 
PCF11 wildtype and the pcf11 RW-A mutant. TDH2 and ACT1 mRNA quantities in the RW-A 39°C 
RNA sample are highlighted red to illustrate their reduction compared to wildtype and the RW-A 30°C 
quantities.  The quantities displayed were determined by comparison to the relevant standard curves and 
are not normalised to or expressed as relative to the expression of any other gene. The figures in brackets 
are the standard error derived from evaluation of the mean.  CT and quantity values generated in all RT-
qPCR experiments are presented in Appendix 8.6. 
 
 
6.5. The Pcf11-Clp1 interaction is important for transcription  
 
Analysis of the raw data from RT-qPCR poly(A) site selection assays revealed 
diminished transcription of the ACT1 and TDH2 genes in the pcf11 RW-A yeast mutant 
at the restrictive temperature.  To further investigate defects in transcription associated 
with the pcf11 RW-A mutation, the quantities of mRNAs transcribed from ACT1, 
TDH2, ADH1, YPT1 and CYC1 genes were determined by RT-qPCR as a measure of 
the amount of the transcription of these genes.  Total RNA samples extracted from 
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PCF11 wildtype and pcf11 RW-A yeast grown in both permissive (30°C) and restrictive 
(39 C) conditions were used as template. 
 
The mean quantity of TDH2 mRNA detected in total RNA samples extracted from the 
pcf11 RW-A yeast mutant grown at 30°C represented 88% of that detected in PCF11 
wildtype total RNA samples (Figure 6.9A).  This indicates the amount of transcription 
of the TDH2 gene in the pcf11 RW-A yeast mutant is not significantly altered compared 
to wildtype at the permissive growth temperature of 30°C.  The amounts of ACT1 and 
YPT1 transcription in the pcf11 RW-A mutant relative to wildtype at 30°C were 113% 
and 85% respectively, demonstrating that transcription of these genes is also not 
significantly affected by the pcf11 RW-A mutation at the permissive temperature 
(Figure 6.9A).  The amount of ADH1 transcription in the pcf11 RW-A yeast mutant was 
slightly decreased at 72% of the wildtype amount, whereas CYC1 transcription was 
increased ~1.5-fold in pcf11 RW-A compared to PCF11 wildtype at 30°C (Figure 
6.9A).  These are relatively small changes in transcriptional level that may be caused by 
the pcf11 RW-A mutation.  However, it was expected that any transcription phenotypes 
generated by the pcf11 RW-A mutation would be more clearly visible after yeast 
underwent a period of growth at the restrictive temperature of 39°C.  After a shift to the 
restrictive temperature (39°C), the mean quantity of TDH2 mRNA detected in RNA 
extracted from the pcf11 RW-A yeast mutant was just 40% of that detected in PCF11 
wildtype RNA samples (Figure 6.9A).  There was also a significant reduction in mutant 
TDH2 transcription relative to wildtype compared to that observed at 30°C (88% mutant 
relative to wildtype). The amounts of ACT1 and YPT1 transcription in the pcf11 RW-A 
mutant relative to wildtype at 39°C were just 31% (3.3-fold reduction) and 22% (4.5-
fold reduction) respectively (Figure 6.9A), showing that transcription of these genes in 
the pcf11 RW-A mutant was significantly reduced at the restrictive temperature.  At 
30°C, ADH1 transcription in the pcf11 RW-A mutant was 72% of the amount observed 
in PCF11 wildtype yeast.  At 39°C, the amount of ADH1 transcription in pcf11 RW-A 
yeast fell further to just 27% (3.7-fold reduction) of wildtype ADH1 transcription 
(Figure 6.9A).  Transcription of CYC1 was 1.5-fold increased in the pcf11 RW-A 
mutant compared to wildtype at 30°C.  However, at the restrictive temperature of 39°C 
the amount of CYC1 transcription in the pcf11 RW-A mutant was reduced to 38% 
relative to wildtype CYC1 transcription (2.7-fold reduction, Figure 6.9A). 
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Figure 6.9.  RT-qPCR analysis of gene expression and transcription termination in 
pcf11 RW-A mutant yeast.  (A) Histogram showing the level of transcription of TDH2, 
ACT1, YPT1, ADH1 and CYC1 genes in the pcf11 RW-A mutant compared to wildtype 
yeast at 30°C (orange) and 39°C (red).  (B) Histogram showing quantification of 
transcription termination on the ACT1 gene (determined by the percentage of ACT1 
readthrough transcription) in wildtype yeast (blue) and the pcf11 RW-A mutant (red) at 
both 30°C and 39°C.  Error bars represent the standard deviation from the mean of two 
experiments and in each experiment targets were detected in triplicate.  
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The amount of transcription of the TDH2, ACT1, YPT1, ADH1 and CYC1 genes was 
unaffected by the temperature sensitive pcf11 RW-A mutation at the permissive 
temperature of 30°C.  However, at the restrictive temperature of 39°C, transcription of 
these genes is severely reduced in the pcf11 RW-A mutant compared to wildtype.  It has 
previously been shown that the Pcf11 RW-A mutation diminishes the Pcf11-Clp1 
interaction at 30°C (see section 6.2.2 and Figure 6.4) and is lethal at 39°C (see section 
6.2.2 and Figure 6.3).  Considering these findings with the RT-qPCR transcription data 
discussed above, it is probable that the maintenance of transcription levels in S. 
cerevisiae is dependent on the Pcf11-Clp1 interaction, and that abrogation of this 
interaction results in severe transcription defects that are lethal to S. cerevisiae.  A wider 
profile of the transcriptome of the conditional pcf11 RW-A mutant would be 
advantageous to determine the proportion and classes of genes in which transcription is 
most and least compromised. 
 
6.6. The Pcf11-Clp1 interaction is required for transcription termination on the 
ACT1 gene 
 
Past studies have shown that mutations in pcf11 cause transcription termination defects 
in S. cerevisiae [106, 110, 122] (see section 1.7.1).  Defective transcription termination 
is characterised by “transcription run-on” or “readthrough transcription”, where PolII 
continues to transcribe after passing the most distal poly(A) site of the gene being 
transcribed.  To determine whether the Pcf11-Clp1 interaction is important for 
transcription termination, a RT-qPCR assay was used to compare the amounts of 
readthrough transcription on the ACT1 gene in wildtype yeast and the pcf11 RW-A 
mutant.  Readthrough transcription was calculated by investigating what proportion of 
total ACT1 mRNA contained sequences downstream of the most distal (from the end of 
the ACT1 ORF) ACT1 poly(A) site (see section 2.9.4 and Figure 2.7 for experimental 
design). 
 
RT-qPCR transcription readthrough experiments using total RNA extracted from 
wildtype yeast cultured at 30°C revealed that ACT1 readthrough mRNA transcripts 
comprised less than 1% of total ACT1 mRNA (Figure 6.9B).  This is indicative of 
highly-efficient transcription termination.  When wildtype yeast was cultured at 39°C, 
ACT1 readthrough transcripts made up ~2% of total ACT1 mRNA, suggesting the 
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increase in temperature had not dramatically affected the efficiency of transcription 
termination (Figure 6.9B).  Total RNA extracted from the pcf11 RW-A yeast mutant 
cultured at 30°C also contained a very low proportion of ACT1 readthrough mRNA 
transcripts at only 1% of total ACT1 mRNA (Figure 6.9B).  However, when the pcf11 
RW-A mutant was grown in restrictive conditions (39°C), ACT1 readthrough transcripts 
accounted for 18% of total ACT1 mRNA.  This represents a large increase in ACT1 
readthrough transcription compared to that observed in the pcf11 RW-A mutant at 30°C 
and wildtype yeast at both temperatures, and denotes an increase in failed transcription 
termination under restrictive conditions. 
 
Transcription termination on the ACT1 gene was unaffected by growth temperature in 
yeast with a wildtype copy of the PCF11 gene.  However, the higher growth 
temperature of 39°C that is restrictive to the growth of yeast containing the pcf11 RW-A 
allele caused failed transcription termination in nearly one-fifth of total ACT1 
transcription.  These findings highlight the necessity of the Pcf11-Clp1 interaction for 
correct transcription termination on the ACT1 gene and raise the possibility that lethality 
caused by loss of the Pcf11-Clp1 interaction may be the result of a combination of 
reduced transcription and impaired transcription termination. 
 
6.7. Summary and conclusions 
 
An in vivo analysis in S. cerevisiae of the effects of mutations in the PCF11 gene 
showed that the R480A, W482A and W489A pcf11-Clp1 ID yeast mutants that 
abolished the Pcf11-Clp1 interaction in vitro did not display any growth abnormalities 
compared to wildtype yeast.  A CoIP experiment showed that mutation of single 
residues in the Pcf11-Clp1 ID was not sufficient to abolish the Pcf11-Clp1 interaction in 
vivo.  A more comprehensive mutational analysis demonstrated that mutation of both 
conserved tryptophans in the Pcf11-Clp1 ID (pcf11 WW-A), or mutation of all three 
highly-conserved residues (pcf11 RWW-A) abolished the Pcf11-Clp1 interaction in vivo 
and was lethal in S. cerevisiae.  Determination of protein half-lives also revealed that 
Pcf11 RWW-A is turned over rapidly in vivo in comparison to wildtype Pcf11, 
demonstrating that the Pcf11-Clp1 interaction is essential in maintaining Pcf11 stability.  
A temperature sensitive allele, pcf11 RW-A, was also uncovered, which permitted the 
investigation of pre-mRNA processing defects associated with loss of Pcf11-Clp1 
binding.  A RT-qPCR assay designed to map the pattern of poly(A) site selection on the 
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ACT1 gene showed that ACT1 poly(A) site selection was not significantly different in 
the pcf11 RW-A yeast mutant compared to wildtype, raising the possibility that the 
Pcf11-Clp1 interaction may not be required for pre-mRNA 3’-end processing.  
However, when the pcf11 RW-A mutant was subjected to restrictive growth conditions, 
the quantities of mRNA transcribed from five different genes was significantly lower 
compared to wildtype yeast.  This suggests that the Pcf11-Clp1 interaction might have a 
key role in transcription in S. cerevisiae.  Furthermore, a RT-qPCR experiment with 
PCF11 wildtype and pcf11 RW-A RNA samples showed that transcription termination 
on the ACT1 gene was severely disrupted when the pcf11 RW-A mutant was exposed to 
the restrictive temperature, demonstrating that the Pcf11-Clp1 interaction is probably 
vital for transcription termination in S. cerevisiae. 
 
These results advocate that the Pcf11-Clp1 interaction is obligatory for the maintenance 
of the stability of both proteins, which is likely important for the integrity of CFIA.  
Evidence points towards the Pcf11-Clp1 interaction as essential for PolII transcription 
and transcription termination in S. cerevisiae.  
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7. Discussion 
 
7.1. Clp1, ATP and the enzyme question 
 
Since the elucidation of the Clp1-Pcf11-ATP crystal structure, research groups working 
in the pre-mRNA 3’-end processing field have postulated that Clp1 might be capable of 
hydrolysing its bound ATP.  Specifically, it has been suggested that Clp1 may be an 
ATPase or a protein kinase that is responsible for the conformational rearrangements 
that are necessary for 3’-end cleavage [116, 121].  The findings presented in this thesis 
are contrary to these theories.  A reversed-phase nucleotide assay demonstrated that a 
recombinant Clp1-Pcf11 complex contained bound ATP at a high stoichiometric ratio, 
whereas if Clp1 was capable of ATP hydrolysis it would be expected to release the 
nucleotide and/or that traces of ADP or even AMP might be present.  The ATP bound 
in Clp1 was also shown to be non-exchangeable with free-ATP, suggesting the Clp1-
ATP interaction is tight and that a continuous cycle of ATP hydrolysis is unlikely.  
Furthermore, mutation of the putative catalytic residue in the Clp1 Switch I motif 
(Asp161) did not appear to affect transcription or pre-mRNA 3’-end processing in S. 
cerevisiae.  Although this does not prove conclusively that Clp1 is not catalytically 
competent (any enzymatic function of Clp1 could be redundant and hence viability of 
the yeast mutant may not be affected), taken with the aforementioned in vitro results it 
seems the most probable scenario.  In support of this, in vitro experiments with 
recombinant Clp1 that were carried out in past studies have failed to detect any ATPase 
activity (I. Taylor, unpublished data) or DNA/RNA/protein kinase activity [189]. 
 
It is curious that Clp1 should contain a domain with conserved structural elements that 
secure its membership in a family of ATPases (SIMIBI-class NTPases [119]), yet 
possess no catalytic potential itself.  Indeed, the two other SIMIBI-class members that 
are closest in structural relation to Clp1 are the active ATPases NifH (Azobacter 
vinelandii) and ArsA (E. coli) [216-218].  These proteins utilise ATP hydrolysis to 
transmit protein conformational changes.  Recent studies that have aimed to characterise 
the human homologue of Clp1 (hClp1) may shed light onto why Clp1 has no catalytic 
function.  The P-loop, Switch I and Switch II motifs are all highly-conserved between 
Clp1 and hClp1 (see Figure 1.5C and Appendix 8.1), and these proteins share sequence 
identity of 23% overall [117].  hClp1 is a mammalian pre-mRNA 3’-end processing 
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factor that is essential for transcript cleavage but not polyadenylation [117].  However, 
an intriguing difference between Clp1 and hClp1 is that hClp1 kinase activity is well 
documented.  hClp1 has been identified as the kinase that phosphorylates the 5’-
hydroxyl of synthetic short interfering RNAs (siRNAs) used for RNA interference 
(RNAi) [188].  However, the natural kinase function of hClp1 is to phosphorylate the 
5’-hydroxyl of 3’-tRNA exons in the yeast-like tRNA splicing pathway in vertebrates 
[189].  Ramirez et al. have found that hClp1 can rescue both growth-defective and 
lethal phenotypes in S. cerevisiae caused by mutations or deletion of the gene that 
encodes the yeast tRNA ligase (trl1) [189].  This was shown to be dependent upon the 
kinase activity of hClp1, as the hclp1 Asp151 mutant (equivalent residue to Switch I 
Asp161 in yeast Clp1) was not able to restore growth to wildtype levels.  These findings 
led the authors to postulate that despite their similarity, the yeast and human Clp1 
proteins are not functional orthologues.  Although the function of hClp1 as a tRNA 
splicing enzyme has been made clear, studies investigating other mammalian 
homologues of yeast-type tRNA splicing enzymes have suggested that the yeast-type 
tRNA splicing pathway may be redundant in mammalian cells [219, 220]. 
 
Considering the information available on hClp1 with our own findings, we postulate 
that yeast Clp1 was also a kinase involved in the yeast tRNA splicing pathway at some 
point in the past.  However, kinase activity has since been lost been lost through a lack 
of evolutionary selective pressure due to its functional redundancy.  There are a number 
of points to reinforce this argument: (1) the stringent conservation of the motifs 
necessary for kinase/ATPase between Clp1 and hClp1 reflecting a conserved function; 
(2) the absence of kinase or ATPase activities in recombinant Clp1; (3) the existence of 
an enzyme in yeast (Trl1) that performs all steps of the tRNA splicing pathway, which 
could have led to the redundancy of Clp1 as a tRNA splicing enzyme; (4) the possible 
redundancy of the yeast-type tRNA splicing pathway in humans; (5) evidence that 
phoClp1, an “ancestral” Clp1 protein from the archaeal species Pyrococcus horikoshii is 
an RNA kinase that can act in lieu of yeast Trl1, suggesting that the common ancestor 
of both Clp1 and hClp1 is a kinase [221] .  
 
 In terms of pre-mRNA 3’-end processing, it is highly likely that the role of Clp1-ATP 
binding is purely to maintain Clp1 structure, which is important for the integrity of 
CFIA.  This will be discussed in section 7.2.  It has been posited that hClp1 may utilise 
its kinase activity to maintain the 5’-phosphate group of the 3’ nascent mRNA chain 
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(after pre-mRNA cleavage) to allow entry of the Xrn1 nuclease and subsequent 
transcription termination (torpedo model of transcription termination, see section 1.7.1).  
However, there is no evidence to support this, and instead, we hypothesise that hClp1 
also plays a structural role that bridges the 3’-end processing complexes as has been 
previously theorised [117]. 
 
7.2. Clp1-ATP binding and the Pcf11-Clp1 interaction are linked 
 
The comprehensive analysis of recombinant mutant proteins presented in this thesis 
demonstrates that both ATP and Pcf11 are crucial for the stability of Clp1.  Figure 7.1 
summarises the events that lead to Clp1 instability, showing that disruption of the 
interaction of Clp1 with either ATP or Pcf11 also results in the loss of the other 
interaction.  This suggests that Clp1 contains a structural element that links the 
nucleotide binding pocket and the Pcf11 ID.  However, in the Clp1-Pcf11 crystal 
structure no obvious link is apparent.  It is instead possible that the binding of either 
ATP or Pcf11 results in a small conformational change in Clp1 that presents or extends 
the binding interface for the other molecule.  Another alternative is that loss of the 
Clp1-Pcf11 interaction (which is always a prerequisite to Clp instability) brings about a 
change in Clp1 that promotes instability.  Examination of the Clp1-Pcf11 crystal 
structure shows that two of the highly-conserved Pcf11 residues (Trp482 and Trp489) 
make hydrophobic contacts with Clp1 residues in a cleft between the Clp1 CD and CTD 
(see Figure 1.4B).  This could be significant, as abrogation of the Pcf11-Clp1 
interaction potentially exposes a hydrophobic region of Clp1 promoting instability, self-
association and aggregation in vitro.  To ascertain if this was a viable theory, 
hydrophobic areas of the Clp1 surface were mapped to the structure of Clp1 using a 
hydrophobicity index described by Fasman [222], the results of which are presented in 
Figure 7.1B.  This analysis revealed that the Clp1 CD-CTD cleft is significantly 
hydrophobic, and that in the absence of Pcf11 this would become exposed.  Moreover, 
the fact that the Clp1 CD-CTD cleft is large and that Pcf11 is so intimately associated 
within it suggests that loss of Pcf11 would likely result in substantial changes in Clp1 
structure, most likely the collapse of the walls of the CD-CTD cleft.  Therefore, based 
upon the results of our experiments, details of the Clp1-Pcf11 structure and the 
hydrophobic map, we postulate that the abrogation of the Clp1-Pcf11 interaction causes 
both a loss of Clp1 structure and the presentation of a hydrophobic surface in Clp1, both 
of which are detrimental to Clp1 tertiary structure and stability. 
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Figure 7.1. The events that lead to Clp1 instability and aggregation. (A) Schematic to 
show that Clp1-ATP binding and the Pcf11-Clp1 interaction are linked events and 
removal of one interaction destabilises the other resulting in Clp1 instability and 
aggregation.  (B) Map of hydrophobic areas observed in the Clp1-Pcf11 crystal 
structure focusing on the Clp1 central domain-C-terminal domain cleft.  A hydrophobic 
residue index described by Fasman [222] was applied to a surface representation of 
Clp1 using deepening shades of green to illustrate increasing hydrophobicity.  The 
structure is shown with (left panel) and without (right panel) the bound Pcf11 fragment 
(cyan cartoon with side chains of Arg480, Trp482 and Trp489 depicted as sticks).  The 
dashed red box indicates the Clp1-Pcf11 interaction site.  PDB code: 2NPI. 
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A recent study has downplayed the importance of ATP as a structural element of Clp1.  
As was observed in this study, Holbein et al. found that recombinant Clp1 mutants 
carrying the K136A or T137A mutations were extremely unstable and resulted in 
protein aggregation [180].  However, they also claimed that these mutant clp1 alleles 
were viable in S. cerevisiae and produced no obvious transcription or 3’-end processing 
abnormalities.  An explanation for these seemingly paradoxical findings that calls into 
question their validity, is that the two alleles were introduced into the clp1 yeast strain 
on 2- plasmid shuttle vectors that replicate to high copy number in yeast cells (50-100 
per cell).  In experiments described in this thesis, Clp1 mutants were introduced on the 
centromeric plasmid pRS315, which is maintained at low copy-number (1-2 per cell).  
Consequently, it is likely that the clp1 K136A and T137A yeast mutants were deemed 
viable due to a copy-number induced overexpression of mutant Clp1 proteins from 
these alleles, which increases a very small portion of ATP-bound functional Clp1.  A 
similar effect was observed in experiments presented in chapter 4 of this thesis, when 
the K136A and T137A mutants were overexpressed from the GAL1 promoter.  
Therefore, we proffer that the true effect of abrogating Clp1-ATP binding is lethality.  
In another study, Ghazy et al demonstrate that clp1 K136E and T137E mutants are 
unable to interact with Pcf11 and are lethal in S. cerevisiae, but they do not associate 
this with a loss of Clp1-ATP binding [122].  Rather, they postulate that these mutations 
trap Clp1 in a conformation in which ATP is repositioned in the nucleotide-binding 
pocket.  They speculate that the nucleotide-binding pocket has “extra-space” that could 
accommodate the differential orientation of ATP as a molecular switch that modulates 
the Pcf11-Clp1 interaction.  By contrast, work presented in this thesis clearly shows that 
mutation of Lys136 or Thr137 in the Clp1 P-loop abrogates Clp1-ATP binding in vitro.   
 
We therefore conclude that both the Clp1-ATP and Pcf11-Clp1 interactions are required 
to maintain stable Clp1 for incorporation into the CFIA complex, and that the lethality 
observed upon removal of the Clp1-ATP or Pcf11-Clp1 interactions is due to a 
structural collapse in Clp1 that prevents the formation and essential functions of CFIA. 
 
7.3. Subunit composition of CFIA during transcription 
 
Previously, it was thought that CFIA was recruited as an intact unit to the PolII 
elongation complex through the interaction of PolII CTD with the Pcf11 CID [50].  
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Crucially, the recruitment of CFIA was found to be dependent on ongoing transcription 
and the maintenance of PolII CTD Ser2 phosphorylation, which increases throughout 
transcription elongation as PolII reaches the 3’-ends of genes [173, 178].  From 
evidence presented here and from recently published data [169, 170], we now propose 
that rather than recruitment of intact CFIA, the subunit composition of CFIA changes 
throughout transcription. 
 
This idea is based upon our finding that disruption of the Pcf11-Clp1 interaction causes 
instability and aggregation of Clp1, and that we hypothesise that this results in the 
abolition of CFIA assembly causing lethality in yeast mutants.  This hypothesis was 
upheld by the findings of another study that was published during the collation of the 
work presented here.  Haddad et al. found that mutations in Clp1 that negated Clp1-
Pcf11 binding also prevented the interaction of Pcf11 with Rna14 and Rna15 (or in 
other terms a complete disintegration of CFIA) [121].  Furthermore, the same mutations 
correlated with loss of transcription termination in vivo and 3’-end formation in vitro, 
reiterating the fact that Clp1 and intact CFIA are obligatory for both processes.  Despite 
the importance of Clp1 to CFIA, there is evidence to suggest that CFIA does not always 
contain Clp1.  The mRNA export factor Yra1 has been shown to interact directly with 
Pcf11 in a manner that is mutually exclusive with Clp1 [169, 170] (see section 1.6.3).  
Consistent with this, the ChIP profiles of Clp1, Yra1 and Pcf11 across a number of 
genes also suggest the subunit composition of CFIA may be flexible.  The peaks of 
Clp1 and Pcf11 recruitment were shown to coincide near the poly(A) sites in the 3’-
UTRs of some genes, whereas Yra1 recruitment peaks near the 3’ ends of ORFs and 
subsequently declines.  In addition, Yra1 and Pcf11 are recruited steadily throughout 
ORFs whereas Clp1 seems to be specifically recruited at 3’-ends [170]. 
 
In light of the observations from the studies outlined above, we postualte that the 
subunit composition of CFIA changes during PolII-mediated gene transcription and that 
CFIA is recruited progressively throughout transcription of a gene.  It is likely that Clp1 
is not initially incorporated, and that instead Yra1 maintains the interaction of Pcf11 
with Rna14 and Rna15.  At a later stage of transcription (possibly after transcription of 
the poly(A) site), Clp1 replaces Yra1 in CFIA.  It is possible that at this point Yra1 is 
“handed off” to the pre-mRNA to assist in its essential role as an mRNA export factor.  
An analysis of the half-lives of Pcf11 and the Pcf11-Clp1 binding defective Pcf11 
RWW-A mutant presented in section 6.3 demonstrated that Clp1 is essential in 
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protecting Pcf11 from protein degradation.  Yra1 may also act to maintain Pcf11 
stability during transcription elongation, where Clp1 is absent from CFIA.  The 
significance of CFIA formation in view of pre-mRNA 3’-end processing and 
transcription termination is discussed below. 
 
7.4. The function of CFIA in transcription, termination and 3’-end processing 
 
Through the exploitation of conditional clp1 and pcf11 yeast mutants and combined RT-
qPCR experiments, we have shown that Clp1 and Pcf11 play a crucial part in 
transcription and transcription termination on the ACT1 gene.  Mutation of the Clp1 P-
loop at Thr137 was shown to abrogate Clp1-ATP binding and was associated with a 
small increase in readthrough transcription at the ACT1 gene locus.  Although this 
represents only a small reduction in transcription termination, it is likely that this is a 
genuine effect of the Clp1 T137A mutation.  This is because removal of ATP from Clp1 
was shown to abrogate the Pcf11-Clp1 interaction, and we have shown that disruption 
of the Pcf11-Clp1 interaction caused by the pcf11 RW-A allele causes a large increase 
in failed ACT1 transcription termination.  The pcf11 RW-A allele was found to negate 
Pcf11-Clp1 binding at the non-permissive temperature and was identified separately in 
both the work described here and by Ghazy et al. [122].  In support of our findings that 
this allele has a negative effect on ACT1 transcription termination, Ghazy et al. 
demonstrated that abrogation of the Pcf11-Clp1 interaction through this allele causes 
increases in readthrough transcription at the 3’-ends of the ADH2 and GAL7 genes.  
Although transcription termination defects are well documented with the pcf11-2, 
pcf11-9 and pcf11-13 temperature sensitive mutants (that remove the CID-PolII CTD 
interaction) [106, 176], the findings of this study and work presented by Ghazy et al. are 
the first reports that the Pcf11-Clp1 interaction is required for efficient PolII 
transcription termination.  Considering these findings with our discovery that Pcf11 is 
rapidly degraded in the absence of Clp1, we suggest that a major function of Clp1 is as 
a chaperone of Pcf11 essential for its functions in transcription termination.  It may also 
be that Clp1 is essential in maintaining a conformation of CFIA that is necessary for the 
recruitment of termination factors including the Rat1 exonuclease. 
 
RT-qPCR experiments also showed that abolition of the Pcf11-Clp1 interaction causes 
significant decreases in the transcription of the ACT1, ADH1, CYC1, TDH2 and YPT1 
genes.  Although such abnormalities in transcription levels have been observed before 
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in Pcf11-depleted yeast or with yeast expressing the pcf11-2 or pcf11-9 temperature 
sensitive alleles [89, 176, 186], our work is the first report that the Pcf11-Clp1 
interaction may be essential in the maintenance of PolII transcription levels.  Similarly, 
the clp1 T137A allele that expresses ATP-deficient Clp1 was associated with significant 
reductions in ACT1, ADH1 and TDH2 transcription.  Holbein et al. have recently 
presented contrasting results that suggest that the Clp1 P-loop and Clp1-ATP binding 
are dispensable for transcription and transcription termination [180].  However, we 
question these findings, and again draw attention to the fact that their use of high-copy 
number plasmids for mutant clp1 allele expression likely results in overexpression of 
Clp1 mutants and masks the true effects of P-loop mutations.  Given that Clp1-ATP 
binding and the Pcf11-Clp1 interaction are linked (and both are obligatory for CFIA 
assembly), it is probable that the transcriptional abnormalities associated with pcf11 
RW-A and clp1 T137A mutants are due to the aberrant or non-existent formation of 
CFIA.  This suggests that CFIA may have an additional function during transcription 
itself.  Support for this comes from the recent finding that CFIA interacts with the 
transcription factor TFIIB in a manner that is required for gene looping and the 
recycling of transcription factors back to the promoter (see section 1.7.2).  In addition to 
this, the hindrance of gene loop formation has been shown to result in decreases in 
transcription levels [181, 182, 184, 185].  If the results of our experiments are 
interpreted in view of the information available on gene looping in yeast, the 
malformation of CFIA caused by abrogation of the Pcf11-Clp1 interaction is likely to 
prevent the formation of gene loops.  The effect of this is that transcription factors are 
no longer recycled from gene terminator regions back to promoters, making 
transcription re-initiation and a continuous transcription cycle impossible.  The end 
result is diminished transcription kinetics and a marked reduction in gene expression. 
 
RT-qPCR experiments using total RNA extracted from the conditional clp1 T137A and 
pcf11 RW-A yeast mutants revealed that Clp1-ATP binding and the Pcf11-Clp1 
interaction had little influence over poly(A) site selection on ACT1 mRNA.  However, 
our RT-qPCR assays do not rule out that mutations affected the efficacy of the cleavage 
and polyadenylation reactions.  Indeed, a study published during the completion of this 
work showed that the pcf11 RW-A yeast mutant is unable to cleave and polyadenylate 
an mRNA precursor both in vitro and in vivo [122].  This fits well with our findings that 
this mutant caused defective transcription termination and that a unified 
allosteric/torpedo model of transcription termination dictates that pre-mRNA cleavage 
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is obligatory for transcription termination (see section 1.7.1) [176].  Another recent 
study uncovered two clp1 temperature sensitive mutants, clp1-5 and clp1-12, that were 
unable to both cleave and polyadenylate CYC1 pre-mRNA in vitro [121].  However, the 
authors did not link these deficiencies with a loss of Clp1-ATP binding.  The true effect 
of Clp1-ATP binding on the cleavage and polyadenylation reactions remains unknown, 
although we speculate both activities would be lost through abrogation of the Pcf11-
Clp1 interaction and the dismantling of CFIA.  To our knowledge, no information was 
previously available regarding the roles of Clp1 and Pcf11 in poly(A) site selection.  
The fact that Clp1-ATP binding and the Pcf11-Clp1 interaction were seemingly 
dispensable in this process was surprising.  However, a fresh characterisation of the 
export factor Yra1 may provide an explanation for the redundancy of Clp1 and Pcf11 in 
poly(A) site selection.  Johnson et al. found that Yra1 competes for Pcf11 binding with 
Clp1 [170].  As discussed in section 7.3, the ChIP profiles of Clp1 were found to be 
distinct to those of Pcf11 and Yra1 across a number of genes, suggesting that the 
composition of CFIA changes during transcription.  Furthermore, excess Yra1 was 
shown to inhibit cleavage and polyadenylation in vitro, suggesting CFIA containing 
Yra1 is not competent for the catalytic steps of 3’-end formation.  To determine if Yra1 
had other influences on 3’-end processing, the authors used an RNA sequencing 
approach to survey the 3’-end transcriptome of wildtype and Yra1-depleted yeast cells.  
They found that Yra1 modulated poly(A) site choice on mRNA transcribed from 1,430 
genes, but had no effect on poly(A) site choice at 2,782 other genes.  An in-depth 
analysis of the 1,430 “Yra1-sensitive” genes revealed that a large proportion of these 
genes (including the ACT1 gene) contain divergent or non-optimally positioned 
efficiency elements.  The authors postulate that one function of Yra1 may be to assist in 
conferring specificity in poly(A) site choice on genes with such sequence elements 
[170].  Interpreting these findings in the light of our own, we speculate that Clp1 and 
the Pcf11-Clp1 interaction is dispensable for poly(A) site selection and that poly(A) site 
choice is likely to be modulated by the Rna14 and Rna15 subunits of CFIA.  The 
assistance of Hrp1 (CFIB) and Yra1 may be required to locate poly(A) sites where pre-
mRNA sequence elements are poorly positioned or degenerate.  In accordance with the 
ChIP profile of Clp1, recruitment of Clp1 may occur at a later stage in transcription near 
to the poly(A) site, to enable the assembly of catalytically competent 3’-end processing 
machineries.   
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An amalgamation of the results presented here with the findings of past (and recent) 
studies has provided enough information to present a hypothesis for how CFIA might 
regulate transcription, pre-mRNA 3’-end processing and transcription termination.  In 
Figure 7.2, a simplified model for CFIA function in these processes is presented.  
Firstly, following transcription initiation, phosphorylation of PolII CTD at Ser2 
increases to facilitate transcription elongation and enable recruitment of Pcf11.  During 
transcription elongation, Pcf11 acts as a scaffold for the recruitment of Rna14, Rna15 
and Yra1, which constitutes a CFIA complex that is required for poly(A) site selection.  
At this stage it is possible that part of the function of Yra1 is to stabilise Pcf11 by 
protecting it from protein degradation (similar to the role we have postulated for Clp1), 
which allows the maintenance of CFIA architecture.  Upon transcription into the gene 
3’-UTR, the Rna14 and Rna15 subunits are essential for poly(A) site selection (two 
copies of Rna15 bind to G/U rich sequences flanking the cleavage site).  Hrp1 and Yra1 
may also assist in poly(A) site selection in 3’-UTRs with divergent or degenerate 
sequence elements through their direct associations with RNA.  Following poly(A) site 
selection, Clp1 competes with Yra1 for Pcf11-binding, leading to an alteration in CFIA 
composition to include Clp1.  The inclusion of Clp1 is required to remodel the 
conformation of CFIA so that it promotes pre-mRNA 3’-end cleavage.  This may 
directly involve interactions between Clp1 and CPF subunits, namely the Ysh1 
endonuclease that is likely to be the effector of cleavage.  After cleavage, 
polyadenylation is initiated by Pap1.  Clp1 acts to bolster the stability of Pcf11 and 
promotes the Pcf11 conformation required for its essential function in transcription 
termination.  Part of this function may be to facilitate the recruitment of Rat1 
(exonuclease) to the free 5’-end of the 3’-RNA cleavage product.  This model also 
accommodates the unified allosteric/torpedo model for transcription termination in 
which transcription of the poly(A) site, recruitment of factors that promote transcription 
termination and degradation of the 3’-RNA cleavage product are all required. 
 
7.5. Completing the picture 
 
In light of current thinking and information in the literature, the findings of work 
presented here can be condensed into three key theories: (1) The function of Clp1-ATP 
binding is purely to maintain Clp1 structure to allow CFIA assembly. (2) The Pcf11-
Clp1 interaction is important for transcription and transcription termination. (3) The 
subunit composition of CFIA may be dynamic to facilitate its roles in transcription,  
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Figure 7.2. A model for CFIA function in transcription, transcription termination and 
pre-mRNA 3’-end processing  (key events are outlined in the headings and are 
numbered). (1) Phosphorylation of PolII CTD Ser2 promotes transcription elongation 
and recruitment of Pcf11. (2) Pcf11 acts as a scaffold to recruit other CFIA subunits 
including Yra1 (and not Clp1) to facilitate poly(A) site selection. (3) Clp1 exchanges 
with Yra1 in the CFIA complex, conformational changes allow direct communication 
with the putative Ysh1 endonuclease of the CPF complex to effect 3’-end cleavage. (4) 
Pap1 polyadenylates the free 3’-end of the transcript, whilst the Pcf11-Clp1 interaction 
ensures that Pcf11 maintains a stable conformation required for recruitment of 
transcription termination factors including the Rat1 exonuclease.  The red arrow 
indicates the promoter of a gene.  The yellow star signifies phosphorylation of PolII 
CTD.  CFIA is composed of Pcf11, Rna14 and Rna15 subunits and either Yra1 or Clp1 
(denoted in brackets, bold text).  Py(A)N: cleavage/polyadenylation site in the 3’-UTR 
of a gene, the yellow lightning bolt signifies pre-mRNA cleavage. 
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pre-mRNA 3’-end processing and transcription termination.  To provide substance to 
these theories, a range of different experiments would be required. 
 
We have postulated that Clp1-ATP binding is required for the cleavage reaction through 
formation of a cleavage competent CFIA.  Other groups have shown that temperature 
sensitive clp1 alleles (clp1-5 and clp1-12) or cellular depletion of Clp1 abolishes 
cleavage and polyadenylation [99, 121, 180].  However, these deficiencies in activity 
have never been linked with Clp1 P-loop mutations or loss of ATP.  Although the 
GAL1-clp1 T137A yeast mutant described here has been shown to be a conditional 
mutant (inactive in glucose), this is not as robust as finding a genuine temperature 
sensitive allele associated with a weakening of the Clp1-ATP interaction.  It would be 
advantageous for future experiments looking at the role of Clp1-ATP binding to identify 
a Clp1-ATP binding mutant that is temperature sensitive.  This would involve a more 
comprehensive mutational analysis of residues in or around the Clp1 P-loop motif.  
Following an in vitro characterisation of such a mutant using the methods already 
described here, an in vitro cleavage assay would be able to quickly determine whether 
loss of Clp1-ATP binding resulted in a loss of cleavage activity.  In this assay, extracts 
from the relevant yeast mutant prepared at both permissive and restrictive temperatures 
would be assessed for the ability to cleave introduced radiolabelled pre-mRNAs, and the 
products visualised by denaturing gel electrophoresis.  
 
 
It was hypothesised that during transcription elongation and poly(A) site selection, the 
CFIA complex may contain Yra1 in place of Clp1.  To investigate this theory further, it 
would be useful to clone and express the Yra1 protein and determine whether it can be 
incorporated into a stable complex with Rna14, Rna15 and Pcf11.  The Yra1-Pcf11 
interaction has already been described [169, 170], therefore a good place to start would 
be to try to reconstitute this interaction in vitro and determine the stoichiometry of a 
Yra1-Pcf11 complex by SEC-MALLS. 
 
To our knowledge, RT-qPCR was a novel approach by which to analyse changes in 
poly(A) site selection on yeast mRNAs.  However, although this is a sensitive 
technique, there were also some drawbacks.  To begin with, this approach requires prior 
knowledge of poly(A) signal locations in 3’-UTRs.  The design of primers and probes is 
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also limited to sequence content, and therefore the experiment may not be possible with 
some gene transcripts.  In addition, as was observed here, when mutant phenotypes 
affect PolII transcription, it is likely that the steady-state levels of mRNA levels are all 
affected.  This renders any endogenous control (usually a stably expressed gene) not fit 
for purpose.  Indeed, because of this fact some of the RT-qPCR data presented here was 
not normalised to the expression of an endogenous control.  Nevertheless, we are 
confident from our replicate datasets and by assaying RNA template quality and 
concentration thoroughly that reductions in transcription are genuine (see section 2.8.8 
and Appendix 8.7).  Moreover, defective transcription in S. cerevisiae as a result pcf11 
mutation is well described in the literature [89, 122, 176, 186].  The greatest 
shortcoming of this RT-qPCR approach is that the readout of the phenotype of a 
mutation is confined to only a single mRNA species.  This renders it very trivial to 
conclude that the effects of a mutation (for example the removal of the Pcf11-Clp1 
interaction) cause a global effect on a cellular process (for example the amount of 
transcription of a large set of yeast genes).  Therefore, we propose that the greatest 
complement to the mutational analyses we have already carried out would be a global 
analysis of transcription and pre-mRNA 3’-end processing.  In practice, this means a 
comparison of the entire transcriptomes of wildtype yeast with the GAL1-clp1 T137A 
and pcf11 RW-A yeast mutants.  In recent years, experiments designed to achieve this 
have been made possible by the advent of next generation sequencing (massively 
parallel or high-throughout sequencing) technologies.  RNA sequencing (RNA-seq) 
refers to the isolation and high-throughput sequencing of an entire transcriptome 
(reviewed in [223]).  This is achieved by making cDNA libraries by reverse 
transcription of total RNA samples using an Oligo (dT) primer complementary to 
poly(A) tails (and followed by second strand synthesis).  The libraries are then 
fragmented into shorter cDNA strands and these smaller strands are sequenced (shotgun 
sequencing) and mapped to the genome in question.  Powerful data analysis techniques 
have been developed to enable characteristics such as transcript quantification to be 
determined.  This would be extremely useful when applied to total RNA derived from 
the pcf11 RW-A yeast mutant, as it would reveal the true extent to which the Pcf11-
Clp1 interaction is involved in transcription.  In terms of an approach to monitor global 
changes in 3’-end processing, RNA-seq has been adapted to analyse changes in poly(A) 
site selection across the entire transcriptome by surveying the junction between the 3’-
UTRs and poly(A) tails of transcripts.  This powerful approach has recently been used 
to characterise the use of poly(A) sites in C. elegans and S. cerevisiae [170, 224], and 
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would be a vastly superior alternative to our RT-qPCR assay.  If applied to total RNA 
extracted from the pcf11 RW-A mutant, this approach could be used to test our 
hypothesis that the Pcf11-Clp1 interaction (and Clp1) is not required for poly(A) site 
choice. 
 
We have hypothesised that the composition of CFIA changes during transcription, with 
the effectual swapping of the Yra1 and Clp1 proteins in order to manage the 
requirement for poly(A) site choice or 3’-end cleavage and transcription termination 
during gene expression.  This idea was formed from the results of ChIP-Chip 
experiments recently performed by Johnson et al, which showed that the peaks of Yra1 
and Pcf11 occupancy across genes differed from the peaks of Clp1 occupancy [170].  
ChIP experiments are used to identify the positions to which proteins or protein 
complexes bind on DNA.  This is achieved by cross-linking genomic DNA to protein, 
shearing DNA into small fragments and isolating the protein of interest by 
immunoprecipitation.  The cross-linking is then reversed, and the bound DNA 
sequences are often analysed by quantitative real-time PCR (qPCR).  The ChIP-Chip 
(ChIP coupled with microarray analysis) and ChIP-seq (ChIP coupled with DNA-seq) 
methods are two further adaptations to ChIP that have allowed the genome-wide 
analysis of DNA sequences to which specific proteins associate (reviewed in [225]).  
The application of either of these approaches would greatly assist in testing our theories 
about CFIA formation and transcription termination.  Although the pcf11 RW-A mutant 
has been used to generate some ChIP data [122], this was far from a global analysis of 
transcription termination.  If our hypotheses are correct then we would expect to see the 
occupancy of Pcf11 carrying the RW-A mutation increase on large numbers of genes 
after poly(A) signals, which would be representative of global defects in transcription 
termination. 
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8. Appendix 
 
8.1.  Clp1 multi-species sequence alignment 
 
  
 
Species names: S.c. Saccharomyces cerevisiae (budding yeast); S.p. Schizosaccharomyces pombe 
(fission yeast); M.m. Mus Musculus (mouse); H.s. Homo sapiens (human); G.g. Gallus gallus (chicken); 
X. l. Xenopus laevis (African clawed frog); D.m. Drosophila melanogaster (fruit fly); C.e. 
Caenorhabditis elegans (nematode worm); A.t. Arabidopsis thaliana (mouse-ear cress). 
 
Species names for Pcf11-Clp1 ID sequence alignment (Figure 1.4, C): S.c. Saccharomyces cerevisiae 
(budding yeast); K.l. Kluyveromyces lactis (lactose yeast); S.p. Schizosaccharomyces pombe (fission 
yeast); M.m. Mus musculus (mouse); H.s. Homo sapiens (human); M.g. Meleagris gallopavo (wild 
turkey); X.t. Xenopus tropicalis (Western clawed frog); D.r. Danio rerio (Zebrafish); C.e. Caenorhabditis 
elegans (nematode worm). 
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8.2. Mutant plasmid constructs 
 
 
Construct name Vector Organism Marker Function 
     
Clp1 K136A-EXP pACYCDUET1 
(Novagen) 
E. coli camR Expression of specified 
mutant Clp1-Pcf11(454-
563) complex 
Clp1 K136E-EXP pACYCDUET1 
(Novagen) 
E. coli camR Expression of specified 
mutant Clp1-Pcf11(454-
563) complex 
Clp1 T137A- EXP pACYCDUET1 
(Novagen) 
E. coli camR Expression of specified 
mutant Clp1-Pcf11(454-
563) complex 
Clp1 S138A- EXP pACYCDUET1 
(Novagen) 
E. coli camR Expression of specified 
mutant Clp1-Pcf11(454-
563) complex 
Clp1 D161A- EXP pACYCDUET1 
(Novagen) 
E. coli camR Expression of specified 
mutant Clp1-Pcf11(454-
563) complex 
Clp1 D251A-EXP pACYCDUET1 
(Novagen) 
E. coli camR Expression of specified 
mutant Clp1-Pcf11(454-
563) complex 
Clp1 K321A-EXP pACYCDUET1 
(Novagen) 
E. coli camR Expression of specified 
mutant Clp1-Pcf11(454-
563) complex 
Pcf11 Q478N-EXP pACYCDUET1 
(Novagen) 
E. coli camR Expression of specified 
mutant Clp1-Pcf11(454-
563) complex 
Pcf11 R480A-EXP pACYCDUET1 
(Novagen) 
E. coli camR Expression of specified 
mutant Clp1-Pcf11(454-
563) complex 
Pcf11 W482A-EXP pACYCDUET1 
(Novagen) 
E. coli camR Expression of specified 
mutant Clp1-Pcf11(454-
563) complex 
Pcf11 W489A-EXP pACYCDUET1 
(Novagen) 
E. coli camR Expression of specified 
mutant Clp1-Pcf11(454-
563) complex 
LEU2-clp1-K136A pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-clp1-K136E pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-clp1-T137A pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-clp1-S138A pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-clp1-D161A pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-clp1-D251A pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
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* Notes: RW-A, R480A and W482A double mutant; WW-A, W482A and W489A double mutant; 
RWW-A, R480A, W482A and W489A triple mutant; CTD∆, deletion of Pcf11 CTD (residues 393-626). 
Construct name Vector Organism Marker Function 
     
LEU2-clp1-K321A pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-pcf11-Q478N pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-pcf11-R480A pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-pcf11-R480K pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-pcf11-W482A pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-pcf11-W489A pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-pcf11-RW-A* pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-pcf11-WW-A* pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-pcf11-RWW-A* pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
LEU2-pcf11-CTD∆* pRS315 
(ATCC) 
S. cerevisiae/ 
E. coli 
LEU2 
ampR 
Testing viability of 
specified mutant allele in 
S. cerevisiae 
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8.3. Oligonucleotide primers for PCR 
 
Primers for cloning 
 
Primer name + 
direction 
Sequence 
(5’ to 3’) 
Restriction 
site 
Pcf11 400 F GCTGGCGGGATCCCAAGAAAATCCCATCGT
CC 
BamHI 
Pcf11 416 F GCTGGCGGGATCCAAGCCAAATAAATGTAG
C 
BamHI 
Pcf11 420 F GCTGGCGGGATCCTGTAGCGTGTGTGGTAA
G 
BamHI 
Pcf11 499 R CGCCAGCGTCGACGGAGGTAATTTCATCAT
C 
SalI 
Pcf11 626 R CGCCAGCGTCGACTTTTGTGACCAATTTCTT
TAAG 
SalI 
CLP1 promoter F CGAACCGCGGTATGGAAGTTTACTTGATCC
GGAG 
SacII 
CLP1 promoter R CGCCAAGCTTCGGATCCACCATGGTGGTT
TAATCGTGTTGGA 
HindIII/ 
NcoI 
PCF11 promoter F CGAACCGCGGCAGCGGCGAAGAAGTCTAG
CCTATTCC 
SacII 
PCF11 promoter R CGCCAAGCTTCGGATCCACCATGGTGAAA
AGAGAGTATTAC 
HindIII/ 
NcoI 
GAL1 promoter F* GCTGGCGCCGCGGCTCTTTGGAACTTTCAG
TAATAC 
SacII 
GAL1 promoter R* CGCCAGCCCATGGTTTTTTCTCCTTGACGTT
AAAG 
NcoI 
CLP1 F CGCCAGCCCATGGCAAGTCTACCTGG NcoI 
CLP1 R CGTGGCGTCTAGACTCTAAATATCTATATG XbaI 
CLP1-HA R GCTGGCGCTGCAGCTCTAAATATCTATATG PstI 
PCF11 F CGCCAGCCCATGGATCACGACACAGAAG NcoI 
PCF11 R GCTGGCGTCTAGATTTTGTGACCAATTTCTT
TAAG 
XbaI 
PCF11-HA R GCTGGCGCTGCAGTTTTGTGACCAATTTCTT
TAAG 
PstI 
PCF11-HA R BglII GCTGGCGAGATCTTTTTGTGACCAATTTCTT
TAAG 
BglII 
 
HA-tag F* 
 
CGCCAAGCTTGGAATTCTTCTAGATAACT
GCAGAGCGGCCGCATCTTTTACCCATAC 
HindIII/ 
XbaI/ 
PstI 
HA-tag R* CGCCCTCGAGCCAACATAGATCAAAATTATA
GCC 
XhoI 
 
HA-tag F  BglII * 
 
CGCCAAGCTTGGAATTCTTCTAGATAAA
GATCTAGCGGCCGCATCTTTTACCCATAC 
HindIII/ 
XbaI/ 
BglII 
 
 
*Notes: The GAL1 promoter was amplified by PCR using the pESC-URA plasmid vector (Stratagene) as 
template.  This plasmid contains the divergent GAL1/GAL10 promoters.  The 3X haemagglutinin tag 
(HA-tag) plus terminator sequence was amplified by PCR using the pRS305-HA construct as template.  
This construct is a yeast shuttle vector (Addgene) that contains a triple repeat of amino acids 98-106 from 
the human influenza haemagglutinin protein (HA epitope) followed by a yeast 3’-UTR sequence.  This 
construct was provided by Dr. M. Geymonat (formerly NIMR). 
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Primers for mutagenesis 
 
Primer name + 
direction 
Sequence 
(5’ to 3’) 
Clp1 P-loop R GGTTTGCGAACCACCAACAATCACCACTCG  
Clp1 K136A F GGGGCGACTTCCCTATCGAGGACACTATG  
Clp1 K136E F GGGGAGACTTCCCTATCGAGGACACTATG  
Clp1 T137A F GGGAAGGCTTCCCTATCGAGGACACTATG  
Clp1 S138A F GGGAAGACTGCCCTATCGAGGACACTATG  
Clp1 D161A F CTATACATCAATCTTGCCCCTCAACAGCCC  
Clp1 D161A R GGGCTGTTGAGGGGCAAGATTGATGTATAG  
Clp1 D251A F CAGGGTGCATTGTCGCTACGCCATCAATATCAC  
Clp1 D251A R GTGATATTGATGGCGTAGCGACAATGCACCCTG  
Clp1 Base loop R CATCAACTGCGGATACACCATCCAATTTAGGAATG  
Clp1 K321A F ATGTATACGCAAGATCCTTGCAGAGGACATCC  
Clp1 K321R F ATGTATACCGCAGATCCTTGCAGAGGACATCC  
Pcf11 Q478N F GGAAAAATATTAACTCAAGAAACTGG  
Pcf11 Q478N R CCAGTTTCTTGAGTTAATATTTTTCC  
Pcf11 R480A F TATTCAATCAGCCAACTGGTATTTGAGTGACTCTC  
Pcf11 R480A R GAGAGTCACTCAAATACCAGTTGGCTGATTGAATA  
Pcf11 R480K F TATTCAATCAAAGAACTGGTATTTGAGTGACTCTC 
Pcf11 R480K R GAGAGTCACTCAAATACCAGTTCTTTGATTGAATA  
Pcf11 W482A F CAATCAAGAAACGCGTATTTGAGTGACTC  
Pcf11 W482A R GAGTCACTCAAATACGCGTTTCTTGATTG  
Pcf11 W489A F GAGTGACTCTCAAGCGGCAGCCTTCAAAG  
Pcf11 W489A R CTTTGAAGGCTGCCGCTTGAGAGTCACTC 
Pcf11 RW-A F ATTCAATCAGCCAACGCGTATTTGAGTGACTC 
Pcf11 RW-A R GAGTCACTCAAATACGCGTTGGCTGATTGAAT 
Pcf11 STOP 499 F GATGAAATTACCTCCTGAGACTCGAGCGGCCGC 
Pcf11 STOP 499 R GCGGCCGCTCGAGTCTCAGGAGGTAATTTCATC 
Pcf11 STOP 626 F GAAATTGGTCACAAAATGAGACTCGAGCGGCCGC 
Pcf11 STOP 626 R GCGGCCGCTCGAGTCTCATTTTGTGACCAATTTC 
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8.4. Primers and probes for reverse-transcription quantitative real-time PCR 
experiments 
 
RT-qPCR primers 
 
Primer name  
+ direction 
Sequence (5’ to 3’) Tm (°C) 
ACT1 3’-UTR F CAACAAATGTGGATCTCAAAACAAG 58.1 
ACT1 3’-UTR R CATAAACATACGCGCACAAAAGCA 59.3 
ACT1 poly(A)-1 F TTCACCACAAGTGTTTCTAATCTCT 58.1 
ACT1 poly(A)-1 R CAGTGCTTAAACACGTCTTTTCC 58.9 
ACT1 poly(A)-2/3 F CTATTTCTATTTTTAAACCA CCTCTCA 59.1 
ACT1 poly(A)-2/3 R GGAGAGACAAAACACATTATATCAATG 58.9 
ACT1 poly(A)-4 R GAAATTTTCGTAGAAAAGGGAGAGA 58.1 
ACT1 R-T F CGCTTTTCAGTTTTATAGGTTTATGC 58.5 
ACT1 R-T R GGTATCAAAACGCCGGACTCA 59.8 
TDH2 F CATCGTTGATGGTCACAAGATC 58.4 
TDH2 R TGGAGTCAATGGCGATGTCAA 57.9 
ADH1 F CAGAGCTGACACCAGAGAAG 59.3 
ADH1 R GTAAATTTCTGGCAAGGTAGACAAG 59.7 
CYC1 F GTACACAGATGCCAATATCAAGA 57.1 
CYC1 R AACCCACCAAAGGCCATCTT 57.3 
YPT1 F CACTCAGAAGAAGGAAGACAAAG 57.1 
YPT1 R AAGGTAGAGGCGCGCTTGTT 57.3 
 
RT-qPCR probes 
 
Probe name Dye/quencher Sequence (5’ to 3’) Tm (°C) 
ACT1 3’-UTR 6-FAM/MGB CGAAAGTGGTCCATCTATCGTTC
ACCACAAGT 
 
68.2 
ACT1 poly(A)-1 6-FAM/MGB TGTGCGCGTATGTTTATGTATGTA
CCTCTCTCTCT 
 
68.3 
ACT1 poly(A) 2/3 6-FAM/MGB AGACGTGTTTAAGCACTGACTTTA
TCTACTTTTTGTACG 
 
67.4 
ACT1 R-T 6-FAM/MGB CCTTCTTGGGAGGATCTTGTAGA
ACCGCCATT 
 
69.5 
TDH2 6-FAM/MGB CCAAGAAAGAGACCCAGCTAACT
TGCCATG 
 
68 
ADH1 6-FAM/MGB CTTCTTCGCCAGAGGTTTGGTCA
AGTCTCCAA 
 
69.5 
CYC1 6-FAM/MGB CATGTCAGAGTACTTGACTAACC
CAAAGAAATATATTCC 
 
67.4 
YPT1 6-FAM/MGB CAACCTGAAGGGACAGAGTTTAA
CCAACACCG 
 
67.4 
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8.5. Clp1 and Pcf11(454-563) mass spectrum deconvolution reports 
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8.6. CT and quantity data from RT-qPCR experiments 
 
 
 
GAL1-CLP1 
 
Amplicon CT Mean (S.D.) 
Exp1 
CT Mean (S.D.) 
Exp2 
Quantity Mean 
(S.D.) Exp1 
Quantity Mean 
(S.D.) Exp2 
ACT1 3’-UTR 20.67 (0.07) 19.71 (0.04) 140.7 (6.35) 132.4 (3.4) 
ACT1 poly(A)-1 22.77 (0.09) 22.24 (0.07) 23.95 (1.45) 31.35 (1.25) 
ACT1 poly(A)-2/3 23.02 (0.02) 21.91 (0.01) 20.7 (0.3) 30.6 (0.15) 
ACT1 poly(A)- 4 24.58 (0.13) 19.89 (0.38) 19.95 (1.45) 33.45 (7.3) 
ACT1 R-T 22.29 (0.04) 22.62 (0.01) 15.7 (0.5) 11.1 (0.01) 
TDH2 (1) 19.22 (0.05) 17.96 (0.01) 210.25 (8) 213.25 (1.9) 
TDH2 (2) 17.95 (0.01) 17.74 (0.11) 223.75 (2.1) 273.6 (23.46) 
ADH1 19.72 (0.05) 17.17 (0.04) 73.25 (2.75) 482.45 13.95) 
CYC1 21.56 (0.06) 21.23 (0.11) 7.4 (0.15) 8.6 (0.75) 
YPT1 22.43 (0.03) 21.99 (0.02) 10.23 (0.19) 13.05 (0.24) 
 
 
 
GAL1-clp1 K136A 
 
Amplicon CT Mean (S.D.) 
Exp1 
CT Mean (S.D.) 
Exp2 
Quantity Mean 
(S.D.) Exp1 
Quantity Mean 
(S.D.) Exp2 
ACT1 3’-UTR 18.92 (0.04) 18.94 (0.05) 199.35 (5.9) 204.85 (7.3) 
ACT1 poly(A)-1 21.56 (0.08) 20.95 (0.08) 33.1 (1.6) 35 (1.9) 
ACT1 poly(A)-2/3 20.89 (0.25) 21.57 (0.22) 33.9 (5.5) 35 (5) 
ACT1 poly(A)- 4 22.52 (0.1) 22.56 (0.11) 29.35 (1.85) 29.8 (2) 
ACT1 R-T 22.88 (0.04) 21.67 (0.13) 7.3 (0.18) 8.2 (0.65) 
TDH2 (1) 17.42 (0.01) 17.3 (0.05) 335 (4.24) 364.15 (13.6) 
TDH2 (2) 17.4 (0.07) 17.66 (0.02) 336.9 (17.6) 289.8 (4.95) 
ADH1 16.91 (0.09) 17.09 (0.02) 563.95 (38.9) 511.8 (7.8) 
CYC1 21.73 (0.01) 21.71 (0.09) 6.55 (0.01) 5.95 (0.45) 
YPT1 22.53 (0.04) 22.58 (0.03) 9.45 (0.28) 8.4 (0.2) 
 
 
 
GAL1-clp1 T137A 
 
Amplicon CT Mean (S.D.) 
Exp1 
CT Mean (S.D.) 
Exp2 
Quantity Mean 
(S.D.) Exp1 
Quantity Mean 
(S.D.) Exp2 
ACT1 3’-UTR 21.8 (0.16) 20.22 (0.05) 66.85 (6.95) 93.75 (3.45) 
ACT1 poly(A)-1 23.78 (0.13) 22.63 (0.11) 12.6 (1) 16.9 (1.2) 
ACT1 poly(A)-2/3 24 (0.17) 21.71 (0.14) 8.7 (1.1) 24.55 (2.35) 
ACT1 poly(A)- 4 26.74 (0.17) 23.55 (0.16) 5.85 (0.6) 17.25 (1.7) 
ACT1 R-T 23.47 (0.02) 21.94 (0.03) 10.3 (0.15) 11.95 (0.2) 
TDH2 (1) 21.77 (0.07) 20.24 (0.09) 37.25 (1.8) 47.5 (2.9) 
TDH2 (2) 20.37 (0.04) 20.67 (0.01) 36.5 (0.95) 29.8 (0.25) 
ADH1 20.07 (0.09) 20.31 (0.03) 56.5 (3.9) 49.3 (1) 
CYC1 21.98 (0.05) 22 (0.11) 5.45 (0.2) 4.75 (0.4) 
YPT1 22.85 (0.08) 22.92 (0.07) 7.45 (0.01) 6.45 (0.33) 
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GAL1-clp1 S138A 
 
Amplicon CT Mean (S.D.) 
Exp1 
CT Mean (S.D.) 
Exp2 
Quantity Mean 
(S.D.) Exp1 
Quantity Mean 
(S.D.) Exp2 
ACT1 3’-UTR 20.49 (0.05) 18.9 (0.06) 75 (2.65) 200.8 (7.5) 
ACT1 poly(A)-1 22.14 (0.06) 21.58 (0.12) 14.7 (0.65) 35.2 (2.9) 
ACT1 poly(A)-2/3 22.67 (0.18) 21.61 (0.22) 9.6 (1.25) 36.4 (5.4) 
ACT1 poly(A)- 4 24.88 (0.03) 22.49 (0.09) 7.35 (0.13) 34.35 (2.2) 
ACT1 R-T 22.91 (0.01) 19.29 (0.21) 6.65 (0.01) 9.2 (1.3) 
TDH2 (1) 18.97 (0.01) 14.38 (0.19) 106.5 (1.1) 345.4 (45.95) 
TDH2 (2) 18.68 (0.05) 18.42 (0.03) 150.2 (5.95) 173.9 (4.5) 
ADH1 13.89 (0.19) 17.6 (0.04) 206.8 (25.95) 413.45 (13.8) 
CYC1 21.85 (0.09) 21.78 (0.06) 7.45 (0.45) 8.35 (0.39) 
YPT1 22.73 (0.1) 22.49 (0.04) 8.45 (0.65) 9.45 (0.33) 
 
 
 
 
GAL1-clp1 D161A 
 
Amplicon CT Mean (S.D.) 
Exp1 
CT Mean (S.D.) 
Exp2 
Quantity Mean 
(S.D.) Exp1 
Quantity Mean 
(S.D.) Exp2 
ACT1 3’-UTR 18.95 (0.03) 18.91 (0.09) 206 (3.6) 185.45 (12.75) 
ACT1 poly(A)-1 21.02 (0.04) 21.38 (0.01) 38.35 (0.95) 38.35 (0.15) 
ACT1 poly(A)-2/3 20.98 (0.09) 21.2 (0.28) 40.3 (2.65) 38.55 (7.1) 
ACT1 poly(A)- 4 22.56 (0.05) 22.67 (0.23) 32.8 (1.1) 32.15 (4.85) 
ACT1 R-T 22.33 (0.39) 22.65 (0.05) 10 (0.25) 8.65 (0.3) 
TDH2 (1) 17.46 (0.04) 17.58 (0.18) 325.65 (9.95) 293.15 (35.6) 
TDH2 (2) 18.79 (0.02) 18.53 (0.04) 138 (2.15) 160.8 (4.8) 
ADH1 13.68 (0.18) 17.66 (0.05) 239.35 (28.95) 397.15 (15) 
CYC1 21.85 (0.08) 21.8 (0.09) 7.55 (0.5) 8.25 (0.55) 
YPT1 22.83 (0.04) 22.64 (0.02) 7.85 (0.25) 8.45 (0.1) 
 
 
 
 
GAL1-clp1 D251A 
 
Amplicon CT Mean (S.D.) 
Exp1 
CT Mean (S.D.) 
Exp2 
Quantity Mean 
(S.D.) Exp1 
Quantity Mean 
(S.D.) Exp2 
ACT1 3’-UTR 19.19 (0.07) 18.93 (0.04) 193.15 (8.85) 198.45 (5.85) 
ACT1 poly(A)-1 21.49 (0.07) 21.05 (0.08) 35.15 (1.6) 31.35 (1.6) 
ACT1 poly(A)-2/3 21.24 (0.21) 21.06 (0.23) 40.15 (5.8) 37.2 (5.7) 
ACT1 poly(A)- 4 22.46 (0.22) 20.46 (0.15) 30.1 (3.95) 31.7 (3.15) 
ACT1 R-T 22.83 (0.09) 22.92 (0.02) 6.25 (0.4) 6.15 (0.09) 
TDH2  17.54 (0.01) 17.56 (0.04) 296.35 (0.85) 305.3 (9.15) 
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PCF11 30°C 
 
Amplicon CT Mean (S.D.) 
Exp1 
CT Mean (S.D.) 
Exp2 
Quantity Mean 
(S.D.) Exp1 
Quantity Mean 
(S.D.) Exp2 
ACT1 3’-UTR 19.95 (0.02) 16.58 (0.01) 113.65 (1.65) 177.35 (1.1) 
ACT1 poly(A)-1 23.83 (0.1) 24.17 (0.04) 7.15 (0.45) 11.85 (0.3) 
ACT1 poly(A)-2/3 24.11 (0.17) 24.85 (0.14) 6.95 (0.75) 6.95 (0.65) 
ACT1 poly(A)- 4 26.4 (0.29) 26.89 (0.08) 3.35 (0.6) 6.15 (0.25) 
ACT1 R-T 25.82 (0.03) 26.28 (0.03) 1.1 (0.01) 1.5 (0.01) 
TDH2  18.89 (0.05) 15.28 (0.41) 131.6 (4.2) 142.7 (40.95) 
ADH1 17.95 (0.02) 15.53 (0.04) 308.8 (5.06) 148.4 (4) 
CYC1 22.58 (0.1) 22.76 (0.14) 3.55 (0.25) 5.2 (0.04) 
YPT1 23.85 (0.06) 23.79 (0.05) 3.2 (0.15) 4.4 (0.15) 
 
PCF11 39°C 
 
Amplicon CT Mean (S.D.) 
Exp1 
CT Mean (S.D.) 
Exp2 
Quantity Mean 
(S.D.) Exp1 
Quantity Mean 
(S.D.) Exp2 
ACT1 3’-UTR 20.9 (0.06) 16.48 (0.08) 51.8 (2.25) 77.85 (3.8) 
ACT1 poly(A)-1 23.85 (0.03) 24.72 (0.05) 5.2 (0.1) 9.3 (0.25) 
ACT1 poly(A)-2/3 24.2 (0.23) 25.33 (0.13) 5.07 (0.85) 6.1 (0.5) 
ACT1 poly(A)- 4 27.36 (0.01) 26.65 (0.1) 1.6 (0.01) 5.85 (0.38) 
ACT1 R-T 24.93 (0.01) 25.58 (0.03) 0.98 (0.01) 2.45 (0.01) 
TDH2  18.79 (0.01) 20.29 (0.49) 134.6 1.45) 94.8 (27.85) 
ADH1 17.97 (0.04) 15.57 (0.02) 303.75 (10.06) 144.45 (1.85) 
CYC1 22.39 (0.06) 22.82 (0.12) 4.1 (0.2) 5.03 (0.4) 
YPT1 24.81 (0.05) 24.75 (0.03) 1.5 (0.01) 2.15 (0.05) 
 
pcf11 RW-A 30°C 
 
Amplicon CT Mean (S.D.) 
Exp1 
CT Mean (S.D.) 
Exp2 
Quantity Mean 
(S.D.) Exp1 
Quantity Mean 
(S.D.) Exp2 
ACT1 3’-UTR 19.87 (0.04) 16.74 (0.09) 126.75 (0.05) 184.1 (11.7) 
ACT1 poly(A)-1 22.87 (0.19) 23.94 (0.03) 11 (1.33) 13.45 (0.3) 
ACT1 poly(A)-2/3 23.17 (0.03) 24.59 (0.24) 10.29 (0.19) 9.8 (1.56) 
ACT1 poly(A)- 4 25.22 (0.09) 25.52 (0.16) 6.7 (0.39) 10.2 (0.95) 
ACT1 R-T 25.65 (0.03) 26.41 (0.07) 1.25 (0.01) 1.38 (0.06) 
TDH2  19.03 (0.07) 20.17 (0.03) 115.1 (5.45) 99.65 (1.8) 
ADH1 18.45 (0.01) 16 (0.18) 211.7 (1.6) 109.55 (12.5) 
CYC1 21.87 (0.05) 22.21 (0.05) 6.05 (0.01) 7.5 (0.24) 
YPT1 23.6 (0.09) 23.52 (0.07) 3.9 (0.28) 5.4 (0.28) 
 
pcf11 RW-A 39°C 
 
Amplicon CT Mean (S.D.) 
Exp1 
CT Mean (S.D.) 
Exp2 
Quantity Mean 
(S.D.) Exp1 
Quantity Mean 
(S.D.) Exp2 
ACT1 3’-UTR 22.95 (0.01) 23.82 (0.09) 15.9 (0.01) 18.35 (1.1) 
ACT1 poly(A)-1 25.72 (0.08) 26.59 (0.04) 2.45 (0.13) 2.55 (0.05) 
ACT1 poly(A)-2/3 25 (0.17) 26.66 (0.13) 3.15 (0.07) 2.45 (0.19) 
ACT1 poly(A)- 4 27.65 (0.071) 28.05 (0.08) 3.11 (0.01) 2.9 (0.14) 
ACT1 R-T 24.24 (0.06) 25.15 (0.02) 3.1 (0.13) 3.35 (0.01) 
TDH2  20.19 (0.03) 21.79 (0.03) 52 (1.2) 34.75 (0.65) 
ADH1 19.87 (0.05) 17.48 (0.14) 71.6 (2.5) 41.8 (3.9) 
CYC1 23.81 (0.09) 24.12 (0.12) 1.3 (0.1) 2.15 (0.17) 
YPT1 26.57 (0.01) 26.45 (0.04) 0.39 (0.004) 0.6 (0.02) 
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